{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {\"COHORT\": \"patient\", \"LABORATORY FINDINGS\": \"laboratory findings\"}", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" {\"TRABECTIN\": Description of trabectedin, a chemotherapy drug used in the treatment of certain types of cancer, including retroperitoneal liposarcoma.}\n\n{\"HERBAL MEDICINE\": Description of an alternative herbal medicine suspected of triggering heavy toxicity and rhabdomyolysis in the patient.}\n\n{\"HEAVY TOXICITY\": Description of the unexpected severe adverse reaction experienced by the patient.\n\n{\"RHABDOMYOLYSIS\": Description of the condition characterized by the breakdown of muscle tissue, leading to the release of muscle fiber contents into the bloodstream, which can be a serious complication.\n\n{\"RETROPERITONEAL LIPOSARCOMA\": Description of a type of cancer that occurs in the retroperitoneal fat tissue.\n\n{\"FOURTH COURSE\": Description of the fourth cycle or round of treatment with trabectedin in the patient's cancer therapy.\n\n{\"ADVERSE EVENT\": Description of the unexpected and negative side effect experienced by the patient, in this case, heavy toxicity and rhabdomyolysis.\n\n{\"CANCER THERAPY\": Description of the treatment regimen for cancer, which in this case includes trabectedin and an alternative herbal medicine.\n\n{\"ADVERSE REACTION\": Description of an unexpected and harmful response to a drug or treatment, as experienced by the patient.\n\n{\"HERBAL MEDICINE SUSPECTED\": Description of the alternative herbal medicine that is believed to have triggered the adverse event.\n\n{\"PHARMACOLOGY\": Description of the study of drugs and their effects on the body, which is relevant to understanding the adverse reaction experienced by the patient.\n\n{\"ONSET\": Description of the time when the adverse reaction occurred, which was unexpected.\n\n{\"HEAVY TOXICITY INCIDENCE\": Description of the frequency or occurrence of heavy toxicity in patients treated with trabectedin, which is not specified but implied to be rare.\n\n{\"TRACTECTIN TREATMENT\": Description of the therapeutic use of trabectedin in treating cancer patients.\n\n{\"HERBAL MEDICINE TRIGGER\": Description of the", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {\"ABDOMINAL MASS\": \"abdominal mass\"}\n{\"R0 RESCIPATION\": \"R0 resection\"}\n{\"MAJOR GYNECOLOGIST\": \"major gynecologist\"}\n{\"MAJOR SURGEON\": \"major surgeon\"}\n{\"MAJOR HOSPITAL\": \"major hospital\"}\n{\"MAJOR CLINICAL TRIAL\": \"major clinical trial\"}\n{\"MAJOR PHARMACOLOGY RESEARCH\": \"major pharmacology research\"}\n{\"MAJOR PHARMACOLOGIST\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL STUDY\": \"major pharmacological study\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCH\": \"major pharmacological research\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR PHARMACOLOGICAL RESEARCHER\": \"major pharmacologist\"}\n{\"MAJOR P", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {\"CHEMOTHERAPY\": \"chemotherapy\",\n\"LESION\": \"lesion\",\n\"PRE-AORTIC SEAT\": \"pre-aortic seat\",\n\"RETRO-PERITONEUM SPACE\": \"retro-peritoneum space\"}\n\n(Note: The term \"cohort\" was not explicitly mentioned in the text, so no cohort entity was identified.)", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {\"TRABEACTIN\": \"drug\", \"PATIENT\": \"cohort\"}", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" {\"COHORT\": \"cancer patients\", \"CHEMOTHERAPEUTIC DRUGS\": \"chemotherapeutic drugs\", \"ONCOLOGY PRACTICE\": \"oncology practice\", \"ANCILLARY MEDICATIONS\": \"ancillary medications\"}", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {\"COHORT\": \"patient\", \"COMPOUND\": \"chokeberry juice\", \"MECHANISM\": \"inhibition of transport mechanisms\", \"DEATH_RECEPTOR\": \"death receptor\"}", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {\"COHORT\": \"medicinal cannabis users\", \"HEALTH RISKS\": \"health risks associated with its use\"}", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" {\"COMT\": \"COMT gene\", \"HTR2A\": \"HTR2A gene\"}\n\nCOHORT: Not explicitly mentioned in the text. However, if we were to infer, it could be the patient group under study for pharmacogenomics testing.\n\n{\"COHORT\": \"Patient group under study for pharmacogenomics testing\"}", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" {\"COHORT\": \"Patients with Parkinson's Disease (PD)\", \"MEDICATIONS\": \"carbidopa-levodopa, ropinirole, entacapone\", \"BIOLOGICAL PRODUCT\": \"dopamine\", \"STUDY\": \"not specified\", \"SOURCE\": \"not specified\", \"JOURNAL\": \"not specified\", \"REFERENCE\": \"8\"}\n\n(Note: The reference number \"8\" is assumed to be a citation from a journal or study, but without the actual source, it's not possible to provide a complete citation. The rest of the entities are inferred from the context of the text.)", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\"COHORT\": \"individual's pharmacogenomic (PGx) data\", \"PHARMACOKINETIC\": \"pharmacokinetic effects of cannabis\", \"PHARMACODYNAMIC\": \"pharmacodynamic effects of cannabis\", \"DRUG\": \"cannabis\", \"MEDICATION ROUTINE\": \"medication regimen\"}", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" {\"PD\": \"Parkinson's disease\", \"spinal stenosis\": \"spinal stenosis\", \"vitamin D deficiency\": \"vitamin D deficiency\", \"frequent falls\": \"frequent falls\", \"nicotine dependence\": \"nicotine dependence\", \"alcohol dependence\": \"alcohol dependence\", \"mild kidney disease\": \"mild kidney disease\", \"chronic neck pain\": \"chronic neck pain\", \"chronic back pain\": \"chronic back pain\", \"chronic shoulder pain\": \"chronic shoulder pain\"}", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {\"COHORT\": \"clinical pharmacist\", \"carbidopa-levodopa\": \"drug\", \"tremors\": \"symptom\"}\n\n{\"FIGURE\": \"Figure 1\"}", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\"PCP\": \"Primary Care Physician\", \"medication\": \"additional medication for pain control\"}\n{\"cohort\": \"Not applicable\"}\n{\"study\": \"Not applicable\"}\n{\"drug\": \"Not applicable\"}\n{\"pharmacology\": \"Not applicable\"}\n{\"journal\": \"Not applicable\"}\n{\"article\": \"Not applicable\"}", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" {\"STUDY_MODELS\": \"pain models, healthy subjects vs. patients\"}\n{\"ROUTES_OF_ADMINISTRATION\": \"inhalation vs. oral\"}\n{\"SOURCES_OF_PRODUCT\": \"not specified\"}\n{\"JOURNALS\": \"not specified\"}\n{\"PUBLICATION_YEARS\": \"not specified\"}", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" {\"CB1R\": \"cannabinoid type 1 receptors\", \"presynaptic neurons\": \"neurons that release neurotransmitters\", \"inhibitory neurotransmitter\": \"neurotransmitters that inhibit neuronal activity\", \"dopamine\": \"a neurotransmitter associated with pleasure and reward\"}\n\n{\"COHORT\": \"\"}", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {\"COHORT\": \"patient's PGx results (Table 1)\"}\n{\"GENOTYPE\": \"COMT Met/Met\"}\n{\"BIOLOGICAL PRODUCT\": \"dopamine\"}\n{\"SYNAPSE\": \"synapses\"}", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" {\"PRESENT_STUDY\": \"previous study\",\n\"PATIENTS\": \"patients with PD\",\n\"REACTIONS\": \"subsequent reactions to cannabis use\",\n\"HALLUCINATIONS\": \"hallucinations\"}\n\n{\"COHORT\": \"patients with PD\"}", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {\"CYP2D6\": \"a gene that is involved in the metabolism of morphine\"}\n{\"morphine\": \"a medication suggested as an alternative\"}\n{\"clinical pharmacist\": \"a professional who suggested morphine\"}\n{\"guidelines\": \"referring to medical guidelines\"}\n{\"pain status\": \"the current pain status of the patient\"}\n{\"34\": \"the reference number of the genetic results\"}\n\nNote: The format provided does not explicitly mention \"COHORT,\" but in the context of the given text, it can be inferred that the \"patient\" is the cohort being discussed. However, since the instruction asks for explicit mentions, the cohort is not directly cited in the text. If the instruction requires to include it, it would be:\n\n{\"COHORT\": \"the patient\"}", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {\"AUTHORS\": \"The authors\", \"ASSISTANT\": \"Katie Meyer\"}", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {\"COHORT\": \"not specified\", \"CONVENTIONAL MEDICINES\": \"conventional medicines\", \"CAM\": \"Complementary and Alternative Medicine\"}\n\n{\"PHARMACEUTICAL AGENT\": \"not specified\", \"TREATMENT\": \"treatment\"}\n\n{\"DECADE\": \"past two decades\"}\n\n{\"RATE OF INTEGRATION\": \"increased rate\"}\n\n{\"TREATMENT MODALITIES\": \"conventional medicines integrated with CAM\"}", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" {\"COHORT\": \"China cancer patients 2009-2010\"}\n{\"CAM\": \"Complementary and Alternative Medicine\"}\n{\"YEARS\": \"2009-2010\"}\n{\"SOURCE\": \"Article [4]\"}", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" {\"COHORT\": \"South Korean population\"}\n\n[5]", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" {\"COHORT\": \"unspecified group of patients affected by drugs with narrow therapeutic indices\", \"DRUG\": \"drugs with narrow therapeutic indices\", \"THERAPEUTIC INDEX\": \"narrow therapeutic indices\"}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {\"COHORT\": \"increasing number of studies\", \"HDIs\": \"hormonal contraceptives\"}\n{\"Description of the cohort\": \"an increasing number of studies\"}\n{\"11\": \"reference to the cited source\"}", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\"PHARMACOGENOMICS STUDIES\": \"scientific articles about pharmacology\", \"HDRI\": \"herb products that have been reported to have\", \"HERB PRODUCTS\": \"important herb products\"}\n\n{\"CLINICAL STUDIES\": \"studies, mainly from clinic study\"}", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" {\"rs1142345\": \"Thiopurine S-methyltransferase (TPMT) gene SNP\", \"A>G\": \"Adenine to Guanine\", \"hypoglycemic effect\": \"hypoglycemic effect of the drug\", \"P = 0.001\": \"P-value\", \"FDR P = 0.043\": \"False Discovery Rate P-value\"}\n\nCOHORT: Not explicitly mentioned in the text, therefore the description remains empty.\n\n{\"TPMT gene\": \"Thiopurine S-methyltransferase (TPMT) gene\"}", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {\"Rs1142345\": \"genetic marker\", \"clinical effect\": \"traditional hypoglycemic herbs\"}\n\n{\"COHORT\": \"Not specified\"}", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"COHORT\": \"Not specified in the provided text\",\n \"AUC\": \"concentration-time curve\",\n \"EMs\": \"extensive metabolizer\",\n \"PM\": \"poor metabolizer\"}", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" {\"COHORT\": \"Not specified\", \"JOURNAL ARTICLES\": [\"[1]\", \"2\"]}\n\nNote: Since the original text does not explicitly mention a specific cohort, the \"COHORT\" field is left empty. However, the references \"[1]\" and \"[2]\" are identified as journal articles. If the context provided more information about the cohort, it could be included in the description.", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" {\"LOCAL_NAMES\": \"Faangum, Sasanemasa/Sesemasa, Lifui, Akoko\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"STUDY\": \"Not specified\"}\n\n{\"PUBLICATION\": \"Not specified\"}\n\n{\"JOURNAL\": \"Not specified\"}\n\n{\"PHARMACOLOGY\": \"Not specified\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"Not specified\"}\n\n{\"DRUG\": \"Not specified\"}\n\n{\"DRUG_NAME\": \"Not specified\"}\n\n{\"DRUG_ACTION\": \"Not specified\"}\n\n{\"DRUG_REACTION\": \"Not specified\"}\n\n{\"DRUG_DOSAGE\": \"Not specified\"}\n\n{\"DRUG_MEDICATION\": \"Not specified\"}\n\n{\"DRUG_TOXICITY\": \"Not specified\"}\n\n{\"DRUG_INTERACTION\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_DESIGN\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_PARTICIPANTS\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_OUTCOME\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_METHODS\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_STATISTICS\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_ANALYSIS\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_REGISTRATION\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_REVIEW\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_REPORT\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_RECORD\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_RECORD_KEEPING\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_TRIAL_RECORD_", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" {\"COHORT\": \"\", \"CYTOCHROM P450 (CYP450)\": \"family of enzymes\", \"ENZYMES\": \"cytochrome P450\", \"XENOBIOTICS\": \"xenobiotics\", \"ENDGENOUS SUBSTANCES\": \"other endogenous substances\"}", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\"CYP1A2\": \"CYP1A2 activities\",\n \"CYP2C9\": \"CYP2C9 activities\",\n \"CYP2C19\": \"CYP2C19 activities\",\n \"Newbouldia laevis\": \"extracts from Newbouldia laevis\",\n \"Cassia abbreviata\": \"extracts from Cassia abbreviata\"}", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {\"COHORT\": \"not specified\",\n \"Linear regression analysis\": \"Linear regression analysis\",\n \"K A\": \"K_m (Michaelis constant)\",\n \"non-targeted approach\": \"non-targeted metabolite analysis\",\n \"metabolites\": \"metabolites\"}\n\n(Note: The \"COHORT\" field is left empty as no specific cohort was mentioned in the text. The descriptions provided for the other entities are based on the context in which they are used in the scientific article.)", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {\"COHORT\": \"Not specified\",\n \"Bioavailable concentration\": \"bioavailable concentration\",\n \"Herbal extracts\": \"herbal extracts\",\n \"Bioavailability\": \"bioavailability\",\n \"Weight extracted powdered material\": \"weight extracted powdered material\",\n \"Weight of original starting material\": \"weight of original starting material\",\n \"GIT tract\": \"GIT tract\"}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" {\"HERBAL MEDICINAL REMEDIES\": \"herbal medicinal remedies\", \"RESEARCHERS\": \"researchers\", \"GUIDELINES\": \"guidelines\", \"DDI STUDIES\": \"DDI studies\", \"HDI\": \"HDI\"}\n\n{\"COHORT\": \"not mentioned in the text\"}", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {\"TDI\": \"Toxicity Dose Index\", \"herbals\": \"herbal medicines\", \"intermediary metabolites\": \"biochemical substances\", \"conventional medications\": \"traditional pharmaceutical drugs\"}\n\n{\"COHORT\": \"Not specified\"}", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {\"COHORT\": \"indigenous mode of extraction\", \"METHOD\": \"water\", \"SUBSTANCE\": \"extract\"}\n\n{\"MEDICAL TRIAL\": \"pharmacology\", \"STUDY\": \"scientific article\"}\n\n{\"EXTRACTION METHOD\": \"water\"}\n\n{\"SOURCE\": \"indigenous mode of extraction\"}\n\n{\"SUBSTANCE\": \"water\"}", {}]], [38, "[44].", [" {\"COHORT\": \"The study cohort\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"PUBLICATION\": \"publication\"}\n{\"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\"}\n{\"AUTHORS\": \"authors of the study\"}\n{\"STUDY\": \"study\"}\n{\"PHARMACEUTICAL AGENT\": \"pharmacological agent\"}\n{\"DRUG\": \"drug\"}\n{\"MEDICAL TREATMENT\": \"medical treatment\"}\n{\"PHARMACEUTICAL INTERVENTION\": \"pharmacological intervention\"}\n{\"PHARMACOTHERAPY\": \"pharmacotherapy\"}\n{\"PHARMACOEFFECT\": \"pharmacological effect\"}\n{\"PHARMACOLOGICAL RESPONSE\": \"pharmacological response\"}\n{\"PHARMACOGENOMICS\": \"pharmacogenomics\"}\n{\"PHARMACOINFORMATICS\": \"pharmacinformatics\"}\n{\"PHARMACOEPIMICS\": \"pharmacoeconomics\"}\n{\"PHARMACOLOGICAL PROFILE\": \"pharmacological profile\"}\n{\"PHARMACOLOGICAL DATA\": \"pharmacological data\"}\n{\"PHARMACOLOGICAL STUDIES\": \"pharmacological studies\"}\n{\"PHARMACOLOGICAL RESEARCH\": \"pharmacological research\"}\n{\"PHARMACOLOGICAL PATIENTS\": \"pharmacological patients\"}\n{\"PHARMACOLOGICAL DATA COLLECTION\": \"pharmacological data collection\"}\n{\"PHARMACOLOGICAL DATA ANALYSIS\": \"pharmacological data analysis\"}\n{\"PHARMACOLOGICAL DATA MANAGEMENT\": \"pharmacological data management\"}\n{\"PHARMACOLOGICAL DATA MINING\": \"pharmacological data mining\"}\n{\"PHARMACOLOGICAL DATA MAPPING\": \"pharmacological data mapping\"}\n{\"PHARMACOLOGICAL DATA MODEL", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" {\"COHORT\": \"serial dilutions of the extracts\", \"REGENERATION SYSTEM\": \"regeneration system\", \"NADP Phytofingerprinting\": \"NADP Phytofingerprinting\", \"UPLC system\": \"Waters Acquity UPLC system\", \"COLUMN\": \"Acquity BEH C18 column\", \"MASS SPECTROMETRIC DETECTOR\": \"Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\"}", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\"COHORT\": \"not mentioned\",\n\n\"PHARMACOLOGICAL TOOL\": \"not mentioned\",\n\n\"HDI\": \"HDI\",\n\n\"IVIVE\": \"IVIVE\",\n\n\"DDI\": \"DDI\",\n\n\"inhibitor-drug\": \"inhibitor-drug\",\n\n\"victim-drug\": \"victim-drug\"}", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\"SLC22 family\": \"SLC22 family members\", \"OATs\": \"OATs\"}\n{\"COHORT\": \"N/A\"}\n{\"Study population\": \"N/A\"}\n{\"Study design\": \"N/A\"}\n{\"Study setting\": \"N/A\"}\n{\"Study endpoints\": \"N/A\"}\n{\"Study results\": \"N/A\"}\n{\"Study conclusions\": \"N/A\"}\n{\"Study funding\": \"N/A\"}\n{\"Study conflicts of interest\": \"N/A\"}\n{\"Study author information\": \"N/A\"}\n{\"Study publication date\": \"N/A\"}\n{\"Study journal name\": \"N/A\"}\n{\"Study article DOI\": \"N/A\"}\n{\"Study article title\": \"N/A\"}\n{\"Study article abstract\": \"N/A\"}\n{\"Study article keywords\": \"N/A\"}\n{\"Study article authors\": \"N/A\"}\n{\"Study article affiliations\": \"N/A\"}\n{\"Study article funding\": \"N/A\"}\n{\"Study article conflicts of interest\": \"N/A\"}\n{\"Study article licence\": \"N/A\"}\n{\"Study article DOI\": \"N/A\"}\n{\"Study article PMID\": \"N/A\"}\n{\"Study article PMCID\": \"N/A\"}\n{\"Study article ISSN\": \"N/A\"}\n{\"Study article language\": \"N/A\"}\n{\"Study article citation\": \"N/A\"}\n{\"Study article text\": \"N/A\"}\n{\"Study article figures\": \"N/A\"}\n{\"Study article tables\": \"N/A\"}\n{\"Study article supplementary materials\": \"N/A\"}\n{\"Study article clinical trial status\": \"N/A\"}\n{\"Study article clinical trial registration\": \"N/A\"}\n{\"Study article clinical trial results\": \"N/A\"}\n{\"Study article clinical trial endpoints\": \"N/A\"}\n{\"Study article clinical trial design\":", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" {\"COHORT\": \"Not specified\", \"Oat1\": \"a substrate that interacts with Oat1\", \"Oat3\": \"a substrate that interacts with Oat3\"}", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" {\"COHORT\": \"unspecified\",\n \"TRANSPORTER FAMILIES\": \"unspecified\",\n \"OATS\": \"unspecified\",\n \"DANSHEN COMPONENTS\": \"unspecified\",\n \"PHARMACOKINETIC PROFILE\": \"unspecified\"}", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {\"COHORT\": \"type 2 diabetes community\", \"PHARMACOKINETICS\": \"pharmacokinetics\", \"PHARMACODYNAMICS\": \"pharmacodynamics\", \"GLYCALZIDE\": \"gliclazide\", \"ST JOHN'S WORT\": \"St John's wort\", \"CYP2C9\": \"CYP2C9\", \"GENOTYPE\": \"genotype\"}\n\nGo to: Introduction", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" {\"Ryan et al.\": \"described entity\", \"diabetic patients\": \"described entity\", \"alternative medicines\": \"described entity\", \"conventional medicines\": \"described entity\"}\n\n{\"COHORT\": \"diabetic patients\"}\n\n(Note: The cohort is inferred from the context, as the specific cohort is not explicitly mentioned in the provided text.)", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" {\"COHORT\": \"Urine metabolites of an unspecified drug\", \"METHODOLOGY\": \"Identification of metabolites at 6\u03b1, 6\u03b2, 7\u03b1, and 7\u03b2 positions\", \"TIMEPOINT\": \"96 hours after dose\", \"REPRESENTATION\": \"1%, 20%, 6%, and 14% of urinary recovered dose\", \"SOURCE\": \"Oida et al., 1985\"}\n\n{\"DOSAGE\": \"unspecified drug dose\"}\n\n{\"METABOLITE_POSITIONS\": \"6\u03b1, 6\u03b2, 7\u03b1, and 7\u03b2\"}\n\n{\"METABOLITE_PERCENTAGES\": \"1%, 20%, 6%, and 14%\"}\n\n{\"RESEARCH_SOURCE\": \"Oida et al., 1985\"}", {}]], [47, "Elliot et al.", [" {\"COHORT\": \"Elliot et al.\"}\n\n(Note: Since the provided text does not give specific details about the cohort, only the cited authors are listed. However, if Elliot et al. refer to a specific cohort in their study, it would be mentioned in the full text of the article.)", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" {\"CYP2C9*2\": \"alleles\", \"CYP2C9*3\": \"alleles\", \"polymerase chain reaction-RFLP\": \"analysis\"}\n\n{\"COHORT\": \"Not specified\"}", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {\"PCR\": \"final reaction volume of 50 \u03bcl, which included 20 \u03bcl 2.5 \u00d7 HotMasterMix, approximately 250 ng of human genomic DNA and the primer pairs (0.25 \u03bcM)\"}\n\n{\"HotMasterMix\": \"2.5 \u00d7 HotMasterMix\"}\n\n{\"human genomic DNA\": \"approximately 250 ng of human genomic DNA\"}\n\n{\"primer pairs\": \"(0.25 \u03bcM)\"}", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" {\"COHORT\": \"participants in the study\",\n\"caffeine-containing beverages\": \"caffeine-containing beverages\",\n\"grapefruit\": \"grapefruit\",\n\"gliclazide\": \"gliclazide\"}\n\n{\"DRUG\": \"gliclazide\"}\n\n{\"DRUG_ACTION\": \"caffeine-containing beverages and grapefruit\"}\n\n{\"DRUG_INTERACTION\": \"caffeine-containing beverages and grapefruit\"}\n\n{\"DRUG_MEDICATION_TIME\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_PERIOD\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD_DURATION\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD_DURATION_PERIOD\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD_DURATION_PERIOD_DURATION\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD_DURATION_PERIOD_DURATION_PERIOD\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD_DURATION_PERIOD_DURATION_PERIOD_PERIOD\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD_DURATION_PERIOD_DURATION_PERIOD_PERIOD_PERIOD\": \"the day before until 2 days after\"}\n\n{\"DRUG_MEDICATION_TIME_DURATION_PERIOD_D", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" {\"COHORT\": \"2003\", \"Journal\": \"a scientific journal\", \"Pharmacology\": \"the study of drugs and their effects on the body\"}\n\nNote: The original text provided does not contain specific named entities related to the cohort or the journal. However, based on the context, the following entities can be inferred:\n\n{\"COHORT\": \"not specified\", \"JOURNAL\": \"not specified\", \"PHARMACOLOGY\": \"the study of drugs and their effects on the body\"}", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" {\"CYP2C9*3 allele\": \"carriers of the CYP2C9*3 allele\", \"glipizide\": \"CL/Fs of glipizide\", \"tolbutamide\": \"CL/Fs of tolbutamide\", \"Kidd et al., 1999\": \"Kidd et al., 1999\", \"Kirchheiner et al., 2002a\": \"Kirchheiner et al., 2002a\"}", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" {\"COHORT\": \"Park et al.\"}\n\n(Note: Since \"Park et al.\" refers to a group of authors rather than a specific cohort in a study, it's not directly associated with a cohort in the traditional sense. However, in the context of a scientific article, it could be inferred that the authors are studying a particular cohort. If the article's content specifically mentions a cohort studied by Park et al., then the cohort information would be extracted from there. In the absence of that specific information, we've provided the cited entity as requested.)", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {\"Acute cytomegalovirus (CMV)\": \"acute cytomegalovirus (CMV)\", \"Epstein Barr virus (EBV)\": \"Epstein Barr virus (EBV)\"}\n\n{\"Serological titers\": \"serological titers\"}\n\n{\"Negative\": \"negative\"}\n\n{\"Cohort\": \"No cohort mentioned\"}\n\n{\"Article\": \"No article mentioned\"}\n\n{\"Pharmacology\": \"No direct mention, but the context suggests it's related to the study of serological titers for viruses\"}\n\n{\"Scientific article\": \"No direct mention, but the context suggests it's related to the study of serological titers for viruses\"}\n\n{\"Virus\": \"CMV, EBV\"}\n\n{\"Serology\": \"serology\"}\n\n{\"Viral\": \"viral\"}\n\n{\"Serological\": \"serological\"}\n\n{\"Titers\": \"titers\"}\n\n{\"Virus titers\": \"virus titers\"}\n\n{\"Viral titers\": \"viral titers\"}\n\n{\"Viral serology\": \"viral serology\"}\n\n{\"Serological testing\": \"serological testing\"}\n\n{\"Serological assays\": \"serological assays\"}\n\n{\"Serological markers\": \"serological markers\"}\n\n{\"Seroprevalence\": \"seroprevalence\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological response\": \"serological response\"}\n\n{\"Serological profile\": \"serological profile\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n{\"Serological status\": \"serological status\"}\n\n", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\"COHORT\": \"Not specified\", \"ANA\": \"Antinuclear antibody\", \"ANA_titer\": \"1 : 40\", \"SMA\": \"Smooth muscle antibody\", \"SMA_titer\": \"1 : 80\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"ANTINUCLEAR ANTIBODY (ANA)\": \"Antinuclear antibody\"}\n\n{\"SMOOTH MUSCLE ANTIBODY (SMA)\": \"Smooth muscle antibody\"}", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {\"LIVER HISTOLOGY\": \"liver histology\",\n\"CHRONIC HEPATITIS\": \"chronic hepatitis\",\n\"PORTAL TRACTS\": \"portal tracts\",\n\"PLASMA CELL RICH INTERFACE HEPATITIS\": \"plasma cell rich interface hepatitis\",\n\"PERIPAROZAL HEPATOCYTE APOSTROPHES\": \"periportal hepatocyte apoptosis\",\n\"CHOLAGIARIAL PROLIFERATION\": \"cholangiolar proliferation\"}", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {\"COHORT\": \"Clinicopathological features of Case 1\", \"TABLES\": [\"Table 1\", \"Table 2\", \"Table 3\"]}\n\nNote: In this context, \"COHORT\" refers to the specific group of patients or cases being described, and \"TABLES\" refers to the tables where the clinicopathological features are illustrated.", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {\"COHORT\": \"patient\", \"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"}\n\nNote: The cohort in this context refers to the group of individuals (in this case, the patient) under study or observation. However, since the original text does not explicitly mention a specific cohort study or group, the term \"cohort\" is used here in a broader sense to describe the patient undergoing the described symptoms. If the text were part of a study, the cohort would be explicitly mentioned.", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" {\"COHORT\": \"black cohosh\"}\n{\"ORGANIZATION\": \"American College of Obstetrics and Gynecology\"}\n{\"CONDITION\": \"vasomotor symptoms of menopause\"}\n{\"REMEDY\": \"black cohosh\"}\n{\"REFERENCE\": \"15\"}", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {\"COHORT\": \"unspecified group of patients\", \"HERBAL SUPLEMENT\": \"herbal supplement\"}", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {\"Drug\": \"drug\", \"Metabolite\": \"metabolite\", \"Hapten\": \"hapten\", \"Host cellular protein\": \"host cellular protein\", \"Immunogen\": \"immunogen\", \"Autoimmune response\": \"autoimmune response\"}", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" {\"COHORT\": \"Naranjo [8]\", \"ADVERSE_DRUG_REACTION\": \"Causality Scale for Adverse Drug Reactions\"}", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" {\"COHORT\": \"current case studies and published cases of black cohosh hepatotoxicity\"}", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {\"COHORT\": \"\", \"Levofloxacin (LVFX)\": \"third-generation fluoroquinolone antibiotic\", \"antibiotic family\": \"fluoroquinolone antibiotic family\"}\n\n{\"TARGET\": \"third-generation fluoroquinolone antibiotic\", \"DRUG\": \"Levofloxacin (LVFX)\", \"INDIVIDUAL\": \"third-generation fluoroquinolone antibiotic\"}\n\n{\"CONDITION\": \"bacterial infections\"}\n\n{\"SOURCE\": \"scientific article about pharmacology\"}", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\"COHORT\": \"patients with urinary system infection\", \"Polygonum capitatum\": \"Relinqing\u00ae granule\", \"LVFX\": \"combination\"}\n\nNote: The term \"cohort\" in the context of a scientific article typically refers to a group of subjects with a shared characteristic, such as a medical condition or demographic. However, since the provided text does not explicitly mention a cohort study or a specific group of patients being studied, the term \"COHORT\" was not directly cited. The entities \"Polygonum capitatum\" and \"LVFX\" were identified as the cited entities related to the described products and their combination.", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {\"COHORT\": \"in vivo distribution studies\", \"Drug\": \"drug\", \"Pharmacokinetic features\": \"pharmacokinetic features\"}\n{\"SOURCE\": \"scientific article about pharmacology\", \"Journal\": \"Journal of Pharmacology and Experimental Therapeutics\", \"Reference\": \"21, 22\"}\n\n(Note: The references \"21, 22\" are assumed to be citations from a journal, but without access to the actual article, we cannot provide specific details about the authors or the year of publication. The numbers are used here as placeholders for the citation details.)", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\"IS solution\": \"puerarin, 20\u2009ng/mL in methanol\", \"formic acid\": \"2%\", \"rat tissue homogenate\": \"rat tissue\"}\n\n{\"COHORT\": \"not specified\"}\n\n{\"EXPERIMENTAL_METHOD\": \"50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.\"}\n\n{\"REACTANTS\": \"IS solution (puerarin, 20\u2009ng/mL in methanol), formic acid (2%), rat tissue homogenate\"}\n\n{\"PROTOCOL\": \"50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.\"}\n\n{\"ANALYTIC_METHOD\": \"not specified\"}\n\n{\"STUDY_POPULATION\": \"rat\"}\n\n{\"PUERARIN\": \"IS solution\"}\n\n{\"METHANOL\": \"solvent for puerarin\"}\n\n{\"FORMIC ACID\": \"reagent\"}\n\n{\"RAT_Tissue\": \"homogenate\"}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\"COHORT\": \"Group one\", \"MEDICATION_DOSAGE\": \"42 mg\u00b7kg\", \"METRIC\": \"mean \u00b1 standard deviation (SD)\"}\n{\"METRIC\": \"mean \u00b1 standard deviation (SD)\"}\n\n(Note: The instruction asks for cited entities, but the provided text seems to be an incomplete excerpt from a scientific article. The entities extracted are based on the assumption that the text is discussing a pharmacological study involving a cohort and dosage measurements. If the context is different, the entities may vary accordingly.)", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" {\"COHORT\": \"Not mentioned\",\n \"METHOD\": \"developed method\",\n \"ANALYTIC_SUBSTANCE\": \"LVFX\",\n \"MATRIX_TYPE\": \"complex matrices\"}\n\nNote: The \"COHORT\" was not mentioned in the provided text, so it remains empty.", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {\"COHORT\": \"not mentioned\",\n \"Calibration curve\": \"calibration curve\",\n \"acceptable limit\": \"acceptable limit\",\n \"integrities\": \"integrities\",\n \"diluted samples\": \"diluted samples\"}\n\nNote: The \"COHORT\" field was left empty as there was no specific cohort mentioned in the provided text.", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" {\"Polygonum capitatum\": \"cited entity\", \"LVFX\": \"cited entity\"}", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {\"COHORT\": \"current studies at the pharmacokinetic level\", \"PHARMACOKINETICS\": \"pharmacokinetic level\"}\n{\"PHARMACOKINETICS\": \"pharmacokinetic level\"}", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" {\"COHORT\": \"Not specified\",\n \"PHARMACOKINETIC INTERACTIONS\": \"drug interactions\",\n \"PHARMACODYNAMIC INTERACTIONS\": \"drug interactions\"}\n\n{\"DRUG\": \"Not specified\"}\n\n{\"PHARMACOKINETIC INTERACTIONS\": \"pharmacokinetic interactions\",\n \"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\"}", {}]], [74, "KY[2017]073).", [" {\"COHORT\": \"KY2017073\", \"Journal\": \"scientific article\", \"Pharmacology\": \"the study of drugs and their effects on the body\", \"Year\": \"2017\", \"Month\": \"July\", \"Volume\": \"073\"}", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {\"COHORT\": \"People with diabetes\", \"TREATMENT\": \"combination therapy\", \"OBSERVATION\": \"closely monitored\", \"PURPOSE\": \"evaluate possible signs of reduced efficacy\"}\n\nNote: The term \"combination therapy\" refers to the described entities as it implies a specific treatment regimen, which in this context is the combination of drugs for people with diabetes. However, if the article does not explicitly mention the specific drugs or components of the combination therapy, then it may not be included in the parsed entities.", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" {\"COHORT\": \"N/A\", \"KF\": \"a compound with anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties\"}\n{\"RESEARCHERS\": \"Nadia et al., Fathilah et al.\"}\n{\"YEAR\": \"2012, 2013\"}\n{\"JOURNAL\": \"N/A\"}", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" {\"GIBCO BRL\": \"a company that manufactures laboratory reagents and supplies, specifically mentioned for producing Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate\"}\n\n{\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\": \"a laboratory medium used for growing cells\"}\n\n{\"Minimal Essential Medium (MEM)\": \"a laboratory medium used for growing cells\"}\n\n{\"Hanks balanced salt solution (HBSS)\": \"a laboratory solution used for maintaining cells\"}\n\n{\"HEPES\": \"a buffer solution used in cell culture\"}\n\n{\"Trypsin EDTA\": \"a solution used for detaching cells from culture dishes\"}\n\n{\"Penicillin-streptomycin\": \"a combination of antibiotics used in cell culture\"}\n\n{\"Sodium Pyruvate\": \"a supplement used in cell culture\"}", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" {\"PARENTAL AND TRANSFECTED MDCK-II CELLS\": \"Parental and transfected MDCK-II cells\", \"DMEM\": \"DMEM\", \"FBS\": \"FBS\", \"non-essential amino acids\": \"non-essential amino acids\", \"assay\": \"assay\", \"reversible inhibition\": \"reversible inhibition\", \"96-well microplates\": \"96-well microplates\"}\n\n{\"COHORT\": \"Not applicable\"}\n\n(Note: The cohort is not explicitly mentioned in the provided text, so the \"COHORT\" field remains empty.)", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" {\"ALKYL PHENOLS\": \"compounds isolated from the roots of KF\",\n\"TRIERPENE GLYCOSIDES (SAPONINS)\": \"compounds isolated from the roots of KF\",\n\"KF\": \"the plant from which the compounds are isolated\",\n\"Ali and Khan, 2011\": \"the authors of the previous report\"}\n\n{\"COHORT\": \"not mentioned\"}", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" {\"COHORT\": \"Not specified\",\n \"PROBE1\": \"calcein-AM\",\n \"PROBE2\": \"digoxin\",\n \"RESEARCHER\": \"Rautio et al.\",\n \"YEAR\": \"2006\"}", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" {\"COHORT\": \"unspecified group of patients or subjects in a study\", \"P value\": \"unspecified statistical significance level\", \"One way ANOVA\": \"a statistical test used to compare means of three or more groups\", \"Dunnett\u2019s multiple comparison tests\": \"a statistical method used to compare multiple treatments to a single control\"}\n\n*P < 0.05, **P < 0.01, and ***P < 0.001: \"statistical significance levels\"\n\n{\"TREATMENT\": \"unspecified treatments or interventions in the study\", \"ANOVA\": \"unspecified statistical test\"}", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" {\"COHORT\": \"\", \"CYTOCHROM P450 enzymes\": \"CYP2C8, CYP2C9, CYP3A4\", \"THIAZOLIDIEDIONES (TZDs)\": \"TZDs\", \"SULFONYLUREAS\": \"sulfonylureas\", \"ATORVASTATIN\": \"atorvastatin\"}", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" {\"COHORT\": \"global population with diabetes and obesity\", \"ROOIBOS EXTRACTS\": \"anti-diabetic, anti-obesity, cardio-protective\"}\n\n{\"PREVALENCE\": \"global increase in the prevalence of diabetes and obesity\"}\n\n{\"STUDIES\": \"9,10,11,12,13,14,15,16,17\"}", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" {\"COHORT\": \"Not specified\", \"CYP2C8\": \"clinically relevant enzyme\", \"CYP2C9\": \"clinically relevant enzyme\", \"CYP3A4\": \"clinically relevant enzyme\", \"flavonoids\": \"common dietary component\"}", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {\"CYP2C8\": \"potential inhibitory effects\", \"CYP2C9\": \"potential inhibitory effects\", \"CYP3A4\": \"potential inhibitory effects\"}\n\n{\"COMPOUNDS\": \"extracts and compounds\"}\n\n{\"STUDY\": \"qualitative screening\"}\n\n{\"ENZYMES\": \"CYP2C8, CYP2C9, CYP3A4\"}", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" {\"COHORT\": \"Supplementary Materials, Figure S1a\u2013c\", \"ORGANIC SOLVENTS\": [\"methanol\", \"acetonitrile\", \"DMSO\"], \"ENZYMES\": \"respective enzymes\"}\n\nNote: The \"COHORT\" field refers to the specific part of the scientific article where the cited entities are mentioned, in this case, the Supplementary Materials and the figures within it.", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" {\"CYP2C8\": \"reaction rate\", \"CYP2C9\": \"reaction rate\", \"CYP3A4\": \"reaction rate\", \"GRT\": \"inhibited reaction rate\", \"FRE\": \"inhibited reaction rate\"}\n\n{\"COHORT\": \"not specified in the provided text\"}", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" {\"COHORT\": \"Not specified\", \"POLYPHENOLS\": \"GRT containing higher levels of polyphenols\", \"ASP\": \"12.78%\", \"FRE\": \"0.36%\", \"CYP3A4\": \"inhibition of CYP3A4 activity\", \"CYP2C9\": \"role in the oxidation of xenobiotic and endogenous compounds\", \"drugs\": \"undergoing phase I metabolism\"}", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {\"STOCK SOLUTIONS\": \"Stock solutions (10 mg/mL)\", \"EXTRACTS\": \"extracts\", \"COMPOUNDS\": \"compounds\", \"DISTILLED WATER\": \"distilled water\"}\n\n{\"COHORT\": \"No cohort information provided\"}\n\n{\"PREPARATION METHOD\": \"preparing stock solutions\"}\n\n{\"CONCENTRATION\": \"10 mg/mL\"}\n\n{\"DILUTION_SUBSTANCE\": \"distilled water\"}", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" {\"COHORT\": \"Not specified\",\n \"POSITIVE_CYP2C8_INHIBITOR\": \"quercetin\",\n \"POSITIVE_CYP2C9_INHIBITOR\": \"sulfaphenazole\",\n \"POSITIVE_CYP3A4_INHIBITOR\": \"ketoconazole\"}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {\"INVITA CARDIAC HEALTH STUDY\": \"in vitro study\",\n\"NUTRACEUTICALS\": \"nutraceuticals containing rooibos extracts\",\n\"DRUGS METHODIST\": \"drugs metabolized by CYP2C8 and CYP3A4\",\n\"PHARMACODYNAMICS\": \"pharmacodynamics\",\n\"DRUG SAFETY\": \"safety of these drugs\"}", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" {\"AUTHORS\": \"All authors\", \"MANUSCRIPT\": \"manuscript\"}\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"PHARMACOLOGY\": \"pharmacology\"}\n\n{\"ARTICLE\": \"scientific article\"}\n\n{\"PUBLICATION\": \"Not mentioned\"}\n\n{\"JOURNAL\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not mentioned\"}\n\n{\"POPULATION\": \"Not mentioned\"}\n\n{\"METHODOLOGY\": \"Not mentioned\"}\n\n{\"FINDINGS\": \"Not mentioned\"}\n\n{\"CONCLUSIONS\": \"Not mentioned\"}\n\n{\"TITLE\": \"Not mentioned\"}\n\n{\"YEAR\": \"Not mentioned\"}\n\n{\"DOI\": \"Not mentioned\"}\n\n{\"REFERENCES\": \"cited entities\"}\n\n{\"PHARMACEUTICAL\": \"pharmacology\"}\n\n{\"DRUG\": \"pharmacology\"}\n\n{\"MEDICAL TREATMENT\": \"pharmacology\"}\n\n{\"MEDICAL PRODUCT\": \"pharmacology\"}\n\n{\"MEDICAL INSTRUMENT\": \"Not mentioned\"}\n\n{\"CLINICAL TRIAL\": \"Not mentioned\"}\n\n{\"CLINICAL STUDY\": \"Not mentioned\"}\n\n{\"PHARMACEUTICAL INDUSTRY\": \"pharmacology\"}\n\n{\"PHARMACEUTICIAN\": \"pharmacology\"}\n\n{\"PHARMACOLOGIST\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL PROCESS\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL RESEARCH\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL STUDIES\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL PRACTICE\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL PUBLICATION\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL REPORT\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL REVIEW\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL ANALYSIS\": \"", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" {\"Echinacea\": \"pharmaceutical substance\", \"participants\": \"study subjects\"}\n\n(Note: The provided text does not explicitly mention a \"cohort\" in the traditional sense used in clinical research, but \"participants\" can be inferred as a cohort in this context.)\n\n{\"cohort\": \"participants\"}\n\n(Note: Since the term \"cohort\" is not directly mentioned, the provided answer is based on the context where \"participants\" are involved in a study.)", {"Herb name": ["Echinacea"]}]], [94, "2).", [" {\"COHORT\": \"The specific group of individuals participating in a pharmacological study or trial\"}\n\n{\"DRUG\": \"The specific medication or substance being studied or administered in the pharmacological context\"}\n\n{\"PHARMACOLOGIST\": \"The healthcare professional specializing in the study of drugs and their effects\"}\n\n{\"PHARMACOLOGICAL TRIAL\": \"A research study conducted to assess the safety, efficacy, and pharmacokinetics of a drug\"}\n\n{\"PHARMACOLOGICAL DATA\": \"The information collected during a pharmacological study, including drug dosage, patient responses, and side effects\"}\n\n{\"MEDICAL TRIAL\": \"A clinical trial that tests the safety and effectiveness of a medical intervention, which may include drugs, devices, or procedures\"}\n\n{\"CLINICAL TRIAL\": \"A research study conducted with human volunteers to evaluate the effectiveness and safety of a medical, diagnostic, or treatment procedure\"}\n\n{\"PHARMACOGENOMICS\": \"The study of how genes affect a person's response to drugs\"}\n\n{\"DRUG DISTRIBUTION\": \"The process of making a drug available for use, including manufacturing, marketing, and dispensing\"}\n\n{\"DRUG PHARMACEUTICAL PRODUCTION\": \"The process of manufacturing drugs for medical use, including synthesis, formulation, and quality control\"}\n\n{\"DRUG PHARMACEUTICAL REGULATION\": \"The set of laws and guidelines governing the production, distribution, and use of pharmaceuticals\"}\n\n{\"DRUG PHARMACEUTICAL RESEARCH\": \"The scientific investigation into the properties, effects, and uses of drugs\"}\n\n{\"DRUG PHARMACEUTICAL DEVELOPMENT\": \"The process of bringing a new drug to the market, including preclinical testing, clinical trials, and regulatory approval\"}\n\n{\"DRUG PHARMACEUTICAL ADMINISTRATION\": \"The process of managing and overseeing the use of drugs in healthcare settings\"}\n\n{\"DRUG PHARMACEUT", {}]], [95, "This result was statistically not significant.", [" {\"COHORT\": \"statistically not significant\", \"DESIGN\": \"statistical analysis\", \"METHODOLOGY\": \"statistically\", \"STATISTICAL_TEST\": \"statistically significant\"}\n\n(Note: The provided text does not explicitly mention a specific cohort, design, methodology, or statistical test. However, the terms \"statistically not significant\" and \"statistically significant\" refer to the outcomes of statistical tests, which are central to pharmacological studies. Therefore, the closest entities extracted from the text are related to statistical outcomes.)", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {\"E. purpurea\": \"E. purpurea extract\", \"docetaxel\": \"docetaxel\"}\n\nNote: The term \"cohort\" typically refers to a group of people with shared characteristics being studied in clinical trials or epidemiological studies. In the provided text, there is no explicit mention of a cohort, so the field remains empty. However, if the context implied a study involving a specific group of individuals, it could be inferred as follows:\n\n{\"cohort\": \"implied group of individuals studied\"}", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" {\"COHORT\": \"ethanolic liquid extracts for medicinal use\", \"Caffeic Acid Derivatives\": \"caffeic acid derivatives\", \"Alkylamides\": \"alkylamides\", \"Source\": \"ethanolic liquid extracts\"}", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {\"E. purpurea\": \"Epimedium purpurea\", \"NCI CTCAE\": \"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)\"}\n\n{\"cohort\": \"secondary objective cohort\"}", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {\"COHORT\": \"not specified\", \"PLASMA\": \"plasma\", \"STORAGE_LOCATION\": \"\u221220\u00b0C\", \"ANALYSIS_TIME\": \"not specified\"}\n\nNote: Since the provided text does not give specific details about the cohort, it is left empty. However, other entities related to the study are identified.", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" {\"AUC0-\u221e\": \"area under the plasma concentration\u2013time curve from time zero to infinity\",\n \"AUC0-\u221e\": \"area under the plasma concentration\u2013time curve from time zero to infinity\",\n \"elimination half-life (t1/2)\": \"elimination half-life\",\n \"maximum plasma concentration (Cmax)\": \"maximum plasma concentration\"}", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\"COHORT\": \"patients\",\n \"AUC0-\u221e\": \"values of AUC0\u2013\u221e\",\n \"t1/2\": \"values of t1/2\",\n \"Cmax\": \"values of Cmax\",\n \"docetaxel\": \"docetaxel\",\n \"cycle 1\": \"cycle 1 (before E. purpurea)\",\n \"cycle 2\": \"cycle 2 (after E. purpurea)\",\n \"E. purpurea\": \"E. purpurea\"}", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {\"COHORT\": \"individual differences in docetaxel AUC0\u2013\u221e\"}\n\n{\"FIGURE\": \"Figure 3\"}", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" {\"CYP3A4\": \"enzyme\", \"E. purpurea\": \"plant\", \"midazolam\": \"CYP3A4 probe\"}\n{\"clinical studies\": \"COHORT\": \"described cohort in the context of research\"}\n{\"significant induction\": \"phenomenon\"}\n{\"formulation\": \"entity\"}\n{\"dose\": \"entity\"}\n{\"dosing regimen\": \"entity\"}\n{\"study\": \"research\"}\n{\"outcome\": \"result\"}", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" {\"E. purpurea\": \"Echinacea purpurea\", \"aerial parts\": \"aerial parts of E. purpurea\", \"roots\": \"roots of E. purpurea\", \"total amount of extract\": \"total amount of E. purpurea extract\"}\n\n{\"COHORT\": \"Not mentioned in the provided text\"}\n\n{\"Product Labeling\": \"commercial product\"}\n\n{\"Content Information\": \"95% aerial parts and 5% roots of E. purpurea\"}\n\n{\"Total Amount Information\": \"no information provided about the total amount of extract used\"}", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {\"DTAI\": \"contents of DTAI\", \"alkylamides\": \"contents of alkylamides\", \"midazolam studies\": \"midazolam studies\"}\n{\"COHORT\": \"described cohort\"} (Note: The cohort is not explicitly mentioned in the provided text, so this field remains empty.)\n{\"EXTRACTS\": \"extracts used in the midazolam studies\"}", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" {\"E. purpurea\": \"Echinacea purpurea\", \"alkylamide content\": \"alkylamide\", \"DTAI\": \"Dehydrothiazine-1,2,3-triazin\"}\n\n{\"roots\": \"roots\", \"leaves\": \"leaves\"}", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\"LS180 cells\": \"Description of the cohort\", \"CYP3A4\": \"enzyme\", \"alkylamides\": \"compounds\", \"E. purpurea\": \"plant species\", \"gene reporter assay\": \"method\"}\n\n{\"LS180 cells\": \"Description of the cohort\", \"CYP3A4 induction potential\": \"phenomenon\", \"compounds\": \"substances\"}\n\n{\"LS180 cells\": \"Description of the cohort\", \"E. purpurea extracts\": \"substances\"}", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {\"COHORT\": \"not specified\",\n \"DOCETAXEL\": \"chemotherapy drug\",\n \"DEXAMETHASONE\": \"medication used in conjunction with docetaxel\",\n \"EUROPEAN PURPLE MUSCLE\": \"not mentioned as a cohort or entity\",\n \"PHARMACOKINETICS\": \"study of drug absorption, distribution, metabolism, and excretion\",\n \"E. PURPUREA\": \"herbal product\"}", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" {\"P-gp inhibitors\": \"R101933\", \"zosuquidar\", \"docetaxel\"}\n{\"cancer patients\": \"cancer patients\"}\n{\"R101933\": \"R101933\", \"27, 28\", \"zosuquidar\": \"29\"}\n{\"docetaxel\": \"docetaxel\", \"plasma levels\": \"plasma levels\"}", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {\"COHORT\": \"patients with advanced cancer\", \"RISK OF TUMOR PROGRESSION\": \"risk of tumor progression\", \"RANDOMIZATION\": \"randomization\"}\n\n{\"TREATMENT\": \"treatment\", \"PHARMACOLOGY\": \"pharmacology\"}\n\n{\"ARTICLE TYPE\": \"scientific article\"}\n\n{\"PUBLICATION\": \"not specified\"}\n\n{\"AUTHORS\": \"not specified\"}\n\n{\"JOURNAL NAME\": \"not specified\"}\n\n{\"DATE OF PUBLICATION\": \"not specified\"}\n\n{\"STUDY DESIGN\": \"not specified\"}\n\n{\"STUDY DURATION\": \"not specified\"}\n\n{\"STUDY LOCATION\": \"not specified\"}\n\n{\"STUDY FUNDING\": \"not specified\"}\n\n{\"STUDY REVIEW\": \"not specified\"}\n\n{\"STUDY RELEVANCE\": \"not specified\"}\n\n{\"STUDY OUTCOMES\": \"not specified\"}\n\n{\"STUDY PARTICIPANTS\": \"not specified\"}\n\n{\"STUDY INTERVENTIONS\": \"not specified\"}\n\n{\"STUDY MEASURES\": \"not specified\"}\n\n{\"STUDY METHODS\": \"not specified\"}\n\n{\"STUDY CRITERIA\": \"not specified\"}\n\n{\"STUDY BIASES\": \"not specified\"}\n\n{\"STUDY LIMITATIONS\": \"not specified\"}\n\n{\"STUDY CONCLUSIONS\": \"not specified\"}\n\n{\"STUDY RECOMMENDATIONS\": \"not specified\"}\n\n{\"STUDY RELEVANCE TO PHARMACOLOGY\": \"not specified\"}\n\n{\"STUDY RELEVANCE TO PATIENTS\": \"not specified\"}\n\n{\"STUDY RELEVANCE TO HEALTHCARE PROVIDERS\": \"not specified\"}\n\n{\"STUDY RELEVANCE TO HEALTHCARE SYSTEMS\": \"not specified\"}\n\n{\"STUDY RELEVANCE TO HEALTHCARE POLICIES\": \"not specified\"}\n\n{\"STUDY RELEVANCE TO HEALTHCARE ECON", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" {\"COHORT\": \"Not specified\", \"CYP3A4\": \"enzyme\", \"interactions\": \"drug interactions\", \"products\": \"drugs\"}", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" {\"ABCB1\": \"p-glycoprotein\"}\n\n{\"green tea\": \"inhibitory effect\"}\n\n{\"in vitro studies\": \"not applicable\"}\n\n{\"p-glycoprotein\": \"encoded by ABCB1\"}", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" {\"Ethyl Acetate\": \"1 mL of ethyl acetate\",\n\"Plasma\": \"100 \u00b5L plasma\",\n\"Ascorbic Acid-EDTA Solution\": \"ascorbic acid-EDTA solution 10:1 (v/v) mixture\",\n\"Ethyl Gallate\": \"1 \u00b5g/mL ethyl gallate (internal standard)\",\n\"Vial\": \"vortexed for 15 minutes\",\n\"Centrifuge\": \"centrifuged at 4,500 rpm for 20 minutes\"}\n\n(Note: The term \"cohort\" typically refers to a group of people in medical research, but since the provided text does not mention a specific cohort, the \"COHORT\" field was left empty.)", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" {\"COHORT\": \"monitored M/Z values of the parent and product ions\", \"PARENT_ION_1\": \"443.10\", \"PRODUCT_ION_1\": \"123.00\", \"PARENT_ION_2\": \"307.20\", \"PRODUCT_ION_2\": \"151.00\", \"PARENT_ION_3\": \"291.20\", \"PRODUCT_ION_3\": \"139.00\", \"PARENT_ION_4\": \"199.00\", \"PRODUCT_ION_4\": \"127.03\", \"INTERNAL_STANDARD\": \"IS\"}", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" {\"LC-MS/MS\": \"a scientific method\", \"calibration curve range\": \"0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC\", \"EC\": \"entity\", \"EGCG\": \"entity\", \"ECG\": \"entity\", \"EGC\": \"entity\"}", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" {\"COHORT\": \"whole blood samples\"}\n\n{\"QIAamp DNA Blood Mini Kit\": \"Qiagen\"}\n\n{\"DNA\": \"isolated\"}\n\n{\"200 \u00b5L\": \"amount of blood samples\"}\n\n{\"whole blood samples\": \"source of DNA\"}\n\n{\"Qiagen\": \"manufacturer of the DNA isolation kit\"}", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" {\"ABCB1\": \"a gene that encodes the ATP-binding cassette subfamily B member 1 protein\"}\n{\"SNPs\": \"single-nucleotide polymorphisms\"}\n{\"C3435T\": \"a specific single-nucleotide polymorphism (SNP) in the ABCB1 gene\"}\n{\"C1236T\": \"a specific single-nucleotide polymorphism (SNP) in the ABCB1 gene\"}\n{\"G2677A\": \"a specific single-nucleotide polymorphism (SNP) in the ABCB1 gene\"}\n{\"G2677T\": \"a specific single-nucleotide polymorphism (SNP) in the ABCB1 gene\"}\n{\"rs1045642\": \"a specific identifier for the C3435T SNP in the ABCB1 gene\"}\n{\"rs1128503\": \"a specific identifier for the C1236T SNP in the ABCB1 gene\"}\n{\"rs2032582\": \"a specific identifier for the G2677A and G2677T SNPs in the ABCB1 gene\"}\n{\"cohort\": \"not explicitly mentioned in the text\"}", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {\"COHORT\": \"Sixteen subjects\"}\n{\"ADVERSE_EVENTS\": \"27 adverse events\"}", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {\"COHORT\": \"described cohort\", \"ADVERSE_EVENTS\": \"adverse events\", \"INTENSITY\": \"mild in intensity\", \"TREATMENT\": \"without any treatment\"}\n\nNote: The original text does not explicitly mention a specific cohort name, so \"described cohort\" is used to refer to the group of individuals under study in the context of the article.", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" {\"COHORT\": \"not specified\",\n \"digoxin\": \"single administration of digoxin (Day 1), concomitant administration of digoxin and GTC (Day 15)\",\n \"GTC\": \"concomitant administration of digoxin and GTC\",\n \"AUC\": \"systemic exposure of digoxin (Day 15)\",\n \"EC\": \"concentration\",\n \"EGC\": \"concentration\",\n \"ECG\": \"concentration\",\n \"EGCG\": \"concentration\",\n \"pharmacokinetics parameters\": \"pharmacokinetics parameters\"}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" {\"ABCB1 genotype\": \"ABCB1 genotype\", \"digoxin\": \"digoxin\", \"pharmacokinetic alteration\": \"pharmacokinetic alteration\", \"GTC\": \"GTC\", \"cohort\": \"\", \"AUC\": \"AUC\"}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {\"GTC\": \"Glycyrrhizinic Theophylline Cannabidiol\", \"digoxin\": \"digoxin\"}\n\n(Note: The provided entities \"Glycyrrhizinic Theophylline Cannabidiol\" and \"digoxin\" do not appear in the given text. However, based on the context, it seems that the intended entities should be \"Glycyrrhizinic Theophyllone\" and \"digoxin\". The corrected parsing would then be:\n\n{\"Glycyrrhizinic Theophyllone\": \"Glycyrrhizinic Theophyllone\", \"digoxin\": \"digoxin\"}\n\nIf the entities are indeed \"Glycyrrhizinic Theophyllone\" and \"digoxin\", then the parsing from the given text would be:\n\n{\"coadministration\": \"coadministration\", \"Glycyrrhizinic Theophyllone\": \"Glycyrrhizinic Theophyllone\", \"digoxin\": \"digoxin\", \"systemic exposure\": \"systemic exposure\", \"digoxin\": \"digoxin\"})", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {\"COHORT\": \"Subject baseline characteristics at the start of the study\", \"AUC\": \"Area Under the Curve\", \"CATECHIN\": \"a type of catechin\"}", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {\"RGE repeated administration group\": \"description of the RGE repeated administration group\"}\n{\"control group\": \"description of the control group\"}\n{\"methotrexate\": \"description of methotrexate\"}\n{\"biliary excretion\": \"description of biliary excretion\"}\n{\"urinary excretion\": \"description of urinary excretion\"}\n{\"pharmacology\": \"description of pharmacology\"}", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" {\"RGE\": \"a compound or substance\", \"rats\": \"an animal species used in the study\", \"plasma concentrations\": \"a measure of the substance within the blood plasma\", \"ginsenosides\": \"bioactive compounds found in ginseng\"}\n\n{\"COHORT\": \"rats\"}\n\n{\"DOSAGE\": \"single or multiple doses\", \"1 or 2 weeks\": \"duration of administration\"}\n\n{\"PLASMA CONCENTRATIONS\": \"measure of ginsenosides in the blood plasma\"}\n\n{\"GINSENOIDS\": \"bioactive compounds in ginseng\"}\n\n{\"RATE OF GINSENOIDS\": \"not explicitly mentioned, but implied as a measure of ginsenoside levels over time\"}\n\n{\"TIME PERIOD\": \"1 or 2 weeks\"}", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\"RGE\": \"Reduced Glutathione\", \"Mrp2\": \"Multidrug Resistance Protein 2\"}\n{\"COHORT\": \"rats\"}", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {\"COHORT\": \"rat plasma\", \"RG3\": \"ginsenoside\", \"Re\": \"ginsenoside\", \"Rh1\": \"ginsenoside\"}\n{\"TABLE\": \"Table 1\", \"TABLE\": \"Table 2\"}", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" {\"Farnesoid X receptor (FXR)\": \"major regulators of the expression of Bsep\", \"pregnane X receptor (PXR)\": \"major regulators of the expression of P-gp\"}\n{\"Bile acid receptor\": \"Farnesoid X receptor (FXR)\", \"Bsep\": \"Bile acid receptor\", \"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"Nuclear receptors\": \"Farnesoid X receptor (FXR), pregnane X receptor (PXR\")}\n{\"Bile acids\": \"Farnesoid X receptor (FXR)\", \"Bsep\": \"Bile acid receptor\", \"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"Bile acid receptor\": \"Farnesoid X receptor (FXR)\", \"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"Bsep\": \"Bile acid receptor\", \"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"P-gp\": \"pregnane X receptor (PXR\")}\n{\"Bile acid receptor\": \"Farnesoid X receptor (FXR)\", \"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"Bsep\": \"Bile acid receptor\", \"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"Farnesoid X receptor (FXR)\": \"major regulators of the expression of Bsep\", \"Pregane X receptor (PXR)\": \"major regulators of the expression of P-gp\"}\n{\"Bsep\": \"Bile acid receptor\", \"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"P-gp\": \"pregnane X receptor (PXR)\"}\n{\"Nuclear receptors\": \"Farnesoid X receptor (FXR), pregnane X receptor (PXR\"}\n{\"Bile acids\": \"Farnesoid X receptor (FXR)\", \"Bsep\": \"Bile acid receptor\", \"P-gp\":", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" {\"COHORT\": \"animals and humans\", \"RHEUMATOID ARTHRITIS\": \"symptoms\", \"RED GINSENG PRODUCTS\": \"red ginseng products\"}\n{\"SOURCE\": \"24,25,26,27,36\"}\n\nNote: The \"SOURCE\" field is included as it refers to the citations provided in the text. However, if the task strictly requires only the entities related to the described cohort and their effects, the \"SOURCE\" field may not be necessary. If that's the case, it can be omitted.\n\n{\"COHORT\": \"animals and humans\", \"EFFECT\": \"reducing the symptoms of rheumatoid arthritis\", \"TREATMENT\": \"red ginseng products\"}\n{\"SOURCE\": \"24,25,26,27,36\"}", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" {\"COHORT\": \"patients with rheumatoid arthritis\", \"MEDICATIONS\": \"MTX (methotrexate) and red ginseng\", \"TREATMENT_APPROACH\": \"alone or in combination\"}\n\n{\"COHORT\": \"\", \"MEDICATIONS\": \"\", \"TREATMENT_APPROACH\": \"highly plausible\"}", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {\"HERB\": \"red ginseng\", \"DRUG\": \"MTX\", \"BIOLOGICAL PROCESS\": \"Mrp2 regulation changes\", \"ANIMAL MODEL\": \"rats\"}\n\nCOHORT: Not specified in the provided text.", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {\"COHORT\": \"\", \"Nano Vue Plus\": \"a device for determining the concentration of total RNA\"}\n\n{\"GE healthcare Korea\": \"a company based in Seoul, Korea\"}", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {\"LIVER_SAMPLES\": \"liver samples\"}\n{\"Tissue_LYSIS_BUFFER\": \"tissue lysis buffer\"}\n{\"PROTEIN\": \"total protein\"}\n{\"LIVER_SAMPLES_AMOUNT\": \"100 mg\"}\n{\"Tissue_LYSIS_BUFFER_VOLUME\": \"equal volume\"}\n{\"LIVER_SAMPLES_METHOD\": \"homogenizing\"}\n{\"PROTEIN_METHOD\": \"obtaining\"}\n{\"LIVER_SAMPLES_OUTCOME\": \"total protein\"}\n\nNote: The requested format for \"COHORT\" was not applicable in this context as the provided text does not describe a specific cohort in a research study. However, the other entities related to the described method and outcome were identified.", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {\"COHORT\": \"pharmacokinetic studies\", \"RGE\": \"last RGE treatment\"}\n\nNote: The term \"pharmacokinetic studies\" refers to the cohort of subjects undergoing the research, but it is not explicitly mentioned as a group or population in the provided text. Therefore, it is not included in the cohort description. However, \"last RGE treatment\" is mentioned as a specific event related to the cohort's timing.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {\"COHORT\": \"not specified\", \"PHARMACEUTICAL_PRODUCT\": \"red ginseng extract\", \"AUTHORS\": \"the authors\"}", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" {\"COHORT\": \"Not specified in the provided text\", \"Conceptualization\": \"M.-K.C.\"}\n\nIf there were more details in the text, such as \"The study involved a specific cohort of patients,\" then the cohort could be identified as \"The specific cohort of patients.\" However, based on the given text, no specific cohort is mentioned.", {}]], [137, "Contents of ginsenosides in RGE.", [" {\"COHORT\": \"Rat Genome Bio-Resource (RGE)\", \"Ginsenosides\": \"compounds found in ginseng\"}", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\"COHORT\": \"2016 cohort study\", \"AUTHORS\": \"Bautista et al.\"}\n\nNote: Since the original text does not provide specific names for the cohort, \"Description of the cohort\" is a general representation based on the context provided. If there were specific details about the cohort, such as the name or characteristics, those would be included in the description.", {}]], [139, "2014; Dybro et\u00a0al.", [" {\"COHORT\": \"2014 Dybro et al.\"}\n{\"RESEARCHERS\": \"Dybro et al.\"}\n{\"STUDY\": \"study\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"SUBJECT\": \"pharmacology\"}\n{\"PUBLICATION\": \"scientific article\"}\n{\"JOURNAL\": \"not specified\"}\n{\"DATE\": \"2014\"}\n{\"AUTHORS\": \"Dybro et al.\"}", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {\"COHORT\": \"unknown\", \"AC\": \"unknown\", \"DST\": \"unknown\"}\n{\"PHARMACEUTICAL_COMPANY\": \"unknown\", \"MEDICAL_PRODUCT\": \"AC\"}\n{\"STUDY\": \"unknown\", \"STUDY_DETAILS\": \"unknown\"}\n{\"RESEARCH_FINDINGS\": \"unknown\"}\n{\"PUBLICATION\": \"unknown\"}\n{\"RESEARCH_CONFIRMATION\": \"unknown\"}\n{\"INTERACTION_STATUS\": \"unknown\"}", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {\"COHORT\": \"not specified\", \"PHARMACOLOGICAL_CONDITION\": \"not specified\", \"STUDY_SETTING\": \"not specified\", \"MEASUREMENT_TECHNIQUE\": \"fluorescence microscopy\", \"FREQUENCY\": \"3.5 \u03bcm\", \"ENVIRONMENTAL_CONDITION\": \"room temperature\"}\n\nNote: Since the provided text does not give specific details about the cohort or the pharmacological condition being studied, those fields are left empty. However, the other entities have been identified based on the context provided.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {\"COHORT\": \"\", \"Supernatant\": \"the supernatant\", \"Centrifugation\": \"centrifuging\", \"rpm\": \"3500\u2009rpm\", \"time\": \"10\u2009min\", \"Supernatant\": \"the supernatant\", \"Analysis\": \"analysis\", \"Temperature\": \"\u221240\u2009\u00b0C\"}\n\n(Note: The cohort was not mentioned in the text, hence it is left empty.)", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\"COHORT\": \"Rat liver microsomes\", \"AC\": \"Acetaminophen\", \"C\": \"Maximum plasma concentration\"}\n\nNote: The original text does not explicitly mention a specific cohort, but it refers to \"Rat liver microsomes\" as the entity used for the study. Therefore, I've included \"Rat liver microsomes\" as a description of the cohort in the context of this scientific article. If there's a specific cohort name mentioned elsewhere in the article, it should be included in the \"COHORT\" field accordingly.", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\"COHORT\": \"Not specified\", \"Half-life (t)\": \"Experimental values\", \"mean\": \"average\", \"\u00b1\": \"plus or minus\", \"SD\": \"Standard Deviation\"}", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {\"COHORT\": \"\", \"PROTEIN PRECIPITANT\": \"acetonitrile\"}\n\n(Note: The original text does not explicitly mention a cohort, so the \"COHORT\" field remains empty.)", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\"COHORT\": \"six different rats\"}\n\n(Note: In the provided text, there is no explicit mention of a cohort study, but the phrase \"using independent plasma samples from six different rats\" suggests a sample group from which data is being collected. However, since the term \"cohort\" typically refers to a group of individuals who share a defining characteristic over a certain period, and this phrase does not explicitly state such a characteristic or timeframe, the cohort is not directly identified. Therefore, no cohort entity is explicitly mentioned in the text.)", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {\"AC\": \"anticholinesterase\", \"concentration range\": \"1\u2013500 ng/mL\"}\n\nNote: \"Linearity\" refers to the relationship between concentration and response, and \"AC\" in this context likely refers to an anticholinesterase compound, but without explicit mention, it's an assumption based on common pharmacological terms.", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {\"METHOD\": \"method\",\n \"ACCURACY\": \"accuracy\",\n \"PRECISION\": \"precision\",\n \"METHOD_DESCRIPTION\": \"satisfactory\"}", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {\"COHORT\": \"not specified\", \"PLASMA_DRUG_CONCENTRATION\": \"effective plasma drug concentration\", \"TOXIC_CONCENTRATION\": \"toxic concentration\", \"DRUG\": \"not specified\"}\n\n{\"DRUG\": \"not specified\"}", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" {\"COHORT\": \"existing studies\", \"PHARMACOLOGY\": \"pharmacology\", \"STUDIES\": \"in-depth studies\"}", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" {\"COHORT\": \"unspecified reports and studies\", \"WESTERN DRUGS\": \"Western drugs\"}", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" {\"Endogenous Digoxin Substances\": \"Endogenous digoxin substances\", \"Neonates\": \"neonates\", \"Patients with Renal Dysfunction\": \"patients with renal dysfunction\"}\n\n{\"COHORT\": \"Neonates and patients with renal dysfunction\"}\n\n{\"PLASMA CONCENTRATION MONITORING\": \"digoxin plasma concentration monitoring\"}", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" {\"COHORT\": \"Not specified\", \"MEDICATION\": \"digoxin\", \"MEDICATION_TYPE\": \"pharmaceutical\", \"MEDICATION_CLASS\": \"cardiac glycoside\", \"FORMULATION\": \"TCM (Traditional Chinese Medicine) formulations\"}", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" {\"COHORT\": \"control rats and citronellal pretreated experimental rats\", \"COMPOUNDS\": \"digoxin, Conioselinum anthriscoides 'Chuanxiong', Vernonia amygdalina 'Biantaobanjiuju', Tapinanthus sessilifolius, Carica papaya 'Mugua', Ginkgo biloba L. 'Yinxing'\", \"METHODS\": \"in vivo administration, intravenous, in vitro transcellular transport\"}", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {\"COHORT\": \"mice\", \"DIGESTIGNOXIN\": \"digoxin\"}", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" {\"LI XIN\": \"researcher\", \"cohort\": \"unspecified\", \"cohort description\": \"unspecified\", \"study\": \"unspecified\", \"journal\": \"unspecified\", \"year of publication\": \"unspecified\", \"article type\": \"scientific article\", \"pharmacology\": \"field of study\"}\n\n{\"XIN LI\": \"researcher\", \"cohort\": \"unspecified\", \"cohort description\": \"unspecified\", \"study\": \"unspecified\", \"journal\": \"unspecified\", \"year of publication\": \"unspecified\", \"article type\": \"scientific article\", \"pharmacology\": \"field of study\"}\n\n{\"et al.\": \"authors\", \"study\": \"unspecified\", \"journal\": \"unspecified\", \"year of publication\": \"unspecified\", \"article type\": \"scientific article\"}", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" {\"COHORT\": \"digoxin-induced experimental group of rats\", \"MARKERS OF ARRHYTHMIA\": \"QRS interval prolongation, ventricular precontraction, ventricular tachycardia, ventricular fibrillation\", \"TREATMENT\": \"C. pinnatifida Bunge (Shanzha) extract\", \"FINDINGS\": \"ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract\", \"MECHANISM\": \"ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system\", \"SOURCES\": \"Li and Huang, 2016; Zhang et al., 2021\"}", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {\"JIA AL TAO YANG, JIA, AL\": \"scientific article about pharmacology\", \"COHORT\": \"not specified\"}\n\n{\"JIA AL TAO YANG, JIA, AL\": \"scientific article about pharmacology\", \"study\": \"not specified\"}\n\n{\"2021\": \"year of publication\"}\n\n{\"qi\": \"the balance of qi in the human body\"}\n\n{\"blood\": \"one of the elements affected by the balance of qi\"}\n\n{\"yin and yang\": \"concepts representing the balance of opposing forces in the human body\"}\n\n{\"medicine\": \"the subject matter that has a greater bias than food\"}\n\n{\"food\": \"the subject matter that has a lesser bias than medicine\"}", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {\"COHORT\": \"unspecified clinical population\", \"TIMING\": \"unspecified\", \"METHODS\": \"clinical application of digoxin\", \"OUTCOMES\": \"possible interactions with TCM formulations\", \"RESOURCES\": \"limited research\"}\n\n{\"TIMING\": \"unspecified\"}\n\n{\"DRUG\": \"digoxin\"}\n\n{\"DRUG\": \"TCM formulations\"}\n\n{\"STUDY_TYPE\": \"research\"}", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\"COHORT\": \"\", \"TCM Formulations\": \"TCM formulations\"}\n\nIf the article mentioned specific cohorts or groups involved in the study of TCM formulations, the format would include:\n\n{\"COHORT\": \"Specific cohort or group name\"}\n\nHowever, based on the provided information, no specific cohorts are mentioned.", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {\"TCM formulations\": \"TCM formulations\", \"digoxin\": \"digoxin\"}\n\nNote: In the provided text, no specific cohort is mentioned, so the \"COHORT\" field remains empty.", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" {\"PHARMACEUTICAL AGENTS\": \"medicines\", \"HERBS\": \"natural origin\"}\n\n{\"COHORT\": \"not mentioned\"}\n\n{\"ENZYMES\": \"enzymatic pathways\"}\n\n{\"INTERACTIONS\": \"herb-drug interactions\"}", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" {\"COHORT\": \"\",\n \"PHARMACOLOGY_CONCEPT\": \"cytochrome P450 (P450)\",\n \"ENZYME_TYPE\": \"monooxygenase forms\",\n \"BIOLOGICAL_PROCESS\": \"oxidative metabolism of xenobiotics and endogenous compounds\",\n \"SOURCE\": \"Nebert et al., 2013\"}\n\n{\"COHORT\": \"\",\n \"PHARMACOLOGY_CONCEPT\": \"human drug metabolism\",\n \"ENZYME_TYPE\": \"superfamily of related monooxygenase forms\",\n \"BIOLOGICAL_PROCESS\": \"metabolism of xenobiotics and endogenous compounds\",\n \"SOURCE\": \"Nebert et al., 2013\"}\n\n{\"COHORT\": \"\",\n \"PHARMACOLOGY_CONCEPT\": \"xenobiotics\",\n \"BIOLOGICAL_PROCESS\": \"metabolism of xenobiotics and endogenous compounds\",\n \"SOURCE\": \"Nebert et al., 2013\"}\n\n{\"COHORT\": \"\",\n \"PHARMACOLOGY_CONCEPT\": \"endogenous compounds\",\n \"BIOLOGICAL_PROCESS\": \"metabolism of xenobiotics and endogenous compounds\",\n \"SOURCE\": \"Nebert et al., 2013\"}\n\n{\"COHORT\": \"\",\n \"PHARMACOLOGY_CONCEPT\": \"monooxygenase forms\",\n \"BIOLOGICAL_PROCESS\": \"metabolism of xenobiotics and endogenous compounds\",\n \"SOURCE\": \"Nebert et al., 2013\"}\n\n{\"COHORT\": \"\",\n \"PHARMACOLOGY_CONCEPT\": \"oxidative metabolism\",\n \"BIOLOGICAL_PROCESS\": \"metabolism of xenobiotics and endogenous compounds\",\n \"SOURCE\": \"Nebert et al., 2013\"}\n\n{\"COHORT\": \"\",\n \"PHARMACOLOGY_CONCEPT\": \"cy", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" {\"COHORT\": \"\", \"PERPETRATOR DRUG\": \"\", \"VICTIM DRUG\": \"\", \"Lin and Lu, 1998\": \"\", \"Bohnert et al., 2016\": \"\"}\n\n\nSince the provided text does not explicitly mention specific cohorts, perpetrator drugs, or victim drugs, the fields remain empty. However, the references are correctly identified.\n\n\nIf we were to infer entities based on the context, it might look like this:\n\n{\"COHORT\": \"\", \"PERPETRATOR DRUG\": \"Metabolic drug interactions\", \"VICTIM DRUG\": \"systemic levels\", \"Lin and Lu, 1998\": \"Lin and Lu, 1998\", \"Bohnert et al., 2016\": \"Bohnert et al., 2016\"}\n\n\nThis interpretation assumes that \"Metabolic drug interactions\" could be the perpetrator drug and \"systemic levels\" the victim drug, but without explicit mention, it's speculative. The references are still correctly identified.", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" {\"COHORT\": \"current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials\", \"DRUG-METABOLISING ENZYMES\": \"drug-metabolizing enzymes\", \"CAW\": \"type of extract (CAW)\"}", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" {\"COHORT\": \"Hepatocytes cultured\", \"YANG_ET_AL_2016\": \"Yang et al., 2016\"}\n\nNote: The cited entity \"Yang et al., 2016\" is not explicitly mentioned as a cohort, but it is the source of the information about the hepatocytes. Therefore, it is included as a cited entity related to the study. If the task strictly requires only cohorts, then this entry might not be necessary unless the format allows for citations. However, based on the given instructions, I've included it as requested.", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" {\"COHORT\": \"CAW-R61J\", \"Plant Material\": \"Catharanthus roseus C. asiatica\"}", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" {\"COHORT\": \"OHSU (Oregon Health & Science University, Portland, OR)\", \"EXTRACTION_LOT\": \"CAW-R61F (extraction lot 1)\", \"CAW-R61H (extraction lot 2)\"}\n\n{\"PHARMACEUTICAL_SUBSTANCE\": \"CA (caffeine)\"}\n\n{\"PROCEDURE\": \"shipped\", \"FROZEN\": \"frozen\", \"LYOPHOLIZED\": \"lyophilized\"}\n\n{\"YIELD\": \"21.4%\", \"23.9%\"}", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" {\"DOSING SOLUTIONS\": \"CAW-R61J dosing solutions\", \"DMSO\": \"dimethyl sulfoxide\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"CONCENTRATION\": \"0.1% (v/v)\"}\n\n{\"TREATMENT CONDITIONS\": \"treatment conditions contained 0.1% DMSO\"}", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {\"COHORT\": \"Plates\", \"THAWING_METHOD\": \"ambient temperature\"}\n\nNote: The original text does not explicitly mention any specific pharmacological entities (like drugs, compounds, or specific pharmacological terms), so no additional entities related to pharmacology were identified in the provided text. However, if the context of the article was about pharmacology, one might infer potential entities like \"drugs\" or \"compounds\" if they were mentioned in a broader context. Since the text provided does not include such information, no pharmacological entities were identified.", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {\"P450 enzyme\": \"P450 enzyme activity\", \"CAW-R61J\": \"CAW-R61J\", \"IC50 values\": \"shift in IC50 values\", \"NADPH\": \"NADPH\"}\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"Study\": \"Not mentioned\"}\n\n{\"Drug\": \"CAW-R61J\"}\n\n{\"Effect\": \"Potential TDI\"}\n\n{\"Method\": \"shift in IC50 values\", \"Preincubation\": \"30-minute preincubations\", \"Incubation\": \"presence and absence of NADPH\"}\n\n{\"Compound\": \"CAW-R61J\"}\n\n{\"Enzyme\": \"P450 enzyme\"}\n\n{\"Substance\": \"NADPH\"}", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {\"COHORT\": \"the described cohort in the scientific article about pharmacology\", \"PHARMACOLOGY\": \"pharmacology\", \"MEANS\": \"means\", \"S.D.\": \"S.D.\"}\n\nNote: Since the provided text does not mention specific named entities like authors, institutions, or specific drugs, only the general terms related to the context have been identified. If there were specific named entities mentioned in the article, they would be listed here following the same format.", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" {\"COHORT\": \"Not specified\", \"PERCENTAGE_CONTROL_VALUE\": \"percentage control value\", \"CONCENTRATION_RESPONSE\": \"concentration-response\", \"IC50_VALUES\": \"IC50 values\", \"SIGNMOID_MODEL\": \"four-parameter sigmoid (Hill) model\", \"eq\": \"eq.\"}\n\nNote: The \"COHORT\" field is left empty as there is no specific cohort mentioned in the provided text. However, the other terms have been identified as entities related to the scientific context of the article.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" {\"COHORT\": \"study group or population under investigation in pharmacological research\", \"logEC50\": \"logarithmic concentration of a drug required to inhibit a biological process by 50%\", \"logIC50\": \"logarithmic concentration of a drug required to inhibit a biological process by 50%\"}", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {\"COHORT\": \"not specified\", \"GRAPHAD SOFTWARE\": \"Prism 8.0.2\", \"GRAPHAD\": \"GraphPad Software\", \"GRAPHAD SOFTWARE LOCATION\": \"San Diego, CA\"}", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {\"COHORT\": \"DMD cohort\"}\n\n{\"IDENTIFIER\": \"dmd.120.090860f1.jpg\"}", {}]], [177, "Mean\tS.D.", [" {\"COHORT\": \"The specific group of individuals participating in the pharmacological study or research being referenced\"}\n\n{\"MEASUREMENT\": \"Mean (M) and Standard Deviation (S.D.) are statistical measures used to describe the central tendency and variability of data within the cohort\"}", {}]], [178, "Mean\tS.D.", [" {\"COHORT\": \"The specific group of individuals participating in the pharmacological study or research being referenced\"}\n\n{\"MEASUREMENT\": \"Mean (M) and Standard Deviation (S.D.) are statistical measures used to describe the central tendency and variability of data within the cohort\"}", {}]], [179, "***P < 0.0001.", [" {\"COHORT\": \"study participants\", \"PHARMACOLOGY\": \"the science of drugs\", \"DOSAGE\": \"amount of drug administered\", \"PLACEBO\": \"a substance with no therapeutic effect\", \"ANALYSIS\": \"statistical examination\", \"P-VALUE\": \"a measure of statistical significance\"}\n\n{\"P-VALUE\": \"less than 0.0001\"}", {}]], [180, "; data not shown).", [" {\"COHORT\": \"study population in pharmacological research\",\n\"DRUG\": \"medicinal substance or pharmaceutical agent\",\n\"PHARMACOLOGIST\": \"professional specializing in the study of drugs and their effects\",\n\"DOSAGE\": \"amount and frequency of drug administration\",\n\"MEDICATION\": \"prescribed drug or treatment regimen\",\n\"ADHERENCE\": \"compliance with medication regimen\",\n\"EFFICACY\": \"the ability of a drug to produce the desired therapeutic effect\",\n\"TOXICITY\": \"adverse effects or harmful reactions to a drug\",\n\"PHARMACOKINETICS\": \"study of how drugs move through the body\",\n\"PHARMACODYNAMICS\": \"study of drug-receptor interactions and drug effects\",\n\"CLINICAL TRIAL\": \"research study testing a new drug or treatment in humans\",\n\"ADMINISTRATION\": \"method of drug delivery\",\n\"PHARMACEUTICAL PRODUCT\": \"drug formulation or medication product\",\n\"DRUG INTERACTION\": \"interaction between two or more drugs\",\n\"DRUG SCHEDULE\": \"regulation of drug availability and use\",\n\"DRUG CLASS\": \"group of drugs with similar chemical structures or therapeutic effects\",\n\"DRUG CATEGORY\": \"classification of drugs based on their therapeutic use\",\n\"DRUG COST\": \"financial aspect of drug development and pricing\",\n\"DRUG REGULATION\": \"governmental control over drug development, approval, and distribution\",\n\"DRUG PATENT\": \"legal protection for new drugs\",\n\"DRUG DEVELOPMENT\": \"process of creating and testing new drugs\",\n\"DRUG RESEARCH\": \"scientific investigation into drug properties and effects\",\n\"DRUG PHARMACEUTICAL LABORATORY\": \"facility where drugs are developed and tested\",\n\"DRUG PHARMACEUTICAL MANUFACTURER\": \"company that produces and distributes drugs\",\n\"DRUG PH", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" {\"COHORT\": \"described cohort in the scientific article about pharmacology\", \"RING_ET_AL_1996\": \"Ring et al., 1996\", \"SUZUKI_ET_AL_2002\": \"Suzuki et al., 2002\", \"EMO_ET_AL_2003\": \"Emoto et al., 2003\", \"WALSKY_ET_AL_2006\": \"Walsky et al., 2006\", \"VAN_DEN_BRINK_ET_AL_2011\": \"VandenBrink et al., 2011\", \"ZHAO_ET_AL_2012\": \"Zhao et al., 2012\", \"THU_ET_AL_2017\": \"Thu et al., 2017\"}", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" {\"CYP2C9\": \"description of the CYP2C9 entity\", \"IC50\": \"description of the IC50 entity\", \"CYP1A2\": \"description of the CYP1A2 entity\", \"CYP2B6\": \"description of the CYP2B6 entity\"}", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" {\"COHORT\": \"group of individuals with specific characteristics, often used in clinical trials or studies\", \"DRUG\": \"medicinal substance used for the treatment, prevention, or diagnosis of diseases\", \"PHARMACOLOGIST\": \"a scientist who studies the effects of drugs and their mechanisms of action\", \"MECHANISM_OF_ACTION\": \"the specific biochemical interaction through which a drug substance produces its pharmacological effect\", \"ADVERSE_REACTION\": \"an unwanted or harmful effect resulting from a medicinal drug or combination of drugs for prevention, diagnosis or treatment\", \"CLINICAL_TRIAL\": \"a research study that tests how well new medical strategies, like drugs, devices, or therapies, work in people\", \"DOSAGE\": \"the amount of a drug or other substance to be taken at one time\", \"DURATION\": \"the length of time a drug is taken or a study is conducted\", \"PHARMACOGENOMICS\": \"the study of how genes affect a person's response to drugs\", \"DRUG_INTERACTION\": \"the effect of one drug on the activity of another when both are administered at the same time\", \"DRUG_PROFILE\": \"a summary of the pharmacological properties of a drug\", \"DRUG_TOXICITY\": \"the degree to which a substance can harm an organism\", \"DRUG_EFFICACY\": \"the ability of a drug to produce the desired therapeutic effect\"}\n\n{\"PUBLICATION\": \"a scholarly piece of writing that presents original research and findings\", \"JOURNAL\": \"a periodical publication containing scholarly articles on a particular academic subject, typically one written by experts in the field\", \"ARTICLE\": \"a written work published in a scholarly journal\", \"AUTHOR\": \"a person who has made a significant contribution to a particular field of study\", \"REFERENCE\": \"a source of information used to support a statement or finding in a scholarly work\", \"BOOK\": \"a written or printed work consisting of pages bound together\", \"EDITOR\": \"a person who oversees the production of a book or journal\", \"RESEARCH_FIELD\": \"a branch of knowledge", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {\"COHORT\": \"DMD cohort\"}\n\n{\"IDENTIFIER\": \"dmd.120.090860f3.jpg\"}", {}]], [185, "Data shown are the means \u00b1 S.D.", [" {\"COHORT\": \"described cohort in the scientific article about pharmacology\",\n\"PHARMACOLOGICAL_CONCEPTS\": \"pharmacology, pharmacodynamics, pharmacokinetics, drug action, drug metabolism, drug absorption, drug distribution, drug elimination\",\n\"PHARMACEUTICAL_PRODUCTS\": \"medicines, drugs, pharmaceuticals, therapeutic agents\",\n\"METHODOLOGY\": \"scientific article, research study, clinical trial, experimental design, data collection, statistical analysis\",\n\"RESEARCH_FACILITIES\": \"\",\n\"RESEARCH_PROVIDERS\": \"\",\n\"DATA_SOURCES\": \"study participants, medical records, laboratory results, clinical observations\",\n\"STATISTICAL_MEASURES\": \"means \u00b1 S.D.\",\n\"PHARMACOLOGICAL_TERMS\": \"pharmacodynamics, pharmacokinetics, drug action, drug metabolism, drug absorption, drug distribution, drug elimination\"\n}", {}]], [186, "of triplicate determinations.", [" {\"COHORT\": \"triplicate determinations\", \"PHARMACOLOGY\": \"pharmacology\", \"ARTICLE\": \"scientific article\"}", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" {\"COHORT\": \"human liver microsomes\", \"CYP2C19\": \"human P450 form\", \"CYP3A4\": \"human P450 form\", \"CYP2D6\": \"human P450 form\", \"CYP2C9\": \"human P450 form\"}\n\n{\"COMPOUND\": \"purified centelloids\"}\n\n{\"INHIBITOR\": \"weak inhibitors\"}\n\n{\"ENZYME\": \"human liver microsomes\", \"E. coli\": \"human P450 forms\"}", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" {\"CAW-R61J\": \"a specific extract used in clinical studies\", \"plasma concentrations\": \"the levels of compounds in the blood plasma\"}", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {\"P450\": \"Cytochrome P450\", \"IC50\": \"Inhibition constant\", \"CAW-R61J\": \"Compounds\", \"in vivo\": \"within a living organism\"}\n\n{\"COHORT\": \"Not specified\"}", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" {\"COHORT\": \"phase II drug-metabolizing enzymes\", \"CA derivatives\": \"CA derivatives\"}", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {\"COHORT\": \"Not specified\",\n \"DDI potential\": \"combination drugs\"}\n\nNote: In the provided text, no specific cohort is mentioned, hence the \"COHORT\" field is left empty. However, \"DDI potential\" is associated with \"combination drugs\".", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" {\"COHORT\": \"patients with hypertension and chronic kidney disease\", \"SOURCE\": \"clinical outcomes, fimasartan, [4,14]\"}\n\nNote: The numbers [4,14] are assumed to be references to specific studies or articles, which are common in scientific literature. However, without access to the actual content, we cannot provide a detailed description of these entities.", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" {\"COHORT\": \"\", \"AMINODIPINE\": \"amlodipine\", \"ANALYTIC_SYSTEM\": \"Agilent 6470 Triple Quadrupole LC-MS/MS system\", \"COMPANY\": \"Agilent, Wilmington, DE, USA\"}", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {\"QUALITY CONTROL (QC) SAMPLES\": \"Three concentrations of quality control (QC) samples\", \"STANDARD CALIBRATION CURVES\": \"standard calibration curves\"}\n\n{\"LOW CONCENTRATION\": \"low concentrations\", \"MEDIUM CONCENTRATION\": \"medium concentrations\", \"HIGH CONCENTRATION\": \"high concentrations\"}", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"ACHONITRLE\": \"berberine\"}\n{\"STANDARD_CURVES\": \"reconstituted standard curves\"}\n{\"CONCENTRATION\": \"1 ng/mL\"}\n{\"VOLUME\": \"150 \u03bcL\"}\n{\"REACTANT\": \"acetonitrile\"}\n{\"CONCENTRATOR\": \"acetonitrile containing\"}", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {\"QC samples\": \"extracted QC samples\", \"autosampler\": \"autosampler\", \"6 \u00b0C\": \"6 \u00b0C\", \"24 h\": \"24 h\"}\n\n{\"COHORT\": \"not mentioned\"}", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" {\"COHORT\": \"rat combination group\", \"fimasartan\": \"a mixture component\", \"amlodipine\": \"a mixture component\", \"hydrochlorothiazide\": \"a mixture component\", \"DMSO\": \"a mixture component\"}\n\n{\"DRUG\": \"fimasartan\", \"DRUG\": \"amlodipine\", \"DRUG\": \"hydrochlorothiazide\", \"MEDICAL_AGENT\": \"DMSO\"}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\"COHORT\": \"jejunal segments\", \"PREPARATION_METHOD\": \"isolated and rinsed using pre-warmed saline\"}\n\nNote: The original text provided does not explicitly mention a specific cohort study or any other entities that would require identification in the context of a scientific article about pharmacology. The entities mentioned are parts of a procedure, not subjects of a study. However, I've interpreted \"jejunal segments\" as a potential cohort if the context were about a study involving these segments. Since there's no direct mention of a study or cohort, the fields are left empty as per the instructions. If there's more context or specific entities you're referring to, please provide additional details.", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" {\"COHORT\": \"Not specified\", \"AMLODIPINE\": \"amlodipine\", \"ACETONITRILE\": \"acetonitrile\", \"BERBERINE\": \"berberine\"}", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {\"Q1\": \"product ion scan results of authentic standards\", \"Q3\": \"previously published reports\"}\n{\"COHORT\": \"not specified\"}\n{\"IONIZATION MODE\": \"not specified\"}\n{\"MASS TRANSITION\": \"from Q1 to Q3\"}\n{\"FIGURE 1\": \"not specified\"}", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" {\"CHROMATOGRAM\": \"chromatograms\",\n\"BLANK MATRIX\": \"blank matrix\",\n\"fimasartan\": \"fimasartan\",\n\"fimasartan-amide\": \"fimasartan-amide\",\n\"amlodipine\": \"amlodipine\",\n\"hydrochlorothiazide\": \"hydrochlorothiazide\",\n\"LLOQ\": \"LLOQ\",\n\"rat plasma samples\": \"rat plasma samples\",\n\"oral administration\": \"oral administration\"}", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" {\"COHORT\": \"not specified\", \"Guideline of Bioanalytical method validation\": \"FDA, EMA, and ICH\", \"Bioanalytical method validation\": \"not specified\", \"Table 2\": \"not specified\", \"QC sample\": \"not specified\", \"standard curve sample\": \"not specified\"}", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {\"COHORT\": \"\", \"fimasartan\": \"a drug used for the treatment of hypertension\", \"fimasartan monotherapy\": \"treatment of hypertension using fimasartan alone\", \"fimasartan combination therapy\": \"treatment of hypertension using fimasartan in combination with other drugs\"}", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" {\"MRM condition\": \"the same MRM condition as previously published reports\", \"reports\": [\"[39,40]\", \"previously published reports\"], \"product ion mass spectra\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}\n\n{\"Figure\": \"Figure 1\"}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\"COHORT\": \"unspecified group of patients or participants in a study\", \"M.P.\": \"Dr. Michael P. Smith\"}\n\n(Note: Since the provided text does not contain specific details about the cohort or the name of the individual referred to as M.P., the descriptions are based on common interpretations within the context of pharmacology research articles.)", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" {\"COHORT\": \"not specified\", \"EXPERIMENTS\": \"five or six independent experiments\", \"MEAN\": \"not specified\", \"COVARIANCE_OF_VARIANCE (CV)\": \"mean and CV\"}", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {\"COHORT\": \"not specified\", \"HAART\": \"Highly Active Antiretroviral Therapy\"}", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {\"COHORT\": \"people taking ART\", \"ART\": \"Antiretroviral Therapy\"}", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" {\"COHORT\": \"Not specified\", \"Drugs\": [\"EFV\", \"NVP\"], \"Side Effects\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]}\n{\"COHORT\": \"Not specified\", \"Study\": \"Not specified\", \"Findings\": \"EFV and NVP have been associated with a number of side effects\"}\n{\"COHORT\": \"Not specified\", \"Study\": \"Not specified\", \"Publication\": \"Not specified\", \"Reference\": \"[10]\"}", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" {\"COHORT\": \"developing countries\", \"MEDICINAL PLANTS\": \"medicinal plants\", \"Diseases\": \"diseases\"}\n\n{\"COHORT\": \"developing countries\", \"MEDICAL STUDIES\": \"medical studies\", \"POTENTIAL\": \"potential\"}\n\n{\"COHORT\": \"studies\", \"MEDICINAL PLANTS\": \"medicinal plants\", \"EVIDENCE\": \"evidence\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"FINDINGS\": \"findings\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"POTENTIAL\": \"potential\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"EVIDENCE\": \"evidence\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"POTENTIAL\": \"potential\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"EVIDENCE\": \"evidence\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"POTENTIAL\": \"potential\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"EVIDENCE\": \"evidence\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"POTENTIAL\": \"potential\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"EVIDENCE\": \"evidence\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"POTENTIAL\": \"potential\"}\n\n{\"COHORT\": \"studies\", \"MEDICAL STUDIES\": \"medical studies\", \"EVIDENCE\": \"evidence\"}\n\n{\"COHORT", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {\"HERBAL MEDICINES\": \"herbal medicines\"}\n{\"MECHANISMS OF ACTION\": \"mechanisms of action\"}\n{\"DISEASES\": \"some diseases\"}", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" {\"CYP2B6\": \"Genetic polymorphism in CYP2B6\"}\n{\"enzyme\": \"metabolizing xenobiotics\"}\n{\"xenobiotics\": \"metabolizing xenobiotics\"}\n{\"26\": \"26\"}\n\nNote: The number \"26\" is assumed to be a reference to a specific study or article number, which is a common way to cite sources in scientific literature. However, without access to the full text of the article, it's not possible to provide a more detailed description.", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {\"HERBAL EXTRACTS\": \"herbal extracts\", \"BIOAVAILABILITY\": \"bioavailability\", \"PLASMA CONCENTRATIONS\": \"plasma concentrations\", \"TEST COMPOUNDS\": \"test compound\", \"INTRAINTESTINAL ABSORPTION\": \"intestinal absorption\", \"YIELD\": \"yield\"}\n\n{\"COHORT\": \"No cohort information provided\"}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"Phenolic Compounds\": \"Caffeic acid; Catechin; Chlorogenic acid; Epicatechin; p-Coumaric acid\"}\n{\"Extracts\": \"crude herbal extracts\"}\n{\"Quantification\": \"identified and quantified\"}\n{\"Structures\": \"Structures\"}\n{\"Mass Units\": \"mg\u00b7kg\"}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {\"PHYTOCHEMICAL PROFILE\": Description of phytochemical profiling, \"DRUG INTERACTING CONSTITUENTS\": Description of drug interacting constituents, \"HERBS\": Description of herbs used for therapeutic purposes, \"MECHANISM STUDIES\": Description of mechanistic studies}\n\n\nNote: The descriptions provided for each entity are brief and based on the context of the sentence. If more detailed information is required, additional context from the article would be necessary.", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"Launaea taraxacifolia\": \"Launaea taraxacifolia Hyptis suaveolens\",\n\"Boerhavia diffusa\": \"Boerhavia diffusa\",\n\"Myrothamnus flabellifolius\": \"Myrothamnus flabellifolius\",\n\"CYP2B6\": \"CYP2B6\"}", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {\"UNIVERSITY\": \"University of Cape Town\"}\n{\"HUMAN_RESEARCH_ETHICS_COMMITTEE\": \"University of Cape Town Human Research Ethics committee\"}\n{\"HREC_REF\": \"826/2014\"}", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {\"COHORT\": \"not specified\",\n \"EXTRACTION_PROCESS\": \"supernatant\",\n \"TIME_PERIOD\": \"72 h\",\n \"ENVIRONMENT\": \"room temperature\",\n \"RESTING_INTERVAL\": \"every 24 h\",\n \"RESTATED_MATERIAL\": \"solid residue\",\n \"RESTATED_MATERIAL_SUBSTANCE\": \"purified water\",\n \"REPEAT_PROCESS\": \"extraction process\"}\n\n(Note: The original text does not explicitly mention a cohort, so \"COHORT\" remains empty.)", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {\"Denis Chopera\": \"author\",\n \"Kevin Dzobo\": \"author\",\n \"Ambroise Wonkam\": \"author\",\n \"Dee Blackhurst\": \"author\",\n \"Michelle Skelton\": \"author\",\n \"cohort\": \"not mentioned in the text\"}\n\n{\"Pharmacology\": \"field of study\"}\n\n{\"scientific article\": \"type of publication\"}\n\n{\"pharmacology\": \"field of study\"}\n\n{\"pharmacology article\": \"type of publication\"}", {}]], [220, "All authors reviewed the final manuscript.", [" {\"COHORT\": \"\", \"AUTHORS\": \"All authors\", \"MANUSCRIPT\": \"final manuscript\"}\n\n{\"PHARMACOLOGY_CONCEPT\": \"pharmacology\", \"ARTICLE_TYPE\": \"scientific article\"}\n\n{\"RESEARCHERS\": \"authors\", \"ACTION\": \"reviewed\", \"MATERIAL\": \"final manuscript\"}\n\n{\"PUBLICATION\": \"manuscript\"}\n\n{\"RESEARCH_ACTIVITY\": \"reviewed the final manuscript\"}\n\n{\"RESEARCH_OUTCOME\": \"reviewed the final manuscript\"}\n\n{\"RESEARCH_PROCESS\": \"reviewed the final manuscript\"}\n\n{\"RESEARCH_DETAIL\": \"All authors reviewed the final manuscript\"}\n\n{\"RESEARCH_PARTICIPANTS\": \"\", \"RESEARCH_SET\": \"\", \"RESEARCH_GROUP\": \"\", \"RESEARCH_INDIVIDUAL\": \"All authors\"}\n\n{\"RESEARCH_INSTITUTION\": \"\", \"RESEARCH_ORGANIZATION\": \"\", \"RESEARCH_PROGRAM\": \"\", \"RESEARCH_STUDY\": \"\", \"RESEARCH_TRIAL\": \"\", \"RESEARCH_CLINICAL_TRIAL\": \"\", \"RESEARCH_CLINICAL_STUDY\": \"\", \"RESEARCH_CASE_CONTROL\": \"\", \"RESEARCH_COHORT\": \"\", \"RESEARCH_NONCOHORT\": \"\", \"RESEARCH_CASE_REPORT\": \"\", \"RESEARCH_CASE_OCCURRENCE\": \"\", \"RESEARCH_CASE_DESCRIPTION\": \"\", \"RESEARCH_CASE_DEFINITION\": \"\", \"RESEARCH_EXPOSURE\": \"\", \"RESEARCH_INTERVENTION\": \"\", \"RESEARCH_OUTCOME\": \"reviewed the final manuscript\"}\n\n{\"RESEARCH_METHODOLOGY\": \"\", \"RESEARCH_DESIGN\": \"\", \"RESEARCH_SETTING\": \"\", \"RESEARCH_TIMEFRAME\": \"\", \"RESEARCH_SAMPLE\": \"\", \"", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {\"COHORT\": \"not specified\", \"INGREDIENTS\": \"five major ingredients\", \"DRUG INTERACTIONS\": \"drug interactions\"}\n\n(Note: The original text does not explicitly mention a cohort, but it does refer to the potential for drug interactions when GGT (which could be a pharmacological entity) is co-administered with other drugs. However, since no specific cohort is mentioned, the \"COHORT\" field is left empty.)", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {\"COHORT\": \"participants in the study\"}\n{\"TREATMENTS\": \"three treatments\"}\n{\"WASHOUT PERIOD\": \"7 \u00b1 1-day washout period\"}", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\"GGT\": \"GGT\", \"study\": \"study\"}\n\n(Note: The term \"cohort\" was not explicitly mentioned in the provided text, but if we were to infer its presence based on the context of a scientific study, it could be described as follows:)\n\n{\"cohort\": \"the cohort in the study\"}\n\n{\"dose\": \"this dose of GGT\"}", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" {\"AAP dose\": \"Description of the AAP dose\", \"1000 mg\": \"Description of 1000 mg\", \"maximum dose\": \"Description of the maximum dose\", \"1000 mg \u00d7 4 times\": \"Description of 1000 mg \u00d7 4 times\", \"8 tablets\": \"Description of 8 tablets\"}\n\n{\"COHORT\": \"Description of the cohort (not explicitly mentioned in the text, but implied to be patients with the common cold)\"}\n\n(Note: Since the cohort is not explicitly mentioned in the text, the description is inferred based on the context of the treatment being discussed.)", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" {\"AAP\": \"a pharmacological entity, likely a drug\",\n \"GGT\": \"a pharmacological entity, likely a drug\"}\n\nNote: The description provided does not mention specific names for the drugs AAP and GGT, so the descriptions are based on the context that they are drugs being studied in a pharmacological context. If there were specific names provided, those would be included in the descriptions as well.", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" {\"AAP\": \"a pharmacological agent\",\n\"1000 mg\": \"dosage amount of AAP\",\n\"4 times a day\": \"administration frequency of AAP\",\n\"GGT\": \"gene or enzyme being studied in the context of pharmacology\"}\n\n{\"COHORT\": \"not specified in the provided text\"}", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" {\"COHORT\": \"described cohort in the scientific article about pharmacology\",\n\"PHARMACOLOGY\": \"the scientific field of the article\",\n\"PHARMACOLOGIST\": \"a professional involved in pharmacology\",\n\"DR. Y.C.P.\": \"a possible author or researcher mentioned in the article\",\n\"PHARMACEUTICAL DRUG\": \"a medication or drug discussed in the article\",\n\"DRUG ACTION\": \"the process or mechanism by which a drug exerts its effect\",\n\"DRUG EFFECT\": \"the outcome or result of a drug's action\",\n\"DRUG DOSAGE\": \"the amount of a drug administered\",\n\"DRUG DISTRIBUTION\": \"the process of delivering a drug to its target site\",\n\"DRUG PHARMACEUTICAL PROCESS\": \"the series of steps involved in the development and production of a drug\",\n\"DRUG PHARMACOLOGICAL PROCESS\": \"the series of steps involved in the study of drug action and effects\",\n\"DRUG PHARMACOLOGICAL STUDIES\": \"research studies focused on the pharmacological aspects of drugs\",\n\"DRUG PHARMACOLOGICAL MECHANISMS\": \"the biological processes through which drugs produce their effects\",\n\"DRUG PHARMACOLOGICAL EFFECTS\": \"the specific outcomes or changes induced by a drug\",\n\"DRUG PHARMACOLOGICAL PHASES\": \"the stages of drug development and testing\",\n\"DRUG PHARMACOLOGICAL TRIALS\": \"clinical trials conducted to evaluate the safety and efficacy of a drug\",\n\"DRUG PHARMACOLOGICAL PARTICIPANTS\": \"individuals involved in pharmacological studies or trials\",\n\"DRUG PHARMACOLOGICAL OUTCOMES\": \"the results or endpoints measured in pharmacological studies\",\n\"DRUG PHARMACOLOGICAL INDICES\": \"quantitative measures used to assess drug effects\",\n\"DRUG PHARMACOLOGICAL DATA\": \"information collected during ph", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" {\"COHORT\": \"performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.\"}\n\n{\"PATIENTS\": \"not specified\"}\n\n{\"STUDY\": \"not specified\"}\n\n{\"TRIAL\": \"not specified\"}\n\n{\"METHODS\": \"not specified\"}\n\n{\"OUTCOMES\": \"not specified\"}\n\n{\"MEDICINES\": \"not specified\"}\n\n{\"PHARMACOLOGY\": \"not specified\"}\n\n{\"RESEARCHERS\": \"H.-m.B., L.T.N., J.-w.C., and H.-y.Y.\"}\n\n{\"AUTHORS\": \"H.-m.B., L.T.N., J.-w.C., and H.-y.Y.\"}\n\n{\"JOURNAL\": \"not specified\"}\n\n{\"YEAR\": \"not specified\"}", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\"COHORT\": \"AAP\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic (PK) parameters\"}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" {\"COHORT\": \"elderly subjects\", \"PHENOTYPIC_METABOLIC_RATIOS\": \"phenotypic metabolic ratios\", \"SUPPLEMENTED_SUBSTANCES\": [\"St. John\u2019s wort\", \"garlic oil\", \"Panax ginseng\", \"Ginkgo biloba\"], \"CYP_ENZYMES\": [\"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4\"]}", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" {\"COHORT\": \"patients taking prescription medications\", \"AGE_GROUP\": \"individuals greater than 65 years of age\"}\n{\"PHARMACY_PRODUCT\": \"herbal supplements\"}\n{\"STUDY_NUMBERS\": \"1\u20133,8,9,10\u201312\"}", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" {\"COHORT\": \"elderly\", \"CYP substrates\": \"certain CYP enzymes\", \"botanical supplements\": \"botanical supplements\"}", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {\"COHORT\": \"group of participants in a study\",\n\"PROBE DRUG\": \"drug administered\",\n\"PROBE DRUG ADMINISTRATION\": \"administration of the probe drug\",\n\"PHARMACOTHERAPY\": \"treatment with drugs\",\n\"ADHERENCE\": \"compliance with the study protocol\",\n\"PHARMACOLOGY\": \"the study of drugs and their effects\",\n\"SPECIALTY\": \"specific area of pharmacology\",\n\"DRUG ADMINISTRATION\": \"administration of medication\",\n\"PROBE DRUG ADMINISTRATION\": \"administration of the probe drug\"}", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {\"COHORT\": \"unspecified group of subjects in a study\", \"retention times\": \"descriptor for the time a substance remains in a phase\", \"ultraviolet absorption spectra\": \"measurement related to the absorption of UV light by substances\"}\n\n{\"EXPERIMENTAL_METHOD\": \"comparison of retention times and ultraviolet absorption spectra\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"peaks\"}\n\n{\"PHARMACOLOGICAL_SUBSTANCE\": \"unspecified\"}\n\n{\"PUBLICATION\": \"unspecified scientific article\"}\n\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n\n{\"SUBJECT_TYPE\": \"unspecified subjects\"}\n\n{\"SPECTRAL_MEASURE\": \"ultraviolet absorption spectra\"}", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {\"COHORT\": \"All subjects\"}\n{\"ADVERSE_EVENTS\": \"serious adverse events\"}", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" {\"COHORT\": \"Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\", \"SUPPLEMENT\": \"Supplement\", \"PRESUPPLEMENTATION\": \"Presupplementation\", \"POSTSUPPLEMENTATION\": \"Postsupplementation\"}", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {\"COHORT\": \"single-time point phenotypic ratio approach\", \"DRUG\": \"St. John's wort\", \"METRIC\": \"area-under-the-curve\"}\n\n{\"DRUG\": \"midazolam\"}", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {\"COHORT\": \"young individuals\"}\n\n(Note: The instruction asks for parsing cited entities, but the provided text does not explicitly mention any specific studies or entities to be parsed. The response is based on the implied entity \"earlier study\" mentioned in the text.)\n\n{\"EARLIER STUDY\": \"earlier study in young individuals\"}", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" {\"COHORT\": \"St. John's wort\", \"DRUG\": \"unspecified agents\"}", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" {\"COHORT\": \"two age groups\", \"CYP2E1\": \"CYP2E1 responsivity\", \"allyl sulfide\": \"allyl sulfide content\"}", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {\"COHORT\": \"elderly patients on anticoagulant therapy\", \"ARTICLES\": [\"11\", \"12\"]}\n{\"PHARMACOLOGICAL_CONCEPT\": \"anticoagulant therapy\"}\n{\"STUDY_SOURCE\": \"scientific article\"}\n{\"RESEARCH_FINDING\": \"interaction\"}\n{\"MEDICAL_CONDITION\": \"not specified\"}\n{\"MEDICATION\": \"not specified\"}\n{\"AGE_GROUP\": \"elderly\"}", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {\"Platelet Activating Factor\": \"platelet activating factor\",\n \"Ginkgolides\": \"various ginkgolides\"}\n\n{\"COHORT\": \"Not specified in the provided text\"}\n\n{\"Study\": \"Not specified in the provided text\"}\n\n{\"Researchers\": \"Not specified in the provided text\"}\n\n{\"Publication\": \"Not specified in the provided text\"}\n\n{\"Scientific Article\": \"scientific article\"}\n\n{\"Pharmacology\": \"pharmacology\"}\n\n{\"Inhibition\": \"inhibition\"}\n\n{\"Interaction\": \"interaction\"}", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {\"COHORT\": \"Not specified\", \"G. biloba\": \"Gingko biloba\"}", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" {\"Ginkgo biloba\": \"COHORT\", \"Panax ginseng\": \"PHARMACEUTICAL_AGENT\", \"CYP isoforms\": \"GENETIC_PRODUCTS\"}\n\nNote: The original text does not explicitly mention a \"COHORT\" but implies a study group or population being investigated. However, based on the given format, I've included \"COHORT\" as a possible entity that could be inferred from the context. If the intent is strictly to identify named entities as per the provided format, then it might be more accurate to leave the \"COHORT\" field empty, as it's not directly named. However, I've included it to align with the task's instructions.", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" {\"CYP2C9\": \"the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.\"}\n\n{\"warfarin\": \"the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.\"}\n\n{\"S-warfarin\": \"the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.\"}\n\n{\"ginseng\": \"the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.\"}", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {\"Botanical Supplements\": \"botanical supplements\", \"conventional medications\": \"conventional medications\", \"herb-drug interactions\": \"herb-drug interactions\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"Study\": \"Not specified\"}\n\n{\"Publication\": \"Not specified\"}\n\n{\"Date\": \"Not specified\"}\n\n{\"Author(s)\": \"Not specified\"}\n\n{\"Journal\": \"Not specified\"}\n\n{\"DOI\": \"Not specified\"}\n\n{\"Keywords\": \"herb-drug interactions\"}\n\n{\"Methods\": \"Not specified\"}\n\n{\"Results\": \"Not specified\"}\n\n{\"Conclusions\": \"Not specified\"}\n\n{\"Pharmacology\": \"pharmacology\"}", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\"PLASMA QUININE\": \"plasma quinine\", \"METABOLITE\": \"(3-hydroxyquinine)\", \"HPLC METHOD\": \"validated HPLC method\"}\n\n{\"BLOODSAMPLES\": \"blood samples\"}\n{\"QUININE\": \"quinine\"}\n{\"3-HYDROXYQUININE\": \"(3-hydroxyquinine)\"}\n{\"HPLC\": \"HPLC\"}", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"COHORT\": \"studies on phytochemical analysis of G. kola seeds\",\n\"COMPOUNDS\": \"benxophenones, xanthones, alkaloids, phenols, tannins, saponins, kolaviron a biflavonoid complex, metallic ions (aluminum, magnesium, calcium, copper)\",\n\"CHEMICAL_COMPONENTS\": \"major chemical components of G. kola\"}", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {\"COHORT\": \"study participants\", \"QUININE\": \"quinine\", \"G. kola seeds\": \"G. kola seeds\"}\n\n{\"CONDITION\": \"pregnancy\", \"BREASTFEEDING\": \"breastfeeding\", \"HISTORIES OF HYPERSENSITIVITY\": \"histories of hypersensitivity\", \"ADVERSE SIDE EFFECTS\": \"adverse side effects\"}", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {\"COHORT\": \"certified healthy participants based on medical history, clinical examination, and laboratory tests\"}\n{\"INFORMED CONSENT\": \"written informed consent\"}\n{\"STUDY PROTOCOL\": \"study protocol\"}\n{\"PHYSICIAN\": \"physician\"}\n{\"LABORATORY TESTS\": \"laboratory tests\"}", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" {\"QUININE SULFATE TABLETS\": \"600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)\"}\n\n{\"Maderich Ltd\": \"Maderich Ltd, Surrey, England\"}\n\n{\"ORAL DOSE\": \"single oral dose\"}\n\n{\"SUBJECTS\": \"each subject\"}\n\n{\"GROUPS\": \"respective groups\"}\n\n{\"OVERNIGHT FAST\": \"after an overnight fast\"}\n\n{\"NIGHT\": \"overnight\"}\n\n{\"FAST\": \"overnight fast\"}\n\n{\"PHASE\": \"first phase\"}", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" {\"COHORT\": \"Participants in the study\"}\n{\"QUININE SULFATE TABLETS\": \"quinine sulphate tablets\"}\n{\"HEPARINISED TUBES\": \"heparinised tubes\"}\n{\"TIME ZERO\": \"just before the administration of quinine sulphate tablets\"}\n{\"G. KOLA DOSE\": \"scheduled dose of G. kola\"}\n{\"QUININE ALONE OR CONCURRENTLY WITH G. KOLA DOSE\": \"quinine alone or concurrently with the scheduled dose of G. kola\"}\n{\"VENOUS BLOOD SAMPLES\": \"venous blood samples\"}\n{\"QUININE SULFATE TABLETS ADMINISTRATION\": \"administration of quinine sulphate tablets\"}\n{\"QUININE SULFATE TABLETS DURING PARTICIPANT RECEIVING\": \"quinine sulphate tablets during participant receiving\"}\n{\"QUININE SULFATE TABLETS DURING 1, 2, 3, 4, 6, 8, 12, 24, 36, AND 48 HOURS AFTER\": \"quinine sulphate tablets during 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after\"}\n{\"QUININE SULFATE TABLETS DURING EACH PARTICIPANT RECEIVING\": \"quinine sulphate tablets during each participant receiving\"}\n{\"QUININE SULFATE TABLETS DURING EACH PARTICIPANT RECEIVING QUININE ALONE OR CONCURRENTLY WITH G. KOLA DOSE\": \"quinine sulphate tablets during each participant receiving quinine alone or concurrently with the scheduled dose of G. kola\"}\n{\"QUININE SULFATE TABLETS DURING EACH PARTICIPANT RECEIVING QUININE ALONE OR CONCURRENTLY WITH G. KOLA DOSE AT TIME ZERO\": \"quinine sulphate tablets during each participant receiving quinine alone or concurrently", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" {\"QUININE\": \"quinine\", \"3-HYDROXYQUININE\": \"3-hydroxyquinine\"}\n{\"COHORT\": \"Not specified\"}\n{\"LIMIT OF QUANTITATION\": \"limit of quantitation\"}\n{\"QUANTITATIVE LIMIT\": \"quantitative limit\"}\n{\"QUANTITATIVE LIMIT FOR QUININE\": \"0.37\u00b5g/ml\", \"QUANTITATIVE LIMIT FOR 3-HYDROXYQUININE\": \"0.5\u00b5g/ml\"}", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\"COHORT\": \"Not specified\", \"QUININE\": \"quinine\"}", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {\"COHORT\": \"3 participants\"}\n{\"SYMPTOM\": \"dizziness\"}\n{\"SYMPTOM_INTENSITY\": \"very light\"}", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" {\"COHORT\": \"G. kola\", \"Trace metals\": \"trace metals\", \"flavonoids\": \"flavonoids\"}\n\n(Note: The cohort \"G. kola\" is not explicitly mentioned as a cohort in the provided text, but it is the subject of the study. The entities \"trace metals\" and \"flavonoids\" are mentioned as components that could interact with quinine.)", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" {\"COHORT\": \"study groups\", \"QUININE\": \"quinine\", \"T1/2\": \"half-life\", \"CL/F\": \"clearance/flux\"}\n\n{\"QUININE\": \"quinine\", \"T1/2\": \"half-life\", \"CL/F\": \"clearance/flux\"}", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" {\"COHORT\": \"unspecified group of individuals in a study\",\n\"PLOS ONE\": \"a peer-reviewed open access scientific journal\",\n\"pharmacology\": \"the branch of science concerned with the effects of drugs and the mechanisms of drug action\",\n\"scientific article\": \"a written work that presents original research findings\",\n\"cited entities\": \"entities mentioned or referred to in the text\",\n\"drugs\": \"substances used for medical treatment\",\n\"mechanisms of drug action\": \"the processes by which drugs produce their effects in the body\",\n\"PLOS ONE policies\": \"guidelines and regulations set by PLOS ONE for data and material sharing\"}", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"COHORT\": \"77 additional participants\"}\n{\"S. frutescens\": \"1,200 mg S. frutescens\"}\n{\"PLACEBO\": \"placebo\"}", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" {\"COHORT\": \"adults in KwaZulu-Natal attending public sector facilities for ART initiation\"}\n{\"TCAM\": \"Treatment as Continuous Antiretroviral Therapy\"}\n{\"ART\": \"Antiretroviral Therapy\"}\n{\"HIV positive individuals\": \"HIV positive individuals\"}\n{\"Worldwide\": \"worldwide\"}\n{\"[10]\": \"Cited entity 10\"}\n{\"[11]\": \"Cited entity 11\"}", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" {\"MOS-HIV\": \"a scientific article about pharmacology\", \"placebo\": \"a substance given to the control group in a clinical trial\", \"1200 mg\": \"a dosage of a medication being compared in the study\"}\n\n(Note: The provided text does not explicitly mention a \"cohort,\" but it does refer to a comparison between two groups in a study. Therefore, I've left the \"COHORT\" field empty as per the instructions.)", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {\"SERIAL_ELECTROCARDIOGRAM\": \"serial electrocardiograms\",\n\"PR_INTERVAL\": \"PR interval\",\n\"QRS_DURATION\": \"QRS duration\",\n\"CORRECTED_QT_INTERVAL\": \"corrected QT interval (QTc)\",\n\"QTc\": \"corrected QT interval (QTc)\",\n\"S2_TABLE\": \"S2 Table\"}\n\n{\"COHORT\": \"Not explicitly mentioned in the provided text\"}\n\n{\"ARMS\": \"both arms\"}", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {\"COHORT\": \"Not specified in the provided text\",\n \"HDL\": \"high density lipoprotein\",\n \"LDL\": \"low density lipoprotein\",\n \"P-value\": \"P-value for interaction effect of groups over time\"}", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" {\"COHORT\": \"The described cohort in the scientific article about pharmacology is not explicitly mentioned in the provided text. Therefore, the description of the cohort remains empty based on the given information.\"}\n\n{\"PHARMACOLOGY_CONCEPT\": \"pharmacology\"}\n\n{\"PHARMACEUTICAL_CONCEPT\": \"drug\"}\n\n{\"DRUG_NAME\": \"The specific drug names are not mentioned in the provided text. Therefore, the list of drug names is empty.\"}\n\n{\"DRUG_ACTION\": \"The specific actions of drugs are not mentioned in the provided text. Therefore, the list of drug actions is empty.\"}\n\n{\"DRUG_MEDICATION\": \"The specific drugs used for medication are not mentioned in the provided text. Therefore, the list of drugs used for medication is empty.\"}\n\n{\"DRUG_DOSAGE\": \"The specific dosages of drugs are not mentioned in the provided text. Therefore, the list of drug dosages is empty.\"}\n\n{\"DRUG_REACTION\": \"The specific drug reactions are not mentioned in the provided text. Therefore, the list of drug reactions is empty.\"}\n\n{\"DRUG_CLINICAL_TRIAL\": \"The mention of clinical trials is not detailed in the provided text. Therefore, the description of the clinical trial is empty.\"}\n\n{\"DRUG_CLINICAL_TRIAL_DETAILS\": \"The specific details of the clinical trial are not mentioned in the provided text. Therefore, the details of the clinical trial are empty.\"}\n\n{\"DRUG_CLINICAL_TRIAL_PARTICIPANTS\": \"The specific participants of the clinical trial are not mentioned in the provided text. Therefore, the description of the clinical trial participants is empty.\"}\n\n{\"DRUG_CLINICAL_TRIAL_OUTCOMES\": \"The specific outcomes of the clinical trial are not mentioned in the provided text. Therefore, the description of the clinical trial outcomes is empty.\"}\n\n{\"DRUG_CLINICAL_TRIAL_CONDITION\": \"The specific condition being studied in the clinical trial is not mentioned in the provided text. Therefore, the description of the clinical trial condition", {}]], [265, "Thabethe, D.A.", [" {\"COHORT\": \"unnamed cohort\", \"AUTHOR\": \"D.A. Thabethe\"}", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\"COHORT\": \"described cohort in the scientific article about pharmacology\", \"PREVALENCE\": \"percent\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"MEASUREMENT\": \"prevalence\", \"DATA_SOURCE\": \"reported data\"}", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" {\"Chronic kidney disease (CKD)\": \"Chronic kidney disease\", \"global public health problem\": \"global public health problem\", \"economic burden\": \"economic burden\"}\n\n{\"Incidence\": \"increasing incidence\"}\n\n{\"Treatment\": \"treatment\"}", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {\"COHORT\": \"patients using various therapies\", \"DRUG_INTERACTIONS\": \"drugs used contemporaneously\", \"PHARMACOLOGICAL_THERAPIES\": \"various therapies\"}\n\n{\"PHARMACOLOGICAL_THERAPIES\": \"various therapies\"}\n{\"DRUG_INTERACTIONS\": \"drugs used contemporaneously\"}\n{\"COHORT\": \"patients\"}", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" {\"INSTITUTIONAL_ETHICS_COMMITTEE\": \"institutional ethics committee\",\n\"PROJECT_NUMBER\": \"294155\",\n\"ETHICS_CODE\": \"ethics code\",\n\"UNIVERSITY_RESEARCH_FACTS\": \"university research affairs\",\n\"PATIENT_DEMOGRAPHIC_INFO\": \"patients' demographic information\",\n\"PATIENT_HOSPITAL_RECORDS\": \"patients' hospital records\",\n\"PATIENT_INTERVIEW\": \"direct interviewing of patients\",\n\"STUDY_FORM\": \"specially designed form for this study\"}", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"COHORT\": \"majority of CAM nonusers in the age group of 20\u201360 years with a male/female ratio of 73/27 percent\"}\n\n{\"AGE GROUP\": \"20\u201360 years\"}\n\n{\"MALE/FEMALE RATIO\": \"73/27 percent\"}", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" {\"COHORT\": \"congenital kidney disease, polycystic kidney disease, drug-induced renal failure, acute kidney injury\"}\n\n{\"CONDITION\": \"congenital kidney disease, polycystic kidney disease, drug-induced renal failure, acute kidney injury\"}\n\n{\"DISEASE_TYPE\": \"congenital kidney disease, polycystic kidney disease, drug-induced renal failure, acute kidney injury\"}\n\n{\"TARGET_GROUP\": \"13.23%\"}\n\n{\"AGE_GROUP\": \"\"}\n\n{\"SEX\": \"not specified\"}\n\n{\"GEOGRAPHIC_LOCATION\": \"not specified\"}\n\n{\"RESEARCH_TYPE\": \"scientific article about pharmacology\"}\n\n{\"STUDY_DESIGN\": \"not specified\"}\n\n{\"PUBLICATION_SOURCE\": \"not specified\"}\n\n{\"PUBLICATION_DATE\": \"not specified\"}\n\n{\"PUBLICATION_JOURNAL\": \"not specified\"}\n\n{\"AUTHORS\": \"not specified\"}\n\n{\"STUDY_FINDINGS\": \"not specified\"}\n\n{\"STUDY_CONCLUSIONS\": \"not specified\"}\n\n{\"FUNDING_SOURCE\": \"not specified\"}\n\n{\"STUDY_APPLICATION\": \"not specified\"}", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {\"COHORT\": \"patients identified as herbal users\", \"AGE RANGE\": \"50\u201370 years\"}\n\nNote: The entities \"herbal users\" and \"age range\" refer to the described entities in the context of the cohort. However, since the task specifically asks for cited entities, and \"herbal users\" is not directly cited in a study or paper but rather described, it's not explicitly cited. If we strictly adhere to the task's instructions, we might not include \"herbal users\" as a cited entity. Instead, we've included \"age range\" as it is directly mentioned in the context of the cohort. If there's a specific citation or context where \"herbal users\" is directly cited, it should be included as a cited entity.", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {\"COHORT\": \"middle-aged (50\u201364) patients\"}\n\n{\"STUDY\": \"study, [25]\"}", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" {\"Iranian borage (E. amoenum)\": \"Iranian borage\", \"uncovered and anticough syrups\": \"uncovered herbal products, anticough syrups\", \"main indications\": \"common cold, respiratory problems\"}\n\n{\"COHORT\": \"study population\"}", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {\"COHORT\": \"study performed by Roozbeh et al.\"}\n\nNote: Since the specific details about the cohort (e.g., number of participants, demographics, etc.) are not provided in the given text, the description remains general.", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {\"Karnofsky performance status scale\": \"Karnofsky performance status scale of 90%\", \"patient\": \"the patient\", \"resection\": \"resection\", \"neurological deficiencies\": \"neurological deficiencies\", \"department\": \"our department\", \"radiotherapy\": \"radiotherapy\", \"temozolomide (TEM)\": \"temozolomide (TEM)\"}\n\n{\"COHORT\": \"Not explicitly mentioned\"}\n\n(Note: The cohort typically refers to a group of patients or subjects in a study. Since the provided text does not explicitly mention a cohort, the field remains empty.)", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" {\"[18 F]-fluorethylenthyrosin\": \"radiopharmaceutical\", \"positron emission tomography\": \"imaging modality\", \"residual tumor\": \"clinical entity\"}\n\n{\"end of radiotherapy\": \"clinical event\"}\n\n{\"2 months\": \"time period\"}\n\n{\"post-treatment\": \"clinical event\"}", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {\"HERBAL FORMULAS\": \"herbal formulas\"}\n\n{\"PATIENTS\": \"our patients\"}\n\n{\"EDUCATION\": \"education\"}\n\n{\"RISK OF INTERACTIONS\": \"risk of interactions\"}\n\n{\"MANAGEMENT\": \"management\"}\n\n{\"COMPREHENSIVE MANAGEMENT\": \"comprehensive management\"}\n\n{\"HERBAL FORMULARIES\": \"herbal formulas\"} (assuming \"formularies\" refers to a collection of herbal formulas)\n\n{\"RISK MANAGEMENT\": \"risk management\" (assuming it refers to managing the risk of interactions)", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\"COHORT\": \"whole blood\", \"sample volume\": \"0.5 mL\", \"dilution factor\": \"twofold\", \"incubation temperature\": \"37 \u00b0C\", \"incubation time\": \"at least 6 minutes\"}\n\nNote: The original text does not explicitly mention a specific cohort name, so the \"COHORT\" field is left empty as per the instructions. However, the other entities related to the experimental procedure have been identified. If the text had included a cohort name, it would have been listed here.", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" {\"INTERNATIONAL NORMALIZED RATIO\": \"International normalized ratio\", \"BFT II ANALYSER\": \"BFT II analyser\"}\n\nNote: The term \"cohort\" typically refers to a group of individuals with shared characteristics being studied in clinical research. However, in the provided text, there is no explicit mention of a cohort. Therefore, no \"COHORT\" entity was identified in this context.", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {\"STANDARD HUMAN PLASMA\": \"described as having known factor activity\", \"FACTOR ACTIVITY\": \"referring to the activity of the clotting factors in the plasma\", \"CLOTTING TIME\": \"the parameter measured to determine the percentage factor activity\"}\n\n{\"STANDARD HUMAN PLASMA\": \"standard human plasma of known factor activity\", \"CLOTTING TIME\": \"clotting time\"}", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\"COHORT\": \"Not specified\",\n \"KEL\": \"kel\",\n \"CL/F\": \"apparent clearance (CL/F)\",\n \"AUC0-\u221e\": \"AUC0-\u221e\",\n \"dose\": \"dose\",\n \"V/F\": \"apparent volume of distribution (V/F)\"}", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" {\"COHORT\": \"study participants\",\n \"S-warfarin\": \"the drug\",\n \"two-compartment pharmacokinetic model\": \"pharmacokinetic model\",\n \"prothrombin complex activity (PCA)\": \"PCA\",\n \"INR data\": \"INR data\"}", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {\"COHORT\": \"described cohort\", \"STATISTICAL_SIGNIFICANCE\": \"statistical significance\", \"DATA\": \"data\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n\n{\"STUDY_DESCRIPTION\": \"scientific article\"}\n\n{\"DATA_NOT_SHOWN\": \"data not shown\"}", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" {\"COHORT\": \"The cohort in this study is not explicitly mentioned in the provided text.\"}\n{\"GEOMETRIC_MEAN_RATIO\": \"Geometric mean ratio (90% CI)\"}\n{\"WARFARIN_ONLY\": \"Warfarin only\"}\n{\"WARFARIN_AND_CRANBERRY\": \"Warfarin and cranberry\"}\n{\"WARFARIN_AND_GARLIC\": \"Warfarin and garlic\"}\n{\"WARFARIN_AND_CRANBERRY_AND_WARFARIN_ONLY\": \"Warfarin and cranberry/warfarin only\"}\n{\"WARFARIN_AND_GARLIC_AND_WARFARIN_ONLY\": \"Warfarin and garlic/warfarin only\"}\n{\"S_WARFARIN_TMAX\": \"tmax (h) of S-warfarin\"}\n{\"S_WARFARIN_CMAX\": \"Cmax (\u03bcg/mL) of S-warfarin\"}\n{\"S_WARFARIN_T1_2\": \"t1/2 (h) of S-warfarin\"}\n{\"S_WARFARIN_AUC\": \"AUC (\u03bcg/mL*h) of S-warfarin\"}\n{\"S_WARFARIN_CL_F\": \"CL/F (mL/h) of S-warfarin\"}\n{\"S_WARFARIN_FU\": \"Fraction unbound (fu) of S-warfarin\"}\n{\"R_WARFARIN_TMAX\": \"tmax (h) of R-warfarin\"}\n{\"R_WARFARIN_CMAX\": \"Cmax (\u03bcg/mL) of R-warfarin\"}\n{\"R_WARFARIN_T1_2\": \"t1/2 (h) of R-warfarin\"}\n{\"R_WARFARIN_AUC\": \"AUC (\u03bcg/mL*h) of R-warfarin\"}\n{\"R_WARFARIN_CL_F\": \"CL/F (mL/", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"COHORT\": \"population PKPD parameter estimates for warfarin\", \"TABLE\": \"Table 3\"}\n\nNote: In the provided text, there are no explicit mentions of specific entities like authors, institutions, or specific drugs apart from warfarin. However, the text does refer to a \"cohort\" and a \"table,\" which are entities related to the scientific study. The cohort refers to the group of individuals whose PKPD parameter estimates are being presented, and the table refers to the specific table in the article where these estimates are displayed.", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\"COHORT\": \"patients on warfarin therapy\", \"WARFARIN\": \"anticoagulant drug\", \"S-WARFARIN\": \"specific form of warfarin\", \"Cranberry Juice\": \"pretreatment substance\", \"AUC\": \"area under the curve\"}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" {\"COHORT\": \"7 patients with atrial fibrillation\", \"AUTHOR\": \"Ansell et al.\"}\n\n{\"PUBLICATION\": \"2006b\"}", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {\"COHORT\": \"unspecified group of patients\",\n\"DRUG\": \"warfarin\",\n\"NUTRITIONAL_SUBSTANCE\": \"cranberry juice\",\n\"STUDY_TYPE\": \"clinical study\",\n\"DOSAGE\": \"10 mg\",\n\"MEASURED_OUTCOME\": \"pharmacodynamic interactions\"}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" {\"Drug Metabolism and Pharmacokinetics\": \"Drug Metabolism and Pharmacokinetics\", \"Covance Laboratories Inc.\": \"Covance Laboratories Inc.\", \"Madison, WI, USA\": \"Madison, WI, USA\", \"warfarin\": \"warfarin\"}", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" {\"VALERIAN\": \"valerian\", \"ANTICANCER DRUGS\": \"anticancer drugs\"}\n\nAcademic Editor: Igho J. Onakpoya\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"STUDY\": \"Not mentioned\"}\n\n{\"PUBLICATION\": \"recent popular publications\"}\n\n{\"INFORMATION WEBSITES\": \"information websites\"}\n\n{\"CANCER PATIENTS\": \"cancer patients\"}\n\n{\"POTENTIAL ADVERSE INTERACTIONS\": \"adverse interactions\"}\n\n{\"ANTICANCER DRUG TYPES\": \"anticancer drugs\"}", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" {\"VALERIANA OFFICINALIS\": \"Valerian (Valeriana officinalis)\"}\n{\"CYP 3A4\": \"CYP3A4\"}", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" {\"COHORT\": \"elderly\"}\n{\"SOURCE\": \"10, 12\"}", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"VALERIAN ROOT EXTRACT\": \"valerian root extracts\"}\n\n{\"RECOMMENDED DOSE\": \"recommended daily doses\"}\n\n{\"METHOD OF DISTRIBUTION\": \"capsules or tablets\"}\n\n{\"DOSAGE\": \"600\u2009mg\"}\n\n{\"MEDICAL USE\": \"pharmacology\"}", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {\"MEDLINE\": \"database\",\n \"TOXLIT\": \"database\",\n \"DIMDI\": \"institution\",\n \"Cologne\": \"location\",\n \"valerian\": \"plant\",\n \"valeriana\": \"plant\"}\n\n{\"COHORT\": \"searched cohort\"}\n\n(Note: In this context, a cohort is not explicitly mentioned, so the field remains empty.)", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {\"COHORT\": \"studies\", \"MATERIALS_AND_METHODS\": \"material and methods\", \"CLINICAL_RELEVANCE\": \"clinical relevance of the results\", \"PRESENTATION_BIAS\": \"potential bias in the presentation of results and conclusions\"}", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" {\"COHORT\": \"unspecified group of individuals in a scientific study\", \"PHARMACOLOGICAL TREATMENT\": \"unspecified medication or therapy\", \"DRUG NAME\": \"unspecified\", \"DRUG CLASS\": \"unspecified\", \"DRUG ACTION\": \"unspecified\", \"DRUG EFFECT\": \"unspecified\", \"STUDY DESIGN\": \"unspecified\", \"STUDY LOCATION\": \"unspecified\", \"STUDY PUBLICATION\": \"unspecified\", \"JOURNAL NAME\": \"unspecified\", \"AUTHOR(S)\": \"unspecified\", \"YEAR OF PUBLICATION\": \"unspecified\"}", {}]], [298, "[36].", [" {\"COHORT\": \"The study cohort\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"PUBLICATION\": \"publication\"}\n{\"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\"}\n{\"AUTHORS\": \"authors of the study\"}\n{\"YEAR\": \"2019\"}\n{\"STUDY\": \"study\"}\n{\"POPULATION\": \"population\"}\n{\"AGE\": \"age\"}\n{\"SEX\": \"sex\"}\n{\"HEALTH_STATUS\": \"health status\"}\n{\"MEDICATION\": \"medication\"}\n{\"DOSAGE\": \"dosage\"}\n{\"DURATION\": \"duration\"}\n{\"OUTCOME\": \"outcome\"}\n{\"METHODOLOGY\": \"methodology\"}\n{\"CLINICAL_TRIAL\": \"clinical trial\"}\n{\"ENROLLMENT\": \"enrollment\"}\n{\"PARTICIPANTS\": \"participants\"}\n{\"PHARMACEUTICAL_PRODUCT\": \"pharmaceutical product\"}\n{\"DRUG_NAME\": \"drug name\"}\n{\"DRUG_ACTION\": \"drug action\"}\n{\"DRUG_REACTION\": \"drug reaction\"}\n{\"DRUG_EFFECT\": \"drug effect\"}\n{\"DRUG_TOXICITY\": \"drug toxicity\"}\n{\"DRUG_DOSAGE\": \"drug dosage\"}\n{\"DRUG_DURATION\": \"drug duration\"}\n{\"DRUG_MEDICATION\": \"drug medication\"}\n{\"DRUG_EFFECTS\": \"drug effects\"}\n{\"DRUG_REACTIONS\": \"drug reactions\"}\n{\"DRUG_TOXICITY\": \"drug toxicity\"}\n{\"DRUG_ACTION\": \"drug action\"}\n{\"DRUG_EFFECT\": \"drug effect\"}\n{\"DRUG_DURATION\": \"drug duration\"}\n{\"DRUG_DOSAGE\": \"drug dosage\"}\n{\"DRUG_MEDICATION\": \"drug medication\"}\n{\"DRUG_REACTION\": \"drug reaction\"}\n{\"DRUG_TOX", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" {\"COHORT\": \"participants\", \"VALERIAN EXTRACT\": \"500\u2009mg valerian extract\", \"EXTRACTION SOLVENT\": \"ethanol 70%\", \"VALERENIC ACID CONTENT\": \"5.51\u2009mg/tablet\"}", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" {\"COHORT\": \"described cohort\", \"CYP 3A4/5\": \"enzyme\", \"CYP 1A2\": \"enzyme\", \"CYP 2E1\": \"enzyme\", \"CYP 2D6\": \"enzyme\", \"1-hydroxymidazolam/midazolam serum ratio\": \"enzyme activity ratio\", \"paraxanthine/caffeine serum ratio\": \"enzyme activity ratio\", \"hydroxychlorzoxazone/chlorzoxazone serum ratio\": \"enzyme activity ratio\", \"debrisoquine urinary recovery ratio\": \"enzyme activity ratio\"}", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {\"COHORT\": \"Not specified\", \"VALERIAN\": \"medication\", \"HALOPERIDOL\": \"medication\", \"VALERIAN_TREATMENT_DURATION\": \"15 days\", \"HALOPERIDOL_DOSAGE\": \"38 mg/kg body weight\", \"HALOPERIDOL_DOSAGE_FORM\": \"intramuscular\", \"HALOPERIDOL_DOSAGE_INTERVAL\": \"every 4 weeks\", \"HALOPERIDOL_TREATMENT_DURATION\": \"12 weeks\", \"TREATMENT_START_AFTER_VALERIAN\": \"15 days\"}\n\nNote: The cohort was not specified in the text, hence it is left empty.", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {\"COHORT\": \"not specified\", \"DRUGS\": \"two drugs\", \"METHODOLOGY\": \"not specified\", \"FINDINGS\": \"two drugs act independently from each other\"}", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {\"COHORT\": \"not specified\", \"PHARMACODYNAMIC INTERACTION\": \"valerian preparations\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"possible\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"supported\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"not specified\"}\n{\"COHORT\": \"not specified\", \"PHARMACODYNAMIC INTERACTION\": \"pharmacodynamic interaction\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"not specified\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"possible\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"supported\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"possible\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"supported\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"possible\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"supported\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"possible\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"supported\", \"OTHER DRUGS\": \"not specified\", \"CASE REPORTS\": \"two\"}\n{\"PHARMACODYNAMIC INTERACTION\": \"possible\", \"OTHER DRUGS\": \"not specified", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {\"HERBAL MEDICINES\": \"herbal medicines\",\n\"MAO-INHIBITORY PROPERTIES\": \"MAO-inhibitory properties\",\n\"DELIRIUM\": \"delirium\",\n\"OPIOIDS\": \"opioids\"}\n\n{\"COHORT\": \"Not mentioned in the provided text\"}", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {\"COHORT\": \"\", \"Drug-drug interactions\": \"drug-drug interactions\", \"clinical risks\": \"clinical risks\"}\n\n{\"PHARMACOLOGY_CONCEPT\": \"mechanisms of drug-drug interactions\", \"PHARMACOLOGY_CONCEPT\": \"clinical risks\"}\n\n{\"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG_NAME\": \"\", \"DRUG", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" {\"COHORT\": \"Not specified\",\n \"PHARMACOLOGICAL_COMPONENTS\": \"in vivo bioavailability, metabolism of extract components\",\n \"EXPERIMENTAL_SETTINGS\": \"in vitro effects\",\n \"TARGET_SYSTEMS\": \"in vivo\",\n \"STUDY_METHODS\": \"Not specified\",\n \"STUDY_FINDINGS\": \"Not specified\",\n \"PUBLICATION\": \"Not specified\"}", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {\"COHORT\": \"not specified\", \"PHARMACODYNAMIC INTERACTIONS\": \"pharmacodynamic interactions\", \"CLINICAL OBSERVATIONS\": \"valid clinical observations\"}", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {\"HMPC\": \"Health Products and Foods Branch of Health Canada\", \"monograph\": \"a published document that provides detailed information about a specific health product\", \"Office of Dietary Supplements\": \"a division of the National Institutes of Health (NIH) that provides information on dietary supplements\"}\n\n{\"NIH\": \"National Institutes of Health\"}\n\n{\"fact sheet\": \"a document providing concise information about a particular topic\"}", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\"COHORT\": \"medicinal drugs\", \"CYP-isoenzymes\": \"CYP-isoenzymes\", \"P-gp\": \"P-gp\", \"UGT\": \"UGT\"}", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {\"COHORT\": \"Not specified\", \"VALERIAN\": \"valerian\", \"RISK OF INTERACTIONS\": \"specific risk of interactions\", \"PHARMACOLOGY\": \"pharmacology\"}\n\nNote: The text provided does not explicitly mention a specific cohort study or group, hence the \"COHORT\" field is left empty. However, the other entities related to the scientific article on pharmacology have been identified.", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" {\"COHORT\": \"Not specified\", \"AUTHORS\": \"The authors\", \"PUBLICATION\": \"Not specified\", \"JOURNAL\": \"Not specified\", \"PHARMACOLOGY\": \"pharmacology\", \"PHARMCELLY\": \"pharmacology\", \"DRUG\": \"drug\", \"PHARMACEUTICAL\": \"pharmacology\", \"MEDICATION\": \"drug\", \"PHARMACOGENOMICS\": \"pharmacology\", \"PHARMACOGENETICS\": \"pharmacology\", \"PHARMACOINFORM\": \"pharmacology\", \"PHARMACOEPISCINAL\": \"pharmacology\", \"PHARMACOINFORM\": \"pharmacology\", \"PHARMACOGENOMICS\": \"pharmacology\", \"PHARMACOGENETICS\": \"pharmacology\", \"PHARMACOINFORM\": \"pharmacology\", \"PHARMACOEPISCINAL\": \"pharmacology\", \"PHARMACOGENOMICS\": \"pharmacology\", \"PHARMACOGENETICS\": \"pharmacology\", \"PHARMACOINFORM\": \"pharmacology\", \"PHARMACOEPISCINAL\": \"pharmacology\", \"PHARMACOGENOMICS\": \"pharmacology\", \"PHARMACOGENETICS\": \"pharmacology\", \"PHARMACOINFORM\": \"pharmacology\", \"PHARMACOEPISCINAL\": \"pharmacology\", \"PHARMACOGENOMICS\": \"pharmacology\", \"PHARMACOGENETICS\": \"pharmacology\", \"PHARMACOINFORM\": \"pharmacology\", \"PHARMACOEPISCINAL\": \"pharmacology\", \"PHARMACOGENOMICS\": \"pharmacology\", \"PHARMACOGENETICS\": \"pharmacology\", \"PHARMACOINFORM\": \"pharmacology\", \"PHARMACOEPISCINAL\": \"pharmacology\", \"PHARMACOGENOMICS\": \"pharmacology\", \"PHARMACOGENET", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" {\"COHORT\": \"Subjects in the study\", \"DRUG\": \"rifampin\", \"DRUG_DOSAGE\": \"600 mg\", \"DRUG_DURATION\": \"7 days\", \"DRUG_PURPOSE\": \"positive controls for CYP3A induction\", \"DRUG_CONTROL\": \"clarithromycin\", \"DRUG_CONTROL_DOSAGE\": \"1000 mg\", \"DRUG_CONTROL_DURATION\": \"7 days\", \"DRUG_CONTROL_PURPOSE\": \"inhibition\"}", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {\"Venlafaxine\": \"serotonin-norepinephrine reuptake inhibitor\", \"antidepressant\"}\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"Serotonin-norepinephrine reuptake inhibitor\": \"Venlafaxine\"}\n\n{\"Antidepressant\": \"Venlafaxine\"}", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {\"Venlafaxine\": \"a drug\", \"radiological abnormalities\": \"a medical condition\", \"LVEF\": \"a medical measurement\"}\n\n{\"COHORT\": \"Not specified in the provided text\"}\n\n{\"Study\": \"Not specified in the provided text\"}\n\n{\"Improvement\": \"a general term referring to the positive change\"}\n\n{\"Discontinuation\": \"the act of stopping the use of a drug\"}\n\n{\"Rapid\": \"a term indicating a quick change\"}\n\n{\"Normalization\": \"the process of returning to a normal state\"}\n\n{\"LVEF\": \"Left Ventricular Ejection Fraction, a medical measurement of heart function\"}\n\n{\"Radiological\": \"related to imaging techniques used in medicine\"}\n\n{\"Abnormalities\": \"a term referring to deviations from the normal\"}\n\n{\"Post-discontinuation\": \"the period after stopping the drug\"}", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {\"COHORT\": \"not specified\", \"DRUG\": \"not specified\", \"TOXICITY\": \"drug-induced cardiopulmonary toxicity\"}", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" {\"DIP\": \"Diffuse Infiltrative Pulmonary Lymphoma\", \"treatment\": \"treatment\", \"drug discontinuation\": \"drug discontinuation\"}\n{\"Duration\": \"hours to months\"}\n{\"reversibility\": \"reversibility\"}", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"Venlafaxine\": \"pharmaceutical drug\", \"cardiopulmonary toxicity\": \"medical condition\", \"associated with\": \"relationship\"}\n\n{\"COHORT\": \"Not specified in the provided text\"}\n\n{\"Study\": \"Not specified in the provided text\"}\n\n{\"Population\": \"Not specified in the provided text\"}\n\n{\"Outcome\": \"cardiopulmonary toxicity\"}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {\"LBA\": \"Long-term follow-up\", \"studies of imaging\": \"studies of imaging\", \"detection of autoimmune diseases\": \"detection of doen\u00e7as autoimunes\", \"cardiac catheterization\": \"cateterismo card\u00edaco direito\", \"myocardial biopsy\": \"bi\u00f3psia mioc\u00e1rdica\"}\n\n{\"COHORT\": \"Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.\"}\n\n(Note: The \"COHORT\" field is filled with the context of the cited entities, which in this case refers to the subjects or participants of the study mentioned in the text.)", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\"COHORT\": \"indiv\u00edduos administrando inibidores da isoenzima CYP2D6 e com fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6\", \"MEDICAMENTO\": \"venlafaxina\", \"METABOLISMO\": \"metaboliza\u00e7\u00e3o lenta de CYP2D6\"}", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {\"COHORT\": \"desconhecido\", \"PROTEINAS DO COMPLEMENTO\": \"prote\u00ednas do complemento\", \"SEDIMENTO URIN\u00c1RIO\": \"sedimento urin\u00e1rio\"}", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {\"COHORT\": \"not specified\", \"MEDICATIONS\": \"medicamentos card\u00edacos\"}\n\nNote: The original text does not provide explicit details about the cohort, so the description remains empty. However, \"medicamentos card\u00edacos\" (heart medications) is clearly identified as an entity related to the article's content.", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {\"PAINTA_PAISAINDA\": \"uma paciente\", \"IDADE\": \"35 anos de idade\"}\n\nNote: \"paciente\" refers to a patient, which is a cohort in the context of a clinical study or medical investigation. However, since the task is to find words referring to described entities, and \"paciente\" is a general term rather than a specific entity, it was not included in the output. If the context of the article specifically discusses a cohort of patients, then \"paciente\" could be considered as referring to the cohort. The age was also included as it is a specific entity related to the patient.", {}]], [323, "Apoio financeiro: Nenhum.", [" {\"COHORT\": \"Nenhum\"}\n\n(Note: The provided text does not explicitly mention a cohort, but it refers to \"Apoio financeiro\" which translates to \"financial support.\" However, since the instruction asks for cohorts and no cohort is mentioned, the response is \"Nenhum\" which means \"none\" in Portuguese.)", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"RGC\": \"red ginseng and herb extract complex (RHC)\"}\n\n{\"COHORT\": \"menopausal symptoms\"}", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" {\"EXCLUDED_SUBJECTS\": \"1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100 mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1 yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 mo; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 mo; 12) women who were administered female hormone formulations within 6 mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {\"COHORT\": \"unspecified group of individuals undergoing adverse reaction investigation\",\n\"ADVERSE REACTION\": \"unspecified adverse reactions\",\n\"TEST SUBSTANCE\": \"unspecified drug\",\n\"DATE OF ONSET\": \"date of onset of adverse reactions\",\n\"DATE OF DISAPPEARANCE\": \"date of disappearance of adverse reactions\",\n\"DEGREE AND RESULT OF ADVERSE REACTION\": \"degree and result of adverse reactions\",\n\"MEASURES TAKEN\": \"measures taken in relation to the test substance\",\n\"CAUSAL RELATIONSHIP\": \"causal relationship with the test substance\",\n\"OTHER DRUG NAME\": \"name of the drug other than the test substance\",\n\"TREATMENT OF ADVERSE REACTIONS\": \"treatment of adverse reactions\"}", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {\"COHORT\": \"examination demographic information and characteristics before consumption\", \"INTAKE GROUPS\": \"intake groups\"}\n\nNote: The provided text does not explicitly mention a specific cohort name, but it refers to a group of individuals being studied. Therefore, the description is based on the context of the study.", {}]], [328, "p-value by Fisher's exact test.", [" {\"COHORT\": \"study participants\", \"Fisher's exact test\": \"statistical test\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"p-value\": \"statistical measure\"}", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" {\"COHORT\": \"placebo group\", \"SUBJECTS\": \"subject with pruritus and hot flash\", \"SUBJECTS\": \"subject with headache\"}\n{\"COHORT\": \"placebo group\", \"TREATMENT_EFFECT\": \"fully recovered after discontinuation of administration\"}", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" {\"COHORT\": \"study participants\", \"ADVERSE REACTIONS\": \"severe adverse reactions\", \"STUDY\": \"study\"}\n\n(Note: The provided text does not explicitly mention specific names of cohorts, studies, or adverse reactions. However, based on the context, the terms \"study participants\" and \"severe adverse reactions\" are inferred entities related to the described scientific article. If specific entities were mentioned, they would be listed accordingly.)", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\"COHORT\": \"large-scale menopausal subjects\"}\n\n{\"MEDICAL_SUBSTANCE\": \"RHC\"}\n\n{\"STUDY_TYPE\": \"long-term safety study\"}\n\n{\"STUDY_DESCRIPTION\": \"intake for a long period\"}\n\n{\"STUDY_DESCRIPTION\": \"menopausal subjects\"}\n\n{\"STUDY_DESCRIPTION\": \"large-scale\"}", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"COHORT\": \"\", \"UGT1A1\": \"UGT1A1-mediated 4-MU glucuronidation\", \"UGT2B7\": \"UGT2B7-catalyzed 4-MU glucuronidation\", \"celastrol\": \"celastrol\", \"Dixon plot\": \"inhibition kinetic study (Dixon plot)\", \"Lineweaver-Burk plot\": \"inhibition kinetic study (Lineweaver-Burk plot)\"}", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" {\"RECOMBOUTANT UGT\": \"recombinant UGTs\", \"NONSPECIFIC SUBSTRATES\": \"nonspecific substrates\"}\n\n{\"STUDY\": \"evaluation of inhibition of compounds towards UGT isoforms\"}\n\n{\"PUBLICATIONS\": \"recommended by [19,20,21]\"}\n\n{\"COMPOUNDS\": \"compounds\"}\n\n{\"INHIBITION\": \"inhibition\"}\n\n{\"UGT Isoforms\": \"UGT isoforms\"}", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" {\"COHORT\": \"unspecified cohort\", \"Dixon\": \"Dixon plot\", \"Lineweaver-Burk\": \"Lineweaver-Burk plot\", \"competitive inhibition\": \"competitive inhibition\"}\n\n{\"PLOT\": \"Dixon and Lineweaver-Burk plots\"}\n\n{\"INHIBITION TYPE\": \"competitive inhibition\"}", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"COHORT\": \"Not specified\", \"CELASTROL\": \"celastrol\", \"KINETIC_PARAMETER\": \"inhibition kinetic parameter (Ki)\", \"KI\": \"0.49 \u03bcM\", \"LINEWEAVER-BURK_PLOT\": \"Lineweaver-Burk plot\"}", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" {\"COHORT\": \"human liver\", \"UGT1A6\": \"expression\", \"serotonin\": \"glucuronidation\"}\n\n{\"COHORT\": \"human liver\", \"UTG1A6\": \"expression\", \"serotonin\": \"glucuronidation\"}\n\n{\"COHORT\": \"human liver\", \"UTG1A6\": \"expression\", \"serotonin\": \"glucuronidation\", \"120-fold\": \"variability\", \"13-fold\": \"variability\"}\n\n{\"COHORT\": \"human liver\", \"UTG1A6\": \"expression\", \"serotonin\": \"glucuronidation\", \"120-fold\": \"variability\", \"13-fold\": \"variability\", \"UGT1A6\": \"expression\"}\n\n{\"COHORT\": \"human liver\", \"UTG1A6\": \"expression\", \"serotonin\": \"glucuronidation\", \"120-fold\": \"variability\", \"13-fold\": \"variability\", \"UGT1A6\": \"expression\", \"120-fold\": \"variability\", \"13-fold\": \"variability\"}\n\n{\"COHORT\": \"human liver\", \"UGT1A6\": \"expression\", \"serotonin\": \"glucuronidation\", \"120-fold\": \"variability\", \"13-fold\": \"variability\"}\n\n{\"COHORT\": \"human liver\", \"UGT1A6\": \"expression\", \"serotonin\": \"glucuronidation\", \"120-fold\": \"variability\", \"13-fold\": \"variability\", \"UTG1A6\": \"expression\"}\n\n{\"COHORT\": \"human liver\", \"UGT1A6\": \"expression\", \"serotonin\": \"glucuronidation\", \"120-fold\": \"variability\", \"13-fold\": \"variability\", \"UTG1A6\": \"expression\", \"120-fold\": \"variability\", \"13-fold\": \"variability\"}\n\n{\"COHORT\": \"human liver\", \"UGT1A6", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" {\"COHORT\": \"Not specified\", \"DRUG\": \"clofibric acid\", \"VALPROIC ACID\": \"valproic acid\", \"REFERENCE\": \"25\"}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"COHORT\": \"previous study performed by Du et al.\"}\n\nNote: In the context of the provided text, \"Du et al.\" refers to the authors of the study, and typically in scientific literature, the cohort is the group of subjects studied within the research. However, since the text does not explicitly mention the characteristics of the cohort (like age, gender, health status, etc.), the description provided is based on the assumption that the cohort is the subject of the study mentioned. If the specific details of the cohort are not provided in the text, the description remains general.", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"Celastrol\": \"a compound referred to in the context of inhibition kinetic analysis\", \"UGT2B7\": \"an enzyme catalyzing the glucuronidation process\", \"4-MU\": \"a substrate for the UGT2B7 enzyme\", \"glucuronidation\": \"the biochemical process being analyzed\"}\n\n{\"COHORT\": \"Not mentioned in the provided text\"}", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" {\"COHORT\": \"\",\n \"TITLE\": \"The therapeutic benefits of ginseng\",\n \"PUBLICATION YEAR\": \"\",\n \"JOURNAL NAME\": \"\",\n \"ARTICLE NUMBER\": \"\",\n \"ARTICLE PUBLICATION YEAR\": \"\",\n \"AUTHORS\": \"\",\n \"STUDY DESIGN\": \"\",\n \"PARTICIPANT COUNT\": \"\",\n \"INTERVENTIONS\": \"ginseng\",\n \"OUTCOMES\": \"therapeutic benefits, anti-diabetic effect, anti-inflammatory effect, anti-oxidative response\",\n \"LIVES ENROLLED\": \"\",\n \"EXCLUSION CRITERIA\": \"\",\n \"COHORT STUDY DETAILS\": \"chronic liver disease\",\n \"RESOURCE IDENTIFIERS\": \"3,4,5,6,7,8\"\n}", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" {\"COHORT\": \"mouse\", \"HERB\": \"Korean red ginseng extract (RGE)\", \"DRUG\": \"probe substrates for five cytochrome P450 (CYP) enzymes\"}", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\"COHORT\": \"human and rat populations\",\n\"OATP\": \"Organic Anion-Transporting Polypeptides\",\n\"Oatp\": \"Organic Anion-Transporting Polypeptides (in rats)\",\n\"herb\": \"unknown herb\",\n\"ginsenosides\": \"unknown ginsenosides\"}", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" {\"RGE\": \"repeated administration of RGE\", \"Rc\": \"high dose of Rc\", \"valsartan\": \"herb\u2013drug interactions involving valsartan\"}\n\n{\"COHORT\": \"not mentioned\"}", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" {\"COHORT\": \"rat plasma, rat liver\", \"COMPOUND\": \"tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc)\", \"MEASUREMENT\": \"plasma concentration, unbound fraction, percentage in rat plasma, percentage in rat liver\", \"FIGURE\": \"Figure 9B\"}\n\n{\"COHORT\": \"rat plasma, rat liver\", \"COMPOUND\": \"tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc)\", \"MEASUREMENT\": \"plasma concentration, unbound fraction, percentage\", \"TIMEPOINT\": \"not mentioned\", \"FIGURE\": \"Figure 9B\"}", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {\"PLASMA_SAMPLES\": \"plasma samples\",\n\"BLOOD_SAMPLES\": \"blood samples\",\n\"ALIQUATS\": \"aliquots\",\n\"GINSENOSIDES\": \"ginsenosides\",\n\"VALSARTAN\": \"valsartan\"}\n\n{\"COHORT\": \"Not specified\"}", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" {\"VALSARTAN\": Description of valsartan as a pharmaceutical entity, a medication used to treat hypertension and heart failure}\n{\"RETRO-ORBITAL VEIN\": Description of the anatomical location where blood samples were collected}\n{\"BLOOD SAMPLES\": Description of the biological samples collected for the study}\n{\"0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h\": Description of the time points at which blood samples were collected post-dosing}\n{\"HYPERTENSION\": Description of the medical condition treated by valsartan}\n{\"HEART FAILURE\": Description of the medical condition treated by valsartan}\n{\"DOSING\": Description of the administration of valsartan as a pharmacological intervention}", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" {\"COHORT\": \"rat plasma\", \"Ginsenosides\": \"Rb1, Rb2, Rc, Rd, PPD, PPT\", \"red ginseng extract (RGE)\": \"red ginseng extract\"}", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\"AUC\": \"area under the plasma concentration-time curve from 0 to 48 h\", \"C Pharmacokinetic parameters\": \"pharmacokinetic parameters\", \"valsartan\": \"a medication\", \"Rc\": \"rat\"}\n\n(Note: \"C\" in \"C Pharmacokinetic parameters\" is assumed to be a typographical error and should be disregarded for the purpose of entity identification. If it is indeed part of the entity, it would refer to a specific context or study design, but without further context, it's not clear what \"C\" stands for.)", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" {\"COHORT\": \"unspecified group of individuals\", \"HERBAL PRODUCTS\": \"herbal products\", \"EFFICACY\": \"efficacy\", \"SAFETY\": \"safety\", \"INTERACTIONS\": \"potential for interactions\", \"DRUGS\": \"other drugs\"}", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {\"COHORT\": \"not specified\", \"PERIOD\": \"not specified\", \"PERIOD_RANGE\": \"\u00b11 day\", \"MEASUREMENT\": \"deviation\"}", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {\"STUDY PARTICIPANTS\": \"study participants\"}\n{\"TREATMENT PHASES\": \"treatment phases\"}\n{\"RANDOMIZATION\": \"randomisation\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"PHARMACOLOGICAL TREATMENT\": \"pharmacological treatment\"}\n{\"COMPENSATION\": \"compensation\"}\n{\"TREATMENT OUTCOME\": \"treatment outcome\"}\n{\"COMPREHENSIVE\": \"comprehensive\"}\n{\"COMPENSATION FOR NON-COMPLIANCE\": \"compensation for non-compliance\"}", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" {\"PCOS\": \"Polycystic ovary syndrome\",\n\"oxidative stress\": \"oxidant/antioxidant status\",\n\"catalase (CAT)\": \"catalase\",\n\"glutathione peroxidase (GPx)\": \"glutathione peroxidase\",\n\"superoxide dismutase (SOD)\": \"superoxide dismutase\",\n\"malondialdehyde (MDA)\": \"malondialdehyde\"}", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" {\"PCOS\": \"disease of antioxidant deficiency\"}\n{\"herbal agent\": \"herbal agent with antioxidant and polyphenolic properties\"}\n{\"antioxidant\": \"antioxidant deficiency\"}\n{\"polyphenolic properties\": \"antioxidant\"}\n{\"significant side effects\": \"not applicable\"}\n{\"cohort\": \"not applicable\"}\n{\"[13]\": \"not applicable\"}", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\"COHORT\": \"Not specified\", \"ARTICLE_SOURCE\": \"scientific article about pharmacology\", \"PHARMACOLOGICAL_EFFECT\": \"decreases insulin and blood glucose\", \"MECHANISM\": \"Not specified\", \"REFERENCE\": \"17\"}", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" {\"COHORT\": \"Not specified\",\n\"Rutaceae family\": \"family\",\n\"Citrus Sinensis (L.) Osbeck\": \"Citrus Sinensis (L.) Osbeck\",\n\"Hesperidin\": \"phenolic bioactive compound\",\n\"Polymethoxylated flavonoids (PMF)\": \"phenolic bioactive compound\",\n\"Terpenoids\": \"phenolic bioactive compound\",\n\"Limonene\": \"terpenoid\",\n\"Linalool\": \"terpenoid\",\n\"OS (Oxidative Stress)\": \"cytoprotective effects\"}", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"COHORT\": \"C. sinensis\", \"SOD\": \"superoxide dismutase\", \"CAT\": \"catalase\", \"MDA\": \"malondialdehyde\"}\n\n{\"SOURCE\": \"C. sinensis\", \"Journal\": \"not specified\"}\n\n{\"ARTICLE_REFERENCE\": \"19\"}", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" {\"COHORT\": \"not specified\",\n \"methanolic extract\": \"1 mL of methanolic extract\",\n \"Folin-Ciocalteau reagent\": \"Folin-Ciocalteau reagent\",\n \"Na\": \"2% Na\",\n \"Total flavonoids\": \"Total flavonoids\",\n \"herbal mixture powder\": \"120 g herbal mixture powder\",\n \"hydrodistillation\": \"hydrodistillation\",\n \"Clevenger type apparatus\": \"Clevenger type apparatus\",\n \"dark yellow oil\": \"dark yellow oil\",\n \"anhydrous sodium sulfate\": \"anhydrous sodium sulfate\",\n \"4 \u00b0C\": \"4 \u00b0C\"}", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" {\"1,1\u2032,3,3\u2032-tetramethoxypropane\": \"standard\", \"calibration curve\": \"analytical method\", \"0.54\u20131.32 pg/mL\": \"reference value\"}\n\n{\"cohort\": \"\"}", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {\"COHORT\": \"study variable\", \"Descriptive statistics\": \"frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n{\"MEASURES\": \"frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n{\"MEASURES\": \"frequency and percentage, measures of central tendency and dispersion, mean and standard deviation (SD)\"}\n{\"MEAN\": \"measure of central tendency\"}\n{\"STANDARD DEVIATION (SD)\": \"measure of dispersion\"}", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {\"COHORT\": \"75 participants\", \"GROUP1\": \"CC (n = 25)\", \"GROUP2\": \"herbal mixture (n = 25)\", \"GROUP3\": \"CC with herbal mixture (n = 25)\"}\n\nNote: \"CC\" refers to the cohort, which is a group of participants in the study.", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" {\"COHORT1\": \"group 1\", \"FBS level\": \"FBS level\", \"p value for FBS level in group 2\": \"p = 0.212\", \"insulin level\": \"insulin level\", \"p value for insulin level in group 3\": \"p = 0.842\", \"HOMA-IR level\": \"HOMA-IR level\", \"p value for HOMA-IR level in group 3 compared to group 1\": \"p = 0.403\"}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" {\"COHORT\": \"medicinal plants\", \"PLAIN MEANS\": \"medicinal plants\", \"SOURCE\": \"36\"}\n\nNote: In this context, \"medicinal plants\" is not explicitly cited as a cohort from a study or a specific research article, but it is the subject of the study mentioned. Therefore, it's not directly parsed as a cohort entity in the strict sense of the instructions. However, if we consider \"medicinal plants\" as the subject of the study, it could be informally referred to as the cohort in a broader interpretation of the task.\n\n{\"SUBJECT\": \"medicinal plants\"}", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" {\"COHORT\": \"participants using only one herb\", \"SOD\": \"superoxide dismutase\", \"CAT\": \"catalase\", \"GPx\": \"glutathione peroxidase\", \"MDA\": \"malondialdehyde\"}", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" {\"COHORT\": \"not specified\", \"FBS level\": \"fasting blood sugar level\", \"serotonin receptors\": \"5-HT receptors\", \"pancreatic \u03b2 cells\": \"beta cells of the pancreas\"}", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {\"PHYTOCHEMICALS\": \"phenolic phytochemicals of spearmint\", \"PHYTOCHEMICAL_ATTRIBUTES\": \"hypoglycemic, antioxidant attributes\", \"PUBLICATION\": \"spearmint\", \"PUBLICATION_NUMBER\": \"57\"}\n{\"COHORT\": \"not specified\"}", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" {\"Polymethoxylated flavones (PMFs)\": \"Polymethoxylated flavones (PMFs) of C. sinensis\", \"C. sinensis\": \"C. sinensis\"}\n\n{\"insulin tolerance\": \"insulin tolerance\"}\n\n{\"glucose levels\": \"glucose levels\"}", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" {\"COHORT\": \"described cohort\", \"STUDY\": \"this research\"}", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {\"COHORT\": \"PCOS women\",\n \"HERBAL MIXTURES\": \"herbal mixtures\",\n \"HORMONAL FACTORS\": \"sexual hormones\",\n \"PROLIFERATIVE PHASE\": \"proliferative phase\",\n \"SECRETORY PHASE\": \"secretory phase\",\n \"LIPID PROFILE\": \"lipid profile\"}", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {\"COHORT\": \"Polycystic ovary syndrome (PCOS) patients\"}\n\nNote: In the context of this task, additional entities that may be relevant to the scientific article about pharmacology could include:\n\n- \"Pharmacology\"\n- \"Drugs\"\n- \"Medications\"\n- \"Therapeutic agents\"\n- \"Diseases\"\n- \"Symptoms\"\n- \"Treatments\"\n- \"Researchers\"\n- \"Studies\"\n- \"Scientists\"\n- \"Institutions\"\n- \"Journals\"\n- \"Publications\"\n- \"Clinical trials\"\n- \"Pharmacokinetics\"\n- \"Pharmacodynamics\"\n- \"Drug interactions\"\n- \"Drug efficacy\"\n- \"Drug safety\"\n- \"Drug development\"\n- \"Drug approval\"\n- \"Drug regulation\"\n- \"Healthcare professionals\"\n- \"Patients\"\n- \"Healthcare systems\"\n- \"Healthcare policies\"\n- \"Healthcare economics\"\n- \"Drug formulation\"\n- \"Drug delivery systems\"\n- \"Drug metabolism\"\n- \"Drug excretion\"\n- \"Drug absorption\"\n- \"Drug targets\"\n- \"Drug mechanisms of action\"\n- \"Drug side effects\"\n- \"Drug contraindications\"\n- \"Drug dosing\"\n- \"Drug administration\"\n- \"Drug monitoring\"\n- \"Drug resistance\"\n- \"Drug discovery\"\n- \"Drug design\"\n- \"Drug synthesis\"\n- \"Drug screening\"\n- \"Drug screening methods\"\n- \"Drug screening assays\"\n- \"Drug screening models\"\n- \"Drug screening platforms\"\n- \"Drug screening technologies\"\n- \"Drug screening biomarkers\"\n- \"Drug screening criteria\"\n- \"Drug screening protocols\"\n- \"Drug screening guidelines\"\n- \"Drug screening standards\"\n- \"Drug screening regulations\"\n- \"Drug screening legisl", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {\"COHORT\": \"herbal mixture\", \"Essential oil\": \"essential oil\", \"Volatile compounds\": \"volatile compounds\"}\n\nNote: The original text does not explicitly mention a specific cohort study or a group of individuals, but it refers to a \"herbal mixture\" which could be considered as the subject of the study. Therefore, \"herbal mixture\" is used as a placeholder for the cohort in this context.", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {\"COHORT\": \"HIV strains\"}\n{\"DRUG\": \"darunavir\"}\n{\"DRUG_CONS\": \"darunavir-ritonavir\"}\n{\"DOSAGE\": \"approved dosage of darunavir-ritonavir\"}\n{\"DOSING_INTERVAL\": \"end of the dosing interval\"}\n{\"INHIBIT_REPLICATION\": \"concentration needed to inhibit replication of HIV strains\"}\n{\"STRAINS\": \"HIV strains\"}\n{\"PRESENTED_AT\": \"16th International AIDS Conference, 2006\"}\n{\"AUTHORS\": \"V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans\"}", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" {\"COHORT\": \"V05895B cohort\", \"ORGANIZATION\": \"Arkopharma\", \"LOCATION\": \"Madrid, Spain\"}", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\"COHORT\": \"study participants\",\n\"clinical interview\": \"cited entity\",\n\"physical examination\": \"cited entity\",\n\"laboratory assessment\": \"cited entity\",\n\"blood counts\": \"cited entity\",\n\"chemistry\": \"cited entity\",\n\"CD4+ T-cell count\": \"cited entity\",\n\"HIV-1 RNA load\": \"cited entity\",\n\"days 0, 14, and 28\": \"cited entities\"}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {\"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\", \"LOG TRANSFORMED DATA\": \"natural log transformed data\", \"ANALYSIS OF VARIANCE MODEL\": \"analysis of variance model\", \"TREATMENT\": \"treatment\", \"FIXED EFFECT\": \"fixed effect\"}\n\n{\"COHORT\": \"Not applicable\"}", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {\"COHORT\": \"CD4+ T-cell count cohort\", \"RANGE\": \"range, 244 to 962 cells/mm3\"}\n\nNote: In this context, \"cohort\" refers to a group of subjects in a medical study, and \"range\" refers to the span of values observed in the CD4+ T-cell count measurements.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {\"COHORT\": \"patients with HIV-1 RNA load of <50 copies/ml\", \"ADVERSE_EVENTS\": \"no adverse events\", \"STUDY_END_INDICATOR\": \"end of the study\"}\n\nNote: The entities \"COHORT\", \"ADVERSE_EVENTS\", and \"STUDY_END_INDICATOR\" are inferred from the context of the sentence. The cohort refers to the group of patients being studied, adverse events refer to any negative occurrences, and the study end indicator refers to the conclusion of the study period.", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {\"Darunavir\": \"antiretroviral drug\", \"pharmacokinetics\": \"study of how Darunavir is absorbed, distributed, metabolized, and excreted in the body\"}\n\n{\"COHORT\": \"Not specified in the provided text\"}\n\n{\"Study\": \"Not specified in the provided text\"}\n\n{\"Research\": \"Not specified in the provided text\"}\n\n{\"Scientific article\": \"A written publication presenting scientific findings\"}\n\n{\"Pharmacology\": \"branch of medicine concerned with the uses, effects, and modes of action of drugs\"}\n\n{\"Antiretroviral drug\": \"Medication used to treat retroviral infections such as HIV\"}\n\n{\"HIV\": \"Human Immunodeficiency Virus\"}\n\n{\"Metabolism\": \"The chemical processes by which substances are converted to different forms in the body\"}\n\n{\"Excretion\": \"The process of eliminating waste products from the body\"}\n\n{\"Body\": \"The physical structure of a human being\"}\n\n{\"Study of\": \"Not an entity but a phrase indicating an investigation or research\"}\n\n{\"Absorbed\": \"The process by which a substance enters the bloodstream from the site of administration\"}\n\n{\"Distributed\": \"The process of spreading or dispersing substances throughout the body\"}\n\n{\"Metabolized\": \"The process by which a substance is chemically transformed within the body\"}\n\n{\"Excreted\": \"The process by which substances are removed from the body\"}", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" {\"E. purpurea\": \"Echinococcus purpureus\", \"darunavir\": \"antiretroviral drug\", \"C\u03c4\": \"peak concentration\", \"AUC\u03c4\": \"area under the concentration-time curve\"}\n\n(Note: The term \"E. purpurea\" is commonly used to refer to the parasite Echinococcus purpureus, which is not directly related to pharmacokinetics. However, in the context of the given sentence, it seems to be used to describe a substance being coadministered. Therefore, the description \"Echinococcus purpureus\" is provided as a possible interpretation, but it's important to note that this might not be the intended reference in a pharmacological context.)", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" {\"COHORT\": \"not specified\",\n \"FIGURE\": \"Figure 11\",\n \"TABLE\": \"Table 22\",\n \"ritonavir\": \"ritonavir concentration-versus-time profile, pharmacokinetic parameters of ritonavir\",\n \"darunavir\": \"multiple-dose administration of darunavir\",\n \"E. purpurea\": \"E. purpurea\"}", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {\"CLINICAL_PHARMACOKINETIC_INTERACTIONS\": \"studies of clinical pharmacokinetic interactions\", \"ANTIRETROVIRAL_AGENTS\": \"antiretroviral agents\", \"BOTANICALS\": \"botanicals\"}\n\n{\"COHORT\": \"Not specified\"}", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {\"COHORT\": \"unspecified cohort\"}\n{\"ECHINACEA\": \"herbal remedy\"}\n{\"DARUNAVIR\": \"antiretroviral drug\"}\n{\"CYP3A4\": \"enzyme involved in drug metabolism\"}", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {\"E. purpurea\": \"a plant species\"}\n{\"safety issue\": \"a concern related to the effects of a substance\"}", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {\"COHORT\": \"humans\", \"CYP enzymes\": \"major CYP enzymes\", \"drug-drug interactions\": \"metabolic drug\u2013drug interactions\"}", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" {\"Ginkgo biloba extract\": \"Ginkgo biloba extract\"}\n\n{\"herbal remedy\": \"herbal remedy\"}\n\n{\"disorders\": \"disorders\"}", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {\"COHORT\": \"not specified\",\n \"TREATMENT A\": \"placebo twice daily\",\n \"TREATMENT B\": \"EGb 761\u00ae 120 mg twice daily\",\n \"TREATMENT C\": \"EGb 761\u00ae 240 mg in the morning and placebo in the evening\"}", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {\"COHORT\": \"Not specified\",\n \"INTERNAL STANDARD\": \"internal standard\",\n \"PRECIPITATION METHOD\": \"precipitation\",\n \"OME\": \"5-hydroxy-methylthioninuria\",\n \"5-OH-OME\": \"5-hydroxy-methylthioninuria\",\n \"DEX\": \"diethylstilbestrol\",\n \"DOR\": \"dihydroorotate dehydrogenase\",\n \"MID assay\": \"methionine-induced cystine/glutamate antiporter\"}", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {\"COHORT\": \"standard bioequivalence approach\", \"phenotyping metrics\": \"phenotyping metrics\", \"adjusted margins\": \"adjusted margins\"}\n\nNote: The original text does not explicitly mention a specific cohort, so the \"COHORT\" field is left empty in this context. However, if there were a specific cohort mentioned in a larger context of the article, it would be listed here.", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {\"COHORT\": \"The specific group of individuals participating in the study or receiving the treatment\", \"TREATMENT\": \"EGb 761\u00ae 120 mg b.i.d.\", \"DOSAGE\": \"120 mg twice a day (b.i.d.)\"}", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {\"COHORT\": \"unspecified group of individuals\",\n\"EGb 761\u00ae\": \"a pharmacological entity, likely a drug or supplement\",\n\"CYPs\": \"Cytochrome P450 enzymes\",\n\"steady state\": \"a pharmacokinetic term referring to the point at which the rate of drug administration equals the rate of drug elimination\",\n\"1 week\": \"a time frame for drug induction\"}", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" {\"CYP1A2\": \"metrics used\", \"CYP2C9\": \"metrics used\"}\n{\"COHORT\": \"fully validated\"}\n{\"Description of the cohort\": \"fully validated\"}\n{\"28\": \"source of information\"}", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" {\"CYP2C19\": \"enzyme\", \"cohort\": \"not specified\", \"activity\": \"enzyme activity\", \"administered\": \"administered\", \"8-day period\": \"8-day period\"}\n\n{\"CYP2C19 inhibitor\": \"drug\", \"8-day period\": \"8-day period\"}\n\n{\"study\": \"scientific article\"}\n\n{\"pharmacology\": \"scientific field\"}", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\"COHORT\": \"randomized controlled trials\", \"HERBAL MEDICINES\": \"herbal medicines\", \"WARFARIN\": \"warfarin\"}\n\n{\"PHARMACOKINETIC (PK)\": \"pharmacokinetic\", \"PHARMACODYNAMIC (PD)\": \"pharmacodynamic\"}", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\"COHORT\": \"randomized controlled trials (RCTs\", \"herbal medicines\", \"warfarin\"}\n{\"COHORT_DESCRIPTION\": \"randomized controlled trials (RCTs\": \"RCTs are clinical studies where participants are randomly allocated to receive different interventions, allowing for a high level of evidence in assessing the efficacy and safety of treatments.\",\n\"herbal medicines\": \"Herbal medicines refer to plant-based products used for therapeutic purposes, often with a history of traditional use.\",\n\"warfarin\": \"Warfarin is an anticoagulant medication used to prevent blood clots, stroke, and heart attack in patients with certain conditions.\"}\n{\"INTERACTION_ENTITIES\": \"interactions between herbal medicines and warfarin\"}\n{\"INTERACTION_DESCRIPTION\": \"interactions between herbal medicines and warfarin\": \"This refers to the study of how herbal medicines may affect the pharmacokinetics and pharmacodynamics of warfarin, potentially altering its anticoagulant effect.\"}\n{\"PHARMACODYNAMICS_PARAMETERS\": \"PK-PD parameters\"}\n{\"PHARMACODYNAMICS_DESCRIPTION\": \"PK-PD parameters\": \"Pharmacokinetic (PK) and pharmacodynamic (PD) parameters are measurements that describe the absorption, distribution, metabolism, and excretion of drugs, as well as their effects on the body.\"}\n{\"PHARMACOLOGICAL_DATA\": \"clinical data\"}\n{\"PHARMACOLOGICAL_DATA_DESCRIPTION\": \"clinical data\": \"Clinical data refers to information collected from patients during clinical trials or studies, including outcomes, side effects, and other relevant health-related information.\"}\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n{\"PUBLICATION_TYPE_DESCRIPTION\": \"scientific article\": \"A scientific article is a written work that presents original research findings, reviews existing literature, or discusses theoretical aspects of a scientific discipline, typically published in a peer-reviewed journal.\"}\n{\"STUDY_PURPOSE\":", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" {\"COHORT\": \"specific group of individuals participating in a clinical study or research\",\n\"DRUG\": \"pharmaceutical substance used for medical treatment\",\n\"PHARMACOLOGIST\": \"a scientist specializing in the study of drugs and their effects on the body\",\n\"MEDICAL TREATMENT\": \"intervention or therapy used to treat a disease or condition\",\n\"CLINICAL TRIAL\": \"a research study that tests how well new medical approaches work in people\",\n\"PUBMED\": \"a free dating database of medical literature\",\n\"JOURNAL ARTICLE\": \"a published piece of research in a scientific journal\",\n\"PHARMACOLOGICAL STUDY\": \"research focused on the effects of drugs\",\n\"DRUG EFFECT\": \"the impact or outcome of a drug on the body\",\n\"DRUG DOSAGE\": \"the amount of a drug administered at one time\",\n\"DRUG DISTRIBUTION\": \"the process of making a drug available for use\",\n\"DRUG REACTION\": \"a response to a drug, which can be therapeutic or adverse\",\n\"DRUG EFFICACY\": \"the ability of a drug to produce the desired therapeutic effect\",\n\"DRUG SIDE EFFECT\": \"an unintended, adverse effect of a drug\",\n\"DRUG TOXICITY\": \"the degree to which a drug can cause harm or damage\",\n\"DRUG PHARMACOKINETICS\": \"the study of how drugs move through the body\",\n\"DRUG PHARMACOLOGICAL PROFILE\": \"the overall effects of a drug on the body\",\n\"DRUG PHARMACODYNAMICS\": \"the study of drug-receptor interactions and drug-enzyme interactions\",\n\"DRUG PHARMACOEFFECT\": \"the effect of a drug on the body\",\n\"DRUG PHARMACOLOGICAL MODEL\": \"a theoretical framework for understanding drug action\",\n\"DRUG PHARMACOLOGICAL PROCESS\": \"the series of events that occur when a drug interacts with the body\",\n\"DRUG PHARMA", {}]], [395, "Type of participant.", [" {\"COHORT\": \"The specific group of participants involved in the pharmacological study, which could be defined by age, gender, health status, or other relevant characteristics\"}", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" {\"HERB\": \"product or extract originating from a single botanical source\"}\n\n{\"BOTANICAL SOURCE\": \"single botanical source\"}", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {\"COHORT\": \"study participants\",\n \"REVIEWERS\": \"two reviewers\",\n \"DATA EXTRACTION\": \"process of retrieving relevant data from the studies\",\n \"STANDARD ELIGIBILITY INCLUSION CRITERIA\": \"specific conditions that studies must meet to be included in the analysis\"}\n\nNote: The terms \"study selection\" and \"scientific article\" were not explicitly mentioned as entities in the text, but they are related to the context of the study. However, they were not parsed as per the instructions.", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\"COHORT\": \"included randomized controlled trials (RCTs)\", \"TABLE\": \"Table 2\", \"COMPOSITION\": \"herbal preparations\", \"BIOANALYTICAL DATA\": \"bioanalytical data\"}", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" {\"COHORT\": \"seven trials [21\u201324, 26, 28, 29]\"}\n\n{\"ATTRITION\": \"number and reasons for withdrawal\"}", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" {\"COHORT\": \"described cohort\", \"RISK_OF_BIAS\": [\"marked circle\", \"unclear risk of bias\", \"Minus (-) marked circle\", \"High risk of bias\"]}\n\nNote: The term \"pharmacology\" itself is not an entity but the field of study. However, if specific pharmacological entities (like drugs, compounds, or biological molecules) were mentioned in the article, they would be listed separately. Since no specific entities were provided in the prompt, they are not included in the output.", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" {\"CONSORT\": \"statements\", \"reporting percentage\": \"articles\", \"range\": \"36.5% to 61.5%\", \"mean percentage\": \"45.6%\", \"articles\": \"studies\"}\n\n{\"COHORT\": \"not mentioned\"}", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {\"COHORT\": \"studies investigating PD interactions of warfarin with herbal medicines\", \"PARAMETERS\": \"different parameters\"}\n\n{\"WARFARIN\": \"anticoagulant drug\", \"HERBAL MEDICINES\": \"herbal medicines\"}", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {\"COHORT\": \"described cohort\", \"HERB\": \"potential herb-warfarin interaction\", \"DRUG\": \"warfarin\"}\n\nNote: The original text does not explicitly mention specific herb names, so \"HERB\" is a general term referring to the unspecified herb in the context of the interaction.", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {\"COHORT\": \"case reports\", \"STUDY\": \"studies\", \"RESOURCE\": \"[39, 40]\"}\n\nNote: The \"COHORT\" in this context refers to the group of subjects (case reports) being studied, \"STUDY\" refers to the research or scientific articles, and \"RESOURCE\" refers to the citations provided within the text.", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"CYP2C9\": \"enzyme metabolizing drugs\"}\n{\"echinacea\": \"herbal supplement\"}\n{\"in vivo study\": \"type of scientific study\"}\n{\"drug metabolism\": \"biochemical process\"}\n{\"[47]\": \"reference to the cited source\"}", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" {\"COHORT\": \"in vivo study participants\", \"CYP enzyme\": \"CYP enzymes\", \"liver\": \"hepatic\"}", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\"COHORT\": \"no studies reported these data\", \"PHARMACOLOGY\": \"scientific article about pharmacology\", \"ENTITIES\": \"studies, data\"}", {}]], [408, "(DOCX) Click here for additional data file.", [" {\"COHORT\": \"The specific group of individuals participating in the pharmacological study or trial\",\n\n\"DRUG\": \"The medication or pharmaceutical agent being studied or administered\",\n\n\"PHARMACOLOGIST\": \"The healthcare professional specializing in the study of drugs and their effects\",\n\n\"CLINICAL TRIAL\": \"The structured scientific study to evaluate medical, surgical, or behavioral interventions\",\n\n\"MEDICAL PROFESSIONAL\": \"Healthcare provider involved in the administration or monitoring of the drug\",\n\n\"PHARMACEUTICAL AGENT\": \"A substance used for its medicinal properties\",\n\n\"PHARMACOLOGICAL STUDY\": \"The research focused on the effects, mechanisms, and uses of drugs\",\n\n\"DRUG NAME\": \"The specific name of the medication or pharmaceutical agent\",\n\n\"DRUG DOSAGE\": \"The amount of drug administered per unit of time\",\n\n\"DRUG EFFECT\": \"The observed therapeutic or side effect of the drug\",\n\n\"DRUG LICENSE\": \"The official permission granted by regulatory authorities to market and sell a drug\",\n\n\"DRUG CATEGORY\": \"The classification of the drug based on its therapeutic use or mechanism of action\",\n\n\"DRUG INDICATION\": \"The approved medical use or indication for the drug\",\n\n\"DRUG SIDE EFFECT\": \"An unwanted or unexpected reaction to a drug\",\n\n\"DRUG ALLERGY\": \"A hypersensitive reaction to a drug\",\n\n\"DRUG ABUSE\": \"The misuse or overuse of a drug\",\n\n\"DRUG REACTION\": \"A response to a drug that may be adverse or unexpected\",\n\n\"DRUG SIDE EFFECTS\": \"The spectrum of adverse reactions to a drug\",\n\n\"DRUG SIDE EFFECTS MANAGEMENT\": \"The strategies to manage and mitigate drug side effects\",\n\n\"DRUG SIDE EFFECTS SEVERITY\": \"The intensity or seriousness of drug side effects\",\n\n\"DRUG SIDE EFFECTS PREVA", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" {\"COHORT\": \"unspecified group of individuals\", \"WARFARIN\": \"anticoagulant medication\"}\n\nNote: Since the specific cohort is not mentioned in the provided text, \"unspecified group of individuals\" is used as a placeholder.", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" {\"COHORT\": \"patient at the time of admission to Emergency Department (ED)\", \"PROTHROMBIN_TIME\": \"prothrombin time (PT)\", \"PT_VALUE\": \"more than 37 seconds\", \"ACTIVATED_PARTIAL_THROMBOPLASTIN_TIME\": \"activated partial thromboplastin time (aPTT)\", \"aPTT_VALUE\": \"more than 70 seconds\", \"INTERNATIONAL_NORMALIZED_RATIO\": \"international normalized ratio (INR)\", \"INR_VALUE\": \"greater than seven\"}\n\nNote: The entities \"ED\" and \"patient\" are not explicitly described as a cohort in the text, but they are contextually related to the cohort being studied. Therefore, they are not included in the \"COHORT\" field as per the instructions.", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" {\"COHORT\": \"patient presenting with coagulopathy of unknown origin\", \"WARFARIN_EXPOSURE\": \"warfarin or super-warfarin exposure\", \"DISSEMPTIBLE_INFLAMMATION\": \"disseminated intravascular coagulation (DIC)\", \"VITAMIN_K_MALABSORPTION\": \"vitamin K malabsorption\", \"PATHOLOGIC_INHIBITORS\": \"pathologic inhibitors of coagulation\"}", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {\"WSU Institutional Review Board\": \"The institution responsible for reviewing and approving the study protocol and consent form for the WSU (Washington State University) research study.\"}\n\n{\"study protocol\": \"The document that outlines the plan for conducting the research study, including objectives, design, methodology, statistical considerations, and organization.\"}\n\n{\"consent form\": \"A document that provides information about the research study to potential participants and outlines their rights, responsibilities, and the procedures they will undergo as part of the study.\"}\n\n{\"WSU research study\": \"The specific scientific investigation being conducted at Washington State University.\"}\n\n{\"subject enrollment\": \"The process of recruiting and registering participants into the WSU research study.\"}", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {\"VITAL_SIGNS\": \"blood pressure, pulse, oxygen saturation\"}\n{\"STUDY_DAY\": \"every study day\"}\n{\"PHARMACOLOGY_ARTICLE\": \"scientific article about pharmacology\"}\n{\"PHARMACOLOGICAL_ENTITIES\": \"study day, vital signs\"}", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {\"Siliphos\": Description of the drug being administered in the study, a blister pack format, pill diary documentation, and adverse events monitoring.}\n\n{\"blister pack\": Description of the packaging format for the drug Siliphos, used for administration to subjects in the study.}\n\n{\"pill diary\": Description of the documentation tool used by subjects to record the time of administration, accompanying beverage, and volume used for swallowing Siliphos, as well as any adverse events.}\n\n{\"adverse events\": Description of the monitoring of any negative reactions or side effects experienced by subjects after taking Siliphos.", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {\"SAS\": \"SAS Institute\", \"v. 9.2\": \"SAS version 9.2\", \"statistical analyses\": \"statistical analyses\", \"terminal elimination rate constant (\u03bb\": \"terminal elimination rate constant (\u03bb\"}\n{\"COHORT\": \"Not specified in the provided text\"}\n{\"study\": \"Not specified in the provided text\"}\n{\"population\": \"Not specified in the provided text\"}\n{\"sample size\": \"Not specified in the provided text\"}\n{\"outcome measure\": \"terminal elimination rate constant (\u03bb\"}\n{\"intervention\": \"Not specified in the provided text\"}\n{\"comparator\": \"Not specified in the provided text\"}\n{\"randomization\": \"Not specified in the provided text\"}\n{\"blinding\": \"Not specified in the provided text\"}\n{\"confounding variable\": \"Not specified in the provided text\"}\n{\"statistical significance\": \"statistical significance\"}\n{\"p-value\": \"p-value\"}\n{\"confidence interval\": \"confidence interval\"}\n{\"adverse event\": \"adverse event\"}\n{\"pharmacokinetics\": \"pharmacokinetics\"}\n{\"pharmacodynamics\": \"pharmacodynamics\"}\n{\"pharmacology\": \"pharmacology\"}\n{\"therapeutic window\": \"therapeutic window\"}\n{\"drug metabolism\": \"drug metabolism\"}\n{\"drug absorption\": \"drug absorption\"}\n{\"drug distribution\": \"drug distribution\"}\n{\"drug excretion\": \"drug excretion\"}\n{\"drug-drug interaction\": \"drug-drug interaction\"}\n{\"drug-food interaction\": \"drug-food interaction\"}\n{\"drug-disease interaction\": \"drug-disease interaction\"}\n{\"drug-genetic interaction\": \"drug-genetic interaction\"}\n{\"pharmacokinetic modeling\": \"pharmacokinetic modeling\"}\n{\"pharmacokinetic parameters\": \"pharmakinetic parameters\"}\n{\"pharmacokinetic analysis\": \"pharmacokinetic analysis\"}\n{\"pharmacokinetic modeling\": \"pharmacokinetic modeling\"}\n{\"pharm", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" {\"COHORT\": \"unspecified group of individuals in the context of herbal products and drug interactions\",\n \"DRUG INTERACTIONS\": \"herbal products\",\n \"ADME PROCESSES\": \"absorption, distribution, metabolism, and excretion\",\n \"HERBAL PRODUCTS\": \"mixtures of multiple constituents\"}", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" {\"COHORT\": \"not specified\",\n \"Silibinin\": \"model herbal product perpetrator\",\n \"herbal product\": \"model herbal product perpetrator\",\n \"raloxifene\": \"drug\",\n \"glucuronidation\": \"intestinal metabolic process\",\n \"intestinal glucuronidation\": \"intestinal metabolic process\",\n \"human pharmacokinetic data\": \"human pharmacokinetic data\",\n \"in vitro inhibitory potency\": \"in vitro inhibitory potency\",\n \"in vitro\": \"in vitro modeling platforms\",\n \"in vivo\": \"not mentioned\",\n \"pharmacokinetic\": \"pharmacokinetic data\",\n \"interaction\": \"interaction\",\n \"drug interaction\": \"drug interaction\",\n \"modeling platforms\": \"modeling platforms\"}", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {\"Silibinin\": \"silicon\",\n \"predosing\": \"pretreatment\",\n \"raloxifene\": \"drug\",\n \"interaction potential\": \"interaction potential\"}", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {\"COHORT\": \"\", \"Drug Molecules\": \"design of drug molecules\", \"Oxidative Metabolism\": \"oxidative metabolism\", \"Conjugative Metabolism\": \"conjugative metabolism\"}\n\n{\"DESIGNED_DRUG_MOLECULES\": \"design of drug molecules\", \"OXIDATIVE_METABOLISM\": \"oxidative metabolism\", \"CONJUGATIVE_METABOLISM\": \"conjugative metabolism\"}\n\n{\"DRUG_MOLUCOLES_DESIGN\": \"design of drug molecules\", \"OXIDATIVE_METABOLISM\": \"oxidative metabolism\", \"CONJUGATIVE_METABOLISM\": \"conjugative metabolism\"}\n\n{\"DRUG_MOL_DESIGN\": \"design of drug molecules\", \"OXIDATIVE_METABOLISM\": \"oxidative metabolism\", \"CONJUGATIVE_METABOLISM\": \"conjugative metabolism\"}\n\n{\"DRUG_MOL_DESIGN\": \"design of drug molecules\", \"OXIDATIVE_METABOLISM\": \"oxidative metabolism\", \"CONJUGATIVE_METABOLISM\": \"conjugative metabolism\"}\n\n{\"DRUG_MOL_DESIGN\": \"design of drug molecules\", \"OXIDATIVE_METABOLISM\": \"oxidative metabolism\", \"CONJUGATIVE_METABOLISM\": \"conjugative metabolism\"}\n\n{\"DRUG_MOL_DESIGN\": \"design of drug molecules\", \"OXIDATIVE_METABOLISM\": \"oxidative metabolism\", \"CONJUGATIVE_METABOLISM\": \"conjugative metabolism\"}\n\n{\"DRUG_MOL_DESIGN\": \"design of drug molecules\", \"OXIDATIVE_METABOLISM\": \"oxidative metabolism\", \"CONJUGATIVE_METABOLISM\": \"conjug", {}]], [420, "Supporting Information Click here for additional data file.", [" {\"COHORT\": \"The specific group of individuals participating in the pharmacological study\",\n\n\"DRUG\": \"The medication or substance being studied in the pharmacological context\",\n\n\"PHARMACOLOGIST\": \"The scientist or researcher specializing in the study of drugs and their effects\",\n\n\"CLINICAL TRIAL\": \"The structured scientific study to evaluate the effectiveness and safety of a drug or treatment\",\n\n\"ADMINISTRATION\": \"The method by which the drug is delivered to the patient\",\n\n\"DOSAGE\": \"The amount and frequency of the drug administered\",\n\n\"PHARMACOKINETICS\": \"The study of how drugs move through the body and are processed\",\n\n\"PHARMACODYNAMICS\": \"The study of the effects of drugs and their mechanisms of action\",\n\n\"ADVERSE EVENT\": \"Any undesirable or harmful effect resulting from a drug or treatment\",\n\n\"PHARMACOEFFECT\": \"The intended therapeutic effect of a drug\",\n\n\"PHARMACOGENOMICS\": \"The study of how genetic makeup affects an individual's response to drugs\",\n\n\"PHARMACOINFORMATICS\": \"The use of computer and informational techniques to solve drug-related problems\",\n\n\"PHARMACOEPIMENTAL\": \"The study of the effects of drugs on the nervous system\",\n\n\"PHARMACOCHEMISTRY\": \"The study of the chemical properties and reactions of drugs\",\n\n\"PHARMACOECONOMICS\": \"The study of the economic aspects of drug development, use, and regulation\",\n\n\"PHARMACOINFORMATION\": \"Data and information related to the pharmacological properties of drugs\",\n\n\"PHARMACOINFORMATICAL ANALYSIS\": \"The use of informatics tools to analyze pharmacological data\",\n\n\"PHARMACOINFORMATICAL DATA\": \"Data collected and analyzed using informatics methods in pharmacology\",\n\n\"PHARMACOINFORMATICAL MODEL\": \"A computational model used to simulate and", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" {\"COHORT\": \"\", \"QUALITY SUPPLEMENTS\": \"Pharmaceutical company providing Curcumin\", \"CURCUMIN\": \"Active ingredient in the capsules\", \"95%\": \"Purity level of Curcumin in the capsules\"}\n\n{\"COHORT\": \"\", \"CURCUMIN\": \"Active ingredient in the capsules\"}\n\n{\"SOURCE\": \"Quality Supplements and Vitamins\", \"LOCATION\": \"Fort Lauderdale, FL, USA\"}\n\n{\"MEDICAL_DEVICE\": \"\", \"MEDICATION\": \"Curcumin powder capsule\"}\n\n{\"PHARMACEUTICAL_COMPANY\": \"Quality Supplements and Vitamins\"}\n\n{\"PURE_INGREDIENT\": \"Curcumin\"}\n\n{\"POWDER_FORM\": \"Curcumin\", \"CAPSULE_FORM\": \"Curcumin powder capsule\"}\n\n{\"PURITY_LEVEL\": \"95%\"}", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\"COHORT\": \"normal rats and rabbits\", \"PHARMACOLOGICAL AGENTS\": \"curcumin, gliclazide\", \"TIME POINTS\": \"3-, 4-, 6-, 8-, 10-, and 12-hour intervals\"}\n\n{\"PHARMACOLOGICAL AGENTS\": \"curcumin, gliclazide\"}\n\n{\"MEASUREMENT\": \"percent blood glucose reduction\"}\n\n{\"TREATMENT GROUPS\": \"multiple-dose combination of curcumin with gliclazide, gliclazide control\"}", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\"COHORT\": \"Not specified\", \"CURCUMIN\": \"curcumin\", \"MECHANISMS\": \"mechanisms\"}", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"COHORT\": \"Traditional Chinese medicine\", \"FOOD\": \"food\", \"DIETARY SUPPLEMENTS\": \"dietary supplements\", \"OTHER HERBS/BOTANICALS\": \"other herbs/botanicals\"}", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" {\"COHORT\": \"\", \"CBZ\": \"Carbazole Alkaloid\", \"pharmacokinetic properties\": \"Pharmacokinetic entities\", \"interaction\": \"Drug interaction entities\", \"coadministered substances\": \"Coadministered entities\", \"drugs\": \"Drug entities\", \"herbal products\": \"Herbal entities\", \"food\": \"Food entities\"}", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {\"CBZ\": \"Cycloheximide\"}\n{\"systematic review\": \"comprehensive systematic review\"}\n{\"healthcare professionals\": \"healthcare professionals\"}\n{\"decision-making\": \"proper decisions\"}\n{\"existing literature\": \"existing literature\"}\n{\"comprehensive\": \"comprehensive systematic review\"}\n{\"focusing\": \"focusing on CBZ\"}\n{\"hurdles\": \"hurdles\"}", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" {\"COHORT\": \"Cochrane Database of Systematic Reviews\", \"DATABASE_START_DATE\": \"2005-10-01\", \"DATABASE_END_DATE\": \"2022-12-31\", \"REVIEW_TYPE\": \"Systematic Reviews\"}", {}]], [428, "2012).", [" {\"COHORT\": \"2012 cohort\", \"STUDY\": \"study\", \"PHARMACOLOGY\": \"pharmacology\", \"ARTICLE\": \"scientific article\"}", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {\"COHORT\": \"human\", \"ORAL BIOAVAILABILITY\": \"oral bioavailability\", \"PHARMACOKINETIC PARAMETERS\": \"pharmacokinetic parameters\"}", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" {\"COHORT\": \"rats\", \"study subjects\": \"two children with epilepsy\"}\n{\"COMPOUND\": \"folinic acid\", \"COMPOUND\": \"CBZ\", \"COMPOUND\": \"nicotinamide\"}\n{\"STUDY\": \"study on dietary supplement-CBZ interactions\", \"SOURCE\": \"research paper [61]\", \"SOURCE\": \"research paper [70]\"}", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {\"COHORT\": \"Patients on antiepileptic therapy\"}\n\n(Note: In the provided text, there is no explicit mention of a specific cohort name or identifier, so the cohort description is based on the general group of patients described.)", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" {\"DATABASES\": \"eleven databases\"}\n\n{\"LITERATURE_SEARCH\": \"comprehensive literature search\"}\n\n{\"PHARMACOLOGY_TOPIC\": \"pharmacology\"}\n\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n\n{\"ENTITY_TYPE\": \"cohort\"}\n\n{\"ENTITY_DESCRIPTION\": \"Not applicable as no specific cohort was mentioned in the provided text.\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"cited entities\"}\n\n{\"CITED_ENTITIES\": \"words referring to described entities\"}\n\n{\"PUBLICATION_SOURCE\": \"Not applicable as no specific source was mentioned in the provided text.\"}\n\n{\"PUBLICATION_DATE\": \"Not applicable as no specific date was mentioned in the provided text.\"}\n\n{\"PUBLICATION_AUTHORS\": \"Not applicable as no specific authors were mentioned in the provided text.\"}\n\n{\"PUBLICATION_JOURNAL\": \"Not applicable as no specific journal was mentioned in the provided text.\"}\n\n{\"PUBLICATION_ARTICLE_NUMBER\": \"Not applicable as no specific article number was mentioned in the provided text.\"}\n\n{\"PUBLICATION_YEAR\": \"Not applicable as no specific year was mentioned in the provided text.\"}\n\n{\"PUBLICATION_DOI\": \"Not applicable as no specific DOI was mentioned in the provided text.\"}\n\n{\"PUBLICATION_METHODOLOGY\": \"Not applicable as no specific methodology was mentioned in the provided text.\"}\n\n{\"PUBLICATION_FINDINGS\": \"Not applicable as no specific findings were mentioned in the provided text.\"}\n\n{\"PUBLICATION_CONCLUSIONS\": \"Not applicable as no specific conclusions were mentioned in the provided text.\"}\n\n{\"PUBLICATION_KEYWORDS\": \"Not applicable as no specific keywords were mentioned in the provided text.\"}\n\n{\"PUBLICATION_INDEX_NUMBER\": \"Not applicable as no specific index number was mentioned in the provided text.\"}\n\n{\"PUBLICATION_TITLE\": \"Not applicable as no specific title was mentioned in the provided text.\"}\n\n{\"PUBLICATION_ABSTRACT\": \"Not applicable as no specific abstract was mentioned", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" {\"EMBASE\": \"a conventional database\",\n \"MEDLINE\": \"a conventional database\",\n \"AMED\": \"an English database\",\n \"CINAHL Plus\": \"an English database\",\n \"Cochrane Database of Systematic Reviews\": \"a database\",\n \"CENTRAL\": \"an English database\",\n \"SciFinder Scholar\": \"a database\",\n \"Chinese databases\": \"Chinese databases\"}", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" {\"Ispaghula husk\": \"Ispaghula husk\",\n \"septilin\": \"septilin\",\n \"soybean\": \"soybean\",\n \"Xiao-cha-hu-tang\": \"Xiao-cha-hu-tang\",\n \"plasma level of CBZ\": \"plasma level of CBZ\",\n \"CBZ\": \"CBZ\"}\n\n{\"cohort\": \"\"}", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {\"COHORT\": \"study participants\",\n\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\",\n\"DRUG\": \"beverage containing alcohol\",\n\"ALCOHOL\": \"beverage containing alcohol\",\n\"STUDY\": \"scientific article\"}", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\"Xiao-yao-san\": \"a randomized double-blinded control trial\", \"CBZ\": \"a drug\", \"major depression\": \"a medical condition\", \"bipolar disorder\": \"a medical condition\"}\n\nNote: The entities \"major depression\" and \"bipolar disorder\" are not drugs, but they are medical conditions mentioned in the context of the study. However, if the task is strictly to find entities related to drugs, then they are not included. If the task is to find all mentioned entities, then they are included.\n\n{\"Xiao-yao-san\": \"a randomized double-blinded control trial\", \"CBZ\": \"a drug\", \"major depression\": \"a medical condition\", \"bipolar disorder\": \"a medical condition\"}\n\nIf we strictly consider entities related to drugs and their effects, the entities would be:\n\n{\"CBZ\": \"a drug\"}\n\n{\"dizziness\": \"a side effect\", \"blurred vision\": \"a side effect\", \"skin rash\": \"a side effect\", \"nausea\": \"a side effect\"}", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" {\"HERBAL_FORMULAE\": \"composition of individual herbs in the included herbal formulae\"}\n\n{\"HERBS\": \"individual herbs in the included herbal formulae\"}", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {\"COHORT\": \"informants\"}\n\n{\"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"PRESCRIPTION DRUGS\": \"prescription drugs\"}", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" {\"HERBAL MEDICINES\": \"herbal medicines\"}\n\n{\"HEALTHCARE PROFESSIONALS\": \"healthcare professionals\"}\n\n{\"PROACTIVE MONITORING\": \"proactive monitoring\"}\n\n{\"PATIENTS\": \"patients\"}\n\n{\"USE OF HERBAL MEDICINES\": \"use of herbal medicines\"}", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" {\"COHORT\": \"not specified\", \"p-value\": \"p < 0.05\"}\n{\"PHARMACOLOGICAL TERM\": \"pharmacology\"}\n{\"STATISTICAL MEASURE\": \"p-value\"}\n{\"SIGNIFICANCE THRESHOLD\": \"p < 0.05\"}", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {\"COHORT\": \"interviewed patients\", \"TABLE\": \"Table 1\"}", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" {\"COHORT\": \"patients with type-2 diabetes\"}\n\n{\"AGE GROUP\": \"that age group\"}", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\"COHORT\": \"patients with diabetes\", \"HYPOGLYCAEMIC AGENTS\": \"hypoglycaemic agents\", \"PHARMACOLOGICAL MANAGEMENT\": \"pharmacological management\"}\n\n{\"PHARMACOLOGICAL AGENTS\": \"hypoglycaemic agents\"}\n\n{\"STUDY\": \"Tabular summary of the pharmacological management\"}\n\n{\"PATIENTS\": \"patients with diabetes\"}\n\n{\"METHODOLOGY\": \"pharmacological management\"}\n\n{\"OUTCOMES\": \"pharmacological management\"}\n\n{\"DESCRIPTION\": \"Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents\"}\n\n{\"TABLE\": \"Tabular summary of the pharmacological management\"}\n\n{\"TITLE\": \"Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents\"}\n\n{\"ARTICLE\": \"scientific article\"}\n\n{\"JOURNAL\": \"not mentioned\"}\n\n{\"AUTHORS\": \"not mentioned\"}\n\n{\"YEAR\": \"not mentioned\"}\n\n{\"JOURNAL NAME\": \"not mentioned\"}\n\n{\"DOI\": \"not mentioned\"}\n\n{\"ABSTRACT\": \"not mentioned\"}\n\n{\"KEYWORDS\": \"not mentioned\"}", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" {\"COHORT\": \"12 identified plants\", \"DISEASE\": \"diabetes\", \"TYPE\": \"pharmacological evidence\", \"SOURCE\": \"traditional use\"}", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" {\"Drugs\": \"drugs commonly prescribed to patients with diabetes\", \"Pharmacokinetic parameters\": \"known pharmacokinetic parameters commonly implicated in drug interactions\", \"Patients\": \"patients with diabetes\"}\n\n{\"COHORT\": \"patients with diabetes\"}\n\nNote: The cohort is inferred from the context of the drugs being prescribed to a specific group of patients. However, since the original text does not explicitly mention a study or trial, the cohort is not directly cited but implied. If a specific cohort study or trial is mentioned in the full article, that would be the appropriate entity to list.", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {\"COHORT\": \"Healthcare practitioners\", \"PATIENTS\": \"patients' use of herbal medicines\", \"IDENTITY\": \"patients' identity\", \"MONITOR\": \"monitor them\", \"INTERACTIONS\": \"possible interactions\", \"TABLES\": \"Tables 3, 4\"}", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {\"COHORT\": \"Not specified\", \"HERB\": \"herbs\", \"DRUG\": \"drugs\"}", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" {\"HERBS\": \"Herbs\"}\n\n{\"PRIMARY HEALTH CARE\": \"primary health care\"}\n\n{\"MODERN MEDICINES\": \"modern medicines\"}\n\n{\"ADVENT\": \"advent\"}\n\n{\"THOUSANDS OF YEARS\": \"thousands of years\"}\n\n{\"TIME PERIOD\": \"thousands of years\"}", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" {\"COHORT\": \"hepaRG cell line derived from a hepatocellular carcinoma\", \"ORGANISM\": \"liver\", \"ENZYMES\": \"liver-specific enzymes\"}\n{\"SOURCE\": \"HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].\"}\n{\"REFERENCES\": [\"5\", \"6\", \"7\"]}\n{\"TARGET\": \"liver-specific enzymes\"}\n{\"LIVER_ORGAN\": \"liver\"}\n{\"CANCER_TYPE\": \"hepatocellular carcinoma\"}\n{\"CELL_LINE\": \"hepaRG cell line\"}", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\", \"administration\": \"drug administration method\", \"hydrolyzed\": \"metabolic process\", \"11,12\": \"cited references\"}\n\n{\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\", \"administration\": \"drug administration method\", \"hydrolyzed\": \"metabolic process\", \"11,12\": \"cited references\"}\n\n{\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\", \"administration\": \"drug administration method\", \"hydrolyzed\": \"metabolic process\"}\n\n{\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\", \"administration\": \"drug administration method\"}\n\n{\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\"}\n\n{\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\"}\n\n{\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\"}\n\n{\"COHORT\": \"\", \"Aspirin\": \"drug\", \"body\": \"organism\", \"elimination half-life\": \"pharmacokinetic parameter\", \"15 min\": \"time unit\"}\n\n{\"COHORT", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {\"COHORT\": \"22 compounds identified or tentatively identified\", \"FIGURE\": \"Figure 1\"}\n\nNote: In the provided text, there are no explicit mentions of specific cohort names or other entities that would require parsing beyond the compounds and Figure. However, the instruction was followed by identifying and providing descriptions for the mentioned entities.", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {\"BNPP\": \"BNPP\", \"PNS\": \"PNS\"}\n{\"COHORT\": \"Not specified\"}\n{\"Dosage\": \"68 \u00b5g/mL\", \"150 \u00b5g/mL\"}\n{\"Study\": \"Not specified\"}\n{\"Significance\": \"No significant difference\"}", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\"LIVER DRUG ENZYMES\": \"Liver drug enzymes\"}\n\n{\"DRUG INTERACTION\": \"drug interaction\"}\n\n{\"HUMAN\": \"human\"}", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" {\"PNS contents\": \"notoginsenoside R\", \"UPLC-MS/MS analysis\": \"UPLC-MS/MS analysis\", \"Ultimate 3000 UPLC system\": \"Ultimate 3000 UPLC system\", \"LTQ-Orbitrap Elite mass spectrometer\": \"LTQ-Orbitrap Elite mass spectrometer\"}", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" {\"Furlong et al.\": \"scientific group or authors\"}\n{\"PON\": \"pharmacological entity\"}", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"COHORT\": \"cells\", \"TRIZOL\": \"Trizol (CW0581, CWbio, Beijing, China)\"}\n\nNote: In the provided text, there are no explicit mentions of a specific cohort study or population group, so the \"COHORT\" field is left empty in this context. However, the entities \"cells\" and \"Trizol\" are identified as cited entities related to the described scientific procedure.", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {\"COHORT\": \"\", \"Aspirin\": \"drug\", \"PNS\": \"pharmacological system\"}", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {\"COHORT\": \"unspecified experimental group\", \"DESIGNER\": \"Dr. Jane Doe\"}\n\n{\"EXPERIMENT\": \"unspecified experiments\"}\n\n{\"RESEARCHER\": \"Dr. Jane Doe\"}\n\n{\"PUBLICATION\": \"unspecified scientific article\"}", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {\"COHORT\": \"study group\", \"control group\": \"control group\", \"p-value\": \"p < 0.01\", \"p-value\": \"p < 0.001\"}", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {\"COHORT\": \"data on the pharmacological safety of these two herbal medicines\", \"HERBAL MEDICINES\": \"two herbal medicines\"}", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\"COHORT\": \"\", \"cytochrome P450 enzymes (CYPs)\": \"cytochrome P450 enzymes (CYPs)\", \"drug transporters\": \"drug transporters\"}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {\"COHORT\": \"L-MDR1 cells over-expressing human P-glycoprotein (P-gp)\"}\n\nNote: The instruction asks for cited entities, which typically refers to specific studies, experiments, or groups mentioned in the text. In this case, the cohort is the specific group of cells being studied. However, the text does not explicitly mention a study or experiment name, so only the cohort is identified. If there were a study or experiment name, it would be listed here.", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" {\"CYP3A4\": \"enzyme\", \"Samento\": \"herbal supplement\", \"Banderol\": \"herbal supplement\", \"CYP2C19\": \"enzyme\"}\n\n{\"HERBAL_SUPPLEMENT\": \"Samento\", \"HERBAL_SUPPLEMENT\": \"Banderol\"}\n\n{\"CONCENTRATION\": \"1%\"}\n\n{\"INHIBITION_PERCENTAGE\": \"around 40%\", \"INHIBITION_PERCENTAGE\": \"around 20%\"}", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" {\"COHORT\": \"Not specified\",\n \"Aryl hydrocarbon receptor (AhR)\": \"transcription factor regulating e.g., CYP1A\",\n \"Samento\": \"can activate AhR\",\n \"omeprazole\": \"positive control\"}", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\"Samento\": \"herbal supplement\", \"Banderol\": \"drug\"}\n{\"Drug Metabolizing Enzymes\": \"important drug metabolizing enzymes\"}\n{\"Drug Transporters\": \"drug transporters\"}\n{\"in vitro\": \"experimental method\"}\n{\"study\": \"scientific study\"}", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" {\"COHORT\": \"Not specified\",\n \"DRUG METABOLISM ENZYMES\": \"drug metabolizing enzymes\",\n \"DRUG TRANSPORTERS\": \"drug transporters\",\n \"PHARMACOGENETIC PRODUCTS\": \"PXR activating drugs\",\n \"PHARMACOGENETIC PRODUCTS EXAMPLES\": \"rifampicin, St. John\u2019s Wort\",\n \"DRUG EFFICACY IMPACT\": \"deteriorate drug efficacy\",\n \"DRUG BIOAVAILABILITY\": \"bioavailability\",\n \"DRUG CLEARANCE\": \"clearance of concomitantly used drugs\",\n \"DRUG SUBSTRATES\": \"substrates of such enzymes and/or transporters\"}", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"MDCKII-BCRP cells\": \"parental cell line MDCKII\"}\n{\"pheophorbide A\": \"specific BCRP substrate\"}\n{\"flow cytometry\": \"method of testing\"}\n{\"MDCKII\": \"cell line\"}\n{\"BCRP inhibition\": \"phenomenon being tested\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cell line with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cell line without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells with BCRP\"}\n{\"MDCKII-parental cell line\": \"MDCKII cells without BCRP\"}\n{\"MDCKII-BCRP cells\": \"MDCKII cells", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {\"Rifampicin\": \"positive control\", \"cyclosporine A\": \"positive control\"}\n{\"[25]\": \"previous publication\"}\n{\"Rifampicin\": \"pharmacological entity\", \"cyclosporine A\": \"pharmacological entity\"}\n{\"positive controls\": \"experimental entities\"}", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"Scientific Article\": \"scientific article\",\n\"pharmacology\": \"pharmacology\",\n\"cohort\": \"\",\n\"Samento\": \"herbal supplement\",\n\"Banderol\": \"herbal supplement\",\n\"induction assay\": \"bioassay\"}\n\n{\"COHORT\": \"\",\n\"Scientific Article\": \"scientific article\",\n\"pharmacology\": \"pharmacology\",\n\"cohort\": \"\",\n\"Samento\": \"herbal supplement\",\n\"Banderol\": \"herbal supplement\",\n\"induction assay\": \"bioassay\"}\n\n{\"COHORT\": \"\",\n\"Scientific Article\": \"scientific article\",\n \"pharmacology\": \"pharmacology\",\n\"cohort\": \"\",\n\"Samento\": \"herbal supplement\",\n\"Banderol\": \"herbal supplement\",\n\"induction assay\": \"bioassay\"}\n\n{\"COHORT\": \"\",\n\"Scientific Article\": \"scientific article\",\n\"pharmacology\": \"pharmacology\",\n\"cohort\": \"\",\n\"Samento\": \"herbal supplement\",\n\"Banderol\": \"herbal supplement\",\n\"induction assay\": \"bioassay\"}\n\n{\"COHORT\": \"\",\n\"Scientific Article\": \"scientific article\",\n\"pharmacology\": \"pharmacology\",\n\"cohort\": \"\",\n\"Samento\": \"herbal supplement\",\n\"Banderol\": \"herbal supplement\",\n\"induction assay\": \"bioassay\"}\n\n{\"COHORT\": \"\",\n\"Scientific Article\": \"scientific article\",\n\"pharmacology\": \"pharmacology\",\n\"cohort\": \"\",\n\"Samento\": \"herbal supplement\",\n\"Banderol\": \"herbal supplement\",\n\"induction assay\": \"bioassay\"}\n\n{\"COHORT\": \"\",\n\"Scientific Article\": \"scientific article\",\n\"pharmacology\": \"pharmacology\",\n\"cohort\": \"\",\n\"Samento\": \"herbal supplement\",\n\"Banderol\": \"herbal supplement\",\n", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {\"GeneElute Mammalian Total RNA Miniprep Kit\": \"RNA isolation kit\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": \"cDNA synthesis kit\"}\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"Manufacturer\": \"Not mentioned\"}\n\n{\"Manufacturer's instructions\": \"manufacturers\u2019 instructions\"}\n\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": \"GeneElute Mammalian Total RNA Miniprep Kit\"}\n\n{\"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"}", {}]], [471, "Data were evaluated as described previously [28].", [" {\"COHORT\": \"Data previously evaluated as described in reference [28]\"}\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n{\"ARTICLE_TYPE\": \"scientific article\"}\n{\"RESEARCH_SOURCE\": \"reference [28]\"}\n{\"STUDY_DESCRIPTION\": \"evaluated as described previously\"}\n{\"DATA_EVALUATION_METHOD\": \"as described\"}\n{\"STUDY_FEATURE\": \"Data\"}\n{\"STUDY_FEATURE\": \"evaluated\"}\n{\"STUDY_FEATURE\": \"as described\"}\n{\"STUDY_FEATURE\": \"previous\"}\n{\"STUDY_FEATURE\": \"described\"}\n{\"STUDY_FEATURE\": \"in\"}\n{\"STUDY_FEATURE\": \"reference\"}\n{\"REFERENCE_NUMBER\": \"28\"}", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {\"Samento\": \"herb\", \"Banderol\": \"drug\"}\n\n{\"IC\": \"in vitro profile\"}\n\n{\"herb\u2013drug interactions\": \"interactions\"}", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" {\"COHORT\": \"P388 and P388/dx cells\", \"COHORT\": \"MDCKII-BCRP cells\", \"COHORT\": \"HEK-OATP1B1 and HEK_OATP1B3 cell lines\", \"COHORT\": \"AZ-AhR cells\"}", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" {\"COHORT\": \"group of individuals participating in a study\",\n\"PHARMACOLOGY\": \"the science of drugs and their effects on living systems\",\n\"DOSAGE\": \"amount of a drug administered at one time\",\n\"PLACEBO\": \"a substance with no therapeutic effect, used as a control in testing new drugs\",\n\"ANALYTICAL_METHODS\": \"techniques and procedures used to analyze data\",\n\"STATISTICAL_SIGNIFICANCE\": \"the probability that the observed effect is due to chance\",\n\"P_VALUE\": \"a measure of the strength of the evidence against the null hypothesis\",\n\"ALPHA_THRESHOLD\": \"the predetermined level of significance\",\n\"BETA_THRESHOLD\": \"the predetermined level of power\",\n\"DRUG_NAME\": \"specific name of a medication\",\n\"DRUG_ACTION\": \"the way a drug produces its effect\",\n\"DRUG_REACTION\": \"the body's response to a drug\",\n\"DRUG_INTERACTION\": \"the effect of one drug on the activity of another drug\",\n\"DRUG_TOXICITY\": \"the harmful effects of a drug\",\n\"DRUG_EFFECTIVENESS\": \"the degree to which a drug achieves its intended therapeutic effect\",\n\"DRUG_DOSAGE_FREQUENCY\": \"how often a drug is taken\",\n\"DRUG_DOSAGE_DURATION\": \"how long a drug is taken\",\n\"DRUG_DOSAGE_FORM\": \"the physical form in which a drug is administered\",\n\"DRUG_MEDICATION_TIME\": \"the time it takes for a drug to start working\",\n\"DRUG_PHARMACEUTICAL_FORM\": \"the physical form of a drug (e.g., tablet, capsule, liquid)\",\n\"DRUG_PHARMACEUTICAL_STRENGTH\": \"the amount of active ingredient in a drug\",\n\"DRUG_PHARMACEUTICAL_CONCENTRATION\": \"the amount of drug per unit volume\",\n\"DRUG_PHARMACE", {}]], [475, "Results of the reporter gene assays.", [" {\"REPORTER GENE ASSAY\": \"Scientific method used to measure the activity of a gene product, often used in pharmacology research to assess the effect of drugs on gene expression\"}\n\n{\"PHARMACOLOGY\": \"The branch of science concerned with the study of the effects of drugs and other substances on living organisms\"}\n\n{\"DRUG ACTION\": \"The process by which a drug exerts its effects on a biological system\"}\n\n{\"DRUG EFFECT\": \"The specific changes in physiological or biochemical processes in an organism caused by a drug\"}\n\n{\"PHARMACOGENETICS\": \"The study of how genetic variation affects drug behavior in individuals\"}\n\n{\"PHARMACOGENETICS RESEARCH\": \"Research involving the study of genetic factors that influence drug response\"}\n\n{\"DRUG RESPONSE\": \"The reaction of a biological system to a drug\"}\n\n{\"DRUG EFFICACY\": \"The ability of a drug to produce the desired therapeutic effect\"}\n\n{\"DRUG SENSITIVITY\": \"The degree to which a biological system responds to a drug\"}\n\n{\"DRUG TOXICITY\": \"The harmful effects of a drug on an organism\"}\n\n{\"DRUG ACTION MECHANISM\": \"The specific biochemical and physiological processes through which a drug produces its effects\"}\n\n{\"DRUG ACTION PATHWAY\": \"The sequence of biochemical events within a cell that leads to a drug's effect\"}\n\n{\"DRUG ACTION SITE\": \"The specific location within a biological system where a drug exerts its effects\"}\n\n{\"DRUG ACTION SITE IDENTIFICATION\": \"The process of determining the specific location within a biological system where a drug exerts its effects\"}\n\n{\"DRUG ACTION SITE ANALYSIS\": \"The detailed study of the specific location within a biological system where a drug exerts its effects\"}\n\n{\"DRUG ACTION SITE EVALUATION\": \"The assessment of the specific location within a biological system where a drug exerts its effects\"}\n\n{\"DRUG ACTION SITE CLARIFICATION\": \"", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"PREGNANE_X_RECEPTOR\": \"pregnane x receptor\"}\n\n{\"SANTOMANO\": \"Samento\"}\n\n{\"RIFAMPERIN\": \"rifampicin\"}\n\n{\"CONCENTRATION_DEPENDENT_EFFECT\": \"concentration-dependent effect\"}\n\n{\"POSITIVE_CONTROL\": \"positive control\"}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" {\"Samento\": \"0.033\u20131%\", \"P-glycoprotein (P-gp)\": \"protein expression\", \"rifampicin\": \"20 \u00b5M\"}\n\n{\"COHORT\": \"not specified\"}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" {\"CYP2J2\": \"enzyme\", \"Samento\": \"plant extract\", \"LS180 cells\": \"cell line\"}", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {\"CYP2J2\": \"description of the CYP2J2 entity\", \"mRNA\": \"description of the mRNA entity\", \"RT-PCR\": \"description of the RT-PCR entity\", \"\u03b22-microglobulin\": \"description of the \u03b22-microglobulin entity\", \"t\": \"description of the time entity\"}\n\nNote: The descriptions provided for each entity are brief and based on the context given in the sentence. For a more comprehensive understanding, additional context from the scientific article would be needed.", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\"Drug\": \"woohwangcheongsimwon suspension\", \"Drug\": \"bupropion\"}\n\n{\"Interaction\": \"drug interactions\"}\n\n{\"Cohort\": \"Not specified\"}", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\"COHORT\": \"unspecified\", \"MEDICAL TREATMENT\": \"tablet form\", \"MEDICAL SUBJECT\": \"unspecified\", \"MEDICAL PRODUCT\": \"tablet form\"}", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" {\"Korean Pharmaceutical Codex\": \"officially listed pharmaceutical codex\", \"aqueous suspension\": \"a form of medication\"}\n\n{\"cohort\": \"not specified in the provided text\"}", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" {\"Bovis Calculus\": \"major ingredient\", \"Dioscoreae Rhizoma\": \"major ingredient\", \"Glycyrrhizae Radix et Rhizoma\": \"major ingredient\", \"Ginseng Radix\": \"major ingredient\", \"Typhae Pollen\": \"major ingredient\", \"Massa Medicata Fermentata\": \"major ingredient\", \"Glycine Semen Germinatum\": \"major ingredient\", \"Cinnamomi cortex\": \"major ingredient\", \"Paeoniae Radix\": \"major ingredient\", \"Liriopis Tuber\": \"major ingredient\", \"Angelicae Gigantis Radix\": \"major ingredient\", \"Saposhnikoviae Radix\": \"major ingredient\", \"Atractylodis Rhizoma Alba\": \"major ingredient\", \"Bupleuri Radix\": \"major ingredient\", \"Platycodonis Radix\": \"major ingredient\", \"Armeniacae Semen\": \"major ingredient\", \"Poria Sclerotium\": \"major ingredient\", \"Cnidii Rhizoma\": \"major ingredient\", \"Civet\": \"major ingredient\", \"Antelopis Cornu\": \"major ingredient\", \"Borneolum\": \"major ingredient\"}", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {\"COHORT\": \"study subjects\", \"PRESCRIPTION AND OVER THE COUNTER MEDICATIONS\": \"prescription and over the counter medications\"}\n\n{\"ABSTINCE FROM TAKING MEDICATIONS\": \"abstain from taking prescription and over the counter medications\"}\n\n{\"STUDY PERIOD\": \"2 weeks before and during the study period\"}", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"CYP2B6\": \"a gene encoding a member of the cytochrome P450 family of enzymes\"}\n{\"pyrosequencing\": \"a method used for determining the sequence of nucleotides in a DNA sample\"}\n{\"polymerase chain reaction (PCR)\": \"a technique used to amplify segments of DNA\"}\n{\"[13]\": \"a reference to the 13th cited work in the scientific article\"}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {\"Safety monitoring\": \"entity\", \"study\": \"entity\"}\n{\"COHORT\": \"entity\"} (No specific cohort mentioned in the provided text)\n{\"Study\": \"entity\"} (General reference to a scientific study)", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {\"TurboIonSpray\": \"interface\", \"positive ion mode\": \"positive ion mode\", \"5500 V\": \"voltage\", \"500\u00b0C\": \"temperature\"}\n\n{\"COHORT\": \"Not applicable\"}", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {\"ANALYST_SOFTWARE\": \"Analyst software\",\n\"ANALYST_SOFTWARE_VERSION\": \"version 1.4\",\n\"ANALYST_SOFTWARE_COMPANY\": \"Applied Biosystems\",\n\"ANALYST_SOFTWARE_LOCATION\": \"Foster City, CA\"}\n\n{\"PUBLICATION\": \"scientific article\"}\n\n{\"PHARMACOLOGY\": \"pharmacology\"}\n\n{\"PUBLICATION_SOURCE\": \"unknown\"}\n\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n\n{\"PUBLICATION_TOPIC\": \"pharmacology\"}\n\n{\"PUBLICATION_DATA_PROCESSING\": \"analytical data\"}\n\n{\"PUBLICATION_DATA_PROCESSING_SOFTWARE\": \"Analyst software\"}\n\n{\"PUBLICATION_DATA_PROCESSING_SOFTWARE_VERSION\": \"version 1.4\"}\n\n{\"PUBLICATION_DATA_PROCESSING_SOFTWARE_COMPANY\": \"Applied Biosystems\"}\n\n{\"PUBLICATION_DATA_PROCESSING_SOFTWARE_LOCATION\": \"Foster City, CA\"}\n\n{\"PUBLICATION_DATA_PROCESSING_METHOD\": \"unknown\"}\n\n{\"PUBLICATION_DATA_PROCESSING_OUTCOME\": \"analytical data\"}", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {\"COHORT\": \"not specified\", \"AUC(0,\u221e)\": \"Geometric means\", \"Cmax\": \"Geometric means\"}\n{\"BUPROPION\": \"drug\", \"4-hydroxybupropion\": \"metabolite\"}", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {\"COHORT\": \"Not specified\", \"GEOMETRIC MEAN RATIOS (GMRs)\": \"Geometric mean ratios\", \"CONFIDENCE INTERVALS (CIs)\": \"90% confidence intervals\", \"LOG TRANSFORMATION\": \"log transformation\", \"WITHIN-SUBJECT DATA\": \"within-subject data\"}\n\n{\"PHARMACOLOGICAL TERM\": \"pharmacology\"}\n\n{\"ARTICLE TYPE\": \"scientific article\"}\n\n{\"DATA TRANSFORMATION\": \"log transformation\"}\n\n{\"STATISTICAL MEASURE\": \"geometric mean ratios\"}\n\n{\"STATISTICAL MEASURE\": \"confidence intervals\"}\n\n{\"DATA DIMENSION\": \"within-subject\"}\n\n{\"DATA TRANSFORMATION\": \"log\"}\n\n{\"METHODOLOGY\": \"calculated\"}\n\n{\"STATISTICAL FIGURE\": \"geometric mean ratios (GMRs)\"}\n\n{\"STATISTICAL FIGURE\": \"confidence intervals (CIs)\"}\n\n{\"STATISTICAL FIGURE\": \"90%\"}\n\n{\"STATISTICAL FIGURE\": \"90% confidence intervals (CIs)\"}\n\n{\"STATISTICAL FIGURE\": \"90% confidence intervals (CIs) were calculated\"}\n\n{\"STATISTICAL FIGURE\": \"geometric mean ratios (GMRs) with 90% confidence intervals (CIs)\"}\n\n{\"STATISTICAL FIGURE\": \"after log transformation\"}\n\n{\"DATA TRANSFORMATION\": \"log transformation after\"}\n\n{\"METHODOLOGY\": \"calculated after\"}\n\n{\"DATA TRANSFORMATION\": \"log transformation after\"}\n\n{\"METHODOLOGY\": \"calculated after log transformation\"}", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {\"COHORT\": \"clinical trial participants\", \"BLOOD PRESSURE\": \"blood pressure\", \"HEART RATE\": \"heart rate\", \"BODY TEMPERATURE\": \"body temperature\"}", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\"CYP2B6\": \"an enzyme\", \"woohwangcheongsimwon suspension\": \"a herbal medicine\", \"bupropion\": \"a pharmaceutical drug\"}\n\n{\"COHORT\": \"Not specified in the provided text\"}\n\n{\"STUDY\": \"a scientific study\"}\n\n{\"PHARMACOLOGY\": \"the study of drugs and their effects\"}\n\n{\"INHIBITORY EFFECTS\": \"the impact of a substance on the activity of an enzyme\"}\n\n{\"PHARMACOTHERAPY\": \"the treatment of disease through the administration of a drug\"}\n\n{\"PHARMACOKINETICS\": \"the study of how drugs move through the body\"}\n\n{\"BUPROPION\": \"a medication used for the treatment of depression and other conditions\"}", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" {\"COHORT\": \"unspecified group of individuals taking different types of statins\", \"STATIN TYPES\": \"some types of statins\", \"HERBALS\": \"grapefruit, pomegranate\"}\n\n{\"COHORT\": \"unspecified group of individuals taking different types of statins\", \"STATIN TYPES\": \"all statin types\", \"HERBALS\": \"grapefruit, pomegranate\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"statins\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"herbal reaction\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"interaction\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {\"TYROSINE KINASES\": \"tyrosine kinases\"}\n{\"MALIGNANCIES\": \"various malignancies\"}\n{\"OVEREXPRESSION OR SOMATIC MUTATIONS\": \"overexpression or somatic mutations\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"PUBLICATION\": \"cited\"}\n{\"PHARMACOLOGICAL INTERVENTIONS\": \"pharmacological interventions\"}\n{\"DYSREGULATION\": \"dysregulation\"}\n{\"MUTATIONS\": \"mutations\"}\n{\"MALIGNANT CELLS\": \"malignant cells\"}\n{\"PHARMACEUTICAL TREATMENTS\": \"pharmacological treatments\"}\n{\"PHARMACOGENETICS\": \"pharmacogenetics\"}\n{\"PHARMACOGENOMICS\": \"pharmacogenomics\"}\n{\"PHARMACOGENETIC COHORT\": \"pharmacogenetic cohort\"}\n{\"PHARMACOGENOMIC COHORT\": \"pharmacogenomic cohort\"}", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" {\"APG-pretreated rats\": \"APG-pretreated rats\", \"Pgp/MDR1 protein\": \"Pgp/MDR1 protein\", \"DAS\": \"DAS\"}\n\n{\"COHORT\": \"APG-pretreated rats\"}\n{\"TARGET\": \"Pgp/MDR1 protein\"}\n{\"TREATMENT\": \"DAS\"}\n{\"STATISTICAL_SIGNIFICANCE\": \"p < 0.05\"}", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"COHORT\": \"\", \"APG\": \"apyrase-4 gene\", \"BCRP/ABCG2\": \"breast cancer resistance protein/ATP-binding cytotoxic protein 2\"}", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {\"APG-pretreated rats\": \"description of the cohort\", \"BCPR/ABCG2 protein\": \"description of the biological entity\", \"DAS only\": \"description of the control group\"}\n\n{\"BCPR/ABCG2 protein\": \"description of the biological entity\", \"66.77%\": \"percentage of inhibition\", \"41.06%\": \"percentage of inhibition\", \"p < 0.05\": \"statistical significance\"}", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" {\"COHORT\": \"Not specified\",\n \"DRUG-MEDICAL PRODUCT\": \"drug-metabolizing enzymes (DME)\",\n \"DRUG-MEDICAL PRODUCT\": \"drug transporters\",\n \"DRUG\": \"drug\",\n \"DRUG-MEDICAL PRODUCT-MECHANISM\": \"inhibition and/or induction of drug-metabolizing enzymes (DME) and drug transporters\",\n \"DRUG-MEDICAL PRODUCT-MECHANISM\": \"herbs\",\n \"DRUG-MEDICAL PRODUCT-MECHANISM\": \"herb-drug interactions\",\n \"DRUG-MEDICAL PRODUCT-MECHANISM\": \"pharmacokinetic disposition of the drug\",\n \"SOURCE\": \"Not specified\",\n \"SOURCE-REFERENCE\": \"24,25\"}", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {\"APG\": \"pharmacokinetic interaction\", \"DAS\": \"pharmacokinetic interaction\"}\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"Study\": \"current study\"}\n\n{\"Purpose\": \"to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.\"}\n\n{\"Pharmacokinetic interaction\": \"interaction\"}", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" {\"COHORT\": \"DAS 25 mg/kg P.O.\"}\n\nNote: In this context, \"DAS 25 mg/kg P.O.\" refers to a specific dosage form and administration route for a pharmacological entity, which is why it's identified as a cohort in the context of pharmacokinetic parameters. However, typically, a \"cohort\" refers to a group of subjects in a study. Here, it's used to represent a specific pharmacological entity under study. If the intent was to identify a study group, additional information would be needed.", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" {\"COHORT\": \"animals\", \"n\": \"6\", \"cage\": \"polypropylene cages\", \"light/dark cycle\": \"12-h light/dark cycle\", \"temperature\": \"25 \u00b0C\", \"humane conditions\": \"humane conditions\", \"adaptation period\": \"one week\", \"experiment groups\": \"four groups\", \"fasting period\": \"12 h\"}", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" {\"COHORT\": \"Group I and Group II\", \"MEDICATION\": \"normal saline, DAS (25 mg/kg)\"}\n{\"TIMEPOINT\": \"7th day\"}\n\n(Note: The original text does not explicitly mention a \"Description of the cohort\" or a \"Timepoint\" in the traditional sense, but based on the context, these entities have been inferred and included.)", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {\"APG\": \"a drug\", \"40 mg/kg\": \"dosage of APG\", \"Group IV\": \"a cohort of subjects\"}\n\n(Note: The term \"cohort\" in the context of a scientific article typically refers to a group of subjects in a study. However, since the provided text does not explicitly mention a study or research design, the identification of \"Group IV\" as a cohort is an assumption based on common scientific terminology. If the context is different, the interpretation may vary.)", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {\"Electrospray ionization\": \"technique\", \"positive direction\": \"ionization mode\"}\n\n{\"COHORT\": \"Not specified in the provided text\"}\n\n{\"Scientific article\": \"genre of publication\"}\n\n{\"pharmacology\": \"field of study\"}\n\n{\"words refering to described entities\": [\"Electrospray ionization\", \"positive direction\", \"technique\", \"ionization mode\", \"genre of publication\", \"field of study\"]}\n\n{\"sample\": \"material being analyzed\"}\n\n{\"ionize\": \"process\"}\n\n{\"direction\": \"mode of ionization\"}", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {\"APG\u2013DAS\": \"interaction\", \"in vivo studies\": \"studies\", \"humans\": \"humans\"}\n{\"COHORT\": \"further in vivo studies in humans\"}\n\n(Note: The term \"cohort\" typically refers to a group of individuals with shared characteristics being studied, but since the provided text does not explicitly mention a specific cohort, the field remains empty.)\n\n{\"COHORT\": \"\"}", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" {\"COHORT\": \"M.A.A. (Master of Applied Anthropology)\", \"PHARMACOLOGY\": \"pharmacology\", \"ARTICLE\": \"scientific article\", \"PUBLICATION\": \"scientific article\", \"JOURNAL\": \"scientific journal\", \"PAPER\": \"scientific paper\", \"AUTHOR\": \"author\", \"RESEARCHER\": \"researcher\", \"STUDY\": \"study\", \"EXPERIMENT\": \"experiment\", \"DATA\": \"data\", \"ANALYSIS\": \"analysis\", \"FINDINGS\": \"findings\", \"CONCLUSION\": \"conclusion\", \"PHARMACEUTICAL\": \"pharmaceutical\", \"DRUG\": \"drug\", \"MEDICATION\": \"medication\", \"DOSAGE\": \"dosage\", \"DURATION\": \"duration\", \"EFFECT\": \"effect\", \"REACTION\": \"reaction\", \"TOXICITY\": \"toxicity\", \"ADMINISTRATION\": \"administration\", \"MEDICAL\": \"medical\", \"CLINICAL\": \"clinical\", \"TRIAL\": \"trial\", \"PHASE\": \"phase\", \"BINDING\": \"binding\", \"METABOLISM\": \"metabolism\", \"DISEASE\": \"disease\", \"CONDITION\": \"condition\", \"TREATMENT\": \"treatment\", \"INTERVENTION\": \"intervention\", \"OUTCOME\": \"outcome\", \"EFFICACY\": \"efficacy\", \"SIDE_EFFECT\": \"side effect\", \"ADVERSE_REACTION\": \"adverse reaction\", \"DOSING\": \"dosing\", \"PHARMACOGENOMICS\": \"pharmacogenomics\", \"PHARMACOKINETICS\": \"pharmacokinetics\", \"PHARMACOCHEMISTRY\": \"pharmacochemistry\", \"PHARMACOEFFECT\": \"pharmacoeffect\", \"PHARMACOECONOMICS\": \"pharmacoeconomics\", \"PHARMACOINFORMATICS\": \"pharmacoinformatics\", \"PHARMACOINVE", {}]], [507, "; supervision, K.M.A.", [" {\"COHORT\": \"described cohort in the scientific article about pharmacology\"}\n\n{\"SUPERVISOR\": \"K.M.A.\"}", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" {\"COHORT\": \"Not specified\", \"AUTHORS\": \"All authors\", \"MANUSCRIPT\": \"Published version of the manuscript\"}\n\n{\"PHARMACOLOGY_CONCEPT\": \"pharmacology\", \"ARTICLE_TYPE\": \"scientific article\"}\n\n{\"PUBLICATION\": \"Not specified\"}\n\n{\"PERFORMERS\": \"Authors\"}\n\n{\"CONSENT\": \"All authors have read and agreed to the published version of the manuscript\"}\n\n{\"PUBLISHER\": \"Not specified\"}\n\n{\"PUBLICATION_DATE\": \"Not specified\"}\n\n{\"JOURNAL_NAME\": \"Not specified\"}\n\n{\"ARTICLE_NUMBER\": \"Not specified\"}\n\n{\"ARTICLE_ID\": \"Not specified\"}\n\n{\"ARTICLE_INDEX\": \"Not specified\"}\n\n{\"ARTICLE_URL\": \"Not specified\"}\n\n{\"ARTICLE_DOI\": \"Not specified\"}\n\n{\"ARTICLE_ABSTRACT\": \"Not specified\"}\n\n{\"ARTICLE_BODY\": \"Not specified\"}\n\n{\"ARTICLE_CONCLUSION\": \"Not specified\"}\n\n{\"ARTICLE_METHODOLOGY\": \"Not specified\"}\n\n{\"ARTICLE_DESIGN\": \"Not specified\"}\n\n{\"ARTICLE_ANALYSIS\": \"Not specified\"}\n\n{\"ARTICLE_FINDINGS\": \"Not specified\"}\n\n{\"ARTICLE_CONCLUSIONS\": \"Not specified\"}\n\n{\"ARTICLE_REFERENCES\": \"Not specified\"}\n\n{\"PHARMACEUTICAL_ENTITIES\": \"Not specified\"}\n\n{\"DRUG_NAMES\": \"Not specified\"}\n\n{\"DRUG_ACTIONS\": \"Not specified\"}\n\n{\"DRUG_MECHANISMS\": \"Not specified\"}\n\n{\"DRUG_DOSAGE\": \"Not specified\"}\n\n{\"DRUG_REACTIONS\": \"Not specified\"}\n\n{\"DRUG_INTERACTIONS\": \"Not specified\"}\n\n{\"DRUG_TOXICITY\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_USES\": \"Not specified\"}\n\n{\"DRUG_CLINICAL_EFFECTS\": \"Not", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" {\"RESEARCH_ETHICS_COMMITTEE\": \"Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia\"}\n{\"KING_SAUD_UNIVERSITY_COLLEGE_OF_PHARMACY\": \"King Saud University College of Pharmacy\"}\n{\"RIYADH\": \"Riyadh\"}\n{\"SAUDI_ARABIA\": \"Saudi Arabia\"}\n{\"KSU-SE-21-58\": \"King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58)\"}", {}]], [510, "All results are presented as the average \u00b1 SD.", [" {\"COHORT\": \"the described cohort in the scientific article about pharmacology\", \"PHARMACOLOGY\": \"pharmacology\", \"ARTICLE\": \"scientific article\", \"PUBLICATION\": \"scientific article\", \"JOURNAL\": \"scientific article\", \"PAPER\": \"scientific article\", \"STUDY\": \"scientific article\", \"RESEARCH\": \"scientific article\", \"EXPERIMENT\": \"scientific article\", \"METHODOLOGY\": \"scientific article\", \"PHARMACEUTICAL\": \"pharmacology\", \"DRUG\": \"pharmacology\", \"MEDICATION\": \"pharmacology\", \"PHARMACY\": \"pharmacology\", \"PHARMACOLOGIST\": \"pharmacology\", \"PHARMACOLOGICAL\": \"pharmacology\", \"PHARMACOLOGICAL_PROCESS\": \"pharmacology\", \"PHARMACOLOGICAL_OUTCOME\": \"pharmacology\", \"PHARMACOLOGICAL_STUDY\": \"pharmacology\", \"PHARMACOLOGICAL_DATA\": \"pharmacology\", \"PHARMACOLOGICAL_ANALYSIS\": \"pharmacology\", \"PHARMACOLOGICAL_RESEARCH\": \"pharmacology\", \"PHARMACOLOGICAL_REPORT\": \"pharmacology\", \"PHARMACOLOGICAL_FINDINGS\": \"pharmacology\", \"PHARMACOLOGICAL_CONCLUSIONS\": \"pharmacology\", \"PHARMACOLOGICAL_RECOMMENDATIONS\": \"pharmacology\", \"PHARMACOLOGICAL_TREATMENT\": \"pharmacology\", \"PHARMACOLOGICAL_TREATMENT_PLAN\": \"pharmacology\", \"PHARMACOLOGICAL_TREATMENT_OUTCOME\": \"pharmacology\", \"PHARMACOLOGICAL_TREATMENT_EFFECTIVENESS\": \"pharmacology\", \"PHARMACOLOGICAL_TREATMENT_SIDE_E", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" {\"COHORT\": \"rats after DAS administration with or without APG pretreatment\"}\n{\"PROTEIN\": \"hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression\"}", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" {\"PHYTOCHEMICAL\": \"natural compounds found in plants\", \"MODIFICATION\": \"modulation of cytochrome P-450 (CYP) activity\", \"CYTOCHROME P-450 (CYP)\": \"a family of enzymes involved in drug metabolism\", \"HERB\": \"plants\", \"DRUG INTERACTIONS\": \"interactions between herbs and pharmaceutical drugs\"}\n\n{\"COHORT\": \"Not mentioned in the text\"}\n\n{\"STUDY\": \"Not mentioned in the text\"}\n\n{\"OBSERVATION\": \"Not mentioned in the text\"}\n\n{\"METHODOLOGY\": \"Not mentioned in the text\"}\n\n{\"FINDINGS\": \"Not mentioned in the text\"}\n\n{\"CONCLUSION\": \"Not mentioned in the text\"}\n\n{\"RELEVANT TERM\": \"phytochemical-mediated modulation\"}\n\n{\"DRUG\": \"pharmaceutical drugs\"}\n\n{\"HERB-DRUG INTERACTION\": \"herb-drug interactions\"}", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" {\"COHORT\": \"population with herb-mediated changes in CYP activity\", \"CYP\": \"cytochrome P450 enzymes\"}\n\nNote: In the provided text, there are no explicit mentions of specific scientific entities such as drug names, researchers, or specific studies. The text refers to a general population and a biological process (CYP activity), which have been identified as entities.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {\"Botanical Supplements\": \"botanical supplements\", \"Prescription Medications\": \"prescription medications\"}\n\n{\"Elderly\": \"elderly\"}\n\n(Note: The provided text does not explicitly mention a \"COHORT,\" but in the context of a scientific article, a cohort could refer to a group of individuals studied within the research. However, since no specific cohort is mentioned, the field remains empty.)", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\"COHORT\": \"adult women\", \"SC extract\": \"Squamae extract\", \"quadriceps muscle strength (QMS)\": \"quadriceps muscle strength\", \"lactate\": \"lactate\"}\n\nIf there are additional entities mentioned in the article that are not listed here, please provide them so that they can be included in the parsing.", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"COHORT\": \"Not specified\",\n \"QMS\": \"Quantitative Measurement System\",\n \"p-value\": \"0.001\",\n \"lactate level\": \"lactate level\"}", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {\"SC extract\": \"Supplement (pharmacology)\", \"humans\": \"Human subjects (cohort)\"}\n\n(Note: The term \"cohort\" typically refers to a group of individuals with shared characteristics being studied in research. However, in the context of this sentence, it seems the term \"cohort\" was used in a broader sense to describe the group of humans being studied. Therefore, the description provided is an interpretation based on the context.)\n\n{\"SC extract\": \"Supplement (pharmacology)\", \"humans\": \"Human subjects\"}\n\n(Note: The term \"cohort\" is not explicitly mentioned in the text, but the phrase \"in humans\" implies a group of human subjects being studied.)\n\n{\"SC extract\": \"Supplement (pharmacology)\", \"muscle strength\": \"Physiological outcome\"}\n\n(Note: \"Physiological outcome\" is a general term that could describe the effect of an intervention on a biological system, in this case, muscle strength.)", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {\"COHORT\": \"subjects in the main test session\", \"ANGULAR_VELOCITY\": \"60 degrees/second\", \"EXERCISE\": \"isokinetic knee extensions\", \"RECOVERY_DURATION\": \"2 min\", \"SOURCES\": \"26,27\"}\n\n(Note: \"SOURCES\" is included as it refers to the cited works, even though it's not explicitly mentioned as a citation entity in the text. If the task strictly requires only entities directly mentioned in the text, then \"SOURCES\" would not be included.)\n\n{\"EXERCISE_ANGULAR_VELOCITY\": \"isokinetic knee extensions at an angular velocity of 60 degrees/second\"}", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\"Femoral epicondyles\": \"joint center reference\", \"knee joint center\": \"subject\u2019s knee joint center\", \"isokinetic dynamometer\": \"axis of the isokinetic dynamometer\"}\n\nNote: The cohort is not explicitly mentioned in the provided text, so the \"COHORT\" field remains empty.", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {\"COHORT\": \"Plasma samples\", \"METHODOLOGY\": \"centrifugation\", \"STORAGE_TEMPERATURE\": \"\u221280 \u00b0C\"}\n\nNote: The original text does not explicitly mention a cohort, but it implies that plasma samples were obtained from a group of individuals. However, since no specific cohort name or description is provided, the \"COHORT\" field remains empty in this context. If there were a specific cohort mentioned, it would be included here with its description.", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {\"SC Extract Supplementation\": \"SC extract supplementation\",\n \"Placebo\": \"placebo\",\n \"SC group\": \"SC group\",\n \"Placebo group\": \"placebo group\"}\n\nNote: The term \"cohort\" typically refers to a group of individuals with shared characteristics being studied in clinical research. However, in the provided text, there is no explicit mention of a cohort as a distinct entity. Therefore, no \"COHORT\" entry was created.", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" {\"COHORT\": \"unspecified group of individuals\", \"TABLE 1\": \"Table 1\"}\n\n{\"MEASUREMENT\": \"height, weight, or BMI\"}", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\"COHORT\": \"study participants\", \"RESEARCH_SETTING\": \"not specified\", \"METHODOLOGY\": \"study with resting lactate level measurement\", \"TIMEPOINT\": \"baseline and after 12 weeks\", \"MEASURED_VARIABLE\": \"resting lactate level\", \"RESULTS_PRESENTATION\": \"Figure 2\"}\n\n{\"COHORT\": \"\", \"RESEARCH_SETTING\": \"\", \"METHODOLOGY\": \"\", \"TIMEPOINT\": \"\", \"MEASURED_VARIABLE\": \"resting lactate level\", \"RESULTS_PRESENTATION\": \"Figure 2\"}\n\n(Note: The fields \"RESEARCH_SETTING\" and \"METHODOLOGY\" were left empty as the provided text does not contain explicit information about the research setting or detailed methodology.)", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {\"COHORT\": \"Not specified\", \"LACTATE PRODUCTION\": \"high lactate production\", \"OXIDATIVE METABOLISM\": \"reduced oxidative metabolism\"}", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" {\"St. John's wort\": \"herbal medicine\", \"anti-depressant effects\", \"drugs\", \"bioavailability\", \"efficacy\"}\n\n{\"COHORT\": \"not mentioned\"}", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" {\"PREGNANE-X-RECEPTOR\": \"pregnane\u2010X\u2010receptor\"}\n\nNote: Since the provided text does not mention a specific cohort, I've left the \"COHORT\" field empty as per the instructions. However, if there were a cohort mentioned, it would be listed here with its description.", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" {\"BORRELI&IZZO\": \"Borrelli & Izzo, 2009\", \"CHRUBASIK-HAUSMANN\": \"Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019\", \"GURLEY\": \"Gurley, Fifer, & Gardner, 2012\", \"IZZO\": \"Izzo, 2004\", \"SOLEYMANI\": \"Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017\", \"WHITTEN\": \"Whitten, Myers, Hawrelak, & Wohlmuth, 2006\"}", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" {\"SJW\": \"SJW extracts\",\n\"isolated constituents\": \"isolated constituents (hyperforin, hypericin, or flavonoids)\",\n\"targets for depression\": \"targets for depression\"}\n\n{\"COHORT\": \"Not specified\"}", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" {\"COHORT\": \"investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014)\", \"SJW extracts\": \"SJW extracts\"}\n\n{\"TEST\": \"tail suspension test\"}\n\n{\"IMMOBILITY\": \"time of immobility\"}\n\n{\"ANTIDEPRESSANT TREATMENT\": \"antidepressant treatment\"}\n\n{\"SJW\": \"SJW extracts\"}", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" {\"PXR\": \"xenobiotic receptor or 'xenosensor', which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.\"}\n\n{\"xenobiotic receptor\": \"xenobiotic receptor or 'xenosensor'\"}\n\n{\"ligand\": \"ligand\"}\n\n{\"nucleus\": \"nucleus\"}\n\n{\"PXRRE\": \"PXR response elements (PXRRE)\"}\n\n{\"promotor\": \"promotor\"}\n\n{\"genes\": \"various genes\"}", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" {\"OATP2B1\": \"a transporter that is inhibited by hyperforin and transports this constituent of SJW\"}\n\n{\"SJW\": \"Schierst\u00e4dt-Johannis-Wacholder\"}\n\n{\"PXR\": \"Pregnane X Receptor\"}\n\n{\"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen\": \"authors of the study showing that OATP2B1 transports hyperforin\"}\n\n{\"Sch\u00e4fer et al., 2019\": \"authors of the study on the intracellular transactivation of PXR by hyperforin\"}", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {\"COHORT\": \"seven test drugs in concomitant application with a low\u2010hyperforin SJW extract\", \"AUTHOR\": \"Zahner et al., 2019\"}\n\nNote: The \"COHORT\" refers to the group of subjects or drugs involved in the study, and \"AUTHOR\" refers to the authors of the study.", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {\"COHORT\": \"high quality clinical data\", \"PHARMOEPIMILOGY METHODS\": \"pharmacoepidemiology methods\", \"BIOINFORMATICS OR DATA MINING\": \"bioinformatics or data mining\", \"HERB-DRUG INTERACTIONS\": \"clinical meaningful herb-drug interactions\", \"CANCER THERAPIES\": \"cancer therapies\"}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {\"Lingzhi\": \"Lingzhi\", \"Yunzhi\": \"Yunzhi\", \"cancer treatment\": \"cancer treatment\", \"systematic reviews\": \"systematic reviews\", \"meta-analysis\": \"meta-analysis\", \"clinical outcomes\": \"clinical outcomes\", \"mechanistic explanations\": \"mechanistic explanations\"}", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" {\"COHORT\": \"control group\", \"TREATMENT GROUP\": \"treatment group\", \"MEDICINAL MUSHROOMS\": \"medicinal mushrooms\"}\n\n{\"CONTROL GROUP\": \"control group\", \"TREATMENT GROUP\": \"treatment group\", \"MEDICINAL MUSHROOMS\": \"medicinal mushrooms\"}\n\n{\"CONTROL GROUP\": \"control group\", \"TREATMENT GROUP\": \"treatment group\", \"MEDICINAL MUSHROOMS\": \"medicinal mushrooms\", \"DOSAGE DIFFERENCES\": \"dosage differences\"}\n\n{\"CONTROL GROUP\": \"control group\", \"TREATMENT GROUP\": \"treatment group\", \"MEDICINAL MUSHROOMS\": \"medicinal mushrooms\", \"DOSAGE DIFFERENCES\": \"dosage differences\"}", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {\"COHORT\": \"database searching and literature selection process\", \"FIGURE\": \"Figure 1\"}", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" {\"COHORT\": \"Not specified\", \"PHARMACODYNAMIC_INTERACTIONS\": \"medicinal mushrooms and cytotoxic drugs\", \"PRECLINICAL_STUDIES\": \"preclinical studies\", \"TUMOR_INHIBITION\": \"tumor inhibition effect\", \"TUMOR_INHIBITION_AND_APOPTOTIC_RATE\": \"tumor inhibition and apoptotic rate\", \"CELL_CYCLE_ARREST\": \"cell cycle arrest\", \"CASPASE_3_AND_8_EXPRESSION_AND_ACTIVITY\": \"caspase 3 and 8 expression and activity\"}", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" {\"COHORT\": \"Yunzhi-drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT)\", \"DRUGS\": \"5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, UFT\", \"OUTCOMES\": \"reduced tumor recurrence, metastasis\"}", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {\"COHORT\": \"Not specified\",\n \"Study 1\": \"inhibition of tumor cell angiogenesis\",\n \"Study 2\": \"increase in the reactive oxygen species production\"}\n{\"TUMOR CELL\": \"tumor cell angiogenesis\",\n \"ANTITUMOR EFFECT\": \"enhancement of the antitumor effect\",\n \"ANGIOGENESIS\": \"inhibition of tumor cell angiogenesis\",\n \"REACTIVE OXYGEN SPICES\": \"increase in the reactive oxygen species production\"}", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" {\"COHORT\": \"patients receiving paclitaxel\", \"SYNTHESIS_EFFECT\": \"synergistic effect\", \"TUMOR_METABOLISM\": \"tumor metabolism\", \"WARWACK_RELATED_PROTEINS\": \"Warburg-related proteins\", \"GUT_DISBIOSIS\": \"gut dysbiosis\"}", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" {\"Yunzhi\": \"a substance that could enhance the cytotoxicity of anticancer drugs via other mechanisms\", \"cohort\": \"\", \"anticancer drugs\": \"anticancer drugs\", \"cytotoxic and tumor-infiltrating lymphocytes\": \"cytotoxic and tumor-infiltrating lymphocytes\", \"suppressor T cells\": \"suppressor T cells\", \"superoxide dismutase (SOD)\": \"superoxide dismutase (SOD)\", \"lipid peroxide levels\": \"lipid peroxide levels\"}", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" {\"COHORT\": \"The specific group of individuals participating in a pharmacological study or trial\"}\n\n{\"DRUG\": \"The specific medication or substance being studied or administered in the pharmacological context\"}\n\n{\"PHARMACOLOGIST\": \"The healthcare professional specializing in the study of drugs and their effects\"}\n\n{\"PHARMACOLOGICAL TRIAL\": \"A research study conducted to assess the safety, efficacy, and pharmacokinetics of a drug\"}\n\n{\"PHARMACOLOGICAL DATA\": \"The information collected during a pharmacological study, including drug dosage, patient responses, and side effects\"}\n\n{\"MEDICAL TRIAL\": \"A clinical trial that tests the safety and effectiveness of a medical intervention, which may include drugs, devices, or procedures\"}\n\n{\"CLINICAL TRIAL\": \"A research study conducted with human volunteers to evaluate the effectiveness and safety of a medical, diagnostic, or treatment procedure\"}\n\n{\"PHARMACOGENOMICS\": \"The study of how genes affect a person's response to drugs\"}\n\n{\"DRUG DISTRIBUTION\": \"The process of making a drug available for use, including manufacturing, marketing, and dispensing\"}\n\n{\"DRUG PHARMACEUTICAL PRODUCTION\": \"The process of manufacturing drugs for medical use, including synthesis, formulation, and quality control\"}\n\n{\"DRUG PHARMACEUTICAL REGULATION\": \"The set of laws and guidelines governing the production, distribution, and use of pharmaceuticals\"}\n\n{\"DRUG PHARMACEUTICAL REGISTER\": \"A database that contains information about drugs, their properties, and their regulatory status\"}\n\n{\"DRUG PHARMACEUTICAL RESEARCH\": \"The scientific investigation of drugs, including their discovery, development, and testing\"}\n\n{\"DRUG PHARMACEUTICAL REPORTING\": \"The process of documenting and communicating the results of drug research and clinical trials\"}\n\n{\"DRUG PHARMACEUTICAL REVIEW\": \"The evaluation of a drug", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" {\"COHORT\": \"\",\n \"T-box protein expressed in T cells (T-bet)\": \"T-box protein expressed in T cells (T-bet)\",\n \"GATA-3\": \"GATA-3\",\n \"T helper cell balance\": \"T helper cell balance\",\n \"Bax expression\": \"Bax expression\",\n \"caspase 3 activity\": \"caspase 3 activity\",\n \"Forkhead box protein 3 (Foxp3)\": \"Forkhead box protein 3 (Foxp3)\",\n \"programmed death 1 (PD-1)\": \"programmed death 1 (PD-1)\"}", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {\"Medicinal mushrooms\": \"medicinal mushrooms\", \"chemotherapeutic drugs\": \"chemotherapeutic drugs\"}\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"Study\": \"Not mentioned\"}\n\n{\"Outcomes\": \"outcomes\"}\n\n{\"Adverse effects\": \"adverse effects\"}\n\n{\"Clinical settings\": \"clinical settings\"}", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {\"COHORT\": \"Table S4\"}", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" {\"COHORT\": \"The specific group of individuals participating in the pharmacological study\"}\n\n{\"DRUG\": \"The medication or substance being studied in the pharmacological research\"}\n\n{\"PHARMACOLOGIST\": \"The scientist or researcher specializing in the study of drugs and their effects\"}\n\n{\"STUDY\": \"The scientific investigation or experiment being conducted in the field of pharmacology\"}\n\n{\"MEDICAL TRIAL\": \"The clinical research study conducted to evaluate the effectiveness and safety of a drug\"}\n\n{\"CLINICAL TRIAL PARTICIPANT\": \"The individual who volunteers to participate in a medical trial\"}\n\n{\"PHARMACEUTICAL DRUG\": \"A drug that is used for the treatment, cure, or prevention of diseases\"}\n\n{\"DRUG EFFECT\": \"The observed effect or response of a drug on the body\"}\n\n{\"DRUG DOSAGE\": \"The amount of a drug administered at one time\"}\n\n{\"DRUG DISTRIBUTION\": \"The process of making a drug available for use\"}\n\n{\"DRUG PHARMACEUTICAL PRODUCTION\": \"The manufacturing process of a drug for pharmaceutical use\"}\n\n{\"DRUG PHARMACEUTICAL REGULATION\": \"The set of rules and guidelines governing the production and distribution of pharmaceutical drugs\"}\n\n{\"DRUG PHARMACEUTICAL REGULATORY AGENCY\": \"The government or independent organization responsible for regulating pharmaceutical drugs\"}\n\n{\"DRUG PHARMACEUTICAL REGULATIONS\": \"The specific rules and guidelines governing the production and distribution of pharmaceutical drugs\"}\n\n{\"DRUG PHARMACEUTICAL REGULATORY COMPLIANCE\": \"The adherence to the rules and guidelines governing the production and distribution of pharmaceutical drugs\"}\n\n{\"DRUG PHARMACEUTICAL REGULATORY COMPLIANCE OFFICER\": \"The individual responsible for ensuring compliance with pharmaceutical regulations\"}\n\n{\"", {}]], [547, "Not applicable.", [" {\"COHORT\": \"The specific group of individuals participating in a pharmacological study or trial\"}\n\n{\"DRUG\": \"The specific medication or substance being studied or administered in the pharmacological context\"}\n\n{\"PHARMACOLOGIST\": \"The healthcare professional specializing in the study of drugs and their effects\"}\n\n{\"PHARMACOLOGICAL TRIAL\": \"A research study conducted to assess the safety, efficacy, and pharmacokinetics of a drug\"}\n\n{\"PHARMACOLOGICAL DATA\": \"The information collected during a pharmacological study, including drug dosage, patient responses, and side effects\"}\n\n{\"MEDICAL TRIAL\": \"A clinical trial that tests the safety and effectiveness of a medical intervention, which may include drugs, devices, or procedures\"}\n\n{\"CLINICAL TRIAL\": \"A research study conducted with human volunteers to evaluate the effectiveness and safety of a medical, diagnostic, or treatment procedure\"}\n\n{\"PHARMACOGENOMICS\": \"The study of how genes affect a person's response to drugs\"}\n\n{\"DRUG DISTRIBUTION\": \"The process of making a drug available for use, including manufacturing, marketing, and dispensing\"}\n\n{\"DRUG PHARMACEUTICAL PRODUCTION\": \"The process of manufacturing drugs for medical use, including synthesis, formulation, and quality control\"}\n\n{\"DRUG PHARMACEUTICAL REGULATION\": \"The set of laws and guidelines governing the production, distribution, and use of pharmaceuticals\"}\n\n{\"DRUG PHARMACEUTICAL REGISTER\": \"A database that contains information about drugs, their properties, and their regulatory status\"}\n\n{\"DRUG PHARMACEUTICAL RESEARCH\": \"The scientific investigation of drugs, including their discovery, development, and testing\"}\n\n{\"DRUG PHARMACEUTICAL REPORTING\": \"The process of documenting and communicating the results of drug research and clinical trials\"}\n\n{\"DRUG PHARMACEUTICAL REVIEW\": \"The evaluation of a drug", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {\"COHORT\": \"Women diagnosed with breast cancer\"}\n\n{\"COMPLEMENTARY AND ALTERNATIVE (CAM) TREATMENTS\": \"complementary and alternative treatment options\"}\n\n{\"CANCER THERAPY\": \"conventional cancer therapy\"}\n\n{\"DISEASE\": \"breast cancer\"}\n\n{\"SIDE EFFECTS\": \"side effects of conventional cancer therapy\"}", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" {\"COHORT\": \"early stage and metastatic ER-positive breast cancer\", \"ESTROGEN RECEPTOR (ER)\": \"estrogen receptor\"}\n\n{\"PHARMACOLOGICAL TREATMENT\": \"hormonal therapy\"}", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" {\"COHORT\": \"breast cancer patients\", \"VISCUM ALBUM EXTRACTS\": \"Viscum album extracts (VAE)\"}\n\n{\"COHORT\": \"other types of cancer\", \"STUDY\": \"Clinical studies\"}\n{\"SOURCE\": \"10-13\"}", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" {\"COHORT\": \"Mistletoe lectin concentration 306 ng/mL\", \"HOST TREE\": \"Malus domestica\", \"LOT NUMBER\": \"7054/0\", \"PHARMACOLOGY TRIAL\": \"VAEM\"}", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" {\"COHORT\": \"Pooled human liver microsomes (HLMs, 50 donors, mixed gender)\"}\n{\"COMPOUND\": \"(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)\", \"\u03b2-estradiol (E2)\", \"dextrorphan-d\"}\n{\"SOURCE\": \"Bioreclamation IVT (Baltimore, USA)\"}", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" {\"COHORT\": \"VAEM untreated values\", \"TREATMENT\": \"endoxifen\", \"MEASURE\": \"concentration-dependent inhibition of proliferation\"}", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" {\"COHORT\": \"patients classified as poor, intermediate, extensive, or ultra-rapid metabolizers\"}\n{\"GENOTYPE COMMISSIONS\": \"genotype combinations encoding for varying enzyme phenotypes\"}\n{\"ENZYME PHENOTYPES\": \"varying enzyme phenotypes\"}\n{\"SOURCES\": \"32, 33\"}", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" {\"CYP2D6\": \"metabolic activity\", \"breast cancer\": \"long-term outcomes\"}", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" {\"COHORT\": \"pooled microsomes from 50 donors\"}\n\n{\"GENE\": \"CYP2D6\"}\n\n{\"PHENOMENON\": \"inter-individual variability\"}\n\n{\"CAUSE\": \"genetic polymorphisms\"}\n\n{\"METHOD\": \"use of pooled microsomes\"}\n\n{\"STUDY\": \"scientific article about pharmacology\"}\n\n{\"ARTICLE\": \"scientific article\"}\n\n{\"REFERENCE\": \"41\"}", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" {\"COHORT\": \"described cohort in the scientific article about pharmacology\", \"PDF\": \"36 kb\", \"FIGURE S2\": \"Figure S2\"}", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" {\"CYP2D6\": \"a human gene that encodes the enzyme cytochrome P450 2D6, which is involved in the metabolism of many drugs\", \"Dextromethorphan\": \"a medication used to suppress coughs in direct-oral cough suppressants\", \"in vitro\": \"a process that is carried out outside of a living organism, typically in a test tube or culture dish\", \"inhibition profiles\": \"a description of how a substance affects the activity of an enzyme\", \"reference inhibitor\": \"a substance used as a standard to compare the effects of other substances\", \"Quinidine\": \"a medication used to treat heart arrhythmias and as a reference inhibitor for CYP2D6\"}", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Springer Nature\": \"publisher\", \"jurisdictional claims\": \"legal entities\", \"published maps\": \"geographical entities\", \"institutional affiliations\": \"institutional entities\"}\n{\"COHORT\": \"group of individuals selected for study in pharmacology\"}\n{\"PHARMACOLOGY\": \"scientific field\"}\n{\"ARTICLE\": \"scientific publication\"}\n{\"Scientific Article\": \"scientific publication\"}\n{\"pharmacology\": \"scientific field\"}\n{\"pharmacological\": \"related to pharmacology\"}\n{\"pharmacological agents\": \"substances used in pharmacology\"}\n{\"pharmacokinetics\": \"scientific field\"}\n{\"pharmacodynamics\": \"scientific field\"}\n{\"drug\": \"pharmacological substance\"}\n{\"drug therapy\": \"medical treatment\"}\n{\"clinical trials\": \"research studies\"}\n{\"medication\": \"pharmacological substance\"}\n{\"therapeutic effect\": \"medical outcome\"}\n{\"adverse effect\": \"medical outcome\"}\n{\"drug efficacy\": \"measure of drug effectiveness\"}\n{\"drug safety\": \"measure of drug safety\"}\n{\"drug interactions\": \"interactions between drugs\"}\n{\"drug metabolism\": \"biological process\"}\n{\"drug excretion\": \"biological process\"}\n{\"drug absorption\": \"biological process\"}\n{\"drug distribution\": \"biological process\"}\n{\"drug half-life\": \"biological property\"}\n{\"drug clearance\": \"biological property\"}\n{\"drug concentration\": \"biological property\"}\n{\"drug plasma levels\": \"biological property\"}\n{\"drug action\": \"mechanism of drug effect\"}\n{\"drug target\": \"biological entity\"}\n{\"drug receptor\": \"biological entity\"}\n{\"drug-receptor interaction\": \"biological process\"}\n{\"drug-enzyme interaction\": \"biological process\"}\n{\"drug-protein interaction\": \"biological process\"}\n{\"drug-lipid interaction\": \"biological process\"}\n{\"drug-carrier interaction\": \"biological process\"}\n{\"drug-cell interaction\": \"biological process\"}", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {\"COHORT\": \"Not specified\", \"PHARMACEUTICAL_AGENTS\": [\"captopril\"], \"PLANT_SPECIES\": [\"H. sabdariffa\"]}\n\nNote: Since the text does not explicitly mention a specific cohort, the \"COHORT\" field is left empty. However, the pharmacological agents and plant species are identified as per the instructions.", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {\"COHORT\": \"Not specified\",\n \"Plasma sample\": \"180 \u00b5L\",\n \"2-4-dibromoacetophenone\": \"520 ppm\",\n \"Ammonia solution\": \"5%\",\n \"Captopril\": \"derivatization agent\",\n \"2-4-dibromoacetophenone\": \"reagent\",\n \"ammonia\": \"reagent\"}", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" {\"COHORT\": \"not specified\", \"MEDICATION\": \"captopril\", \"DOSAGE\": \"4.5 mg/200 g BW\", \"METHOD\": \"oral (p.o.)\", \"DURATION\": \"two weeks\", \"TIME_FRAME\": \"morning\"}", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {\"COHORT\": \"animals\", \"ANESTHETICATED\": \"anaesthetized\", \"BLOOD COLLECTION PROCESS\": \"blood collection process\"}\n\n{\"COHORT\": \"blood samples\"}\n\n{\"PROCEDURE\": \"anaesthetized\"}\n\n{\"MEASUREMENT\": \"blood collection process\"}", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"COHORT\": \"Not specified\", \"MEDICATION\": \"1.0 mL saline solution\", \"METHOD\": \"oral (p.o.)\"}", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {\"COHORT\": \"not specified\", \"TABLE 3\": \"within-run accuracy and precision of captopril analysis\"}", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"COHORT\": \"six rats\"}\n\n{\"PLASMA\": \"six rats plasma\"}\n\nNote: The provided text does not explicitly mention a specific cohort study or a detailed description of the cohort, but it does refer to a sample of rats' plasma. Therefore, the cohort is inferred from the context of the testing.", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"2-4-dibromoacetophenone\": \"derivatization agent\", \"captopril\": \"sulfhydryl group\", \"plasma sulfhydryl groups\": \"sulfhydryl group\"}\n\n{\"COHORT\": \"Not mentioned\"}", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" {\"Ammonia\": \"chemical entity used during derivatization\", \"reaction\": \"chemical process optimal at basic pH\"}\n\n{\"COHORT\": \"Not specified in the provided text\"}\n\n{\"pH\": \"descriptive entity referring to the acidity or alkalinity of a solution\"}\n\n{\"derivatization\": \"chemical process\"}\n\n{\"optimal\": \"descriptive entity referring to the best or most favorable condition for a reaction\"}", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"COHORT\": \"\", \"FORMIC ACID\": \"formic acid\"}", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"H. sabdariffa extract\": \"H. sabdariffa extract\", \"GSH level\": \"GSH level\", \"PEPT1 transporter\": \"PEPT1 transporter\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"Study\": \"Two weeks of coadministration\"}\n\n{\"Effect\": \"affect the GSH level or the expression of the PEPT1 transporter\"}", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\"COHORT\": \"2016 cohort\", \"RESEARCHERS\": \"Eng et al.\"}\n\nNote: \"Eng et al.\" refers to the authors of the study, which is a common way to cite researchers in scientific literature. However, in the context of parsing cited entities, we typically refer to the specific subjects or objects mentioned in the text, such as cohorts, studies, or specific entities being researched. In this case, \"Eng et al.\" is not an entity but a reference to the authors. If we strictly follow the instruction to identify cited entities, we would not include \"Eng et al.\" as an entity. However, if we consider the authors as the entities conducting the research, then it could be included. The provided answer assumes the strict interpretation of entities as subjects or objects of study.\n\nIf we consider \"Eng et al.\" as the authors conducting the research, the answer could be:\n\n{\"RESEARCHERS\": \"Eng et al.\"}", {}]], [572, "2016).", [" {\"COHORT\": \"2016 cohort\", \"STUDY\": \"study\", \"PHARMACOLOGY\": \"pharmacology\", \"ARTICLE\": \"scientific article\", \"RESEARCHERS\": \"researchers\", \"PUBLICATION\": \"publication\", \"JOURNAL\": \"journal\", \"YEAR\": \"2016\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n{\"PHARMACEUTICAL_PRODUCT\": \"\"}\n{\"MEDICAL_CONDITION\": \"\"}\n{\"STUDY_DESIGN\": \"study\"}\n{\"RESEARCH_TYPE\": \"research\"}\n{\"PUBLICATION_TYPE\": \"publication\"}\n{\"JOURNAL_NAME\": \"journal\"}\n{\"YEAR_OF_PUBLICATION\": \"2016\"}", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {\"COHORT\": \"laboratory rodent chow\", \"LOCATION\": \"Shanghai, China\"}\n\nNote: The term \"laboratory rodent chow\" refers to the food provided to the cohort, and \"Shanghai, China\" refers to the location where the chow was sourced. However, since the task is to find words referring to described entities, and \"laboratory rodent chow\" is a product rather than a cohort, it might not be the primary focus in this context. If the primary focus is on cohorts, the provided information does not directly mention a specific cohort. Therefore, based on the given text, there is no explicit \"cohort\" entity mentioned. However, if we consider \"laboratory rodent chow\" as the food source for a cohort of laboratory rodents, then it could be inferred as part of the cohort context.\n\n{\"COHORT\": \"laboratory rodents\", \"LOCATION\": \"Shanghai, China\", \"FOOD_SOURCE\": \"laboratory rodent chow\"}", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {\"AGILAND TECHNOLOGIES\": \"Agilent 1290 series liquid chromatography system\", \"LOCATION\": \"Palo Alto, CA, USA\"}\n\nNote: The entities \"Agilent Technologies\" and \"Agiland Technologies\" are not explicitly mentioned in the text, but the context suggests that the chromatography system is produced by Agilent Technologies. Therefore, I've included \"Agilent Technologies\" as the entity responsible for the product. If the entity should be referred to differently based on the context not provided here, please adjust accordingly.", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {\"Student\u2019s paired t-test\": \"statistical analysis\", \"clinical study\": \"cited entity\"}", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"GLT\": \"herb\", \"AC\": \"drug\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"interaction\": \"herb-drug interaction\"}", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" {\"CLINICAL PHARMACOLOGY\": \"the field of pharmacology that studies the effects of drugs and their mechanisms of action in humans\", \"TRANSLATIONAL SCIENCE\": \"the process of applying discoveries made in the laboratory to develop new clinical diagnostic tools, treatments, or procedures\", \"DRUGS\": \"substances used for medical treatment\", \"MECHANISMS OF ACTION\": \"the specific biochemical interactions through which a drug substance produces its pharmacological effect\", \"PHARMACOLOGICAL EFFECTS\": \"the response of a living organism to a drug\", \"PHARMACOLOGIST\": \"a scientist who specializes in the study of drug action\", \"PHARMACOGENOMICS\": \"the study of how genes affect a person's response to drugs\", \"PHARMACOGENETICS\": \"the study of the role of genetics in drug response\", \"PHARMACOINFORMATICS\": \"the use of computer and informational techniques to solve problems in drug discovery and development\", \"PHARMACOLOGICAL STUDIES\": \"research studies that investigate the effects of drugs\", \"PHARMACOLOGICAL DATA\": \"data related to the effects of drugs\", \"PHARMACOLOGICAL PROFILE\": \"the pattern of drug response in an individual\", \"PHARMACOLOGICAL POPULATION\": \"a group of individuals with similar drug response patterns\", \"PHARMACOLOGICAL DATA ANALYSIS\": \"the process of analyzing data related to drug effects\", \"PHARMACOLOGICAL DATA MINING\": \"the process of discovering patterns in pharmacological data\", \"PHARMACOLOGICAL DATA MANAGEMENT\": \"the process of organizing and storing pharmacological data\", \"PHARMACOLOGICAL DATA ANALYZER\": \"a software tool used for analyzing pharmacological data\", \"PHARMACOLOGICAL DATA MODELING\": \"the process of creating mathematical models to represent drug effects\", \"PHARMACOLOGICAL DATA MINING TOOLS\": \"software tools used for discovering patterns in pharmacological data\", \"PHAR", {}]], [578, "(n\u00a0=\u00a06).", [" {\"COHORT\": \"group of individuals participating in a clinical study or research, often defined by specific characteristics such as age, gender, or health condition\", \"DRUG\": \"a substance used for medical treatment, typically in the form of a pill, injection, or topical application\", \"PHARMACEUTICAL COMPANY\": \"a business entity that develops, produces, and markets drugs and other healthcare products\", \"DOCTOR\": \"a medical professional who diagnoses and treats illnesses and injuries\", \"CLINICAL TRIAL\": \"a research study conducted to evaluate the safety and effectiveness of a new drug or treatment\", \"PHARMACOLOGIST\": \"a scientist specializing in the study of drugs and their effects on the human body\", \"MEDICAL TREATMENT\": \"the management and care of a patient to combat disease or disorder\", \"HEALTHCARE PRODUCT\": \"a product designed to maintain or improve health, such as a drug, medical device, or diagnostic test\", \"PATIENT\": \"an individual receiving medical care or treatment\"}", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" {\"MANUSPRIPT_AUTHOR\": \"wrote the manuscript\"}\n\n{\"MANUSPINTER_TITLE\": \"scientific article about pharmacology\"}\n\n{\"SUBJECT_TOBE_STUDIED\": \"pharmacology\"}\n\n{\"PUBLICATION_TYPE\": \"scientific article\"}\n\n{\"PUBLICATION_SOURCE\": \"Not specified\"}\n\n{\"MANUSPINTER_AUTHORS\": \"Not specified\"}\n\n{\"MANUSPINTER_PUBLISHER\": \"Not specified\"}\n\n{\"MANUSPINTER_YEAR\": \"Not specified\"}\n\n{\"PHARMACOLOGY_CONCEPT\": \"pharmacology\"}\n\n{\"PHARMACOLOGY_SUBFIELD\": \"Not specified\"}\n\n{\"PHARMACOLOGY_APPLICATION\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_TYPE\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_DESC\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_DETAILS\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_COHORT\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_PARTICIPANTS\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_METHODOLOGY\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_OUTCOME\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_IMPACT\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_FINDINGS\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_CONCLUSIONS\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_FUTURE_WORK\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_RECOMMENDATIONS\": \"Not specified\"}\n\n{\"PHARMACOLOGY_RESEARCH_APPLICATION\": \"Not specified\"}\n\n{\"PHARMACOLOGY_", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" {\"COHORT\": \"S.M., Y.O., R.T., E.H., T.O., H.O., K.S.\"}\n\nNote: The description provided does not specify the context in which these entities are being referred to, such as whether they are participants in a study, researchers, or other relevant roles. However, based on the instruction, we've identified them as entities within the context of a scientific article about pharmacology.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" {\"COHORT\": \"S.M., Y.O., R.T., J.K., H.W., M.F., K.S.\"}\n\nNote: The description provided does not specify the context in which these entities are being referred to, such as whether they are participants in a study, researchers, or other relevant roles. However, based on the instruction, we've identified them as entities within the context of a scientific article about pharmacology.", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" {\"Eugenia jambolana\": \"Eugenia jambolana (EJ)\"}\n\nNote: In this context, \"Eugenia jambolana\" is the primary entity referred to in the text, and it is also given the specific name \"EJ\" as per the instruction. However, if the task requires identifying additional entities such as \"traditional herb\" or \"treatment of diabetes mellitus,\" they are not explicitly labeled with a unique identifier in the provided format. The primary entity is still Eugenia jambolana.", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\"SITA\": \"a compound\", \"pharmacodynamic study\": \"a type of scientific study\"}\n\n{\"blood glucose level\": \"a biological parameter\"}\n\n{\"combination\": \"a mixture of substances\"}\n\n{\"individual drug\": \"a single pharmacological agent\"}\n\n{\"individual extract\": \"a substance obtained from a single source\"}\n\n{\"pharmacodynamic study\": \"a type of scientific study\"}", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" {\"COHORT\": \"research groups studying the protective and therapeutic effect of EJE\", \"Bioactive constituents\": \"anthocyanins, flavonoids\", \"Therapeutic agents\": \"Gliptins\"}\n\n{\"COHORT\": \"\", \"Bioactive constituents\": \"anthocyanins, flavonoids\", \"Therapeutic agents\": \"Gliptins\"}", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {\"COHORT\": \"diabetic patient\", \"CONTRATIVE TREATMENT\": \"concomitant treatments\", \"STUDY\": \"present work\"}\n\nIf there are specific entities or additional details mentioned in the article, please provide them for a more comprehensive extraction.", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {\"Eugenia jambolana\": \"Dried seed\"}\n\n{\"aqueous extract\": \"preparation\"}\n\n{\"double maceration technique\": \"technique\"}\n\n{\"cohort\": \"Not applicable in this context\"}\n\n{\"article\": \"scientific article\"}\n\n{\"pharmacology\": \"field of study\"}\n\n{\"word\": \"Not applicable in this context\"}\n\n{\"description\": \"Not applicable in this context\"}\n\n{\"method\": \"double maceration technique\"}\n\n{\"double\": \"Not applicable in this context\"}\n\n{\"maceration\": \"technique\"}\n\n{\"technique\": \"double maceration technique\"}\n\n{\"preparation\": \"process\"}\n\n{\"process\": \"preparation\"}\n\n{\"powdered\": \"state\"}\n\n{\"state\": \"powdered\"}\n\n{\"water\": \"solvent\"}\n\n{\"solvent\": \"water\"}\n\n{\"extract\": \"product\"}\n\n{\"product\": \"extract\"}\n\n{\"seed\": \"part\"}\n\n{\"part\": \"seed\"}\n\n{\"double\": \"Not applicable in this context\"}\n\n{\"maceration\": \"Not applicable in this context\"}\n\n{\"technique\": \"Not applicable in this context\"}\n\n{\"cohort\": \"Not applicable in this context\"}\n\n{\"article\": \"Not applicable in this context\"}\n\n{\"scientific\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"field\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable in this context\"}\n\n{\"study\": \"Not applicable", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {\"COHORT\": \"not mentioned\",\n \"DRUG\": \"not mentioned\",\n \"PHARMACEUTICAL TRIAL\": \"not mentioned\",\n \"PHARMACOLOGIST\": \"not mentioned\",\n \"PHARMACOLOGICAL STUDY\": \"not mentioned\",\n \"PHARMACOLOGICAL RESEARCH\": \"not mentioned\",\n \"PHARMACOLOGICAL REPORT\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE IDENTIFIER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE TITLE\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE YEAR\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE VOLUME\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE ISSUE\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE PAGE\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL REFERENCE NUMBER\": \"not mentioned\",\n \"PHARMACOLOGICAL", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" {\"COHORT\": \"not specified\", \"FILTRATE\": \"filtrate\", \"PREVIOUS FILTRATE\": \"previous filtrate\"}\n\n{\"PHARMACOLOGICAL TERM\": \"pharmacology\", \"PHARMACOLOGICAL EVENT\": \"not specified\", \"PHARMACOLOGICAL STUDY\": \"not specified\", \"PHARMACOLOGICAL INDICES\": \"not specified\", \"PHARMACOLOGICAL AGENT\": \"not specified\"}\n\n{\"EXPERIMENTAL SETUP\": \"experimental step\", \"MIXTURE\": \"filtrate\"}\n\n{\"PHARMACOLOGICAL PUBLICATION\": \"not specified\"}", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"GOD-POD\": \"diagnostic kits\"}\n\n(Note: While \"GOD-POD\" is mentioned as a diagnostic kit, it is not a standard entity name in pharmacology. However, for the purpose of this task, it is treated as a cited entity related to the glucose level determination.)", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" {\"COHORT\": \"unspecified cohort in the scientific article about pharmacology\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"unspecified pharmacological products\"}\n\n{\"STUDY_DESIGN\": \"study design\"}\n\n{\"STUDY_SET\": \"unspecified study set\"}\n\n{\"STUDY_PARTICIPANTS\": \"study participants\"}\n\n{\"STUDY_OUTCOME\": \"study outcome\"}\n\n{\"STUDY_CONCLUSION\": \"study conclusion\"}\n\n{\"PUBLICATION\": \"scientific article\"}\n\n{\"AUTHOR\": \"unspecified author\"}\n\n{\"JOURNAL\": \"unspecified journal\"}\n\n{\"YEAR\": \"unspecified year\"}\n\n{\"SECTION\": \"unspecified section\"}\n\n{\"ARTICLE_NUMBER\": \"unspecified article number\"}\n\n{\"ARTICLE_TITLE\": \"unspecified article title\"}\n\n{\"ARTICLE_ABSTRACT\": \"unspecified article abstract\"}\n\n{\"ARTICLE_BODY\": \"unspecified article body\"}\n\n{\"ARTICLE_REFERENCES\": \"unspecified article references\"}", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {\"COHORT\": \"Mass chromatograms of SITA and PRM\", \"PEAK_TIMES\": {\"SITA\": \"0.642min\", \"PRM\": \"0.482min\"}}\n\n{\"PEAK_TIMES\": {\"SITA\": \"0.642min\", \"PRM\": \"0.482min\"}}\n\n{\"COMPONENTS\": [\"SITA\", \"PRM\"]}\n\n{\"CHROMATOGRAPHY_TYPE\": \"mass chromatograms\"}\n\n{\"TIME_INTERVAL\": \"0.642min, 0.482min\"}", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {\"Diabetes\": \"underlying mechanism\", \"liver damage\": \"liver\", \"oxidative stress\": \"oxidative stress\", \"inflammatory response\": \"inflammatory response\"}\n\n{\"COHORT\": \"Not applicable\"}\n\n(Note: The original text does not explicitly mention a cohort, so the \"COHORT\" field remains empty.)", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" {\"COHORT\": \"six rats\"}\n\n{\"MEAN_\u00b1_SEM\": \"mean \u00b1 standard error of the mean (SEM)\"}\n\n{\"RATS\": \"rats\"}\n\n{\"MEAN\": \"mean\"}\n\n{\"SEM\": \"standard error of the mean (SEM)\"}", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"COHORT\": \"significantly different from normal group, # significantly different from diabetic control group at p < 0.001\"}\n{\"DIABETIC CONTROL GROUP\": \"diabetic control group\"}\n{\"P_VALUE\": \"p < 0.001\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"SIGNIFICANT DIFFERENCE\": \"significantly different\"}\n{\"STANDARD GROUP\": \"normal group\"}\n{\"SUBJECTS\": \"cohort\"}\n{\"TREATMENT GROUP\": \"normal group, diabetic control group\"}", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" {\"COHORT\": \"The specific cohort is not mentioned in the provided text.\",\n\"EJE\": \"Enalapril Jevity, a pharmaceutical entity\",\n\"EJE_SITA\": \"Enalapril Jevity + Sitagliptin, a pharmaceutical entity\",\n\"BUN\": \"Blood Urea Nitrogen, a biomarker\"}", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" {\"COHORT\": \"Table 2 cohort\", \"TABLE\": \"Table 2\", \"PHARMACOLOGY\": \"pharmacology\", \"ARTICLE\": \"scientific article\"}", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"COHORT\": \"significantly different from normal group, # significantly different from diabetic control group at p < 0.001\"}\n{\"DIABETIC CONTROL GROUP\": \"diabetic control group\"}\n{\"P_VALUE\": \"p < 0.001\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"SIGNIFICANT DIFFERENCE\": \"significantly different\"}\n{\"STANDARD GROUP\": \"normal group\"}\n{\"SUBJECTS\": \"cohort\"}\n{\"TREATMENT GROUP\": \"normal group, diabetic control group\"}", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\"A. officinarum\": Description: A plant species used for oral administration in the study, producing significant alterations in the pharmacokinetic parameters of indomethacin, \"indomethacin\": Description: The drug whose pharmacokinetic parameters were altered by oral administration of A. officinarum in the study}\n\n(Note: The \"cohort\" entity was not explicitly mentioned in the provided text, so it remains empty.)", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" {\"Officinarum\": \"plant\", \"indomethacin\": \"drug\", \"metabolites\": \"substances\", \"bile\": \"biofluid\", \"feces\": \"biofluid\"}\n\n{\"COHORT\": \"rats\"}", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {\"COHORT\": \"tissue homogenates\", \"PLASMA_SAMPLE\": \"plasma sample preparation\"}\n\nNote: The original text does not explicitly mention a specific cohort, but it refers to a method of treatment for tissue homogenates and plasma samples. Therefore, the \"COHORT\" field is left empty as per the instruction to not add supplementary information. However, if we were to infer a cohort based on the context, it could be the samples being treated for a particular study or experiment.\n\n{\"COHORT\": \"samples\"}", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\"MODEL GROUP\": \"group with six rats\",\n\"M-AOE GROUP\": \"group with six rats\"}\n\n{\"RATS\": \"six rats\"}", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {\"COHORT\": \"patients\", \"Bile collection time points\": \"0\u20131 h, 1\u20132 h, 2\u20133 h, 3\u20134 h, 4\u20135 h, 5\u20136 h and 6\u20137 h after dosing\"}\n\n{\"Dosing\": \"dosing\"}\n\n{\"Dosing time frame\": \"0\u20131 h, 1\u20132 h, 2\u20133 h, 3\u20134 h, 4\u20135 h, 5\u20136 h and 6\u20137 h\"}\n\n{\"Drug\": \"bile\"}\n\n{\"Drug administration\": \"dosing\"}", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\"COHORT\": \"study participants\",\n\"MEASUREMENT_TIMES\": \"0\u20136 h, 6\u201318 h, 18\u201328 h\",\n\"BIOMETRIC_SUBSTANCES\": \"urine, feces\",\n\"MEASUREMENT_TYPES\": \"collection\",\n\"MEDICAL_PRODUCT\": \"administered substance\"}", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {\"U.S. Food and Drug Administration (USFDA)\": \"regulatory agency responsible for protecting public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices, as well as ensuring the accuracy of labeling and advertising of these products\"}\n\n{\"bioanalytical method validation\": \"process of confirming that a method is suitable for its intended purpose, which includes assessing selectivity, matrix effect, linearity, recovery, accuracy, precision, dilution integrity, and stability\"}\n\n{\"selectivity\": \"the ability of a method to measure the analyte of interest in the presence of other components in the sample\"}\n\n{\"matrix effect\": \"the impact of other substances in the sample on the measurement of the analyte of interest\"}\n\n{\"linearity\": \"the ability of a method to obtain results that are directly proportional to the concentration of the analyte in the sample within a given range\"}\n\n{\"recovery\": \"the process of retrieving the analyte from the sample matrix and measuring the amount that can be accurately quantified\"}\n\n{\"accuracy\": \"the closeness of a measured value to the true value\"}\n\n{\"precision\": \"the degree of repeatability or reproducibility of a measurement method\"}\n\n{\"dilution integrity\": \"the ability of a method to accurately measure the analyte in a diluted sample without loss of accuracy or precision\"}\n\n{\"stability\": \"the ability of a method to produce consistent results over time\"}", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {\"COHORT\": \"indomethacin-induced gastric injury\", \"A. officinarum\": \"A. officinarum\", \"indomethacin\": \"indomethacin\", \"metabolites\": \"indomethacin metabolites\"}\n\nNote: The original text does not explicitly mention a \"cohort\" in the traditional sense (a group of people with shared characteristics being studied), but the phrase \"indomethacin-induced gastric injury\" can be interpreted as the subject of the study. However, since the instruction asks for a specific \"COHORT\" entity and none is directly mentioned, the field remains empty. If the context implies a study group, it could be inferred but not explicitly stated.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"COHORT\": \"S-AOE and M-AOE groups\", \"MODEL GROUP\": \"model group\"}\n\n{\"MEDICAL TRIAL\": \"study\"}\n\n{\"MEDICAL TRIAL\": \"plasma concentration-time curves\"}\n\n{\"MEDICAL TRIAL\": \"indomethacin\"}\n\n{\"MEDICAL TRIAL\": \"Figure\"}", {}]], [607, "1).", [" {\"COHORT\": \"The specific group of individuals participating in a pharmacological study or clinical trial\"}\n\n{\"DRUG\": \"The specific medication or therapeutic substance being studied or administered in the pharmacological context\"}\n\n{\"PHARMACOLOGIST\": \"A medical professional specializing in the study of drugs and their effects on the human body\"}\n\n{\"CLINICAL TRIAL\": \"A research study conducted to evaluate the effectiveness and safety of a drug or treatment in humans\"}\n\n{\"MEDICAL TRIAL\": \"A research study conducted to evaluate the effectiveness and safety of a drug or treatment in humans\"}\n\n{\"PHARMACEUTICAL PRODUCT\": \"A drug or medication that is manufactured and sold for use as a medical treatment\"}\n\n{\"DRUG NAME\": \"The specific name of a medication or therapeutic substance\"}\n\n{\"DRUG CLASS\": \"A group of drugs that share similar chemical structures, properties, and modes of action\"}\n\n{\"DRUG ACTION\": \"The specific biochemical interaction through which a drug substance produces its pharmacological effect\"}\n\n{\"DRUG EFFECT\": \"The specific physiological response or therapeutic outcome produced by a drug\"}\n\n{\"DRUG DOSAGE\": \"The amount and frequency of a drug administered to achieve the desired therapeutic effect\"}\n\n{\"DRUG DISTRIBUTION\": \"The process of delivering a drug to its intended target site in the body\"}\n\n{\"DRUG PHARMACOKINETICS\": \"The study of how drugs are absorbed, distributed, metabolized, and excreted by the body\"}\n\n{\"DRUG PHARMACODYNAMICS\": \"The study of the time course of drug concentration in the body and its relationship to the drug's effect\"}\n\n{\"DRUG PHARMACOEFFECTIVE DOSE\": \"The minimum dose of a drug that produces the desired therapeutic effect\"}\n\n{\"DRUG PHARMACOLOGICAL PROFILE\": \"A summary of the pharmacological properties of a drug, including its mechanism of action, therapeutic effects,", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" {\"COHORT\": \"patient\", \"medication\": \"warfarin\", \"INR\": \"International Normalized Ratio\"}\n\n(Note: The term \"cohort\" in the context of a scientific article typically refers to a group of subjects participating in a study. However, in the provided text, there is no explicit mention of a study or research group, so the term \"cohort\" may not be directly applicable. Instead, the term \"patient\" is used to describe the individual participating in the treatment and monitoring process.)", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" {\"COHORT\": \"patients undergoing anticoagulant therapy\", \"ALCOHOL_CONSUMPTION\": \"375 ml wine\", \"DRUG_TREATMENT\": \"anticoagulant therapy\", \"THROMBIN_TIMES\": \"thrombin times (TTs)\", \"MEASUREMENT_OUTCOME\": \"thrombin times (TTs) outside the therapeutic range\"}", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" {\"COHORT\": \"unspecified patient groups or populations in pharmacological studies\",\n\"DRUG_NAMES\": [\"aspirin\", \"ibuprofen\", \"acetaminophen\", \"danshen\", \"ginkgo biloba\", \"dong quai\"],\n\"HERB_NAMES\": [\"danshen\", \"ginkgo biloba\", \"dong quai\"],\n\"STUDY_TYPE\": \"pharmacological studies\",\n\"RESEARCH_METHODS\": \"not specified\",\n\"RESEARCH_FINDINGS\": \"not specified\",\n\"PUBLICATION_SOURCES\": \"not specified\",\n\"RESEARCH_CONCLUSIONS\": \"not specified\",\n\"PHARMACOLOGIC_CONCEPTS\": \"not specified\"}", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" {\"Gouqizi\": \"a popular component of the daily diet in China\", \"patients taking warfarin\": \"patients\"}", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" {\"COHORT\": \"patients with atrial fibrillation in China\"}\n\n{\"DRUG\": \"warfarin\"}\n\n{\"RISK\": \"risk of bleeding\"}\n\n{\"HEALTHCARE_PROVIDER\": \"allopathic doctors\"}\n\n{\"GEOGRAPHICAL_REGION\": \"China\"}\n\n{\"STUDY\": \"study mentioned in the article\"}\n\n{\"PUBLICATION\": \"scientific article\"}\n\n{\"PUBLICATION_NUMBER\": \"5\"}", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" {\"COHORT\": \"patients with prosthetic heart valves who were concomitantly taking warfarin\", \"DRUG\": \"Gouqizi\", \"DOSAGE\": \"6 g daily for 3 days\", \"DRUG_USE_CONDITION\": \"to enhance the effects of warfarin\", \"SOURCE\": \"Chinese Pharmacopoeia\"}\n\n{\"DRUG\": \"warfarin\"}", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {\"COHORT\": \"Not specified\", \"CONFLICT_OF_INTEREST\": \"No conflict of interests\"}", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"COHORT\": \"Fujian Medical University Union Hospital ethics committee\", \"DRUG1\": \"warfarin\", \"DRUG2\": \"Lycium barbarum L.\"}\n\n(Note: The \"COHORT\" in this context refers to the ethics committee, but typically, \"COHORT\" is used to refer to a group of individuals participating in a study. However, since the ethics committee is the entity approving the study, it's been included here for completeness. If strictly following the definition, the \"COHORT\" field might be left empty.)", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {\"HS extract\": \"High-Salt (Hypertensive) extract\", \"blood pressure\": \"blood pressure\"}\n\n{\"COHORT\": \"Animal studies\"}", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" {\"Anthocyanins\": \"active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS\"}\n\n{\"delphinidin-3-sambubioside\": \"active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS\"}\n\n{\"cyanidin-3-sambubioside\": \"active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS\"}\n\n{\"HS\": \"Hibiscus\"}\n\n{\"aqueous extracts\": \"source of anthocyanins\"}\n\n{\"[8, 11, 13, 16]\": \"references\"}", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" {\"HS varieties\": \"HS varieties with deeper red calyxes\", \"antioxidant activity\": \"greater antioxidant activity\", \"lighter red or white varieties\": \"lighter red or white varieties\"}\n\n{\"COHORT\": \"HS varieties with deeper red calyxes\"}\n{\"TARGET\": \"greater antioxidant activity\"}\n{\"COMPARANDS\": \"lighter red or white varieties\"}\n{\"SOURCES\": \"44, 45\"}", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" {\"COHORT\": \"unspecified group of patients or participants in a study\", \"DRUG\": \"unspecified pharmacological substance\", \"PHARMACOLOGIST\": \"unspecified medical professional specializing in pharmacology\", \"STUDY\": \"unspecified scientific research or clinical trial\", \"JOURNAL\": \"unspecified scientific journal or publication\", \"YEAR\": \"unspecified year of publication\"}", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" {\"CHOLINESTEROL RCT\": \"Cholesterol RCT interventions\", \"TOTAL CHOLESTEROL\": \"effects of cholesterol RCT interventions on total cholesterol\", \"HDL-C\": \"effects of cholesterol RCT interventions on HDL-C\", \"LDL-C\": \"effects of cholesterol RCT interventions on LDL-C\", \"TRIGLYCERIDES\": \"effects of cholesterol RCT interventions on triglycerides\"}", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {\"COHORT\": \"hypertensive patients\", \"TREATMENT\": \"HS\", \"STUDY\": \"15 day study\", \"MEASURED_OUTCOME\": \"total cholesterol\"}", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {\"RCT\": \"Randomized Controlled Trial\", \"study design\": \"study design problems\"}", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" {\"VASODILATORY_MECHANISM\": \"vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx\", \"ACE_INHIBITION\": \"ACE inhibition\", \"ANTHOCYANINS\": \"anthocyanins competing with the substrate for the active site\", \"CYCLOOXYGENASE_INHIBITION\": \"decrease in blood viscosity through cyclooxygenase inhibitory activity\", \"ADIPOSE_DIFFERENTIATION_INHIBITION\": \"inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway\"}", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {\"HS\": \"High-Sugar\", \"liver\": \"liver function\", \"kidney\": \"kidney function\", \"extremely high doses\": \"high doses\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"Studies\": \"Research studies\"}\n\n{\"adversely\": \"negatively\", \"hepatotoxic\": \"liver toxicity\"}\n\n{\"high doses\": \"high dosage\"}", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {\"COHORT\": \"Not specified\", \"HS extracts\": \"High-salt extracts\", \"electrolyte levels\": \"electrolyte levels\"}\n\n{\"PHARMACEUTICAL AGENT\": \"HS extracts\", \"DIURETIC\": \"diuretic effects\", \"PHARMACOLOGY\": \"pharmacology\"}\n\n{\"STUDY\": \"Not specified\", \"ARTICLE\": \"scientific article\", \"PHARMACOLOGIST\": \"Not specified\"}\n\n{\"PUBLICATION\": \"Not specified\", \"JOURNAL\": \"Not specified\", \"ARTICLE TYPE\": \"scientific article\"}\n\n{\"DIETARY INGREDIENT\": \"HS extracts\", \"DIET\": \"Not specified\", \"ELECTROLYTE\": \"electrolyte levels\"}\n\n{\"MEASUREMENT\": \"electrolyte levels\", \"EFFECT\": \"diuretic effects\"}\n\n{\"PHARMACEUTICAL EFFECT\": \"diuretic effects\"}\n\n{\"PHARMACOLOGICAL FINDING\": \"Not specified\"}\n\n{\"PHARMACOLOGICAL STUDY\": \"Not specified\"}\n\n{\"PHARMACOLOGICAL RESEARCH\": \"Not specified\"}\n\n{\"PHARMACOLOGICAL RESEARCH FINDING\": \"Not specified\"}", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" {\"COHORT\": \"described cohort in the scientific article\",\n\"PHARMACOLOGY\": \"pharmacology\",\n\"PHARMACEUTICAL AGENTS\": \"pharmaceutical agents\",\n\"DRUG NAMES\": \"drug names\",\n\"DRUG CLASS\": \"drug class\",\n\"DRUG EFFECTS\": \"drug effects\",\n\"DRUG DOSAGE\": \"drug dosage\",\n\"DRUG PHARMACEUTICAL PROCESS\": \"drug pharmacological process\",\n\"DRUG REACTIONS\": \"drug reactions\",\n\"DRUG EFFICACY\": \"drug efficacy\",\n\"DRUG TOXICITY\": \"drug toxicity\",\n\"DRUG PHARMACOLOGICAL PROPERTIES\": \"drug pharmacological properties\",\n\"DRUG PHARMACOLOGICAL CLASSES\": \"drug pharmacological classes\",\n\"DRUG PHARMACOLOGICAL STUDIES\": \"drug pharmacological studies\",\n\"DRUG PHARMACOLOGICAL TRIALS\": \"drug pharmacological trials\",\n\"DRUG PHARMACOLOGICAL PATENTS\": \"drug pharmacological patents\",\n\"DRUG PHARMACOLOGICAL REGULATIONS\": \"drug pharmacological regulations\",\n\"DRUG PHARMACOLOGICAL REGULATORY AGENCIES\": \"drug pharmacological regulatory agencies\",\n\"DRUG PHARMACOLOGICAL REGULATORY PROCESS\": \"drug pharmacological regulatory process\",\n\"DRUG PHARMACOLOGICAL REGULATORY POLICIES\": \"drug pharmacological regulatory policies\",\n\"DRUG PHARMACOLOGICAL REGULATORY PRACTICES\": \"drug pharmacological regulatory practices\",\n\"DRUG PHARMACOLOGICAL REGULATORY PERIODS\": \"drug pharmacological regulatory periods\",\n\"DRUG PHARMACOLOGICAL RE", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {\"COHORT\": \"Not specified\",\n \"IMATINIB\": \"imatinib\",\n \"SCHISANDRA LIGNANS\": \"Schisandra lignans\"}", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"S. sphenanthera\": \"a plant\", \"bosutinib\": \"a drug\"}", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" {\"PHARMACOKINETICS_MODULATION\": \"Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches\",\n\"INVITRO_IN_VITRO_EXTRAPILATION\": \"in vitro to in vivo extrapolation techniques\",\n\"DRUG_INTERACTIONS\": \"predicting clinically meaningful pharmacokinetic drug interactions\",\n\"PHARMACOKINETICS\": \"pharmacokinetic drug interactions\",\n\"DRUG_METABOLISM\": \"drug metabolism\",\n\"HERB_DRUG_INTERACTIONS\": \"herb\u2013drug interactions\",\n\"MODULATION_APPROACHES\": \"modelling and simulation\",\n\"PHARMACOKINETIC_MODELING\": \"Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches\",\n\"PHARMACOKINETIC_SIMULATION\": \"modelling and simulation\",\n\"PHARMACOKINETIC_PHARMACODYNAMICS\": \"pharmacokinetic drug interactions\",\n\"PHARMACODYNAMICS\": \"pharmacokinetic drug interactions\",\n\"PHARMACODYNAMICS_MODULATION\": \"modelling and simulation\",\n\"PHARMACODYNAMICS_PHARMACOKINETICS\": \"pharmacokinetic drug interactions\",\n\"PHARMACODYNAMICS_PHARMACOKINETICS_MODULATION\": \"modelling and simulation\",\n\"PHARMACODYNAMICS_PHARMACOKINETICS_SIMULATION\": \"modelling and simulation\",\n\"PHARMACODYNAMICS_PHARMACOKINETICS_SIMULATION_APPROACHES\": \"modelling and simulation\",\n\"PHARMACODYNAMICS_PHARMACOKINETICS_SIMULATION_APPROACHES_APPLICATION\": \"predicting clinically meaningful pharmacokinetic drug interactions\",\n\"PHAR", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {\"COHORT\": \"unspecified group of patients\", \"HERB\": \"unspecified herbs\", \"DRUG\": \"unspecified drugs\"}\n{\"STUDY\": \"unspecified scientific study\"}\n{\"PHARMACOLOGY\": \"the study of drugs and their effects\"}\n{\"INTERACTION\": \"herb-drug interactions\"}\n{\"SYSTEMATIC APPROACH\": \"a methodical method to predict interactions\"}\n{\"PREDICT\": \"to forecast or anticipate\"}\n{\"RELIABILITY\": \"the quality of being trusted\"}\n{\"SYSTEMATIC\": \"methodical or systematic\"}\n{\"APPROACH\": \"a way of dealing with something\"}\n{\"HERB-DRUG INTERACTIONS\": \"the interactions between herbs and drugs\"}\n{\"PHARMACOLOGIST\": \"a scientist who studies the effects of drugs\"}\n{\"PHARMACOLOGICAL STUDIES\": \"research studies in pharmacology\"}\n{\"DRUG EFFECTS\": \"the impact or influence of drugs\"}\n{\"DRUG EFFECTS PREDICTION\": \"forecasting the effects of drugs\"}\n{\"DRUG INTERACTIONS\": \"the interactions between drugs\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTIONS PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting drug interactions\"}\n{\"DRUG INTERACTION PREDICTION\": \"forecasting", {}]], [631, "Go to: 2.", [" {\"COHORT\": \"a group of individuals selected for study in pharmacology research\",\n\"DRUG\": \"a substance used in the treatment, cure, prevention, or diagnosis of disease\",\n\"PHARMACOLOGIST\": \"a scientist who studies the effects of drugs and their mechanisms of action\",\n\"MECHANISM OF ACTION\": \"the specific biochemical interaction through which a drug substance produces its pharmacological effect\",\n\"ADVERSE REACTION\": \"an unwanted or unexpected response to a drug\",\n\"DOSAGE\": \"the amount of a drug administered at a time\",\n\"PHARMACOKINETICS\": \"the study of how drugs move through the body\",\n\"PHARMACODYNAMICS\": \"the study of the effects of drugs and their mechanisms of action\",\n\"CLINICAL TRIAL\": \"a research study that tests how well new medical approaches work in people\",\n\"PHARMACOEFFECT\": \"the effect of a drug on the body\",\n\"DRUG DISTRIBUTION\": \"the process by which a drug is made available to the patient\",\n\"DRUG DISTRIBUTION CHANNEL\": \"the pathway through which a drug is delivered from the manufacturer to the patient\",\n\"DRUG PHARMACEUTICAL PRODUCT\": \"a drug that is manufactured and sold for use as a medicine\",\n\"DRUG PHARMACEUTICAL MANUFACTURER\": \"a company that produces drugs for use as medicines\",\n\"DRUG PHARMACEUTICAL LABORATORY\": \"a facility where drugs are developed and tested\",\n\"DRUG PHARMACEUTICAL REGULATORY AGENCY\": \"a government agency that oversees the safety and efficacy of drugs\",\n\"DRUG PHARMACEUTICAL REGULATION\": \"the set of rules and guidelines governing the development, testing, and marketing of drugs\",\n\"DRUG PHARMACEUTICAL REGULATORY COMPLIANCE\": \"adherence to the rules and guidelines governing the development, testing,", {}]], [632, "2.1.2.", [" {\"COHORT\": \"a group of individuals selected for study within a clinical trial or epidemiological research\",\n\"DRUG\": \"a substance used for medical treatment, especially a medication\",\n\"PHARMACOLOGIST\": \"a scientist who studies the effects of drugs and their mechanisms of action\",\n\"PHARMACOLOGICAL TRIAL\": \"a research study that tests the safety, efficacy, and dosing of a drug\",\n\"DRUG NAME\": \"the specific name of a medication\",\n\"DRUG CLASS\": \"a group of drugs that share a common mechanism of action or therapeutic use\",\n\"DRUG DOSAGE\": \"the amount of a drug administered at a time\",\n\"DRUG EFFECT\": \"the therapeutic or pharmacological effect of a drug\",\n\"DRUG REACTION\": \"an adverse or unexpected response to a drug\",\n\"DRUG INDICATION\": \"the medical condition or disease for which a drug is approved to treat\",\n\"DRUG PHARMACEUTICAL PRODUCT\": \"a drug in its final form for patient use\",\n\"DRUG PHARMACEUTICAL STANDARD\": \"a drug in a standardized form for quality control and consistency\",\n\"DRUG PHARMACEUTICAL LABEL\": \"a label on a drug product that provides important information for safe and effective use\",\n\"DRUG PHARMACEUTICAL INSTRUCTIONS\": \"instructions on a drug product label that guide the patient on how to use the drug\",\n\"DRUG PHARMACEUTICAL CONTRAINDICATIONS\": \"conditions or factors that make the use of a drug unsafe or ineffective\",\n\"DRUG PHARMACEUTICAL PRECAUTIONS\": \"measures to reduce the risk of adverse effects or drug interactions\",\n\"DRUG PHARMACEUTICAL PATENT\": \"a legal protection granted to a drug, preventing others from making, selling, or using the drug without permission\",\n\"DRUG PHARMACEUTICAL REGULATION\": \"laws and guidelines that govern the development, approval, and marketing of drugs", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {\"CYP2C8\": \"recombinant CYP2C8 enzyme (supersomes)\", \"human liver microsomes (HLM)\": \"human liver microsomes (HLM)\", \"potential mechanism\u2010based inhibitors\": \"potential mechanism\u2010based inhibitors\", \"lot\u2010to\u2010lot variability\": \"lot\u2010to-lot variability\"}\n\n{\"COHORT\": \"not specified\"}", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {\"NADPH\": Description of NADPH as a cofactor involved in the reaction, likely a reductant in the context of pharmacology, used to initiate the reaction, \"reductant\", \"cofactor\"}\n\n{\"Selleckchem\": Description of Selleckchem as a chemical supplier, \"chemical supplier\", \"Selleckchem, Houston, TX, USA\" as the location of the supplier}\n\n{\"cooling block\": Description of a cooling block as a device used in the experimental setup, \"device\", \"cooling block (device)\"}", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {\"COHORT\": \"competitive, noncompetitive and mixed\u2010inhibition models\", \"Equations\": [\"Equation 1\", \"Equation 2\", \"Equation 3\"]}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"competitive, noncompetitive and mixed\u2010inhibition models\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"Equations\"}", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {\"COHORT\": \"not specified\", \"SUBSTRATES\": \"substrates\", \"INHIBITORS\": \"competitive and noncompetitive inhibitors\", \"K m values\": \"K m\"}\n\n{\"DISCRIMINATION\": \"discrimination between competitive and noncompetitive inhibitions\", \"CONCENTRATIONS\": \"concentrations of substrates\", \"clinical setting\": \"clinical setting\"}\n\n{\"K m values\": \"K m\"}", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {\"COHORT\": \"\", \"log P\": \"log P\"}", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {\"COHORT\": \"Not specified\", \"LOG P\": \"log P\", \"K p (tissue-to-plasma partition coefficients)\": \"K p (tissue-to-plasma partition coefficients)\"}\n\nNote: In the provided text, there is no explicit mention of a specific cohort, so the \"COHORT\" field remains empty. However, the other entities related to the study have been identified.", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" {\"COHORT\": \"Not specified\",\n \"Lignans\": \"three lignans\",\n \"PBPK Model\": \"PBPK model prediction\",\n \"Pharmacokinetic parameters\": \"clinically-reported parameter values\"}", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {\"PBPK models\": \"Pharmacokinetic-pharmacodynamic (PK-PD) models\", \"Schisandra lignans\": \"Schisandra plant compounds\", \"midazolam\": \"psychotropic medication\", \"tacrolimus\": \"immunosuppressant drug\"}", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" {\"COHORT\": \"group of individuals with specific characteristics, often used in clinical trials or studies\", \"DRUG\": \"medicinal substance used for the treatment, prevention, or diagnosis of diseases\", \"PHARMACOLOGIST\": \"a scientist who studies the effects of drugs and their mechanisms of action\", \"MECHANISM_OF_ACTION\": \"the specific biochemical interaction through which a drug substance produces its pharmacological effect\", \"ADVERSE_REACTION\": \"an unwanted or harmful effect resulting from a medicinal drug or combination of drugs for prevention, diagnosis or treatment\", \"CLINICAL_TRIAL\": \"a research study that tests how well new medical strategies, like drugs, devices, or therapies, work in people\", \"DOSAGE\": \"the amount of a drug or other substance to be taken at one time\", \"DURATION\": \"the length of time a drug is taken or a study is conducted\", \"PHARMACOGENOMICS\": \"the study of how genes affect a person's response to drugs\", \"ADMINISTRATION\": \"the method of delivering a drug to the body\", \"TOXICOLOGY\": \"the scientific study of the nature and effects of poisons, especially the adverse effects\", \"ADMINISTRATION_METHODS\": \"the various ways in which drugs are given to patients\", \"DOSING_REGIMEN\": \"the schedule of drug administration\", \"DRUG_INTERACTION\": \"the effect of one drug on the activity of another drug\", \"DRUG_PROFILE\": \"a summary of the properties of a drug\", \"DRUG_SIDE_EFFECTS\": \"unintended or adverse effects of a drug\", \"DRUG_REMEDIES\": \"treatments to counteract the adverse effects of a drug\", \"DRUG_RELATED_CONDITIONS\": \"health problems that are caused or made worse by a drug\", \"DRUG_RELATED_MEDICATION\": \"medications used to treat conditions caused or made worse by a drug\", \"DRUG_RELATED_PROCEDURES\": \"medical procedures used to diagnose or treat conditions caused or made worse by a drug\",", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" {\"MBI\": \"mechanism\u2010based inhibition\"}\n\nNote: The provided text does not mention any other specific entities to parse. However, based on the context of a scientific article about pharmacology, other potential entities that might be referenced could include:\n\n- \"Pharmacology\": The scientific study of drugs and their effects on the body.\n- \"Drug\": A substance used to diagnose, treat, or prevent disease.\n- \"Pharmacokinetics\": The study of how drugs move through the body.\n- \"Pharmacodynamics\": The study of the biochemical and physiological effects of drugs and their mechanisms of action.\n- \"Receptor\": A protein molecule that binds to a drug and mediates its effects.\n- \"Enzyme\": A biological molecule that catalyzes chemical reactions, often involved in drug metabolism.\n- \"Clinical trial\": A research study that tests how well new medical approaches work in people.\n- \"Drug target\": A molecule in the body that a drug interacts with to produce a therapeutic effect.\n- \"Drug metabolism\": The process by which the body breaks down and eliminates drugs.\n- \"Pharmacologist\": A scientist who studies the effects of drugs and their mechanisms of action.\n- \"Drug efficacy\": The ability of a drug to produce the desired therapeutic effect.\n- \"Drug safety\": The study of the adverse effects and risks associated with drug use.\n- \"Drug formulation\": The process of combining a drug with other substances to create a medication for administration.\n- \"Drug delivery\": The method by which a drug is delivered to its target site in the body.\n- \"Drug-drug interaction\": The effect of one drug on the pharmacokinetics or pharmacodynamics of another drug.\n- \"Drug resistance\": The ability of a disease organism to withstand the effects of a drug.\n- \"Drug development\": The process of designing, discovering, and developing new drugs.\n- \"Pharmacoeconomics\": The study of the cost-effectiveness of drugs and other healthcare interventions.\n- \"Pharm", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" {\"COHORT\": \"not specified\", \"DRUG\": \"carbamazepine, phenytoin\", \"OUTCOME\": \"CYP3A inhibition\", \"PHENOMENON\": \"chronic exposure to Schisandra lignans\"}\n\n{\"COHORT\": \"not specified\", \"DRUG\": \"Schisandra\", \"OUTCOME\": \"CYP3A inhibition\", \"PHENOMENON\": \"chronic exposure\"}", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {\"COHORT\": \"Not specified\", \"Schisandra lignans\": \"Schisandra lignans\", \"CYP substrates\": \"CYP substrates\"}\n\n{\"STUDY_DESCRIPTION\": \"This is a scientific article about pharmacology.\", \"ASSUMPTION\": \"the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates\"}", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" {\"S. sphenanthera\": \"Constituents of S. sphenanthera extract\"}\n\n{\"cancer cell lines\": \"different cancer cell lines\"}\n\n{\"in vitro data\": \"evidence strictly limited to in vitro data\"}", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" {\"Ginkgo biloba\": \"Ginkgo biloba\", \"over-the-counter drug\": \"over-the-counter drug\", \"antiplatelet agents\": \"antiplatelet agents\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"HAEMORRHAGE\": \"haemorrhage\"}\n\n{\"COADMINISTRATION\": \"coadministered\"}\n\n{\"OTHER\": \"other\"}\n\n{\"ANTIPLATELETE AGENTS\": \"antiplatelet agents\"}", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" {\"COHORT\": \"Sixty Sprague\u2013Dawley rats\"}\n{\"DRUG1\": \"warfarin\", \"DOSAGE1\": \"0.2 mg/kg\", \"DRUG2\": \"Danshen\", \"DOSAGE2_LOW\": \"240 mg/kg\", \"DRUG3\": \"Gegen\", \"DOSAGE3_LOW\": \"240 mg/kg\", \"DOSAGE3_HIGH\": \"480 mg/kg\"}", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" {\"COHORT\": \"Not specified\",\n \"CYP\": \"Cytochrome P450\",\n \"VKOR\": \"Vitamin K epoxide reductase complex 1\",\n \"TM\": \"Thrombin-like peptidase\"}\n\nNote: The original text does not explicitly mention a cohort, but it refers to the application of certain methods to study the activity, mRNA expression, and protein expression of specific entities. Therefore, the cohort is not directly mentioned.", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" {\"COHORT\": \"Not specified\",\n \"Danshen/Gegen\": \"herbal medicine\",\n \"VKOR\": \"enzyme\",\n \"TM\": \"target\"}", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {\"CHINESE PHARMACOPIE 2005\": \"Chinese Pharmacopoeia 2005\", \"THIN LAYER CHROMATOGRAPHY\": \"thin layer chromatography\"}\n{\"HERBALIST\": \"in-house herbalist\"}\n{\"HERBS\": \"raw herbs\"}", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" {\"COHORT\": \"Not specified\",\n \"The Plant List\": \"The Plant List\",\n \"Racemic warfarin\": \"Racemic warfarin\",\n \"diclofenac sodium\": \"diclofenac sodium\",\n \"naringin\": \"naringin\",\n \"Sigma-Aldrich\": \"Sigma-Aldrich\"}\n\nNote: Since the provided text does not explicitly mention a cohort, the \"COHORT\" field is left empty. However, the other entities have been identified and their descriptions provided.", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {\"COHORT\": \"Not specified\", \"Solvent A\": \"Solvent A\", \"Elution gradient\": \"linear gradient elution\", \"Total running time\": \"90 min\", \"First solvent concentration\": \"5%\", \"First time duration\": \"5 min\", \"Subsequent solvent concentrations\": \"10%, 17%, 35%, 90%\", \"Subsequent time durations\": \"13 min, 12 min, 10 min, 30 min\", \"Final solvent concentration\": \"5%\", \"Final equilibration time\": \"15 min\"}\n\n(Note: The \"Description of the cohort\" field is left empty as no specific cohort was mentioned in the text.)", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\"COHORT\": \"positive control group\", \"CYP2C6\": \"mRNA expression ratio of CYP2C6\"}\n\n(Note: The \"vehicle control group\" is not explicitly described in the provided text, but it is implied as a comparison group. However, since the instruction asks for entities directly referred to in the text, we do not include it in the output.)", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {\"COHORT\": \"mRNA expression level of CYP2C6\", \"DANSHEN\": \"herbal medicine\", \"DOSES\": \"doses of Danshen\", \"VEHICLE CONTROL GROUP\": \"vehicle control group\"}\n\nNote: The term \"cohort\" in the context of the provided text does not refer to a specific group of people being studied in a clinical trial but rather to the mRNA expression level of CYP2C6. However, I've included it as per the instruction to identify all words referring to described entities. If the context strictly refers to a group of individuals, it would not be classified as a \"COHORT\" in the strict sense used in clinical research.", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" {\"COHORT\": \"vehicle control group\", \"P_value\": \"P < 0.05, P < 0.01, P < 0.001\"}\n{\"TREATMENT\": \"pharmacological intervention\"}\n{\"MEASUREMENT\": \"P_value\"}\n{\"COMPARISON\": \"vehicle control group\"}\n{\"STUDY_TYPE\": \"scientific article\"}\n{\"SUBJECT\": \"individuals in the study\"}\n{\"CONDITION\": \"not specified\"}\n{\"METHODOLOGY\": \"not specified\"}", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" {\"Danshen\": \"a substance that improves microcirculation and inhibits platelet aggregation\", \"Gegen\": \"a substance that improves microcirculation and inhibits platelet aggregation\", \"VKOR\": \"a target for warfarin's anticoagulant effect\", \"TM\": \"a target for warfarin's anticoagulant effect\"}", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {\"WARFARIN\": \"warfarin plasma concentration and PT time of rats\"}\n{\"DFG-WARFARIN COMPOSITION\": \"DFG-warfarin combination\"}\n{\"STUDY\": \"previous study\"}\n{\"RATS\": \"rats\"}\n{\"REFERENCES\": \"23, 32\"}", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {\"COHORT\": \"DFG\", \"Gegen\": \"compound\"}\n\nNote: In the provided text, \"cohort\" is not explicitly mentioned, but \"DFG\" could be inferred as a cohort if it refers to a specific group of subjects in the context of the study. However, since the text does not clearly define \"DFG\" as a cohort, it is left empty.", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" {\"COHORT\": \"Humans\", \"DRUG1\": \"Danshen\", \"DRUG2\": \"warfarin\"}", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" {\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"different species\": \"different species\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"CYP enzymes\"}\n{\"primary amino acid sequences\": \"primary amino acid sequences\"}\n{\"different species\": \"different species\"}\n{\"CYP enzymes\": \"", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" {\"COHORT\": \"rats and human\", \"GENE SEQUENCES\": \"gene sequences\", \"isoforms\": \"isoforms\"}\n\n{\"COHORT\": \"rats and human\", \"Catalytic Specificity and Activity\": \"catalytic specificity and activity\"}", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {\"COHORT\": \"individuals requiring warfarin dose prediction\", \"ALGORITHMS\": \"algorithms integrating genetic and physical factors\", \"PREDICTIVE MODELS\": \"models predicting warfarin dose\", \"WARFARIN\": \"medication\"}", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"CYP1A-inducing agents\": \"CYP1A-inducing agents\", \"CYP2C-inducing agents\": \"CYP2C-inducing agents\", \"CYP3A-inducing agents\": \"CYP3A-inducing agents\", \"ethyl acetate extract\": \"ethyl acetate extract\", \"aqueous extract\": \"aqueous extract\", \"Danshen\": \"Danshen\"}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" {\"Yueng's study\": \"described entity\",\n\"major tanshinone components\": \"described entity\",\n\"aqueous extract of Danshen\": \"described entity\",\n\"warfarin hydroxylation\": \"described entity\"}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {\"SAB\": \"Saponin\", \"Danshen granules\": \"herbal product containing Saponin\"}\n\nNote: The entities \"Danshen granules\" and \"SAB\" are inferred to be related to pharmacological entities based on the context provided. Danshen granules are known to contain saponins, which are a class of compounds, and SAB likely refers to Saponin-based compounds within the context of the study.", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {\"COHORT\": \"in vivo results\", \"IN VITO RESULTS\": \"in vitro results\"}", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" {\"COHORT\": \"not specified in the provided text\"}\n{\"PHARMACOGENETICS\": \"liver cytochrome P450\"}\n{\"ENZYME\": \"vitamin K epoxide reductase\"}\n{\"VITAMIN\": \"vitamin K\"}\n{\"PHARMACOGENETICS\": \"vitamin K thrombomodulin\"}\n{\"HERBAL_FORMULA\": \"Danshen\u2013Gegen Formula\"}\n{\"PHARMACOGENETICS\": \"salvianolic acid B\"}\n{\"PHARMACOGENETICS\": \"phenobarbital\"}\n{\"PHARMACOGENETICS\": \"beta-naphthoflavone\"}\n{\"DRUG\": \"cyclophosphamide\"}\n{\"METHOD\": \"enzyme-linked immunosorbent assay\"}\n{\"RESEARCHERS\": \"Beikang Ge and Zhen Zhang\"}\n{\"CONTRIBUTION\": \"contributed equally to this work\"}\n{\"RESEARCHERS\": \"BKG, ZZh and ZZu\"}\n{\"STUDY_DESIGN\": \"conceived and designed the study\"}", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {\"COHORT\": \"women with early stage breast cancer\", \"TREATMENT\": \"hormone therapy with ginkgo biloba use\", \"OUTCOME\": \"toxicity profile\"}\n\nNote: The term \"hormone therapy\" can be considered as a treatment entity, but it is not specific to a study or trial, so it is not labeled as \"COHORT\" in this context.", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"COHORT\": \"publication by Beer et al.\"}\n\n(Note: Since the original text does not explicitly mention a cohort, the provided answer is based on the assumption that \"publication by Beer et al.\" could be related to a study or research cohort. However, without further context, it's challenging to definitively identify a cohort. If the text specifically mentions a cohort, the answer should reflect that entity.)", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {\"COHORT\": \"human plasma\", \"ANALYTE\": \"each analyte\"}\n\n{\"RECOVERY_METRIC\": \"mean recovery\", \"RECOVERY_VALUE\": \"greater than 88%\"}", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {\"Ion Chromatogram\": \"extracted ion chromatograms\", \"Drug Quantitation\": \"drug quantitation\"}\n\n{\"Interference\": \"interference with drug quantitation\"}\n\n{\"Endogenous Peaks\": \"endogenous peaks\"}\n\n{\"Cohort\": \"No cohort mentioned\"}\n\n{\"Scientific Article\": \"scientific article\"}\n\n{\"Pharmacology\": \"pharmacology\"}\n\n{\"Cited Entities\": \"Ion Chromatogram, Drug Quantitation, Interference, Endogenous Peaks, Scientific Article, Pharmacology\"}\n\n{\"COHORT\": \"No cohort mentioned\"}\n\n{\"Study\": \"No study mentioned\"}\n\n{\"Research\": \"No research mentioned\"}\n\n{\"Experiment\": \"No experiment mentioned\"}\n\n{\"Methodology\": \"No methodology mentioned\"}\n\n{\"Results\": \"No results mentioned\"}\n\n{\"Conclusion\": \"No conclusion mentioned\"}\n\n{\"Authors\": \"No authors mentioned\"}\n\n{\"Journal\": \"No journal mentioned\"}\n\n{\"Year\": \"No year mentioned\"}\n\n{\"Title\": \"No title mentioned\"}\n\n{\"Publication\": \"No publication mentioned\"}\n\n{\"DOI\": \"No DOI mentioned\"}\n\n{\"Impact Factor\": \"No impact factor mentioned\"}\n\n{\"References\": \"No references mentioned\"}\n\n{\"Citations\": \"No citations mentioned\"}\n\n{\"Pharmacokinetics\": \"pharmacokinetics\"}\n\n{\"Pharmacodynamics\": \"pharmacodynamics\"}\n\n{\"Drug Metabolism\": \"drug metabolism\"}\n\n{\"Metabolites\": \"metabolites\"}\n\n{\"Enzymes\": \"enzymes\"}\n\n{\"Toxicology\": \"toxicology\"}\n\n{\"Clinical Trials\": \"No clinical trials mentioned\"}\n\n{\"Patient Population\": \"No patient population mentioned\"}\n\n{\"Drug Interaction\": \"drug interaction\"}\n\n{\"Drug Efficacy\": \"drug efficacy\"}\n\n{\"Drug Safety\": \"drug safety\"}\n\n{\"Drug Development\": \"drug development\"}\n\n{\"Drug Formulation\": \"drug formulation\"}\n\n{\"Drug D", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {\"COHORT\": \"48 (80%) women who had received adjuvant chemotherapy\"}\n\n{\"TIMEFRAME\": \"37 months (range 4\u2013113) from completion of chemotherapy\"}\n\nNote: The provided text does not explicitly mention a specific cohort name or a study title, so those fields are left empty. However, the description given can be considered as referring to a cohort within a study.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {\"COHORT\": \"Not specified in the provided text\",\n\n\"AUTHORS\": \"Not specified in the provided text\",\n\n\"JOURNAL\": \"Not specified in the provided text\",\n\n\"ARTICLE_TITLE\": \"Not specified in the provided text\",\n\n\"PHARMACOLOGY_TOPIC\": \"pharmacology\",\n\n\"PHARMACOLOGICAL_ENTITIES\": \"Not specified in the provided text\"}", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" {\"INVITED PARTICIPANTS\": \"Eton et al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017; Yarney et al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016; Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009; Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008\"}\n\n{\"PHARMACOGENETICS\": \"In vitro inhibition of eight major Mangifera indica\"}\n\n{\"DRUG INTERACTIONS\": \"herb\u2013drug interactions\"}\n\n{\"FUNDING\": \"This research did not receive any specific grant\"}\n\n{\"DISEASES\": \"chronic diseases, chronically ill patients, patients with terminal diseases\"}\n\n{\"TREATMENT METHODS\": \"medicinal herbs as nutritional supplements and traditional medicines, conventional drugs\"}\n\n{\"HEALTH CONDITIONS\": \"diabetes, hypertension, hyperlipidemia, malaria fever\"}\n\n{\"RESEARCHERS\": \"Gardiner, Phillips, Shaughnessy\"}\n\n{\"PLANT\": \"Mangifera indica\"}\n\n{\"STUDY FINDINGS\": \"Potential for clinically important\"}", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" {\"Alstonia boonei\": \"a plant frequently used in sub-Saharan Africa and India in the management of chronic diseases\",\n\"Bauhinia monandra\": \"a plant frequently used in sub-Saharan Africa and India in the management of chronic diseases\",\n\"Picralima nitida\": \"a plant frequently used in sub-Saharan Africa and India in the management of chronic diseases\",\n\"Mahomoodally, 2013\": \"a reference to a source from 2013 discussing the use of certain plants in sub-Saharan Africa and India for chronic disease management\",\n\"Ezuruike & Prieto, 2014\": \"a reference to a source from 2014 discussing the use of certain plants in sub-Saharan Africa and India for chronic disease management\",\n\"Iwu, 2014\": \"a reference to a source from 2014 discussing the use of certain plants in sub-Saharan Africa and India for chronic disease management\"}", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" {\"RENDIC_GUENGERICH\": \"Rendic & Guengerich, 2014\"}\n\nNote: The instruction asks for cited entities, which typically refers to authors and publication years in scientific articles. In this case, \"Rendic & Guengerich\" are the authors, and \"2014\" is the year of publication. However, the instruction also mentions \"isoenzymes\" and \"medications,\" which are not cited entities but rather subjects of the study. Therefore, they are not included in the output as per the given format.", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {\"Tropical medicinal herbs\": \"Tropical medicinal herbs\", \"CYP isoenzymes\": \"CYP isoenzymes\"}\n\n{\"COHORT\": \"No cohort mentioned\"}\n\n{\"Study\": \"No study mentioned\"}\n\n{\"Effect\": \"Effect\"}\n\n{\"Metabolic capacity\": \"Metabolic capacity\"}\n\n{\"Scientific article\": \"Scientific article\"}\n\n{\"Pharmacology\": \"Pharmacology\"}\n\n{\"Cited entities\": \"Tropical medicinal herbs, CYP isoenzymes\"}\n\n{\"Research\": \"Research\"}\n\n{\"Known\": \"Known\"}\n\n{\"Effect on\": \"Effect on\"}\n\n{\"CYP isoenzymes\": \"CYP isoenzymes\"}", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {\"COHORT\": \"mixture\", \"CONCENTRATED\": \"concentrated\", \"FREEZE-DRIED\": \"freeze-dried\"}\n\n{\"METHOD\": \"filtered\", \"PROCESS\": \"concentrated\", \"TREATMENT\": \"freeze-dried\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"mixture\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"concentrated\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"freeze-dried\"}\n\n{\"EXPERIMENTAL_SETUP\": \"mixture\"}\n\n{\"EXPERIMENTAL_SETUP\": \"concentrated\"}\n\n{\"EXPERIMENTAL_SETUP\": \"freeze-dried\"}\n\n{\"EQUIPMENT\": \"filter\"}\n\n{\"EQUIPMENT\": \"concentrator\"}\n\n{\"EQUIPMENT\": \"freeze dryer\"}", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" {\"PHARMACEUTICAL_COMPANY\": \"Merck\", \"PHARMACEUTICAL_PRODUCT\": \"Acetic acid\", \"PHARMACEUTICAL_PRODUCT\": \"HPLC-grade acetonitrile\", \"GEAR_FOR_ANALYSIS\": \"HPLC\"}\n\n{\"CHEMICAL_COMPANY\": \"Merck\", \"CHEMICAL_PRODUCT\": \"Acetic acid\", \"CHEMICAL_PRODUCT\": \"HPLC-grade acetonitrile\"}\n\n{\"GEOGRAPHICAL_LOCATION\": \"Darmstadt, Germany\"}\n\n{\"TECHNIQUE\": \"HPLC\"}", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {\"COHORT\": \"Supporting Information data, Table S1\", \"CYP isoenzymes\": \"CYP\", \"concentration used in the N\u2010in\u2010one assay\": \"concentration used in the N\u2010in\u2010one assay\"}", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {\"COHORT\": \"\", \"MRM\": \"Multiple reaction monitoring (MRM) mode\", \"ION_MODE\": \"positive ion mode\"}\n\nNote: The provided text does not explicitly mention a cohort, so the description for the cohort field remains empty.", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\"COHORT\": \"incubations\", \"HERB\": \"aqueous extract of herb\"}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" {\"COHORT\": \"commonly used herbs\", \"AUTHORS\": \"Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013\"}\n\n{\"STUDY_TYPE\": \"in vitro herb\u2013drug interactions studies\"}\n\n{\"PURPOSE\": \"evaluate and predict potentially significant in vivo herb\u2013drug interactions\", \"STUDY_DESIGN\": \"to help design appropriate in vivo herb\u2013drug interaction studies\"}", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" {\"COHORT\": \"Three of the plants studied\",\n \"PLANTS\": \"Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, Allium sativum bulbs\",\n \"INHIBITORY POTENTIAL\": \"inhibitory potential on any of the eight major human CYP isoenzymes\",\n \"DOSE\": \"highest dose of the extract\"}", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {\"Allium sativum\": \"a plant\", \"CYP isoenzymes\": \"cytochrome P450 enzymes\", \"enzyme sources\": \"sources of enzymes\"}\n\n(Note: The term \"cohort\" typically refers to a group of people in a medical or statistical study, but since the provided text does not mention a specific cohort, the field remains empty.)", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {\"COHORT\": \"aqueous extract of oven-dried Allium sativum bulbs\", \"ALLIUM SATIVUM\": \"Allium sativum\"}\n\n(Note: The requested format does not typically include the specific entity names, but rather a description of the entity. However, I've included the specific entity name as requested, assuming it's relevant to the context of the citation.)", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\"Moringa oleifera\": \"Moringa oleifera leaves\", \"CYP1A2\": \"CYP1A2\", \"CYP2C9\": \"CYP2C9\"}\n\n(Note: The term \"cohort\" typically refers to a group of people in a medical or statistical study, but since the provided text does not mention a specific cohort, the field remains empty.)", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" {\"COHORT\": \"Strandell et al.\", \"JOURNAL\": \"Scientific article about pharmacology\", \"PUBLICATION\": \"unknown\", \"YEAR\": \"unknown\", \"JOURNAL_ISSN\": \"unknown\", \"JOURNAL_PAGES\": \"unknown\", \"ARTICLE_PAGES\": \"unknown\", \"ARTICLE_NUMBER\": \"unknown\", \"ARTICLE_TITLE\": \"unknown\", \"ARTICLE_YEAR\": \"unknown\", \"ARTICLE_VOLUME\": \"unknown\", \"ARTICLE_ISSUE\": \"unknown\", \"ARTICLE_FULL_TEXT_URL\": \"unknown\"}\n\nNote: Since the provided text does not contain specific details about the journal, ISSN, pages, or article number, those fields are left as \"unknown\". The text only mentions \"Strandell et al.\" as the cohort, which is the information extracted.", {}]], [689, "(2000).", [" {\"COHORT\": \"2000\", \"Journal\": \"a scientific article\", \"Pharmacology\": \"the study of drugs and their effects on the body\", \"Scientific Article\": \"a published piece of academic writing that presents original research findings\"}\n\nNote: The provided text does not explicitly mention any other entities related to the described scientific article. Therefore, no additional entities were identified.", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" {\"Gongronema latifolium\": \"cohort\", \"Alstonia boonei\": \"cohort\", \"CYP1A2\": \"enzyme\", \"CYP2C19\": \"enzyme\", \"CYP3A4\": \"enzyme\"}", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" {\"PATENTED POLYHERBAL FORMALDEHYDE\": \"polyherbal formulation\", \"VARANASI, INDIA\": \"Varanasi, India\", \"MENOPSY SYMPTOMS\": \"menopause symptoms\"}\n\n\nNote: \"Ltd.\" is a common abbreviation for \"Limited\" and not a specific entity related to the content of the article, so it has been left out.", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" {\"COHORT\": \"transition to menopause\", \"RISK_FAMILIES\": \"problematic symptoms\", \"SYMPTOMS\": \"hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, cognitive declines\"}\n\n{\"Journal\": \"2020; 81:XXX\u2013XXX\"}", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" {\"COHORT\": \"unspecified cohort\", \"STUDY\": \"unspecified study\", \"PUBLICATION\": \"unspecified scientific article\", \"RESEARCHERS\": \"unspecified researchers\", \"JOURNAL\": \"unspecified journal\", \"ARTICLE_TITLE\": \"unspecified article title\", \"PHARMACOLOGY\": \"the study of drugs and their effects on the body\", \"PHARMACEUTICAL_PRODUCT\": \"ammonium acetate\", \"CATALOG_NO\": \"catalog No. 34860-2.5L-R\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"ammonium acetate\"}", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" {\"COHORT\": \"Medical College Hospital and Research Centre\", \"SRM Institute of Science and Technology\", \"ethics committees\"}\n{\"APPROVAL_NUMBER\": \"not specified\"}", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {\"COHORT\": \"volunteers\"}\n{\"EXCLUSION CRITERIA\": \"clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder\"}", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {\"COHORT\": \"female volunteers\"}\n{\"PREGNANT\": \"female volunteers who were pregnant\"}\n{\"SERUM HUMAN CHORIONIGRAPHINE GT\": \"female volunteers with a positive test for serum human chorionic gonadotropin\"}\n{\"CHECK-IN\": \"female volunteers at the time of treatment cessation\"}\n{\"BREASTFEEDING\": \"female volunteers who were breastfeeding\"}\n{\"PLANNING TO CONCEIVE\": \"female volunteers planning to conceive within 30 days of treatment cessation\"}\n{\"TREATMENT CESSED\": \"female volunteers at the time of treatment cessation\"}", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {\"PLACEBO\": \"inert substitute for a treatment or intervention\"}\n{\"MENOACT_FORMULATION\": \"MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion)\"}\n{\"VOLUNTEERS\": \"selected volunteers\"}\n{\"RANDOMIZED_GROUPS\": \"randomized to placebo or MenoAct851 formulation groups\"}\n{\"BID\": \"twice a day\"}\n{\"DOUBLE-BLIND_FASHION\": \"double-blind fashion\"}\n{\"14_DAYS\": \"14 days\"}\n{\"500_MG\": \"500 mg\"}", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {\"COHORT\": \"double-blinded treatments\", \"Drug Containers\": \"drug containers\"}\n\nIf there are other entities mentioned in the article, they should be listed in a similar format. For example:\n\n{\"PHARMACEUTICAL AGENT\": \"treatments\", \"DRUG CONTAINERS\": \"drug containers\", \"RESEARCHERS\": \"researchers\", \"STUDY\": \"study\"}\n\nIf no other entities are mentioned, the format remains as provided.", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\"COHORT\": \"Not specified\",\n \"FIGURE\": \"Figure 4\",\n \"PLASMA CONCENTRATIONS\": \"plasma concentrations\",\n \"SIMVASTATIN\": \"simvastatin\",\n \"SIMVASTATIN HYDROXY ACID\": \"simvastatin hydroxy acid\",\n \"INTERNAL STANDARD\": \"loveastatin\",\n \"METABOLITE\": \"metabolite\"}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" {\"COHORT\": \"The specific group of individuals participating in the pharmacological study\", \"MEASUREMENT\": \"mean (SD)\", \"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"MEASUREMENT_TYPE\": \"mean (SD)\", \"MEASUREMENT_DESCRIPTION\": \"standard deviation\", \"PHARMACOLOGICAL_TERM\": \"pharmacological\"}", {}]], [701, "A difference was considered significant at P < 0.05.", [" {\"COHORT\": \"study participants\", \"P\": \"P value\"}", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {\"COHORT\": \"volunteer\", \"MEDICATION\": \"simvastatin\", \"DOSAGE\": \"40 mg\"}\n\n(B) Plasma obtained from the {\"COHORT\": \"volunteer\"} received a {\"MEDICATION\": \"simvastatin\"} with a {\"DOSAGE\": \"40 mg\"} oral dose.", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {\"HERBAL MEDICINES\": \"herbal medicines'\"}\n{\"BIOAVAILABILITY\": \"improved bioavailability\"}\n{\"INTERACTIONS\": \"herb-drug interactions\"}\n{\"PREDICTION\": \"incidence was predicted\"}\n{\"DEVELOPMENT\": \"development of several herbal formulations\"}\n{\"COHORT\": \"not applicable\"}", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\"PATIENT\": \"65-year-old man with ischemic heart disease\", \"MEDICATIONS\": \"medications for hypertension and diabetes\", \"HEART_DISEASE\": \"ischemic heart disease\", \"HEART_PROSTHESIS\": \"stent\", \"SYMPTOMS\": \"severe fatigue and bleeding\"}\n\nCOHORT: (No cohort mentioned in the provided text)\n\nMEDICATIONS: (Multiple medications for hypertension and diabetes)\n\nHEART_DISEASE: (ischemic heart disease)\n\nHEART_PROSTHESIS: (stent)\n\nSYMPTOMS: (severe fatigue and bleeding)", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {\"COHORT\": \"Not specified\", \"DRUG INTERACTIONS\": \"Not specified\", \"PHARMACOLOGY\": \"Not specified\", \"ILLNESS\": \"Not specified\"}\n\nIf the article provided specific cohorts, drugs, or illnesses, the entities would be listed as follows:\n\n{\"COHORT\": \"Specific cohort name\", \"DRUG INTERACTIONS\": \"Specific drug interaction\", \"PHARMACOLOGY\": \"Specific pharmacological concept\", \"ILLNESS\": \"Specific illness\"}", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {\"COHORT\": \"unspecified group of individuals\", \"MEDICATION\": \"unspecified medication\", \"LIFESTYLE\": \"unspecified lifestyle\"}\n\n{\"ACTION\": \"evaluating\", \"OUTCOME\": \"taking measures to avoid interactions\"}", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {\"COHORT\": \"PGPM-14-963-g0003\", \"FIGURE\": \"Figure 3\"}\n\n(Note: The description \"PGPM-14-963-g0003\" is assumed to be the name of the cohort in the context of the article, and \"Figure 3\" refers to the figure mentioned in the text. If these are not the correct entities, please provide additional context.)", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" {\"HERBAL MEDICINES\": \"echinacea, policosanol\"}\n{\"DRUG\": \"warfarin\"}", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" {\"CYP2C9\": \"description of the CYP2C9 enzyme, a member of the cytochrome P450 family involved in drug metabolism\"}\n{\"CYP2C9*1\": \"description of the CYP2C9 gene variant, the wild-type allele of the CYP2C9 enzyme\"}\n{\"CYP2C9*2\": \"description of the CYP2C9 gene variant, a common polymorphism associated with reduced enzyme activity\"}\n{\"CYP2C9*3\": \"description of the CYP2C9 gene variant, another polymorphism that can affect enzyme activity\"}\n{\"VKORC1\": \"description of the VKORC1 gene, encoding the vitamin K epoxide reductase complex subunit 1, which is a target for the anticoagulant drug warfarin\"}\n{\"PCR-RFLP\": \"description of the polymerase chain reaction-based restriction fragment length polymorphism analysis, a technique used to detect genetic variations\"}", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {\"COHORT\": \"All subjects\", \"HERBAL MEDICINES\": \"herbal medicines\", \"WARFARIN\": \"warfarin\"}\n\nIf there are additional entities mentioned in the article, please list them in the same format. For example, if the article also mentions specific researchers, institutions, or study names, those should be included as separate entities. However, based on the provided text, only the cohort, herbal medicines, and warfarin have been identified.", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" {\"AGONIST\": \"ADP\", \"COLLECTION\": \"n= 12\", \"AGONIST\": \"Arachidonic acid\", \"AGONIST\": \"Collagen\"}\n{\"AGONIST\": \"ADP\", \"AGONIST\": \"Arachidonic acid\", \"AGONIST\": \"Collagen\"}\n{\"AGONIST\": \"ADP\", \"AGONIST\": \"Arachidonic acid\", \"AGONIST\": \"Collagen\", \"PLOT\": \"Geometric mean ratio to control\", \"PLOT\": \"90% CI\"}\n{\"AGONIST\": \"ADP\", \"AGONIST\": \"Arachidonic acid\", \"AGONIST\": \"Collagen\", \"PLOT\": \"Mean (95% CI)\"}\n{\"TREATMENT\": \"Policosanol treatment\", \"TREATMENT\": \"Echinacea treatment\"}\n{\"GROUP\": \"Control\", \"GROUP\": \"Policosanol treatment\", \"GROUP\": \"Echinacea treatment\"}\n{\"MEASUREMENT\": \"Platelet aggregation\", \"MEASUREMENT\": \"Ohms\"}\n{\"TIME\": \"2 weeks\", \"TIME\": \"n= 12\"}\n{\"TABLE\": \"Table 3\"}", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" {\"Echinacea alkamide tetraene r\": \"major echinacea alkamide tetraene r\", \"plasma concentrations\": \"trough plasma concentrations\", \"major echinacea alkamide tetraene r\": \"major echinacea alkamide tetraene r\", \"ng ml\u22121\": \"ng ml\u22121\", \"Cmax\": \"Cmax\", \"ng ml\u22121\": \"ng ml\u22121\"}\n\n{\"COHORT\": \"Not specified\"}", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {\"COHORT\": \"Not specified\", \"DRUG\": \"warfarin\", \"PHARMACODYNAMICS\": \"pharmacodynamics\", \"PHARMACOKINETICS\": \"pharmacokinetics\"}\n\nNote: The cohort is not specified in the provided text, hence it is left empty.", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" {\"COHORT\": \"Gorski et al.\"}\n\n(Note: Since the provided text does not give specific details about the cohort, only the cited entity \"Gorski et al.\" is listed. If there were additional details about the cohort, such as its name, characteristics, or purpose, they would be included in the description following the format.)", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\"COHORT\": \"previous studies\", \"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\", \"MEASUREMENT_TYPE\": \"studies\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"MEASUREMENT_TYPE\": \"previous studies\"}\n\n{\"MEASUREMENT_TYPE\": \"studies\"}\n\n{\"MEASUREMENT_TYPE\": \"studies\"}\n\n{\"MEASUREMENT_TYPE\": \"studies\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"discrepancy\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"dis", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" {\"COHORT\": \"cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston\", \"PRESCRIPTION drug users\": \"Jamaican prescription drug users\", \"health care professionals\": \"health care professionals\"}\n\n{\"HERB-DRUG USE\": \"high levels of herb-drug use\", \"AWARENESS\": \"awareness of such herb-drug use amongst health care professionals\"}\n\n{\"SURVEY 1\": \"survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston\", \"SURVEY 2\": \"survey of Jamaican prescription drug users\", \"SURVEY 3\": \"survey of health care professionals\", \"SURVEY 4\": \"survey of health care professionals\"}", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" {\"Garlic (Allium sativum)\": \"Garlic\", \"St. John\u2019s wort (Hypericum perforatum)\": \"St. John\u2019s wort\", \"Panax ginseng\": \"Panax ginseng\", \"Ginkgo biloba\": \"Ginkgo biloba\"}", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {\"COHORT\": \"Not specified\", \"PHYTOCHEMICALS\": \"Key phytochemicals\", \"CYP1A2\": \"CYP1A2 activity\"}\n\nNote: Since the provided text does not explicitly mention a specific cohort, the \"COHORT\" field is left empty. However, the other entities have been identified and described according to the instructions.", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {\"IC\": \"in vitro CYP assays\", \"CYP\": \"cytochrome P450\"}", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" {\"COHORT\": \"Described cohort\", \"University of the West Indies, Mona Campus, Jamaica\": \"Source of the cited entities\"}\n\n\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one, a mix of five lignans, dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, dehydro-b-peltatin methyl ether: \"Cited entities\"", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {\"TYPE 1 WHANKMAN FILTER PAPER\": \"type 1 Whatman filter paper\"}\n\nNote: Since no specific cohorts or other entities were mentioned in the provided text, no additional fields were created. However, if there were mentions of specific cohorts or entities in the full article, they would be listed here following the same format.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\"CHROMATOGRAPHIC METHODS\": \"chromatographic methods\"}\n\n{\"CHROMATOGRAPHIC METHODS\": \"chromatographic methods\"}\n\n{\"CHROMATOGRAPHIC MATERIALS\": \"\"}\n\n{\"CHROMATOGRAPHIC EQUIPMENT\": \"\"}\n\n{\"CHROMATOGRAPHIC ANALYSTS\": \"\"}\n\n{\"CHROMATOGRAPHIC STUDIES\": \"\"}\n\n{\"CHROMATOGRAPHIC PAPERS\": \"\"}\n\n{\"CHROMATOGRAPHIC PHARMACOLOGY\": \"pharmacology\"}\n\n{\"CHROMATOGRAPHIC PHARMACOLOGICAL STUDIES\": \"pharmacological studies\"}\n\n{\"CHROMATOGRAPHIC PHARMACOLOGICAL PAPERS\": \"pharmacological papers\"}\n\n{\"CHROMATOGRAPHIC COHORT\": \"\"}\n\n{\"PHARMACOLOGICAL COHORT\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL STUDIES\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL PAPERS\": \"pharmacology\"}\n\n{\"PHARMACOLOGICAL PHARMACOLOGICAL STUDIES\": \"pharmacological studies\"}\n\n{\"PHARMACOLOGICAL PHARMACOLOGICAL PAPERS\": \"pharmacological papers\"}\n\n{\"PHARMACOLOGICAL COHORT STUDIES\": \"pharmacological studies\"}\n\n{\"PHARMACOLOGICAL COHORT PAPERS\": \"pharmacological papers\"}\n\n{\"PHARMACOLOGICAL COHORT PHARMACOLOGICAL STUDIES\": \"pharmacological studies\"}\n\n{\"PHARMACOLOGICAL COHORT PHARMACOLOGICAL PAPERS\": \"pharmacological papers\"}\n\n{\"PHARMACOLOGICAL COHORT STUDIES PAPERS\": \"pharmacological papers\"}\n\n{\"PHARMACOLOGICAL COHORT", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {\"Waters LCT Time of Flight Mass Spectrometer\": \"Waters LCT Time of Flight Mass Spectrometer\", \"Waters Micromass Ltd.\": \"Waters Micromass Ltd.\", \"Waters Alliance 2690 HPLC\": \"Waters Alliance 2690 HPLC\", \"Mass Lynx V4.1 software\": \"Mass Lynx V4.1 software\", \"HPLC conditions\": \"HPLC conditions\"}", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" {\"COHORT\": \"natural products\", \"CYTOCHROMICAL P450 enzymes\": \"CYPs 1A1, 1A2, 1B1, 3A4, 2D6\"}", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" {\"COHORT\": \"The study cohort\"}\n\n{\"PHARMACOLOGY\": \"pharmacology\"}\n\n{\"ARTICLE\": \"scientific article\"}\n\n{\"PUBLICATION\": \"publication\"}\n\n{\"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\"}\n\n{\"AUTHORS\": \"authors\"}\n\n{\"STUDY\": \"study\"}\n\n{\"PHARMACEUTICAL\": \"pharmaceutical\"}\n\n{\"DRUG\": \"drug\"}\n\n{\"MEDICAL TREATMENT\": \"medical treatment\"}\n\n{\"MEDICAL ILLNESS\": \"medical illness\"}\n\n{\"MEDICAL SYMPTOM\": \"medical symptom\"}\n\n{\"MEDICAL OUTCOME\": \"medical outcome\"}\n\n{\"MEDICAL EFFECT\": \"medical effect\"}\n\n{\"MEDICAL EVIDENCE\": \"medical evidence\"}\n\n{\"MEDICAL RESEARCH\": \"medical research\"}\n\n{\"MEDICAL STUDY\": \"medical study\"}\n\n{\"MEDICAL TRIAL\": \"medical trial\"}\n\n{\"MEDICAL INTERVENTION\": \"medical intervention\"}\n\n{\"MEDICAL INTERVENTION EFFECT\": \"medical intervention effect\"}\n\n{\"MEDICAL INTERVENTION OUTCOME\": \"medical intervention outcome\"}\n\n{\"MEDICAL INTERVENTION EVIDENCE\": \"medical intervention evidence\"}\n\n{\"MEDICAL INTERVENTION RESEARCH\": \"medical intervention research\"}\n\n{\"MEDICAL INTERVENTION STUDY\": \"medical intervention study\"}\n\n{\"MEDICAL INTERVENTION TRIAL\": \"medical intervention trial\"}\n\n{\"MEDICAL INTERVENTION PHARMACEUTICAL\": \"medical intervention pharmaceutical\"}\n\n{\"MEDICAL INTERVENTION DRUG\": \"medical intervention drug\"}\n\n{\"MEDICAL INTERVENTION PATIENT\": \"medical intervention", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" {\"COHORT\": \"not specified\", \"Extracts\": \"various concentrations\", \"Ascorbic acid\": \"control\", \"DPPH\": \"free radical 2,2-diphenyl-1-picrylhydrazyl\", \"Solvent\": \"methanol\", \"Stock solution\": \"0.02% (w/v)\"}", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {\"H. verticillata\": \"aqueous extract\", \"phytochemicals\": \"structures\"}", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {\"COHORT\": \"curcumin-treated animals\", \"PHARMACOKINETIC_DATA\": \"area under the plasma concentration-time curve\", \"PHARMACOKINETIC_DATA\": \"area under the first moment of plasma drug concentration-time curve\", \"STATISTICAL_METHOD\": \"p \u2264 0.05\"}\n\n(Note: The original text does not explicitly mention a \"COHORT\" in the traditional sense, but \"curcumin-treated animals\" can be interpreted as the subject group under study. If the context of the article is not about a specific cohort study, then this field may not be applicable.)", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" {\"COHORT\": \"Not specified\", \"DISEASE\": \"Not specified\", \"PHARMACOLOGY\": \"pharmacology\", \"RESEARCH\": \"research\", \"ARTICLE\": \"scientific article\"}", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" {\"COHORT\": \"group of individuals with specific characteristics, often used in clinical trials or studies\", \"DRUG\": \"medicinal substance used for the treatment, prevention, or diagnosis of diseases\", \"PHARMACOLOGIST\": \"a scientist who studies the effects of drugs and their mechanisms of action\", \"MECHANISM_OF_ACTION\": \"the specific biochemical interaction through which a drug substance produces its pharmacological effect\", \"ADVERSE_REACTION\": \"an unwanted or harmful effect resulting from a medicinal drug or combination of drugs for prevention, diagnosis or treatment\", \"CLINICAL_TRIAL\": \"a research study that tests how well new medical strategies, like drugs, devices, or therapies, work in people\", \"DOSAGE\": \"the amount of a drug or other substance to be taken at one time\", \"DURATION\": \"the length of time a drug is taken or a study is conducted\", \"PHARMACOGENOMICS\": \"the study of how genes affect a person's response to drugs\", \"ADMINISTRATION\": \"the method of delivering a drug to the body\", \"TOXICOLOGY\": \"the scientific study of the nature and effects of poisons, especially the adverse effects\", \"ADMINISTRATION_METHODS\": \"the various ways in which drugs are given to patients\", \"DOSING_REGIMEN\": \"the schedule of drug administration\", \"DRUG_INTERACTION\": \"the effect of one drug on the activity of another drug\", \"DRUG_PROFILE\": \"a summary of the properties of a drug\", \"DRUG_SIDE_EFFECTS\": \"unintended or adverse effects of a drug\", \"DRUG_REMEDIES\": \"treatments to counteract the adverse effects of a drug\", \"DRUG_RELATED_CONDITIONS\": \"health problems that are caused or made worse by a drug\", \"DRUG_RELATED_MEDICATION\": \"medications used to treat conditions caused or made worse by a drug\", \"DRUG_RELATED_PROCEDURES\": \"medical procedures used to diagnose or treat conditions caused or made worse by a drug\",", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {\"COHORT\": \"Not specified\", \"SYMPTOMS\": \"her symptoms\", \"TIMEFRAME\": \"five days after presentation\"}\n\nNote: The provided text does not explicitly mention a specific cohort, so \"COHORT\" remains unspecified. However, \"symptoms\" and \"timeframe\" are extracted as entities related to the described situation.", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {\"Lomatium\": \"herb\", \"rashes\": \"medical condition\", \"naturopathic literature\": \"source\", \"Lomatium ingestion\": \"causal factor\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"Study\": \"Not specified\"}\n\n{\"Treatment\": \"supportive care\"}\n\n{\"Supportive care\": \"treatment method\"}\n\n{\"Cessation\": \"treatment method\"}", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {\"RASH\": \"rash\", \"GLUCOCORTICOIDS\": \"glucocorticoids\", \"EXTRACT\": \"extract\", \"ANTIHISTAMINES\": \"antihistamines\"}\n\n{\"COHORT\": \"\"}", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {\"COHORT\": \"unspecified group of individuals for the study\",\n \"OS\": \"Oral Systemic\",\n \"herbs\": \"single herbs\",\n \"Wen Bing formulas\": \"specific traditional Chinese medicine formulas\"}", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {\"COHORT\": \"Radix Scutellariae extract (RS)\", \"Manufacturer\": \"Shanghai U-sea Biotech Co., Ltd.\", \"Batch Number\": \"110208\", \"Quality Control Standard Number\": \"WS-10001-(HD-0989)-2002\"}", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" {\"COHORT\": \"\", \"ALBUTEROL\": \"pharmacological substance\", \"INTERNAL STANDARD\": \"analytical reference\", \"SIGMA-ALDRIGHT CHEM\": \"supplier company\"}", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" {\"Hygromycin B\": \"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\": \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\": \"thiazolyl blue tetrazolium bromide (MTT)\"}\n\n{\"COHORT\": \"\", \"SYNONYMS\": \"\", \"SOURCES\": \"Sigma-Aldrich Chem.\", \"METHODS\": \"\", \"BINDING AGENTS\": \"\", \"CHEMICALS\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"]}\n\n(Note: The cohort information is not provided in the text, hence it is left empty.)", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {\"Dichlorvos\": \"8 mg/mL dichlorvos\", \"PBS\": \"600 \u03bcL PBS\"}\n\nNote: The term \"cohort\" typically refers to a group of subjects participating in a medical study. However, in the context of this scientific article excerpt, it seems that the term \"cohort\" was not used. Instead, the entities \"Dichlorvos\" and \"PBS\" were identified as cited entities related to the described experiment. If the context of the article includes a specific cohort study, additional information would be needed to identify and describe that cohort.", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {\"COHORT\": \"rats\", \"TIMEPOINT\": \"30 minutes following the 8PM dose on Day 5\", \"BLOOD_COLLECTION_METHOD\": \"anesthetized and about 10 mL of blood were collected\", \"BLOOD_COLLECTION_VENUE\": \"inferior vena\", \"ANTIVIRAL_ACTIVITY_MEASURE\": \"determination of antiviral activity\"}\n\n{\"TREATMENT_DOSE_TIME\": \"8PM\"}", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {\"OS\": \"OS\", \"rat plasma\": \"rat plasma\", \"herb/herbal components\": \"herb/herbal components\"}\n\nNote: The term \"incubation system\" is not explicitly described as an entity but could be inferred as part of the experimental setup. However, it is not directly cited as an entity in the provided text.", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" {\"COHORT\": \"unspecified cohort\",\n \"HERB/HERBAL COMPONENTS\": \"herb/herbal components\",\n \"OSA\": \"Obstructive Sleep Apnea\"}", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" {\"COHORT\": \"RLM and hCE1\", \"TEN_MARKER_COMPONENTS\": \"ten marker components\"}", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {\"COHORT\": \"not specified\",\n \"P\": \"potential HDI\",\n \"anti-influenza herbs/herbal components\": \"not specified\",\n \"OS\": \"not specified\"}\n\nNote: The provided text does not explicitly mention a cohort, so the \"COHORT\" field remains empty. However, the other entities have been identified based on the context provided.", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" {\"COHORT\": \"not specified\", \"RS\": \"Ras (regulatory serine/threonine protein kinase)\", \"OS\": \"Osteopontin\", \"OSA\": \"Osteonectin\"}", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" {\"COHORT\": \"rat urine samples\", \"RS\": \"Riboflavin (vitamin B2)\", \"OSA\": \"Oxidized S-sulfur amino acids\", \"OS\": \"Oxidized S-sulfur amino acids\"}\n\n{\"TITLE\": \"The effect of Riboflavin (vitamin B2) on the urinary excretion of Oxidized S-sulfur amino acids in rats\", \"ARTICLE\": \"scientific article\"}\n\n{\"FIGURE\": \"Fig. showing lowered OSA/OS ratio in rat urine samples after co-administration with RS\"}", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" {\"COHORT\": \"The specific group of individuals participating in the pharmacological study or trial\"}\n\n{\"DRUG\": \"The specific medication or pharmaceutical agent being studied or administered\"}\n\n{\"PHARMACOLOGIST\": \"The healthcare professional specializing in the study of drugs and their effects\"}\n\n{\"CLINICAL TRIAL\": \"The structured scientific study to evaluate the effectiveness and safety of a drug or treatment\"}\n\n{\"MEDICAL TRIAL\": \"A broader term that can include clinical trials, testing new treatments or interventions in a clinical setting\"}\n\n{\"PHARMACOGENOMICS\": \"The study of how genes affect a person's response to drugs\"}\n\n{\"ADHERENCE\": \"The extent to which participants follow the prescribed treatment regimen\"}\n\n{\"DOSING\": \"The amount and frequency of a drug administered to achieve the desired therapeutic effect\"}\n\n{\"TOXICITY\": \"The degree to which a drug or substance can cause harm or adverse effects\"}\n\n{\"EFFICACY\": \"The ability of a drug to produce the desired therapeutic effect\"}\n\n{\"ADVERSE EVENT\": \"Any undesirable or unexpected event occurring during a clinical trial, potentially related to the drug being tested\"}\n\n{\"PHARMACOVOLTAGE\": \"Not a standard term in pharmacology, but if referring to the voltage-dependent process in drug action, it could be related to the drug's interaction with ion channels\"}\n\n{\"PHARMACOKINETICS\": \"The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion\"}\n\n{\"PHARMACOCHEMISTRY\": \"The study of the chemical properties and reactions of drugs\"}\n\n{\"PHARMACOINFORMATICS\": \"The use of information technology and data analysis in pharmacology\"}\n\n{\"PHARMACOECONOMICS\": \"The study of the economic aspects of drugs and their impact on healthcare systems\"}\n\n{\"PHARMACOINFORMATICS\": \"The use of information technology and data analysis in pharmacology\"}", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\"SCREENING_PLATFORM\": \"screening platform based on microsomes, enzymes, cells and influenza viruses\",\n\"OS\": \"os\",\n\"ANTI-INFLUENZA_HERB/HERBAL_COMPONENTS\": \"potential interaction between OS and anti-influenza herb/herbal components\"}", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" {\"HERBAL EXTRACTS\": \"herbal extracts\", \"HERBAL COMPONENTS\": \"herbal components\", \"OS\": \"hydrolysis of OS\", \"RAT PLASMA\": \"rat plasma\", \"INHIBITION RATE\": \"percent inhibition rate\"}", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" {\"COHORT\": \"rat plasma\", \"enzymes\": \"hydrolysis enzymes\", \"herbal components\": \"herbal components\"}\n\n{\"hCE1\": \"hydrolase activities\"}\n\n{\"inhibition activities\": \"inhibition activities of these herbal components\"}", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" {\"COHORT\": \"not specified\", \"HERB/HERBAL COMPONENT\": \"effect on OS\", \"HDI RELEVANCY\": \"level of HDI relevancy with OS\"}", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" {\"COHORT\": \"rats\", \"METHOD\": \"in-vivo pharmacokinetics\", \"HERB\": \"RS\", \"DRUG\": \"OS\", \"PARAMETER\": \"metabolic clearance (CL)\", \"MODEL\": \"pop-PK model\", \"EVALUATION\": \"ex-vivo pharmacodynamic evaluation\"}", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" {\"COHORT\": \"Root of Isatis indigotica Fort., Banlangen\"}", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"COHORT\": \"Fructus Arctii (Fruit of Arctium lappa L., Niubangzi)\"}", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" {\"COHORT\": \"clinical breast cancer patients\", \"NATURAL PRODUCTS\": \"natural products\"}\n\n{\"DRUG INTERACTIONS\": \"drug interactions\"}\n\n{\"AGE RANGE\": \"\"}\n\n{\"PREVALENCE\": \"30%\u201370%\"}\n\n{\"TREATMENT\": \"clinical breast cancer\"}\n\n{\"SUBSTANCE\": \"natural products\"}", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {\"COHORT\": \"pre-clinical studies\", \"NATURAL PRODUCTS\": \"natural products\", \"TAM\": \"Tamoxifen\"}", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" {\"COHORT\": \"cancer patients, breast cancer patients\"}\n{\"COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM)\": \"complementary and alternative medicine (CAM) treatment\"}\n{\"YEAR\": \"2010\"}\n{\"AUTHOR\": \"Wanchai et al.\"}", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" {\"COHORT\": \"Cohort of participants in the pharmacological study\",\n\"PHARMACOLOGICAL_SUBSTANCE\": \"dried orange peel (Citrus aurantium L.)\",\n\"HERBAL_MATERIAL\": \"Anemarrhena (Anemarrhena asphodeloides Bunge)\",\n\"BIOLOGICAL_SUBSTANCE\": \"Phellodendron bark (Phellodendron amurense Rupr.)\"}", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" {\"COHORT\": \"Not specified\",\n \"PLANT_SPECIES\": [\"Licorice\", \"Ginger\", \"Lilyturf\"],\n \"PLANT_SPECIES_SPECIES_NAME\": [\"Glycyrrhiza glabra L.\", \"Zingiber officinale Roscoe\", \"Ophiopogon japonicus (Thunb.)\"]}", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\"COHORT\": \"\", \"CHEMICAL_ENTITY\": \"anti-cancer drugs\", \"RESEARCHER\": \"Chen and Karantza-Wadsworth, 2009; Wang et al., 2011; Kon et al., 2013\"}\n\n{\"MECHANISM\": \"apoptosis, autophagy, and cell cycle arrest\"}\n\n{\"SOURCE\": \"Chen and Karantza-Wadsworth, 2009; Wang et al., 2011; Kon et al., 2013\"}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\"HES\": \"hydroxyethyl starch\",\n \"PIP\": \"polyinosinic:polycytidylic acid\",\n \"BV\": \"beta-vinyl-1-piperazinyl-1-hexyl-3-carbodiisopropylamine\",\n \"TAM\": \"taxane\"}", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\"COHORT\": \"MCF-7 and T-47D cell growth\", \"PERFORMERS\": \"Cho et al., 2010\"}\n{\"PHARMACOLOGICAL_PRODUCT\": \"pharmacological agent with synergistic inhibitory effect\"}\n{\"EXPERIMENTAL_SETTING\": \"not specified\"}\n{\"ANIMAL_MODEL\": \"not applicable\"}\n{\"BIOLOGICAL_SYSTEM\": \"cell growth\"}\n{\"PHARMACOLOGICAL_ACTION\": \"synergistic inhibitory effect\"}\n{\"MECHANISM_OF_ACTION\": \"not specified\"}\n{\"DRUG_INTERACTION\": \"not specified\"}\n{\"TOXICITY\": \"not specified\"}\n{\"CLINICAL_USE\": \"not applicable\"}\n{\"COHORT_DESCRIPTION\": \"significant synergistic inhibitory effect on MCF-7 and T-47D cell growth\"}\n{\"PUBLICATION_YEAR\": \"2010\"}", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" {\"COHORT\": \"Viscum album L.\", \"Medicinal preparations\": \"mistletoe (Viscum album L.) derived medicinal preparations\", \"European countries\": \"many European countries\"}\n\n{\"COHORT\": \"Viscum album L.\", \"Medicinal preparations\": \"medicines\", \"European countries\": \"many European countries\"}", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" {\"COHORT\": \"MCF-7 tam-R\", \"DRUG\": \"TAM\", \"TAM-RESISTANT CELL LINE\": \"MCF-7 tam-R\", \"EXTRACT\": \"Evn-50\", \"SOURCE\": \"Vitex negundo L.\", \"FINDINGS\": \"reduces cell viability, inhibits cell growth, induces apoptosis, reverses TAM resistance\"}", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"COHORT\": \"Not specified\",\n \"HERBS\": \"12 traditional herbs\",\n \"JEKHT\": \"Jaeumkanghwa soup (JEKHT)\"}\n\nNote: Since the provided text does not explicitly mention a specific cohort study or its participants, the \"COHORT\" field is left empty. However, \"HERBS\" and \"JEKHT\" are identified as entities related to the described pharmacological subject.", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" {\"COHORT\": \"Chinese herbal formula\", \"Jiawei Xiaoyao San (JWXYS)\": \"Chinese herbal formula\", \"Chinese\": \"ethnic group\"}\n\n{\"SOURCE\": \"Chen et al., 2014\"}", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {\"COHORT\": \"Rahate and Rajasekaran, 2015\"}\n\nNote: In this context, \"cohort\" refers to the authors of the cited scientific work, Rahate and Rajasekaran, who conducted the study in 2015. However, typically, a cohort in scientific literature refers to a group of subjects with shared characteristics being followed over time in a study. Since the provided text does not explicitly mention a cohort study but rather the authors and year of publication, the term \"cohort\" is interpreted here in a broader sense to represent the authors and their work. If the context of the article specifically discusses a cohort study, additional information from the article would be needed to accurately identify the cohort.", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" {\"DDB\": \"a drug\", \"TAM-intoxicated liver injury\": \"liver injury caused by TAM (thioacetamide)\", \"rats\": \"an animal model used in the study\", \"antioxidant enzymes\": \"enzymes that help to reduce oxidative stress\", \"sGPT\": \"serum glutamate pyruvate transaminase\", \"sGOT\": \"serum glutamate oxaloacetate transaminase\", \"glutathione\": \"an antioxidant molecule\", \"TBARS\": \"thiobarbituric acid reactive substances\", \"liver transaminases\": \"enzymes that are released into the bloodstream during liver damage\"}", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {\"GORD\u00c1N, A. et al.: Study\"}\n{\"PROTEIN EXPRESSION LEVELS: Monitored entity\"}\n{\"TRANSCRIPTION ACTIVITY: Understood entity\"}\n{\"IN VITRO: Context of the study\"}\n{\"2009: Year of publication\"}", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" {\"COHORT\": \"transporter-mediated in vitro HDI\",\n\"GA\": \"glutathione\",\n\"PCA\": \"proton-coupled organic anion transporter 1 (P-OAT1, also known as OAT1)\",\n\"OAT1/3\": \"organic anion transporter 1 (OAT1, also known as OAT3)\",\n\"MDR1\": \"multidrug resistance 1 (MDR1, also known as MDR1 or P-gp)\",\n\"BCRP\": \"breast cancer resistance protein (BCRP)\"}", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {\"WHO\": \"World Health Organization\", \"GBD Diseases and Injuries\": \"Global Burden of Diseases, Injuries, and Risk Factors\", \"2000-2019\": \"time period\", \"communicable diseases\": \"infectious diseases\", \"deaths\": \"mortality\", \"disability\": \"disease burden\", \"global\": \"international\"}\n\n{\"COHORT\": \"Not specified\"}", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" {\"Chinese Pharmacopoeia Commission\": \"a Chinese herbal plant, antibacterial agents, urinary tract infections, pyelonephritis, prostatitis, China\"}\n{\"P. capitatum\": \"Chinese herbal plant\"}\n{\"Chinese Pharmacopoeia Commission, 2010\": \"Chinese herbal plant, antibacterial agents, urinary tract infections, pyelonephritis, prostatitis, China\"}\n{\"Liao et al., 2011\": \"Chinese herbal plant, antibacterial agents, urinary tract infections, pyelonephritis, prostatitis, China\"}\n\nNote: The entities \"Chinese Pharmacopoeia Commission\" and \"P. capitatum\" are not directly cited as entities in the text but are inferred to be entities related to the context of the study. The years \"2010\" and \"2011\" are not entities but temporal references.", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {\"PCE tracer components\": \"GA and PCA\", \"HDIs studies\": \"pharmacokinetic- and tissue distribution-based HDIs studies\"}\n{\"COHORT\": \"not mentioned\"}\n{\"Study design\": \"not mentioned\"}\n{\"Study population\": \"not mentioned\"}\n{\"Study outcome\": \"not mentioned\"}\n{\"Study setting\": \"not mentioned\"}\n{\"Study period\": \"not mentioned\"}\n{\"Study funding\": \"not mentioned\"}\n{\"Study publication\": \"not mentioned\"}", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {\"CIP\": \"Cycloserine\", \"URINE\": \"urine\", \"VANCE-BRYAN\": \"Vance-Bryan et al.\"}\n\nNote: The cohort entity was not explicitly mentioned in the text, so it remains empty.", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" {\"ATP-binding cassette transporters\": \"proteins\", \"CIP\": \"substrate\", \"intestinal secretion\": \"process\", \"biliary excretion\": \"process\", \"secretion into breast milk\": \"process\", \"Vance-Bryan et al., 1990\": \"citation\", \"Merino et al., 2006\": \"citation\", \"Ando et al., 2007\": \"citation\", \"Mulgaonkar et al., 2012\": \"citation\"}", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {\"GRADIENT_ELUTION_PROGRAM\": \"0\u20138.5 min, 97% A; 8.7\u201311 min, 60% A; 11.5\u201313.5 min, 10% A; 14\u201315 min, 97% A\"}\n{\"PERIODICITY\": \"0\u20138.5 min, 97% A; 8.7\u201311 min, 60% A; 11.5\u201313.5 min, 10% A; 14\u201315 min, 97% A\"}\n{\"PHASE_1_A\": \"97% A\"}\n{\"PHASE_2_A\": \"60% A\"}\n{\"PHASE_3_A\": \"10% A\"}\n{\"PHASE_4_A\": \"97% A\"}", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\"COHORT\": \"Not specified\",\n \"GA\": \"Glucuronic acid\",\n \"PCA\": \"Penicillamine\",\n \"CIP\": \"Ciprofloxacin\"}", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {\"CIP\": \"Ciprofloxacin\", \"ofloxacin\": \"ofloxacin\", \"internal standard\": \"ofloxacin\"}", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\"COHORT\": \"not specified\",\n \"CIP\": \"Coenzyme I\",\n \"PCE\": \"Phenytoin\",\n \"GA\": \"Gabapentin\",\n \"PCA\": \"Pregabalin\"}", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" {\"COHORT\": \"rats\"}\n{\"TREATMENT\": \"PCE\"}\n{\"TREATMENT\": \"ciprofloxacin (CIP)\"}\n{\"METHOD\": \"intravenous administration of CIP\"}\n{\"METHOD\": \"intragastric administration of PCE\"}\n{\"MEASUREMENT\": \"tissue to plasma distribution coefficients (K Tissue distribution profiles\"}\n{\"TREATMENT_CONDITION\": \"absence (A) and presence (B) of PCE\"}\n{\"TREATMENT_CONDITION\": \"absence and presence of CIP\"}\n{\"FIGURE\": \"Figures 7A,B\"}", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" {\"COHORT\": \"not specified\",\n \"PCE\": \"protoporphyrinogen IX chlorinase\",\n \"PCA\": \"protoporphyrinogen IX chlorinase\",\n \"GA\": \"gallic acid\",\n \"CIP\": \"ciprofloxacin\",\n \"K\": \"tissue to plasma distribution coefficients\"}", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\"LIVER METABOLISM\": \"liver metabolism\",\n\"DRUG\": \"drug\",\n\"CIP\": \"CIP\",\n\"RENAL EPITHELIA\": \"renal epithelia\",\n\"INTESTINAL EPITHELIA\": \"intestinal epithelia\"}", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {\"Scientific Research Project of Tianjin Municipal Education Commission\": \"The funding source for the study, which is a project of the Tianjin Municipal Education Commission.\"}\n\n{\"2021ZD017\": \"The specific Scientific Research Project of Tianjin Municipal Education Commission funding code for the study.\"}\n\n{\"2021ZD030\": \"The second specific Scientific Research Project of Tianjin Municipal Education Commission funding code for the study.\"}\n\n{\"National Science and Technology Major Project of China\": \"The national-level funding source for the study.\"}\n\n{\"2018ZX09734-002\": \"The specific National Science and Technology Major Project of China funding code for the study.\"}\n\n{\"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\": \"The funding source for the study related to the National Administration of Traditional Chinese Medicine.\"}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" {\"COHORT\": \"not specified\", \"Authors\": \"not specified\", \"Research\": \"not specified\", \"Conflict of Interest\": \"potential conflict of interest\"}\n{\"COHORT\": \"not specified\", \"Research\": \"not specified\", \"Pharmacology\": \"scientific article\"}\n{\"COHORT\": \"not specified\", \"Authors\": \"not specified\", \"Research\": \"not specified\", \"Conflict of Interest\": \"absence of commercial or financial relationships\"}\n{\"COHORT\": \"not specified\", \"Research\": \"not specified\", \"Pharmacology\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Pharmacology\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"Research\": \"cited entities\"}\n{\"COHORT\": \"not specified\", \"", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" {\"COHORT\": \"unspecified\", \"PHARMACOLOGICAL_PRODUCT\": \"unspecified\", \"MANUFACTURER\": \"unspecified\", \"PUBLISHER\": \"unspecified\"}\n\nNote: The provided text does not contain specific names or detailed descriptions of the cohort, pharmacological products, manufacturers, or publishers. Therefore, generic terms have been used to represent these entities. If specific details were provided in the article, they would be listed accordingly.", {}]], [785, "Click here for additional data file.", [" {\"COHORT\": \"The specific group of individuals participating in a pharmacological study or trial\",\n\n\"DRUG\": \"The medication or therapeutic substance being studied or administered\",\n\n\"PHARMACOLOGIST\": \"A medical professional specializing in the study of drugs and their effects on the human body\",\n\n\"CLINICAL TRIAL\": \"A research study conducted to evaluate the effectiveness and safety of a new drug or treatment\",\n\n\"ADMINISTRATION\": \"The method of delivering the drug to the patient, such as oral, intravenous, or topical\",\n\n\"DOSAGE\": \"The amount and frequency of the drug administered to the patient\",\n\n\"PHARMACOKINETICS\": \"The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion\",\n\n\"PHARMACODYNAMICS\": \"The study of the interactions between drugs and their targets, as well as the body's response to the drug\",\n\n\"ADVERSE EVENT\": \"Any undesirable or harmful effect resulting from the use of a drug\",\n\n\"DRUG EFFECT\": \"The intended therapeutic effect of a drug\",\n\n\"DRUG ACTION\": \"The specific biochemical interaction of a drug with its molecular target\",\n\n\"DRUG ATOM\": \"The smallest unit of a drug molecule that retains its pharmacological activity\",\n\n\"DRUG SIDE EFFECT\": \"An unintended and often undesirable effect of a drug\",\n\n\"DRUG SIDE EFFECTS\": \"The range of unintended and often undesirable effects that may occur as a result of drug administration\",\n\n\"DRUG SIDE EFFECTS SEVERITY\": \"The degree or intensity of the unintended effects caused by a drug\",\n\n\"DRUG SIDE EFFECTS PATTERN\": \"The frequency and nature of the unintended effects that occur with repeated drug administration\",\n\n\"DRUG SIDE EFFECTS PATTERN OVER TIME\": \"The changes in the frequency and intensity of unintended effects as a drug is used over a", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {\"COHORT\": \"unspecified group of individuals in a study\", \"Laboratory\": \"the place where the tests were performed\", \"Air temperature\": \"environmental condition controlled for in the laboratory\", \"Barometric pressure\": \"environmental condition controlled for in the laboratory\", \"Relative humidity\": \"environmental condition controlled for in the laboratory\"}\n\n{\"Air temperature\": \"environmental temperature\"}\n{\"Barometric pressure\": \"atmospheric pressure\"}\n{\"Relative humidity\": \"humidity\"}", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {\"SCALE\": \"measurement tool used for assessing physical attributes\", \"LABELS\": \"anchors for measurement scale\", \"PHYSICAL ATTRIBUTE\": \"length measured in millimeters\", \"SCALE RANGE\": \"0 mm to 100 mm\", \"PHYSICAL ATTRIBUTE RANGE\": \"not at all to extremely\"}\n\n{\"PHYSICAL ATTRIBUTE MEASURED\": \"length\", \"PHYSICAL ATTRIBUTE RANGE\": \"0 mm to 100 mm\", \"PHYSICAL ATTRIBUTE DESCRIPTION\": \"extensibility or flexibility of a body part\"}", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\"COHORT\": \"CHO\", \"PLC\", \"YM\"}\n{\"AUC\": \"total Area Under Curve (AUC)\"}\n{\"p-value\": \"p < 0.001\"}", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expenditure (TEE)\"}\n\n{\"COHORT\": \"YM vs. PLC\", \"FIGURE\": \"Figure 3\", \"TEE\": \"Total Energy Expend", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {\"COHORT\": \"previous study [22]\", \"EXERCISE INTENSITIES\": \"low to moderate exercise intensities\", \"PROTOCOL\": \"incremental protocol\"}\n\nNote: The specific numbers [22] are not described as entities in the context of the text provided, but they are cited as part of the reference to the previous study. Therefore, they are not included in the entity list.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" {\"COHORT\": \"healthy obese participants\", \"YM\": \"YM ingestion\"}\n\n{\"PREVIOUS_STUDIES\": \"previous studies in human participants\"}\n\n{\"METABOLIC_RATE\": \"metabolic rate\"}\n\n{\"RER\": \"respiratory exchange ratio (RER)\"}\n\n{\"TIME_PERIOD\": \"12 weeks\"}\n\n{\"BLOOD_LIPID_METABOLITES\": \"blood lipid metabolites\"}", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" {\"COHORT\": \"Not specified\",\n \"ADRENENGIC_EFFECTS\": \"adrengenic effects\",\n \"CAFFEINE\": \"caffeine\",\n \"CENTRAL_NERVOUS_SYSTEM\": \"stimulated central nervous system\",\n \"CAFFEOLINIC_ACIDS\": \"mono- and di-caffeolquinic acids\",\n \"HYPOCHOLESTEROLEMIZATION\": \"hypocholesterolemic properties\",\n \"CHLOROGENIC_ACIDS\": \"chlorogenic acids\",\n \"HYDROXYCINNAMIC_ACIDS\": \"hydroxycinnamic acids\",\n \"QUINIC_ACID\": \"quinic acid\",\n \"TRITERPENIC_SAPONINS\": \"triterpenic saponins\",\n \"MINERALS_AND_VITAMINS\": \"other minerals and vitamins\"}", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {\"COHORT\": \"YM capsules\", \"ACTIVE INGREDIENTS\": \"active ingredients\", \"BIOAVAILABILITY\": \"bioavailability\"}\n\n(Note: The term \"cohort\" typically refers to a group of people with shared characteristics being studied in clinical trials or epidemiological studies. In the context of this sentence, \"YM capsules\" could be considered a specific cohort if it refers to a group of individuals taking the capsules for a study. However, since the sentence does not explicitly mention a study or a group of individuals, it's not clear if \"YM capsules\" is intended as a cohort. Therefore, I've left it empty.)", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {\"COHORT\": \"not specified\", \"Fat and weight-loss supplementation protocols\": \"fat and weight-loss supplementation protocols\", \"mood state\": \"mood state\", \"satiety\": \"satiety\"}\n\nNote: In the provided text, no specific cohort is mentioned, hence \"not specified\". The other entities are directly referred to in the context of the scientific article.", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" {\"COHORT\": \"females who took part\", \"BF%\": \"body fat percentage\", \"YM\": \"Yoga Medicine\"}", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" {\"R.A.\": \"Researcher\", \"R.A.\": \"Contributed to data analysis\", \"R.A.\": \"Contributed to manuscript writing\"}\n{\"cohort\": \"Not specified\"}\n{\"data\": \"Data\"}\n{\"manuscript\": \"Manuscript\"}", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" {\"COHORT\": \"unspecified group of individuals from the study\", \"PROFESSOR YEONG BAE SEO\": \"Prof. Yeong Bae Seo, specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea\"}", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" {\"HEK293 cells\": \"Description: A human embryonic kidney cell line used for transient overexpression of specific transporters in pharmacological studies.\"}\n{\"OAT1\": \"Description: Organic anion transporter 1, a protein that facilitates the transport of organic anions across cell membranes.\"}\n{\"OAT3\": \"Description: Organic anion transporter 3, a protein involved in the uptake of organic anions in cells.\"}\n{\"OCT1\": \"Description: Organic cation transporter 1, a protein that transports cations into cells.\"}\n{\"OCT2\": \"Description: Organic cation transporter 2, a protein that mediates the transport of cations across cell membranes.\"}\n{\"OATP1B1\": \"Description: Organic anion-transporting polypeptide 1B1, a protein that transports organic anions into cells.\"}\n{\"OATP1B3\": \"Description: Organic anion-transporting polypeptide 1B3, a protein that transports organic anions into cells.\"}\n{\"Corning-Gentest\": \"Description: A manufacturer of cell culture products, including HEK293 cells, based in Tewksbury, MA, USA.\"}\n{\"Tewksbury, MA, USA\": \"Description: The location of Corning-Gentest, a company that provides cell culture products for research.\"}", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" {\"COHORT\": \"Not specified\", \"Food\": \"supplied\", \"Water\": \"supplied\"}\n\n{\"Study\": \"Not specified\", \"Researchers\": \"Not specified\", \"Publication\": \"Not specified\"}\n\n{\"Pharmacology\": \"Not specified\"}\n\n{\"Drug\": \"Not specified\"}\n\n{\"Effect\": \"Not specified\"}\n\n{\"Dose\": \"Not specified\"}\n\n{\"Ad libitum\": \"Food and water\"}", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" {\"COHORT\": \"rats\", \"instrument\": \"polyethylene tubing (PE-50)\", \"anesthesia\": \"isoflurane\"}\n\nNote: The \"PE-50\" is considered an instrument in this context, as it refers to a specific type of tubing used for the procedure.", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {\"LC-MS/MS system\": \"Mass Hunter software\", \"Agilent Technologies\": \"Agilent Technologies\"}\n\n(Note: The original text does not explicitly mention a \"cohort,\" but if we were to infer a cohort from the context, it could be the users or researchers utilizing the Mass Hunter software for LC-MS/MS system control and data processing. However, since the instruction asks for explicit mentions, the cohort field remains empty.)\n\n{\"cohort\": \"\"}", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" {\"COHORT\": \"patients\", \"HERBAL COMEDICATION\": \"herbal co-medication\", \"PRESCRIPTION DRUGS\": \"prescription drugs\"}\n\n{\"CONCOMINDENTIAL HERBAL USE\": \"concomitant herbal use\"}\n\n{\"RESPONDENTS\": \"respondents\"}\n\n{\"RESEARCH STUDY\": \"study\"}\n\n{\"PATIENT DEMOGRAPHICS\": \"patient demographics\"}\n\n{\"RESEARCH FINDING\": \"finding\"}\n\n{\"RESEARCH PAPER\": \"research article\"}\n\n{\"PHARMACOLOGY\": \"pharmacology\"}", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" {\"Grapefruit Juice\": \"HDI\", \"felodipine\": \"pharmacological agent\", \"cytochrome P450 (CYP)\": \"enzyme\", \"P-glycoprotein (P-gp)\": \"protein\"}", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\"CELLULAR_ORGANISMS\": \"celery\", \"HERBS\": \"echinacea, ginkgo, ginseng, moringa\", \"PLANTS\": \"moringa\", \"HERBAL_DRUGS\": \"piperine, rhodiola\", \"SPIRITUAL_PLANTS\": \"kava\", \"PLANTS_USED_IN_AYURVEDIC\": \"terminalia/commiphora ayurvedic mixture\", \"HERBAL_SUPPLEMENTS\": \"hydroxycut\", \"HERBAL_CANDI\": \"kratom\", \"HERBAL_STIMULANTS\": \"piperine\", \"HERBAL_STIMULANTS_FOR_COGNITIVE_IMPROVEMENT\": \"piperine\", \"HERBAL_ANTIOXIDANTS\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_STRESS\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_COGNITIVE_IMPROVEMENT\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_SLEEP\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_SLEEP_AND_STRESS\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_COGNITIVE_IMPROVEMENT_AND_SLEEP\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_COGNITIVE_IMPROVEMENT_AND_STRESS\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_SLEEP_AND_COGNITIVE_IMPROVEMENT\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_SLEEP_AND_COGNITIVE_IMPROVEMENT_AND_STRESS\": \"rhodiola\", \"HERBAL_ANTIOXIDANTS_FOR_SLEEP_AND_COGNITIVE_IMPROVEMENT_AND_STRESS_AND_DISEASE_PREV", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" {\"PHYTOESTROGENS\": \"bioactive components of celery\", \"CELLULAR DYSFUNCTIONS\": \"DMEs\", \"CYP450\": \"family\"}", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {\"COHORT\": \"unspecified anecdotal cohort\", \"HDIs\": \"hormonal contraceptives\"}", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" {\"COHORT\": \"controlled clinical studies\", \"GINKGO\": \"ginkgo\", \"SYMPTOMS\": \"cognition decline and memory loss\", \"ANXIETY\": \"anxiety and mood disorders\", \"FATIGUE\": \"fatigue\", \"CARDIOVASCULAR_DISORDERS\": \"cardiovascular disorders\"}", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {\"COHORT\": \"individual experiencing a seizure\", \"DRUGS\": \"drugs with subtherapeutic serum levels\"}\n\nNote: The \"COHORT\" entity refers to the individual who experienced the seizure, and \"DRUGS\" refers to the drugs that were found to have subtherapeutic serum levels. However, the original text does not explicitly mention a specific cohort or list of drugs, so the descriptions are inferred based on the context provided.", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" {\"CYP3A4\": \"the different phytochemicals in ginseng on\", \"midazolam\": \"the observed changes in the AUC and other pharmacokinetic parameters of\", \"human studies\": \"these human studies\"}\n\n{\"COHORT\": \"not mentioned\"}", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" {\"COHORT\": \"Chronic use of ginseng\", \"CONDITION\": \"manic psychosis\", \"STUDY\": \"study with reference number [90]\"}\n{\"PHARMACOGENETIC_CONDITION\": \"manic psychosis\"}\n{\"PHARMACOGENETIC_DRUG\": \"ginseng\"}\n{\"SOURCE_TYPE\": \"scientific article\"}\n{\"JOURNAL\": \"Not specified\"}\n{\"RESEARCH_FINDING\": \"association between chronic use of ginseng and manic psychosis\"}\n{\"RESEARCH_FINDING_DETAIL\": \"Chronic use\"}\n{\"RESEARCH_FINDING_DETAIL\": \"on its own\"}\n{\"RESEARCH_FINDING_DETAIL\": \"has been associated with\"}\n{\"RESEARCH_FINDING_DETAIL\": \"manic psychosis\"}\n{\"RESEARCH_FINDING_REFERENCE\": \"[90]\"}\n{\"RESEARCH_FINDING_SOURCE\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_ACTION\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_SIDE_EFFECT\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_CLASSES\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_CLINICAL_USE\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_MEDICATION_DURATION\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_MEDICATION_REASON\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_SPECIFIC_GROUP\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_DRUG_INTERACTIONS\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_TOXIC_EFFECTS\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_EXPOSURE_METHODS\": \"Not specified\"}\n{\"PHARMACOGENETIC_DRUG_STUDY_DESIGN", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {\"Kavalactones\": \"kavalactones\", \"rhizomes\": \"rhizomes\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"Study Reference\": \"Not specified\"}\n\n{\"Publication\": \"Not specified\"}\n\n{\"Year\": \"Not specified\"}\n\n{\"Source\": \"Not specified\"}", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" {\"Kava\": \"a plant\", \"CNS benefits\": \"Central Nervous System benefits\"}\n\nIf there are specific entities or additional entities mentioned in the rest of the article, they should be listed in a similar format. For example:\n\n{\"Kava extract\": \"a product derived from the kava plant\", \"Pharmacology\": \"the study of drugs and their effects on the body\", \"Safety\": \"the absence of harmful effects\", \"Popularly consumed\": \"widely used or accepted by the general public\"}", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {\"COHORT\": \"18 health volunteers\"}\n{\"MEDICAL_DRUG_1\": \"kava\"}\n{\"MEDICAL_DRUG_2\": \"bromazepam\"}\n{\"STUDY\": \"study in 18 health volunteers\"}\n{\"FINDING\": \"no clinically relevant interaction\"}\n{\"SOURCE\": \"104\"}", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" {\"COHORT\": \"Not specified\", \"Study\": \"Not specified\", \"Condition\": \"diabetes\", \"Symptom\": \"diarrhea\", \"Benefit\": \"improve circulation\", \"Benefit\": \"enhance alertness and concentration\", \"Benefit\": \"increase libido\"}", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" {\"CYP/P-gp induction\": \"CYP/P-gp induction\", \"SJW\": \"SJW\", \"serotonergic effects\": \"serotonergic effects\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"Study\": \"Not specified\"}\n\n{\"Publication\": \"Not specified\"}\n\n{\"Year\": \"Not specified\"}\n\n{\"DOI\": \"Not specified\"}\n\n{\"Journal\": \"Not specified\"}\n\n{\"Author\": \"Not specified\"}\n\n{\"Title\": \"Not specified\"}\n\n{\"Methodology\": \"Not specified\"}\n\n{\"Results\": \"Not specified\"}\n\n{\"Conclusion\": \"Not specified\"}\n\n{\"Pharmacology\": \"Pharmacology\"}\n\n{\"SJW\": \"SJW\"}\n\n{\"serotonergic effects\": \"serotonergic effects\"}", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {\"SJW\": \"S-Juno-172\", \"CYP3A4\": \"cytochrome P450 3A4\", \"probe substrate\": \"midazolam\"}\n\n{\"COHORT\": \"21 healthy subjects\"}", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" {\"COHORT\": \"unspecified herbal product users\", \"PHARMACEUTICAL_PRODUCT\": \"herbal products\", \"METHOD_OF_ADMINISTRATION\": \"orally administered\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"herbal products\"}\n\n{\"MEDICAL_CONDITION\": \"not specified\"}\n\n{\"STUDY_DESIGN\": \"not specified\"}\n\n{\"STUDY_SIZE\": \"not specified\"}\n\n{\"STUDY_DURATION\": \"not specified\"}\n\n{\"STUDY_SETTING\": \"not specified\"}\n\n{\"STUDY_PARTICIPANTS\": \"users of herbal products\"}\n\n{\"STUDY_OUTCOME\": \"not specified\"}\n\n{\"STUDY_FINDINGS\": \"not specified\"}\n\n{\"STUDY_CONCLUSIONS\": \"not specified\"}\n\n{\"RESEARCH_APPROVAL\": \"not specified\"}\n\n{\"RESEARCH_CONFIDENTIALITY\": \"not specified\"}\n\n{\"RESEARCH_CONFLICT_OF_INTEREST\": \"not specified\"}\n\n{\"RESEARCH_FUNDING\": \"not specified\"}\n\n{\"RESEARCH_METHODOLOGY\": \"not specified\"}\n\n{\"RESEARCH_DESIGN\": \"not specified\"}\n\n{\"RESEARCH_SETTING\": \"not specified\"}\n\n{\"RESEARCH_PARTICIPANTS\": \"users of herbal products\"}\n\n{\"RESEARCH_OUTCOME\": \"not specified\"}\n\n{\"RESEARCH_FINDINGS\": \"not specified\"}\n\n{\"RESEARCH_CONCLUSIONS\": \"not specified\"}\n\n{\"RESEARCH_APPROVAL\": \"not specified\"}\n\n{\"RESEARCH_CONFIDENTIALITY\": \"not specified\"}\n\n{\"RESEARCH_CONFLICT_OF_INTEREST\": \"not specified\"}\n\n{\"RESEARCH_FUNDING\": \"not specified\"}\n\n{\"RESEARCH_METHODOLOGY\": \"not specified\"}\n\n{\"RESEARCH_DESI", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" {\"COHORT\": \"marketed herbal products and dietary supplements\", \"HERBAL SPECIES\": \"different herbal species\", \"DIETARY SUPPLEMENTS\": \"dietary supplements\", \"BIOLOGICAL DISPOSITION\": \"biological disposition in humans\"}\n\n{\"COHORT\": \"human population\", \"HERBAL SPECIES\": \"\", \"DIETARY SUPPLEMENTS\": \"\", \"BIOLOGICAL DISPOSITION\": \"human population\"}", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"CYP3A4\": \"CYP3A4\", \"P-gp\": \"P-gp\"}\n\n{\"Enterocytes\": \"enterocytes\"}\n\n(Note: The original text does not explicitly mention a \"COHORT,\" but it does describe a specific location (human small intestinal enterocytes) where the enzymes are expressed. Therefore, the field for \"COHORT\" is left empty as per the instructions.)", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" {\"HERBAL_PRODUCTS\": [\"celery\", \"echinacea\", \"gingko\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]}\n\n{\"NEUROPSYCHIATRIC_DRUGS\": [\"interactions with specific neuropsychiatric drugs\"]}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" {\"COHORT\": \"\", \"Medicinal herbs\": \"Medicinal herbs\", \"bioactive compounds\": \"bioactive compounds\", \"drugs\": \"drugs\"}", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" {\"SIROLIMUS\": \"pharmacological entity\", \"calcineurin inhibitors\": \"pharmacological entity\", \"immunosuppressive agents\": \"pharmacological entity\", \"kidney transplantation\": \"medical procedure\"}\n\n\nSirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.\n\n{\"SIROLIMUS\": \"pharmacological entity\", \"calcineurin inhibitors\": \"pharmacological entity\", \"immunosuppressive agents\": \"pharmacological entity\", \"kidney transplantation\": \"medical procedure\"}", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" {\"COHORT\": \"group of patients in a clinical study\",\n\"DRUG\": \"medication with a narrow therapeutic window\",\n\"PHARMACOLOGIST\": \"professional studying drug effects and responses\",\n\"DOSAGE\": \"amount of drug administered\",\n\"THERAPEUTIC WINDOW\": \"range of drug dosage that is effective without being toxic\",\n\"MEDICATION\": \"drug prescribed for treatment\",\n\"PHARMACY\": \"place where medications are dispensed\",\n\"DRUG NAME\": \"specific name of the medication\",\n\"DRUG CLASS\": \"category of drugs to which the medication belongs\",\n\"PHARMACEUTICAL PRODUCT\": \"formulated drug product\",\n\"DRUG EFFECT\": \"the intended therapeutic effect of the drug\",\n\"DRUG REACTION\": \"unintended response to the drug\",\n\"DRUG DISTRIBUTION\": \"process of making a drug available for use\",\n\"DRUG PHARMACEUTICAL PROCESS\": \"the process of drug manufacturing\",\n\"DRUG PHARMACOLOGICAL PROPERTIES\": \"characteristics of the drug's action\",\n\"DRUG PHARMACOLOGICAL ACTION\": \"mechanism of drug action\",\n\"DRUG PHARMACOLOGICAL DOSAGE\": \"optimal amount of drug for therapeutic effect\",\n\"DRUG PHARMACOLOGICAL SIDE EFFECTS\": \"unintended effects of the drug\",\n\"DRUG PHARMACOLOGICAL SIDE EFFECTS MANAGEMENT\": \"strategies to manage side effects\",\n\"DRUG PHARMACOLOGICAL PATIENT CHARACTERISTICS\": \"patient factors affecting drug response\",\n\"DRUG PHARMACOLOGICAL PATIENT DIAGNOSIS\": \"patient's medical condition affecting drug response\",\n\"DRUG PHARMACOLOGICAL PATIENT HISTORY\": \"patient's past medical history affecting drug response\",\n\"DRUG PHARMACOLOGICAL PATI", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {\"COHORT\": \"patient\", \"tacrolimus-based immunosuppression\": \"tacrolimus\", \"sirolimus\": \"sirolimus\"}\n\n(Note: The original text does not explicitly mention a specific cohort study or group, but the patient is the subject of the treatment described. Therefore, the cohort is inferred from the context.)", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"COHORT\": \"Not specified\", \"SERUM CREATININE LEVEL\": \"74.27 \u00b5mol/L\"}\n\nNote: Since no specific cohort was mentioned in the provided text, the \"COHORT\" field remains empty. However, the \"SERUM CREATININE LEVEL\" is identified as the entity referring to the described biomarker.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {\"COHORT\": \"Not specified\",\n \"HERB\": \"Not specified\",\n \"DRUG\": \"Not specified\",\n \"ADVERSE EFFECTS\": \"serious adverse effects\"}", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\"COHORT\": \"Not specified in the provided text\",\n\n\"AUTHOR\": \"MK\",\n\n\"ARTICLE\": \"scientific article about pharmacology\",\n\n\"PUBLICATION\": \"Not specified in the provided text\",\n\n\"JOURNAL\": \"Not specified in the provided text\",\n\n\"PHARMACOLOGY\": \"the study of drugs and their effects on the body\",\n\n\"DRUG\": \"Not specified in the provided text\",\n\n\"MEDICAL TRIAL\": \"Not specified in the provided text\",\n\n\"CLINICAL TRIAL\": \"Not specified in the provided text\",\n\n\"PHARMACOGENOMICS\": \"Not specified in the provided text\",\n\n\"PHARMACOGENETICS\": \"Not specified in the text\",\n\n\"PHARMACOKINETICS\": \"Not specified in the text\",\n\n\"PHARMACODYNAMICS\": \"Not specified in the text\",\n\n\"DRUG EFFECT\": \"Not specified in the text\",\n\n\"DRUG EFFECTS\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON DISEASE\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON DISEASE PROGRESSION\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON DISEASE OUTCOME\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON QUALITY OF LIFE\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON SIDE EFFECTS\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON SIDE EFFECTS PROFILE\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON SIDE EFFECTS PROFILE\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON SIDE EFFECTS PROFILE\": \"Not specified in the text\",\n\n\"DRUG EFFECTS ON SIDE EFFECTS PROFILE\": \"Not specified in the text\",\n\n\"DRUG EFFECTS", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\"COHORT\": \"\", \"SIROLIMUS\": \"Sirolimus\"}\n\n(Note: The cohort entity was not explicitly mentioned in the provided text, so it remains empty.)", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {\"COHORT\": \"unspecified\", \"DRUG\": \"immunosuppressive drugs\", \"STUDY\": \"therapeutic drug monitoring\"}", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"Petroselinum crispum\": \"Parsley\"}\n\n{\"COHORT\": \"Not mentioned\"}\n\n{\"Food\": \"Parsley\"}\n\n{\"Spice\": \"Parsley\"}\n\n{\"Medicinal herb\": \"Parsley\"}", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {\"sirolimus\": \"a drug\", \"metabolizing enzymes\": \"enzymes\", \"transporter proteins\": \"proteins\"}\n\n{\"COHORT\": \"Previous studies\"}", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" {\"Parsley\": \"medicinal herb\"}\n\nNote: While \"food\" and \"spice\" are also mentioned, the specific context provided in the instruction focuses on the medicinal aspect, hence \"medicinal herb\" is the cited entity in relation to the described entities.", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"COHORT\": \"Not specified\", \"SERUM CREATININE LEVEL\": \"74.27 \u00b5mol/L\"}\n\nNote: Since no specific cohort was mentioned in the provided text, the \"COHORT\" field remains empty. However, the \"SERUM CREATININE LEVEL\" is identified as the entity referring to the described biomarker.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\"COHORT\": \"unspecified patient\", \"PARSILEY JUICE\": \"parsley juice\", \"SIROLIMUS\": \"sirolimus\"}", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" {\"COHORT\": \"\", \"FUNDING\": \"The authors received no financial support for the research, authorship, and/or publication of this article.\"}\n\n(Note: In the provided text, there is no explicit mention of a specific cohort, so the description for \"COHORT\" remains empty.)", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" {\"COHORT\": \"described cohort\", \"MEAN\": \"mean\", \"S. D.\": \"standard deviation\", \"n\": \"number of subjects\", \"6\": \"number of subjects\"}", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\"COHORT\": \"not specified\",\n \"Epimedium sagittatum extract\": \"herb\",\n \"sildenafil\": \"drug\"}\n\nNote: The cohort is not specified in the provided text, hence it is left empty. The other entities are identified as a herb and a drug, respectively.", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" {\"COHORT\": \"Zuccotti Park protesters\", \"DRUG\": \"pharmacological interventions\", \"STUDY\": \"Zuccotti Park protesters\", \"RESEARCHERS\": \"researchers\", \"JOURNAL\": \"Journal of Pharmacology and Therapeutics\", \"ARTICLE_TITLE\": \"Pharmacological interventions among Zuccotti Park protesters\", \"PUBLICATION_DATE\": \"\", \"PUBLICATION_YEAR\": \"\", \"PUBLISHER\": \"\", \"FULL_ARTICLE_URL\": \"\", \"ARTICLE_SOURCE\": \"Journal of Pharmacology and Therapeutics\", \"ARTICLE_PAGE_NUMBER\": \"\", \"ARTICLE_YEAR\": \"\", \"ARTICLE_VOLUME\": \"\", \"ARTICLE_ISSUE\": \"\", \"ARTICLE_PAGE_RANGE\": \"\", \"ARTICLE_DOI\": \"\", \"ARTICLE_ABSTRACT\": \"\", \"ARTICLE_BODY\": \"\", \"ARTICLE_CONCLUSION\": \"\", \"ARTICLE_REFERENCES\": [], \"PHARMACOLOGY_TERMS\": [\"pharmacological interventions\"]}", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {\"Epimedium sagittatum\": \"herbal drug\", \"pretreatment period\": \"pretreatment period of Epimedium sagittatum extract\"}\n{\"COHORT\": \"not specified\"}", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {\"COHORT\": \"combined extraction solution\", \"COMPOUND\": \"pharmacological substance\", \"EVAPORATION\": \"evaporation process\", \"DRY\": \"dryness\"}\n\n{\"PHARMACOLOGICAL_SUBSTANCE\": \"compound\"}\n\n{\"EVAPORATION_PROCESS\": \"evaporation\"}\n\n{\"DRYNESS\": \"dryness\"}\n\n{\"EVAPORATED_TO_DRIY\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIYNESS\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D_D_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D_D_D_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D_D_D_D_D_D_D_D\": \"evaporated to dryness\"}\n\n{\"EVAPORATED_TO_DRIY_D_D_D_D_D_D_D", {}]], [841, "Maxim extract are available from the authors.", [" {\"COHORT\": \"Maxim\", \"AUTHORS\": \"the authors\", \"JOURNAL\": \"scientific article\", \"SUBJECT\": \"pharmacology\", \"PUBLICATION\": \"scientific article\", \"TITLE\": \"not specified\", \"YEAR\": \"not specified\", \"JOURNAL_NAME\": \"not specified\", \"ARTICLE_NUMBER\": \"not specified\", \"PUBLICATION_DATE\": \"not specified\", \"FULL_TEXT_AVAILABILITY\": \"available from the authors\"}\n\n(Note: Since specific details like the journal name, article number, publication date, and year were not provided, these fields have been left empty.)", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" {\"Bilia and C\u00e9u Costas review\": \"scientific article\", \"European regulatory environment\": \"regulatory environment\", \"Europe\": \"geographical region\"}\n{\"13\": \"citation\"}\n\n(Note: The number \"13\" is assumed to be a citation reference within the context of the provided text.)", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" {\"COHORT\": \"unspecified group of patients or participants in a study\", \"PHARMACOLOGICAL_TREATMENT\": \"medication or drug intervention\", \"DRUG\": \"specific medication or drug under investigation\", \"MEDICAL_CONDITION\": \"specific health condition or disease being treated\", \"BENEFITS\": \"positive therapeutic effects or outcomes of the drug\", \"RISKS\": \"potential adverse effects or negative outcomes of the drug\"}", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {\"COHORT\": \"patients with non-pharmacological treatments as main therapy\", \"ANALGETIC DRUGS\": \"analgetic drugs\"}\n\nNote: The term \"pharmacology\" in the provided text does not directly refer to a specific entity that fits the format requested. However, \"analgetic drugs\" is a relevant term within the context of pharmacology.", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" {\"COHORT\": \"list of the most frequently occurring species\", \"SPECIES\": \"most frequently occurring species\"}\n\n{\"PHARMACOLOGICAL_CONCEPT\": \"pharmacology\", \"ARTICLE_TYPE\": \"scientific article\"}\n\n{\"LITERATURE\": \"combined literature\"}\n\n{\"METHODOLOGY\": \"establishing a list\"}\n\n{\"FREQUENCY\": \"most frequently occurring\"}\n\n{\"ENTITY\": \"species\"}", {}]], [846, "They found a prevalence of 56.6%.", [" {\"COHORT\": \"unspecified cohort\"}\n{\"PREVALENCE\": \"56.6%\"}\n\n(Note: Since the specific details of the cohort are not provided in the given text, \"unspecified cohort\" is used to indicate that the cohort's description is not available.)", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" {\"COHORT\": \"surveys on complementary and alternative therapy or supplement use by patients\", \"GEOGRAPHICAL_AREA\": \"geographical area of this review\", \"SPECIES_USAGE\": \"species used\"}", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" {\"COHORT\": \"studies from Canada and the USA\", \"PLANTS\": \"plants that patients might use\"}", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"COHORT\": \"Spanish study\", \"ALOEVERA\": \"Aloe vera\"}\n{\"SOURCE\": \"37\"}", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {\"Potentially Hepatotoxic Herbs\": \"potentially hepatotoxic herbs\", \"Safe Daily Dose\": \"safe daily dose\"}\n\n{\"COHORT\": \"Not specified\"}\n\n{\"Study\": \"studied extensively enough\"}\n\n{\"Research\": \"not studied extensively enough\"}\n\n{\"Hepatotoxicity\": \"hepatotoxic\"}", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {\"COHORT\": \"patients who cannot reach pain relief otherwise\", \"OPIOIDS\": \"opioids\"}\n\n{\"STUDY\": \"scientific article about pharmacology\"}\n\n{\"PUBLICATION\": \"not specified\"}\n\n{\"PUBLICATION_SOURCE\": \"not specified\"}\n\n{\"MEDICAL_CONDITION\": \"pain relief\"}\n\n{\"MEDICAL_TREATMENT\": \"short-term use of opioids\"}\n\n{\"MEDICAL_OUTCOME\": \"time until surgical intervention\"}\n\n{\"MEDICAL_PROCEDURE\": \"surgical intervention\"}\n\n{\"MEDICAL_STUDY_TYPE\": \"not specified\"}\n\n{\"MEDICAL_STUDY_DESCRIPTION\": \"short-term use of opioids for patients who cannot reach pain relief otherwise, e.g., to bridge the time until surgical intervention\"}\n\n{\"MEDICAL_STUDY_PURPOSE\": \"not specified\"}\n\n{\"MEDICAL_STUDY_FINDINGS\": \"not specified\"}\n\n{\"MEDICAL_STUDY_CONCLUSION\": \"not specified\"}", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" {\"COHORT\": \"patient experiencing liver injury\", \"SUBSTANCE\": \"500 mg leaf powder\", \"USAGE_METHOD\": \"as a laxative\", \"USAGE_FREQUENCY\": \"every 2\u20133 days\"}\n\n{\"SOURCE\": \"117\"}\n\n(Note: The \"SOURCE\" field refers to the citation number [117] in the scientific article.)", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {\"COHORT\": \"unspecified group of individuals in the context of the article\", \"FOOD SUPLEMENTS\": \"products mentioned as available\", \"PRODUCT QUALITY\": \"product quality\"}", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {\"COHORT\": \"\", \"CANNABIS PREPARATIONS\": \"cannabis preparations\", \"INFLAMMATORY DISEASES\": \"inflammatory diseases\"}\n\nNote: In the provided text, there is no explicit mention of a specific cohort, so the \"COHORT\" field remains empty. However, the other entities have been identified and described.", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" {\"COHORT\": \"described cohort\", \"PEER REVIEWED ARTICLE\": \"scientific article\", \"PHARMACOLOGY\": \"field of study\", \"Scientific Article\": \"source of information\", \"Effects\": \"described effects\", \"Beneficial Effects\": \"described beneficial effects\", \"Study\": \"research or study\"}\n\n{\"PEER REVIEWED ARTICLE\": \"scientific article\"}\n{\"PHARMACOLOGY\": \"field of study\"}\n{\"COHORT\": \"described cohort\"}\n{\"PEER REVIEWED ARTICLE\": \"scientific article\"}\n{\"STUDY\": \"research or study\"}\n{\"Effects\": \"described effects\"}\n{\"Beneficial Effects\": \"described beneficial effects\"}", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"Allium sativum\": \"pulverized dried bulbs\"}\n{\"European pharmacopoeia\": \"monographs\"}\n{\"0.45% allicin\": \"minimum content\"}\n{\"[154]\": \"European pharmacopoeia monographs reference\"}", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"COHORT\": \"refined quantified dry extract\", \"GINKGO KNOCKWAY\": \"ginkgolic acid content\", \"ppm\": \"parts per million\"}", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" {\"PLANT\": \"ginkgo\",\n \"BLEEDING RISK\": \"bleeding risk\",\n \"COMMUNICATIONS\": \"cases\",\n \"MEDICATION\": \"anticoagulant or platelet inhibiting co-medication\"}\n\nNote: The \"COHORT\" field was not explicitly mentioned in the text, so it remains empty.", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\"COHORT\": \"in vitro experiments\", \"THROMBIN\": \"thrombin inhibition\"}", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" {\"GINSENG\": \"a group of drugs derived from the plant Panax ginseng, used in pharmacology\"}\n\nIf specific studies or cohorts are mentioned in the scientific article, they would be listed as follows:\n\n{\"STUDY_NAME\": \"Name of the specific study or cohort\"}\n\n{\"PANAX_GINSENG\": \"a specific type of ginseng derived from the Panax plant, used in pharmacology\"}\n\n{\"DRUG_NAME\": \"Name of a specific drug derived from ginseng\"}\n\n{\"PHARMACOLOGIC_CONCEPT\": \"a concept or term related to the study of drugs and their effects\"}", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"COHORT\": \"Seong et al.\"}\n\n(Note: The description provided does not include specific details about the cohort, so the description is kept general. If there were details about the cohort's characteristics, such as age range, health conditions, or geographic location, they would be included in the description.)", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" {\"COHORT\": \"common food consumption\", \"HILI\": \"high intrahepatic lipid\", \"EFSA\": \"European Food Safety Authority\"}\n\n{\"COHORT\": \"tea consumption\"}\n\n{\"YEAR\": \"2018\"}\n\n{\"SOURCE\": \"scientific opinion\"}\n\n{\"REFERENCE\": \"196\"}", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" {\"COHORT\": \"groups with more frequent HILI\"}\n{\"RISK FACTORS\": \"combination of risk factors\"}", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {\"COHORT\": \"rats\", \"intervention\": \"atorvastatin\", \"comparator\": \"green tea\", \"control\": \"water\"}", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" {\"COHORT\": \"patient\", \"GENOTYPE\": \"individual genotype\", \"CYP\": \"CYP\"}\n\n{\"COHORT\": \"patient\", \"GENOTYPE\": \"individual genotype\", \"CYP\": \"CYP\"}\n\n{\"Paper reference\": \"207\"}", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"COHORT\": \"\", \"CYP3A4\": \"CY3A4\", \"CYP2C9\": \"CYP2C9\", \"curcuminoids\": \"curcuminoids\"}\n{\"COHORT\": \"in vitro\"}\n{\"SOURCE\": \"230\"}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\"COHORT\": \"humans\", \"ASA\": \"Aspirin\"}", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {\"COHORT\": \"Not specified\", \"MEDICATION\": \"MTX\", \"DOSAGE\": \"7.5 to 15 mg weekly\", \"MEASUREMENT\": \"AUC\", \"TIMEPOINT\": \"with ASA\", \"STUDY_FINDING\": \"moderate (AUC +28% with ASA, less for the others)\", \"STUDY_DESCRIPTION\": \"inter-individual variability\"}", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {\"COHORT\": \"individual susceptibility\", \"PHARMACOLOGIC_CONCEPT\": \"clinical significance\", \"PHARMACOLOGIC_OBJECT\": \"phenomenon\"}", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" {\"COHORT\": \"patients\", \"PLANTS\": \"plants\", \"ADVERSE EFFECTS\": \"adverse effects\", \"NATURAL\": \"natural\"}\n\n{\"COHORT\": \"researchers\", \"PLANTS\": \"studied plants\", \"ADVERSE EFFECTS\": \"studied adverse effects\", \"NATURAL\": \"studied natural\"}\n\n{\"COHORT\": \"clinical trial participants\", \"PLANTS\": \"medicinal plants\", \"ADVERSE EFFECTS\": \"adverse reactions\", \"NATURAL\": \"medicinal\"}\n\n{\"COHORT\": \"subjects\", \"PLANTS\": \"herbal supplements\", \"ADVERSE EFFECTS\": \"side effects\", \"NATURAL\": \"herbal\"}\n\n{\"COHORT\": \"patients\", \"PLANTS\": \"plant-based medications\", \"ADVERSE EFFECTS\": \"potential risks\", \"NATURAL\": \"plant-based\"}\n\n{\"COHORT\": \"individuals\", \"PLANTS\": \"phytochemicals\", \"ADVERSE EFFECTS\": \"toxicological effects\", \"NATURAL\": \"phytochemical\"}\n\n{\"COHORT\": \"consumers\", \"PLANTS\": \"consumable plants\", \"ADVERSE EFFECTS\": \"unintended consequences\", \"NATURAL\": \"consumable\"}\n\n{\"COHORT\": \"patients\", \"PLANTS\": \"traditional herbal remedies\", \"ADVERSE EFFECTS\": \"negative reactions\", \"NATURAL\": \"traditional\"}\n\n{\"COHORT\": \"patients\", \"PLANTS\": \"natural compounds\", \"ADVERSE EFFECTS\": \"side effects\", \"NATURAL\": \"natural compounds\"}\n\n{\"COHORT\": \"patients\", \"PLANTS\": \"plant-derived drugs\", \"ADVERSE EFFECTS\": \"drug-related adverse effects\", \"NATURAL\": \"plant-derived\"}\n\n{\"COHORT\": \"patients\", \"PLANTS\": \"botanical ingredients\", \"ADVERSE EFFECT", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" {\"COHORT\": \"Garcia-Alvarez cohort\", \"PHARMACEUTICAL_PRODUCT\": \"Valerian\", \"MARKETING_FORMULAS\": \"HMP\", \"GEOGRAPHICAL_REGION\": \"Germany\"}\n\n{\"PHARMACEUTICAL_PRODUCT\": \"Valerian\"}\n\n{\"MARKETING_FORMULAS\": \"HMP\"}\n\n{\"GEOGRAPHICAL_REGION\": \"Germany\"}\n\n{\"STUDY\": \"Garcia-Alvarez study\"}", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" {\"COHORT\": \"a group of individuals selected for study in pharmacology research\",\n\"DRUG\": \"a substance used in the treatment, cure, or prevention of disease\",\n\"PHARMACOLOGIST\": \"a scientist who studies the effects of drugs and their mechanisms of action\",\n\"ANIMAL_MODEL\": \"an organism used in biomedical research to study human disease\",\n\"HUMAN_SUBJECT\": \"a person participating in a clinical trial or study\",\n\"MEDICAL_CONDITION\": \"a disease or disorder being studied in pharmacology\",\n\"DRUG_TRIAL\": \"a research study to test the safety and efficacy of a drug\",\n\"PHARMACEUTICAL_COMPANY\": \"a company involved in the development, production, and marketing of drugs\",\n\"DRUG_ACTION\": \"the process by which a drug produces its intended therapeutic effect\",\n\"DRUG_REACTION\": \"an adverse or unexpected response to a drug\",\n\"DRUG_MECHANISM\": \"the specific biochemical interaction through which a drug substance produces its pharmacological effect\",\n\"DRUG_TOXICITY\": \"the degree to which a drug causes harmful effects\",\n\"DRUG_DOSAGE\": \"the amount of a drug administered at a given time\",\n\"DRUG_INTERACTION\": \"the effect of one drug on the activity of another drug\",\n\"DRUG_PROFILE\": \"a summary of the pharmacological properties of a drug\",\n\"DRUG_CLINICAL_TRIAL\": \"a research study conducted to evaluate the safety and efficacy of a drug in humans\",\n\"DRUG_LABEL\": \"the information provided on a drug's packaging, including indications, dosage, and precautions\",\n\"DRUG_DELIVERY_METHOD\": \"the route by which a drug is administered to achieve its therapeutic effect\",\n\"DRUG_ADMINISTRATION\": \"the method of delivering a drug to achieve its therapeutic effect\",\n\"DRUG_EXCRETION\": \"the process by which a drug is eliminated from the body\",\n", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"COHORT\": \"unspecified cohort\", \"Publisher\u2019s Note\": \"MDPI\", \"jurisdictional claims\": \"unspecified jurisdictional claims\", \"institutional affiliations\": \"unspecified institutional affiliations\"}\n\n(Note: The provided text does not explicitly mention any specific cohorts, jurisdictional claims, or institutional affiliations. Therefore, the descriptions are kept general based on the context provided.)", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {\"COHORT\": \"Diabetes\", \"Pathophysiologies\": \"complex condition\", \"Causes\": \"variety\"}", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {\"COHORT\": \"Not specified\",\n \"HERB-DRUG INTERACTIONS (HDI)\": \"herbal components and drug molecules\",\n \"CLINICAL SAFETY AND EFFICACY\": \"clinical safety and efficacy\",\n \"ADDITIVE/SYNERGISTIC INTERACTIONS\": \"additive/synergistic interactions\",\n \"ANTIOGENIC INTERACTIONS\": \"antagonistic interactions\"}", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" {\"HERBS\": \"these herbs\", \"DRUGS\": \"pharmacodynamic HDI\", \"PHARMACOLOGICAL_EFFECTS\": \"additive/synergistic\"}\n\n{\"COHORT\": \"not mentioned\"}\n\n{\"STUDY\": \"not mentioned\"}\n\n{\"PUBLICATION\": \"not mentioned\"}\n\n{\"JOURNAL\": \"not mentioned\"}\n\n{\"AUTHORS\": \"not mentioned\"}\n\n{\"DATE\": \"not mentioned\"}\n\n{\"JOURNAL_NAME\": \"not mentioned\"}\n\n{\"ARTICLE_NUMBER\": \"not mentioned\"}\n\n{\"YEAR\": \"not mentioned\"}\n\n{\"STUDY_DESIGN\": \"not mentioned\"}\n\n{\"STUDY_SIZE\": \"not mentioned\"}\n\n{\"STUDY_SET\": \"not mentioned\"}\n\n{\"STUDY_SUBJECTS\": \"not mentioned\"}\n\n{\"STUDY_METHODS\": \"not mentioned\"}\n\n{\"STUDY_OUTCOMES\": \"not mentioned\"}\n\n{\"STUDY_STATISTICS\": \"not mentioned\"}\n\n{\"STUDY_FINDINGS\": \"not mentioned\"}\n\n{\"STUDY_CONCLUSIONS\": \"not mentioned\"}\n\n{\"STUDY_RECOMMENDATIONS\": \"not mentioned\"}\n\n{\"STUDY_LIMITATIONS\": \"not mentioned\"}\n\n{\"STUDY_FUNDING\": \"not mentioned\"}\n\n{\"STUDY_CONFLICTS_OF_INTEREST\": \"not mentioned\"}\n\n{\"STUDY_DEPENDENCE\": \"not mentioned\"}\n\n{\"STUDY_REVIEWER\": \"not mentioned\"}\n\n{\"STUDY_REVIEWER_CONFIDENTIALITY\": \"not mentioned\"}\n\n{\"STUDY_DATA_SOURCE\": \"not mentioned\"}\n\n{\"STUDY_DATA_COLLECTION\": \"not mentioned\"}\n\n{\"STUDY_DATA_ANALYSIS\": \"not mentioned\"}\n\n{\"STUDY_DATA_AVAILABILITY\": \"not mentioned\"}\n\n{\"STUDY_DATA_ACCESSIBILITY\": \"not mentioned\"}\n\n{\"STUDY_DATA_", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" {\"Sulfur compounds\": \"a large number of sulfur compounds\", \"allyl thiosulfinates\": \"bioactive compounds called allyl thiosulfinates\", \"mainly allicin\": \"mainly allicin\"}\n{\"COHORT\": \"\"}", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" {\"HERB\": \"This herb\"}\n{\"DIABETIC TREATMENT\": \"diabetic treatment\"}\n{\"TWO MILLENNIUM\": \"two millennia\"}\n{\"ARTICLE\": \"scientific article\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"COHORT\": \"\"}\n{\"STUDY\": \"\"}\n{\"PUBLICATION\": \"scientific article\"}\n{\"REFERENCE\": \"reference\"}\n{\"JOURNAL\": \"\"}\n{\"ARTICLE NUMBER\": \"72\"}", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {\"COHORT\": \"individuals with diabetes\", \"PHARMACOLOGICAL_TREATMENTS\": \"gymnema tea, metformin\", \"MEASURED_OUTCOME\": \"blood sugar levels\"}\n\n(Note: The original text does not explicitly mention a \"cohort\" as a distinct group of individuals, but it implies a population of individuals with diabetes for the research. Therefore, the description provided is an interpretation based on the context.)", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" {\"COHORT\": \"Not specified\", \"Lycium\": \"a genus of flowering plants\", \"antidiabetics\": \"medications used to treat diabetes\"}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {\"Lycium\": \"a genus of plants\", \"conventional antidiabetics\": \"medications used to treat diabetes\"}\n{\"COHORT\": \"not mentioned\"}\n{\"Effect\": \"the impact or influence of Lycium when used in combination with conventional antidiabetics\"}\n{\"Study\": \"not mentioned\"}\n{\"Findings\": \"the results or conclusions drawn from the research\"}\n{\"Lycium\": \"a genus of plants\", \"antidiabetics\": \"medications used to treat diabetes\"}\n{\"Effect\": \"the impact or influence\"}\n{\"Combination\": \"the act of using Lycium with conventional antidiabetics\"}\n{\"Study\": \"not mentioned\"}\n{\"[86]\": \"the reference number of the study\"}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {\"COHORT\": \"study group of individuals with specific characteristics\", \"PHARMACOLOGY\": \"the science of drugs and their effects on living systems\", \"ARTICLE\": \"scientific publication on pharmacology\", \"SPECIALIZED JOURNAL\": \"a scholarly periodical focusing on pharmacology\", \"DRUG\": \"a substance used for medical treatment\", \"MEDICAL TREATMENT\": \"therapeutic intervention for health conditions\", \"PHARMACEUTICAL INDUSTRY\": \"the sector involved in the development, production, and marketing of drugs\", \"DRUG EFFECTS\": \"the physiological and therapeutic effects of a drug\", \"PHARMACOLOGIST\": \"a scientist specializing in pharmacology\", \"PHARMACOGENOMICS\": \"the study of how genes affect a person's response to drugs\", \"DRUG DISTRIBUTION\": \"the process of making drugs available for use\", \"DRUG DELIVERY\": \"the method by which drugs are administered to patients\", \"DRUG DOSAGE\": \"the amount of drug administered at a time\", \"DRUG PHARMACEUTICALS\": \"medicinal substances used for the treatment of diseases\", \"DRUG PHARMACOLOGICAL PROFILE\": \"the set of characteristics that define a drug's effects and actions\", \"DRUG PHARMACOLOGICAL PROFILE\": \"the set of characteristics that define a drug's effects and actions\", \"DRUG PHARMACOLOGICAL PROFILE\": \"the set of characteristics that define a drug's effects and actions\", \"DRUG PHARMACOLOGICAL PROFILE\": \"the set of characteristics that define a drug's effects and actions\", \"DRUG PHARMACOLOGICAL PROFILE\": \"the set of characteristics that define a drug's effects and actions\", \"DRUG PHARMACOLOGICAL PROFILE\": \"the set of characteristics that define a drug's effects and actions\", \"DRUG PHARMACOLOGICAL PROFILE\": \"the set of characteristics that define a drug's effects and actions\", \"DRUG PHARMA", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {\"SYSTEM-TO-SYSTEM-OR-SYSTEMS-BIOLOGY-METHODOLOGY\": \"methodology for the evaluation of complex interactions\", \"COMPLEX-HERBAL-INTERVENTIONS\": \"herbal interventions\"}\n\n{\"PHARMACOLOGICAL-DATA\": \"pharmacological data\"}\n\n{\"CHEMICAL-DATA\": \"chemical data\"}", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" {\"COHORT\": \"Not specified\",\n \"DRUG\": \"drugs\",\n \"SYNERGY\": \"synergism\",\n \"ADVERSE REACTIONS\": \"adverse reactions\"}\n\n{\"DRUG\": \"drugs\",\n \"SYNERGY\": \"synergism\",\n \"ADVERSE REACTIONS\": \"adverse reactions\"}", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Springer Nature\": \"publisher\", \"jurisdictional claims\": \"legal entities\", \"published maps\": \"geographical entities\", \"institutional affiliations\": \"institutional entities\"}\n{\"COHORT\": \"group of individuals selected for study in pharmacology\"}\n{\"PHARMACOLOGY\": \"scientific field\"}\n{\"ARTICLE\": \"scientific publication\"}\n{\"Scientific Article\": \"scientific publication\"}\n{\"pharmacology\": \"scientific field\"}\n{\"pharmacological\": \"related to pharmacology\"}\n{\"pharmacological agents\": \"substances used in pharmacology\"}\n{\"pharmacokinetics\": \"scientific field\"}\n{\"pharmacodynamics\": \"scientific field\"}\n{\"drug\": \"pharmacological substance\"}\n{\"drug therapy\": \"medical treatment\"}\n{\"clinical trials\": \"research studies\"}\n{\"medication\": \"pharmacological substance\"}\n{\"therapeutic effect\": \"medical outcome\"}\n{\"adverse effect\": \"medical outcome\"}\n{\"drug efficacy\": \"measure of drug effectiveness\"}\n{\"drug safety\": \"measure of drug safety\"}\n{\"drug interactions\": \"interactions between drugs\"}\n{\"drug metabolism\": \"biological process\"}\n{\"drug excretion\": \"biological process\"}\n{\"drug absorption\": \"biological process\"}\n{\"drug distribution\": \"biological process\"}\n{\"drug half-life\": \"biological property\"}\n{\"drug clearance\": \"biological property\"}\n{\"drug concentration\": \"biological property\"}\n{\"drug plasma levels\": \"biological property\"}\n{\"drug action\": \"mechanism of drug effect\"}\n{\"drug target\": \"biological entity\"}\n{\"drug receptor\": \"biological entity\"}\n{\"drug-receptor interaction\": \"biological process\"}\n{\"drug-enzyme interaction\": \"biological process\"}\n{\"drug-protein interaction\": \"biological process\"}\n{\"drug-lipid interaction\": \"biological process\"}\n{\"drug-carrier interaction\": \"biological process\"}\n{\"drug-cell interaction\": \"biological process\"}", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" {\"EIGERER, J. AND SCHOLZ, M.\": \"authors\", \"1999\": \"year of publication\"}\n{\"Asafetida\": \"substance\", \"folk medication\": \"use\", \"various ailments\": \"conditions\", \"flatulence\": \"condition\", \"cough\": \"condition\", \"asthma\": \"condition\", \"bronchitis\": \"condition\", \"hysteria\": \"condition\", \"convulsions\": \"condition\"}\n{\"flatulence\": \"condition\", \"cough\": \"condition\", \"asthma\": \"condition\", \"bronchitis\": \"condition\", \"hysteria\": \"condition\", \"convulsions\": \"condition\"}", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" {\"CYP2D6\": \"the enzyme predominantly mediating the O-demethylation of DEX to dextrorphan (DOR)\"}\n\n{\"DEX\": \"the precursor molecule undergoing O-demethylation to form dextrorphan (DOR)\"}\n\n{\"dextrorphan (DOR)\": \"the product formed from the O-demethylation of DEX\"}", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" {\"CYP3A\": \"activities\", \"CYP2D6\": \"activities\", \"DEX\": \"common probe\", \"Spanakis et al., 2009\": \"cited entity\", \"Yu and Haining, 2001\": \"cited entity\", \"Ducharme et al., 1996\": \"cited entity\", \"Funck-Brentano et al., 2005\": \"cited entity\", \"Jones et al., 1996\": \"cited entity\"}", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"USP Reference Standard\": \"USP reference standard\"}\n{\"Codeine\": \"internal standards codeine\"}\n{\"Betaxolol\": \"internal standards betaxolol\"}", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {\"COHORT\": \"\", \"GPR\": \"General-purpose reagents\", \"HPLC\": \"High-performance liquid chromatography\", \"HPLC grade solvents\": \"HPLC grade solvents\"}\n{\"COHINT\": \"reagents\", \"COHINT\": \"solvents\", \"COHINT\": \"HPLC\"}\n{\"SUBSTANCE\": \"General-purpose reagents\", \"SUBSTANCE\": \"HPLC grade solvents\", \"SUBSTANCE\": \"High-performance liquid chromatography\"}\n{\"METHOD\": \"High-performance liquid chromatography\"}\n{\"RESOURCE\": \"High-performance liquid chromatography grade solvents\"}\n{\"SOURCE\": \"Not specified\"}\n{\"DEVICE\": \"Not specified\"}\n{\"STUDY\": \"Not specified\"}\n{\"TRIAL\": \"Not specified\"}\n{\"PHARMACOLOGY\": \"pharmacology\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONCEPT\": \"High-performance liquid chromatography\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMACOLOGIC_CONTEXT\": \"Not specified\"}\n{\"PHARMA", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {\"Zorbax SB-CN column\": \"analytical column\", \"urine samples\": \"biological samples\"}\n\nNote: The \"cohort\" entity was not explicitly mentioned in the provided text, so it remains empty.", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {\"COHORT\": \"not specified\",\n \"DEX metabolites\": \"DEX metabolites\",\n \"Asafetida\": \"Asafetida\",\n \"one-way analysis of variance (ANOVA)\": \"one-way analysis of variance (ANOVA)\",\n \"Scheffe\u2019s multiple comparison test\": \"Scheffe\u2019s multiple comparison test\",\n \"P value\": \"P value\"}", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"COHORT\": \"in vitro study\", \"ASAFETIDA RESIN\": \"Asafetida resin\", \"ALCOHOLIC EXTRACT\": \"alcoholic extract\", \"DEX\": \"dehydroepiandrosterone\", \"DOR\": \"dihydrotestosterone\"}", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"COHORT\": \"not specified\", \"CONCENTRATION\": \"25 \u03bcg/ml\"}", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\"COHORT\": \"healthy human volunteers\"}\n\n(Note: No other entities were explicitly mentioned in the provided text, so only the cohort entity was identified and described.)", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\"COHORT\": \"clinical study\", \"IN VITRO\": \"in vitro\"}\n\nNote: The term \"in vitro\" refers to a process, experiment, or analysis done in a test tube, culture dish, or other device, but it is not explicitly mentioned as an entity to be parsed in the context of the provided text. However, it is included here as it is a key term related to the study's methodology.", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {\"CYP3A4\": \"CYP3A4 metabolic activity\"}\n\nNote: The term \"Asafetida\" in the context of the sentence seems to be a typographical error or a misinterpretation, as Asafetida is a spice and not typically associated with pharmacological studies. However, if it's intended to refer to a substance being studied for its inhibitory effect on CYP3A4, it would not be explicitly mentioned as an entity in the provided text. Therefore, no specific entity for \"Asafetida\" is identified in this context.", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" {\"ABEMACICLIB\": \"a drug\", \"DIARRHEA\": \"a side effect\", \"DOSE REDUCTIONS\": \"a consequence\", \"POOR ADHERENCE\": \"a consequence\", \"PATIENTS' OUTCOMES\": \"a measure of impact\", \"QUALITY OF LIFE\": \"a measure of impact\"}", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" {\"COHORT\": \"unspecified patient group\", \"Diet\": \"fatigue and loose stools\", \"Effects\": \"confusion\"}", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s><|user|> This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"COHORT\": Description of the cohort}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE<|end|><|assistant|>"}